<SEC-DOCUMENT>0001824293-25-000106.txt : 20250814
<SEC-HEADER>0001824293-25-000106.hdr.sgml : 20250814
<ACCEPTANCE-DATETIME>20250814065722
ACCESSION NUMBER:		0001824293-25-000106
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		58
CONFORMED PERIOD OF REPORT:	20250630
FILED AS OF DATE:		20250814
DATE AS OF CHANGE:		20250814

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GRI Bio, Inc.
		CENTRAL INDEX KEY:			0001824293
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				824369909
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40034
		FILM NUMBER:		251214199

	BUSINESS ADDRESS:	
		STREET 1:		2223 AVENIDA DE LA PLAYA
		STREET 2:		SUITE 208
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
		BUSINESS PHONE:		(619) 400-1171

	MAIL ADDRESS:	
		STREET 1:		2223 AVENIDA DE LA PLAYA
		STREET 2:		SUITE 208
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GRI BIO, Inc.
		DATE OF NAME CHANGE:	20230424

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Vallon Pharmaceuticals, Inc.
		DATE OF NAME CHANGE:	20200910
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ck0001824293-20250630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:63feccd5-3134-497b-93bb-cd3b539b0c1f,g:6dd00c0f-69b4-4831-9595-c67011349d66,d:beb529ed7e2d4f5fb095c3c93743cecb-->
<html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ck0001824293="http://www.vallon-pharma.com/20250630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ck0001824293-20250630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-27">0001824293</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" id="f-28">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-29">2025</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-30">Q2</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-31">FALSE</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-54" decimals="4" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="f-227">0.1429</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-55" decimals="4" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="f-228">0.0769</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-56" decimals="4" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="f-229">0.0588</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ck0001824293-20250630.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="year"><xbrli:measure>ck0001824293:year</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>ck0001824293:segment</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-08-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ck0001824293:CommonStockAndPrefundedWarrantsInFinancingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ck0001824293:CommonStockAndPrefundedWarrantsInFinancingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ck0001824293:CommonStockAndPrefundedWarrantsInFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ck0001824293:CommonStockOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ck0001824293:CommonStockOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ck0001824293:CommonStockOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:ThroughFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:ThroughFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-01-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-29</xbrli:startDate><xbrli:endDate>2024-01-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-17</xbrli:startDate><xbrli:endDate>2024-06-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-21</xbrli:startDate><xbrli:endDate>2025-02-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-01</xbrli:startDate><xbrli:endDate>2024-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-20</xbrli:startDate><xbrli:endDate>2024-05-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-21</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-26</xbrli:startDate><xbrli:endDate>2024-06-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesBCommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-21</xbrli:startDate><xbrli:endDate>2024-10-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesB1CommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesB2CommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesB1CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesB2CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesA1WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-23</xbrli:startDate><xbrli:endDate>2025-05-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesC1CommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesC2CommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesC1CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesC2CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedAndSeriesCWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:June2024PAWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesBCommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesD1WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesD2WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesDWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-21</xbrli:startDate><xbrli:endDate>2024-10-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:October2024PAWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesE1CommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesE2CommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesE3CommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesECommonWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:April2025PAWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesECommonWarrantsAndApril2025PAWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesECommonWarrantsAndApril2025PAWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesECommonWarrantsAndApril2025PAWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesECommonWarrantsAndApril2025PAWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInAugust2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInJanuary2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInFebruary2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInMarch2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInApril2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInOctober2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInMay2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInJuly2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInApril2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInFebruary2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInJune2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInSeptember2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInOctober2029OneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInOctober2029TwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInApril2030OneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInApril2030TwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:AmendedAndRestated2018EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:AmendedAndRestated2018EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ck0001824293:FormerChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-21</xbrli:startDate><xbrli:endDate>2023-04-21</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_1"></div><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:2.5pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">____________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">____________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.150%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">For the quarterly period ended </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">June 30, 2025</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.150%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from_________to_________</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number:&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-40034</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">____________________________________</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><img src="ck0001824293-20250630_g1.jpg" alt="GRI_ LOGO SELECT_ColorJPG.jpg" style="height:101px;margin-bottom:5pt;vertical-align:text-bottom;width:201px" id="i-1"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">GRI BIO, INC.</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">____________________________________</span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">82-4369909</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">incorporation or organization)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Identification No.)&#160;</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">2223 Avenida de la Playa</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-10">#208</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">La Jolla</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-12">CA</ix:nonNumeric>  <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">92037</ix:nonNumeric></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(Address of principal executive offices, including zip code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"> (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">619</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">400-1170</ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:8pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.650%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.513%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common Stock, par value $0.0001<br/>per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">GRI</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">The Nasdaq</ix:nonNumeric> Capital Market</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-19">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-20">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-bottom:8pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">o</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-21">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-22">x</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="f-23">x</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="f-24">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-25">x</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">As of August&#160;13, 2025, <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-26">2,515,305</ix:nonFraction> shares of the Registrant&#8217;s common stock were outstanding.</span></div><div style="margin-bottom:8pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_7"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-bottom:8pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:80.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.484%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_13">PART&#160;I. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_13">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_16">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_16">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_19">Consolidated Balance Sheets as of June 30, 2025 (unaudited) and December 31, 2024</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_19">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_22">Consolidated Statements of Operations (unaudited) for the three and six months ended June 30, 2025 and 2024</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_22">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_25">Consolidated Statements of Changes in Stockholders&#8217; Equity (unaudited) for the six months ended June 30, 2025 and 2024</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_25">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_28">Consolidated Statements of Cash Flows (unaudited) for the six months ended June 30, 2025 and 2024</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_28">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_31">Notes to Unaudited Interim Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_31">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_85">Item&#160;2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_85">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_85">17</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_109">Item&#160;3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_109">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_109">23</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_112">Item&#160;4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_112">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_112">23</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_115">PART&#160;II. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_115">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_115">25</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_118">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_118">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_118">25</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_121">Item&#160;1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_121">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_121">25</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_124">Item&#160;2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_124">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_124">25</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_127">Item&#160;3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_127">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_127">25</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_130">Item&#160;4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_130">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_130">25</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_133">Item&#160;5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_133">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_133">25</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_136">Item&#160;6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_136">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_136">26</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_139">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_139">27</a></span></div></td></tr></table></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_13"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PART I&#8212;FINANCIAL INFORMATION</span></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_16"></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Financial Statements.</span></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_19"></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">GRI Bio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.166%"><tr><td style="width:1.0%"/><td style="width:70.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.360%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.207%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-32">5,122</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-33">5,028</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="f-34">454</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="f-35">587</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-36">5,576</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-37">5,615</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-38">2</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-39">4</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="f-40">97</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="f-41">120</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-42">5,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-43">5,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders' equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-44">1,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="f-45">897</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="f-46">960</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="f-47">691</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, current</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-48">52</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-49">48</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-50">2,309</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-51">1,636</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-52">44</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-53">71</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-54">2,353</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-55">1,707</ix:nonFraction></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 9)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-3" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-56"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-57"></ix:nonFraction></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, <ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-58"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-59">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="0" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-60"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="0" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-61">250,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of June&#160;30, 2025 and December&#160;31, 2024; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-62"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="0" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-63">2,496,800</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="0" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-64"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-65">525,485</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of June&#160;30, 2025 and December&#160;31, 2024, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockValueOutstanding" format="ixt:fixed-zero" scale="3" id="f-66">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValueOutstanding" format="ixt:fixed-zero" scale="3" id="f-67">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-68">49,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-69">43,772</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-70">45,678</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-71">39,740</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-72">3,322</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-73">4,032</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-74">5,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-75">5,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to unaudited interim consolidated financial statements.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_22"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">GRI Bio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:8pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-76">1,879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="f-77">877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-78">3,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-79">1,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-80">1,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-81">1,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-82">2,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-83">2,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28.35pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-84">2,897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-85">2,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-86">5,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-87">4,153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-88">2,897</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-89">2,257</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-90">5,949</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-91">4,153</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ck0001824293:ChangeInFairValueOfWarrantLiability" format="ixt:fixed-zero" scale="3" id="f-92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ck0001824293:ChangeInFairValueOfWarrantLiability" scale="3" id="f-93">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:ChangeInFairValueOfWarrantLiability" format="ixt:fixed-zero" scale="3" id="f-94">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ck0001824293:ChangeInFairValueOfWarrantLiability" scale="3" id="f-95">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="f-96">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="f-97">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="f-98">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="f-99">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-100">2,892</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-101">2,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-102">5,938</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-103">4,137</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share of common stock, basic and diluted</span></div></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-104"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-105">1.31</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-106"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-107">61.85</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-108"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-109">4.33</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-110"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-111">150.32</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-112"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-113">2,205,139</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-114"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-115">36,379</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-116"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-117">1,369,933</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-118"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-119">27,522</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to unaudited interim consolidated financial statements.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_25"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">GRI Bio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Changes in Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except shares)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"/><td style="width:45.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.218%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.218%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.891%"/><td style="width:0.1%"/></tr><tr><td colspan="30" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="12" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Additional&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Paid-in Capital</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Stockholders&#8217; Equity</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Balance,&#160;December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-120">525,485</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-121">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-122">43,772</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-123">39,740</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-124">4,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-125">220</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-126">220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Fractional share adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="ck0001824293:StockIssuedDuringPeriodSharesFractionalShareAdjustment" scale="0" id="f-127">127</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="ck0001824293:StockIssuedDuringPeriodValueFractionalShareAdjustment" scale="3" id="f-128">1</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="ck0001824293:StockIssuedDuringPeriodValueFractionalShareAdjustment" scale="3" id="f-129">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-130">3,046</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-131">3,046</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Balance,March 31, 2025 (unaudited)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-132">525,358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-133">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-134">43,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-135">42,786</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-136">1,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-137">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-138">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock and prefunded warrants in financing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-139">1,388,888</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-140">4,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-141">4,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-23" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-142">582,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-143">825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-144">825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-145">2,892</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-146">2,892</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2025 (unaudited)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-147">2,496,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-148">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-149">49,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-150">45,678</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-151">3,322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.876%"/><td style="width:0.1%"/></tr><tr><td colspan="30" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2024</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="12" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Additional&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Paid-in Capital</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Stockholders&#8217; Equity</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Balance,&#160;December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-30" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-152">2,909</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-153">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-154">31,792</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-155">31,533</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-156">259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-157">37</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-158">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Fractional share adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-36" decimals="INF" name="ck0001824293:StockIssuedDuringPeriodSharesFractionalShareAdjustment" scale="0" id="f-159">1</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock and prefunded warrants in financing</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-36" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-160">1,495</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-161">4,389</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-162">4,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Prefunded warrant exercise</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-36" decimals="INF" name="ck0001824293:StockIssuedDuringPeriodSharesWarrantExercise" format="ixt:num-dot-decimal" scale="0" id="f-163">10,047</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-164">1,887</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-165">1,887</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March 31, 2024 (unaudited)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-38" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-166">14,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-167">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-168">36,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-169">33,420</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-170">2,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-171">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-172">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Fractional share adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-43" decimals="INF" name="ck0001824293:StockIssuedDuringPeriodSharesFractionalShareAdjustment" scale="0" id="f-173">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-43" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-174">20,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-175">4,134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-176">4,134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Prefunded warrant exercise</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-43" decimals="INF" name="ck0001824293:StockIssuedDuringPeriodSharesWarrantExercise" format="ixt:num-dot-decimal" scale="0" id="f-177">11,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-178">2,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-179">2,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2024 (unaudited)</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-45" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-180">47,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-181">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-182">40,389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-183">35,670</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-184">4,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to unaudited interim consolidated financial statements. </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_28"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">GRI Bio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:8pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.540%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-185">5,938</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-186">4,137</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-187">2</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-188">2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="f-189">261</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="f-190">74</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of warrant liability</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:fixed-zero" scale="3" id="f-191">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="f-192">3</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Change in operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="f-193">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ck0001824293:OperatingLeaseRightOfUseAssetPeriodicAddition" scale="3" id="f-194">127</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Change in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-195">133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-196">370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="f-197">371</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="f-198">400</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="f-199">269</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="f-200">250</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-201">23</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-202">127</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-203">4,902</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-204">4,344</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock in financing transactions</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-205">5,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-206">9,499</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under ATM facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="f-207">941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="f-208">961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Payment for fractional shares in connection with reverse stock split</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:PaymentForFractionalSharesReverseStockSplit" scale="3" id="f-209">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ck0001824293:PaymentForFractionalSharesReverseStockSplit" format="ixt:fixed-zero" scale="0" id="f-210">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Payment of stock issuance costs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="f-211">944</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-212">1,571</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-213">4,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-214">8,889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Net increase in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="f-215">94</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-216">4,545</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-217">5,028</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-218">1,808</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-219">5,122</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-220">6,353</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Supplemental disclosure of non-cash financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Deferred stock issuance costs in accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid" scale="3" id="f-221">29</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ck0001824293:DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid" scale="3" id="f-222">367</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Issuance of warrants for payment of stock issuance costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:WarrantsIssued" scale="3" id="f-223">123</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ck0001824293:WarrantsIssued" format="ixt:fixed-zero" scale="3" id="f-224">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to unaudited interim consolidated financial statements. </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_31"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">GRI Bio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Interim Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_34"></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:NatureOfOperations" id="f-225" continuedAt="f-225-1" escape="true">ORGANIZATION AND DESCRIPTION OF BUSINESS</ix:nonNumeric></span></div><ix:continuation id="f-225-1" continuedAt="f-225-2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">GRI Bio, Inc. (GRI or the Company), based in La Jolla, CA, was incorporated in Delaware in May 2009, which is the date of inception.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">GRI is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic and autoimmune disorders. The Company&#8217;s goal is to be an industry leader in developing therapies to treat these diseases and to improve the lives of patients suffering from such diseases. The Company&#8217;s lead product candidate, GRI-0621, is an oral inhibitor of type 1 invariant Natural Killer T (iNKT) cells and is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF). The Company&#8217;s product candidate portfolio also includes GRI-0803 and a proprietary library of 500+ compounds. GRI-0803, the lead molecule selected from the library, is a novel oral agonist of type 2 diverse Natural Killer T (dNKT) cells and is being developed for the treatment of autoimmune disorders, with much of its preclinical work in Systemic Lupus Erythematosus Disease (SLE) or lupus and multiple sclerosis (MS).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recapitalization</span></div></ix:continuation><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-225-2">On January 29, 2024, the Company effected a reverse stock split of its common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-53" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-226">0.0001</ix:nonFraction> per share (the Common Stock),  at a ratio of one-for-seven (the January 2024 Reverse Stock Split). On June 17, 2024, the Company effected a reverse stock split of its Common Stock at a ratio of one-for-thirteen (the June 2024 Reverse Stock Split). On February 21, 2025, the Company effected a reverse stock split of its Common Stock at a ratio of one-for-seventeen (the February 2025 Reverse Stock Split and together with the January 2024 Reverse Stock Split and the June 2024 Reverse Stock Split, the Reverse Stock Splits). Unless otherwise noted, all references to share and per share amounts in these consolidated financial statements reflect the Reverse Stock Splits.</ix:continuation> </span></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_40"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock" id="f-230" continuedAt="f-230-1" escape="true">LIQUIDITY</ix:nonNumeric></span></div><ix:continuation id="f-230-1" continuedAt="f-230-2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited interim consolidated financial statements have been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has not generated any significant revenues from operations since inception and does not expect to do so in the foreseeable future. The Company has incurred operating losses since its inception in 2009 and as a result has incurred $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-231">45,678</ix:nonFraction> in accumulated deficit through June&#160;30, 2025. The Company has financed its working capital requirements to date through the issuance of equity and debt securities. As of June&#160;30, 2025, the Company had cash of approximately $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-232">5,122</ix:nonFraction>. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2024, the Company entered into a securities purchase agreement (the February 2024 Purchase Agreement), pursuant to which the Company issued and sold Common Stock, pre-funded warrants and common warrants in a public offering (the February 2024 Offering) for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="f-233">4,389</ix:nonFraction>, after deducting offering expenses of $<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="ck0001824293:StockIssuanceCostsOfferingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-234">1,110</ix:nonFraction>. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On May 20, 2024, the Company entered into an At The Market Offering Agreement (the Sales Agreement) with H.C. Wainwright &amp; Co., LLC (Wainwright), pursuant to which the Company may sell and issue, subject to the limitations in the Sales Agreement, up to $<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-5" name="ck0001824293:SaleOfStockMaximumValueOfSharesOffered" format="ixt:num-dot-decimal" scale="6" id="f-235">10.0</ix:nonFraction>&#160;million shares of Common Stock from time to time through Wainwright as its sales agent (the ATM Offering). Under the Sales Agreement, Wainwright is entitled to compensation of <ix:nonFraction unitRef="number" contextRef="c-58" decimals="3" name="ck0001824293:SaleOfStockAgentCompensationPercentage" scale="-2" id="f-236">3.0</ix:nonFraction>% of the gross offering proceeds of all shares of Common Stock sold through it pursuant to the Sales Agreement. As of June&#160;30, 2025, the Company has sold <ix:nonFraction unitRef="shares" contextRef="c-59" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-237">908,172</ix:nonFraction> shares of Common Stock in the ATM Offering at a weighted-average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-60" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-238">5.01</ix:nonFraction> per share, for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="f-239">4,292</ix:nonFraction>, after deducting commissions to the sales agent and other ATM Offering related expenses of $<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="ck0001824293:StockIssuanceCostsOfferingExpenses" scale="3" id="f-240">254</ix:nonFraction>. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On June 26, 2024, the Company entered into a securities purchase agreement (the June 2024 Purchase Agreement), pursuant to which the Company issued and sold Common Stock, pre-funded warrants and common warrants, in a public offering (the June 2024 Offering), for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="f-241">3,172</ix:nonFraction>, after deducting offering expenses of $<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="ck0001824293:StockIssuanceCostsOfferingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-242">1,057</ix:nonFraction>.</span></div></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><ix:continuation id="f-230-2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On October 21, 2024, the Company entered into letter agreements (the Repricing Letter Agreements) with certain holders (the Holders) of certain of its issued and outstanding common warrants to purchase shares of its Common Stock, pursuant to which these Holders exercised their common warrants for cash at a reduced exercise price. In addition, these Holders received new unregistered common warrants. The net proceeds to the Company from the exercise of the common warrants were $<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="f-243">609</ix:nonFraction>, after deducting placement agent fees and offering expenses of $<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="ck0001824293:ClassOfWarrantsOrRightAgentFeesAndOfferingExpense" scale="3" id="f-244">154</ix:nonFraction>.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2025, the Company entered into a securities purchase agreement (the April 2025 Purchase Agreement), pursuant to which the Company issued and sold Common Stock, pre-funded warrants and common warrants, in a public offering (the April 2025 Offering), for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="f-245">4,020</ix:nonFraction>, after deducting offering expenses of $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="ck0001824293:StockIssuanceCostsOfferingExpenses" scale="3" id="f-246">979</ix:nonFraction>.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Company&#8217;s current operating plan, the Company believes that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2025.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue as a going concern is dependent on its ability to raise additional capital to fund its business activities, including its research and development program. The Company intends to raise capital through additional issuances of equity securities and/or short-term or long-term debt arrangements, but there can be no assurances any such financing will be available when needed, even if the Company&#8217;s research and development efforts are successful. If the Company is not able to obtain additional financing on acceptable terms and in the amounts necessary to fully fund its future operating requirements, it may be forced to reduce or discontinue its operations entirely. Therefore, there is substantial doubt about the Company&#8217;s ability to continue as a going concern for a period of one year from the issuance of these unaudited interim consolidated financial statements. These unaudited interim consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty.</span></div></ix:continuation><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_43"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="f-247" continuedAt="f-247-1" escape="true">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="f-247-1" continuedAt="f-247-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-248" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial periods and pursuant to the rules of the U.S. Securities and Exchange Commission (the SEC). Any reference in the accompanying unaudited interim financial statements to &#8220;authoritative guidance&#8221; is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). The December&#160;31, 2024 balance sheet was derived from the Company&#8217;s audited consolidated financial statements.</span></div></ix:nonNumeric><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the unaudited interim consolidated financial statements furnished herein include all normal and recurring adjustments considered necessary to present fairly the Company&#8217;s financial position as of June&#160;30, 2025, and the consolidated results of operations and consolidated stockholders&#8217; equity for the three and six months ended June&#160;30, 2025 and 2024 and consolidated cash flows for the six months ended June&#160;30, 2025 and 2024. Consolidated results of operations for the three and six months ended June&#160;30, 2025, are not necessarily indicative of the operating results that may be expected for the year ending December&#160;31, 2025. The unaudited interim consolidated financial statements, presented herein, do not contain the required disclosures under GAAP for annual consolidated financial statements. The accompanying unaudited interim consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and related notes as of and for the year ended December&#160;31, 2024, included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March&#160;14, 2025.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-249" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited interim consolidated financial statements include the accounts of GRI Bio, Inc. and its wholly owned subsidiary, GRI Bio Operations, Inc. All intercompany balances and transactions have been eliminated.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-250" continuedAt="f-250-1" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, warrant issuance and subsequent revaluations, valuation allowances relating to deferred tax assets, accrued expenses and estimation of the incremental borrowing rate for the operating lease. If actual results differ from the </span></div></ix:nonNumeric></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><ix:continuation id="f-247-2" continuedAt="f-247-3"><ix:continuation id="f-250-1"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Company&#8217;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#8217;s consolidated results of operations could either benefit from, or be adversely affected by, any such change in estimate.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="f-251" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820), establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The three levels of fair value hierarchy defined by ASC 820 are described below:</span></div><div style="margin-bottom:8pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></div><div style="margin-bottom:8pt;padding-left:67.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">:  Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="margin-bottom:8pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">:  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, the Company&#8217;s financial instruments included cash, cash equivalents, prepaid expenses and other current assets, accounts payable, accrued expenses and certain liability classified warrants. The carrying amounts reported in the consolidated balance sheets for cash, cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair value based on the short-term maturity of these instruments. The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. At June&#160;30, 2025, there were no financial assets or liabilities measured at fair value on a recurring basis other than the liability classified warrants.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, Vallon Pharmaceuticals, Inc. (Vallon) issued warrants (the May 2022 Warrants) in connection with a securities purchase agreement. Vallon evaluated the May 2022 Warrants in accordance with ASC 815-40, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 815-40), and concluded that a provision in the May 2022 Warrants related to the reduction of the exercise price in certain circumstances precluded the May 2022 Warrants from being accounted for as components of equity. As a result, the May 2022 Warrants were recorded as a liability on the consolidated balance sheet. Vallon recorded the fair value of the May 2022 Warrants upon issuance using a Black-Scholes valuation model. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to revalue the May 2022 Warrants at each reporting date with any changes in fair value recorded in its consolidated statements of operations. The valuation of the May 2022 Warrants is considered under Level 3 of the fair value hierarchy due to the need to use assumptions in the valuation that are both significant to the fair value measurement and unobservable. The change in the fair value of the Level 3 warrant liability is reflected in the consolidated statements of operations for the three and six months ended June&#160;30, 2025. As of June&#160;30, 2025 and December&#160;31, 2024, the fair value of the warrant liability was immaterial.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:DeferredChargesPolicyTextBlock" id="f-252" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Deferred Stock Issuance Costs</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Deferred stock issuance costs represent incremental costs incurred that are directly attributable to proposed offerings of securities. The costs are charged against the gross proceeds of the respective offering upon closing.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-253" continuedAt="f-253-1" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss Per Common Share</span></div></ix:nonNumeric><div style="margin-bottom:8pt"><ix:continuation id="f-253-1" continuedAt="f-253-2"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. For the six-month period ended June&#160;30, 2024, basic net loss per common share includes the weighted average of the June 2024 Pre-Funded Warrants (as defined below). Diluted net loss per common share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during each period, plus the dilutive effect of common stock equivalents outstanding during each period, in accordance with ASC 260,&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-253-2">. As the Company had a net loss in each of the three and six months ended June&#160;30, 2025 and 2024, diluted net loss per common share is the same as basic net loss per common share for the period because the effects of potentially dilutive securities are antidilutive</ix:continuation>.</span></div></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><ix:continuation id="f-247-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-254" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Common stock equivalents excluded from the diluted net loss per common share calculations are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-64" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-255">21,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-65" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="f-256">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-66" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-257">4,623,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-67" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-258">311,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-259">4,644,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-260">312,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-261" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company considered the applicability and impact of all ASUs issued during the quarter ended June&#160;30, 2025. ASUs not discussed below were assessed and determined to be either not applicable or expected to have minimal impact on these unaudited interim consolidated financial statements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280):</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Improvements to Reportable Segment Disclosures </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(ASU 2023-07). This amended guidance applies to all public entities and aims to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. This guidance is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The Company has adopted the provisions of ASU 2023-07 and has included the required disclosures in this Quarterly Report on Form 10-Q. See Note 8 for additional disclosures.</span></div></ix:nonNumeric></ix:continuation><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_55"></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-262" continuedAt="f-262-1" escape="true">PROPERTY AND EQUIPMENT</ix:nonNumeric></span></div><ix:continuation id="f-262-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-263" escape="true"><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.512%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-264">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-265">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-266">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-267">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-268">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-269">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="f-270">32</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="f-271">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-272">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-273">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense related to property and equipment was $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-274"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-275">1</ix:nonFraction></ix:nonFraction> in each of the three-month periods ended June&#160;30, 2025 and 2024 and  $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-276"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-277">2</ix:nonFraction></ix:nonFraction> in each of the six-month periods ended June&#160;30, 2025 and 2024.</span></div></ix:continuation><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_58"></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="f-278" continuedAt="f-278-1" escape="true">ACCRUED EXPENSES</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-279" escape="true"><ix:continuation id="f-278-1"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following:</span></div><div style="margin-bottom:8pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ck0001824293:AccruedResearchAndDevelopmentCostsCurrent" scale="3" id="f-280">550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ck0001824293:AccruedResearchAndDevelopmentCostsCurrent" scale="3" id="f-281">342</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent" scale="3" id="f-282">73</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent" scale="3" id="f-283">12</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="f-284">337</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="f-285">337</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="f-286">960</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="f-287">691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_64"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-288" continuedAt="f-288-1" escape="true">STOCKHOLDERS&#8217; EQUITY </ix:nonNumeric></span></div><ix:continuation id="f-288-1" continuedAt="f-288-2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">February 2024 Securities Purchase Agreement</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2024, the Company entered into the February 2024 Purchase Agreement, pursuant to which the Company sold, in the February 2024 Offering, (i) <ix:nonFraction unitRef="shares" contextRef="c-57" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-289">1,495</ix:nonFraction> shares (the February 2024 Shares) of Common Stock, (ii) <ix:nonFraction unitRef="shares" contextRef="c-72" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-290">21,131</ix:nonFraction> pre-funded warrants (the February 2024 Pre-Funded Warrants) exercisable for an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-72" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-291">21,131</ix:nonFraction> shares of Common Stock, (iii) <ix:nonFraction unitRef="shares" contextRef="c-73" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-292">22,631</ix:nonFraction> Series B-1 common warrants (the Series B-1 Common Warrants) exercisable for an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-73" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-293">22,631</ix:nonFraction> shares of Common Stock and (iv) <ix:nonFraction unitRef="shares" contextRef="c-74" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-294">22,631</ix:nonFraction> Series B-2 common warrants (the Series B-2 Common Warrants and together with the Series B-1 Common Warrants, the Series B Common Warrants) exercisable for an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-74" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-295">22,631</ix:nonFraction> shares of Common Stock for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="f-296">4,389</ix:nonFraction>, after deducting offering expenses of $<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="ck0001824293:StockIssuanceCostsOfferingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-297">1,110</ix:nonFraction>. The Series B Common Warrants together with the February 2024 Pre-Funded Warrants are referred to in this Quarterly Report on Form 10-Q (the Quarterly Report) as the &#8220;February 2024 Warrants.&#8221; The securities were offered in combinations of (a) <ix:nonFraction unitRef="shares" contextRef="c-75" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-298">one</ix:nonFraction> February 2024 Share or <ix:nonFraction unitRef="shares" contextRef="c-72" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-299">one</ix:nonFraction> February 2024 Pre-Funded Warrant, together with (b) <ix:nonFraction unitRef="shares" contextRef="c-73" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-300">one</ix:nonFraction> Series B-1 Common Warrant and <ix:nonFraction unitRef="shares" contextRef="c-74" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-301">one</ix:nonFraction> Series B-2 Common Warrant, for a combined purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-75" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-302">243.10</ix:nonFraction> (less $<ix:nonFraction unitRef="usdPerShare" contextRef="c-76" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-303">0.0221</ix:nonFraction> for each February 2024 Pre-Funded Warrant).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain ownership limitations, the February 2024 Warrants were exercisable upon issuance. Each February 2024 Pre-Funded Warrant was exercisable for <ix:nonFraction unitRef="shares" contextRef="c-76" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="f-304">one</ix:nonFraction> share of Common Stock at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-76" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-305">0.0221</ix:nonFraction> and expired when exercised in full. Each Series B-1 Common Warrant is exercisable into <ix:nonFraction unitRef="shares" contextRef="c-77" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="f-306">one</ix:nonFraction> share of Common Stock at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-77" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-307">243.10</ix:nonFraction> for a <ix:nonNumeric contextRef="c-77" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen" id="f-308">five-year</ix:nonNumeric> period after February 6, 2024, the date of issuance. Each Series B-2 Common Warrant is exercisable into <ix:nonFraction unitRef="shares" contextRef="c-78" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="f-309">one</ix:nonFraction> share of Common Stock at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-78" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-310">243.10</ix:nonFraction> for an <ix:nonNumeric contextRef="c-78" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durmonth" id="f-311">18</ix:nonNumeric>-month period after February 6, 2024, the date of issuance. The February 2024 Warrants were classified as equity and the allocated fair value of $<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-312">4,279</ix:nonFraction> is included in additional paid-in capital. As of June&#160;30, 2025, all of the February 2024 Pre-Funded Warrants have been exercised.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of the securities pursuant to the February 2024 Purchase Agreement, the exercise price of the Company&#8217;s previously outstanding Series A-1 Warrants was reduced to par, or $<ix:nonFraction unitRef="usdPerShare" contextRef="c-80" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-313">0.0001</ix:nonFraction>, per share pursuant to the terms of the Series A-1 Warrants. As of June&#160;30, 2025, all of the Series A-1 Warrants have been exercised.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">May 2024 At The Market Offering</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On May 20, 2024, the Company entered into the Sales Agreement with Wainwright, pursuant to which the Company may sell and issue, subject to the limitations in the Sales Agreement, shares up to $<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-5" name="ck0001824293:SaleOfStockMaximumValueOfSharesOffered" format="ixt:num-dot-decimal" scale="6" id="f-314">10.0</ix:nonFraction>&#160;million of Common Stock from time to time in the ATM Offering. Under the Sales Agreement, Wainwright is entitled to compensation of <ix:nonFraction unitRef="number" contextRef="c-58" decimals="3" name="ck0001824293:SaleOfStockAgentCompensationPercentage" scale="-2" id="f-315">3.0</ix:nonFraction>% of the gross offering proceeds of all shares of Common Stock sold through it pursuant to the Sales Agreement.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, the Company has sold <ix:nonFraction unitRef="shares" contextRef="c-59" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-316">908,172</ix:nonFraction> shares of Common Stock in the ATM Offering at a weighted-average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-60" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-317">5.01</ix:nonFraction> per share, for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="f-318">4,292</ix:nonFraction>, after deducting commissions to the sales agent and other ATM Offering related expenses of $<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="ck0001824293:StockIssuanceCostsOfferingExpenses" scale="3" id="f-319">254</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> of which <ix:nonFraction unitRef="shares" contextRef="c-81" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-320">582,554</ix:nonFraction> shares of Common Stock were sold during the quarter ended June 30, 2025, for gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="f-321">941</ix:nonFraction> and net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="3" id="f-322">825</ix:nonFraction>. On May 23, 2025, the Company filed a prospectus supplement to its registration statement on Form S-3 (File No. 333-279348) to increase the amount of shares of Common Stock that the Company may offer and sell under the Sales Agreement and applicable registration statement to an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="ck0001824293:SaleOfStockMaximumValueOfSharesOffered" format="ixt:num-dot-decimal" scale="3" id="f-323">1,759</ix:nonFraction>, which amount does not include the shares of Common Stock having an aggregate gross sales price of approximately $<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-324">4,546</ix:nonFraction> that were sold under the ATM Offering through May 22, 2025, in accordance with the limitations set forth in Instruction I.B.6 of Form S-3.</span></div></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><ix:continuation id="f-288-2" continuedAt="f-288-3"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">June 2024 Securities Purchase Agreement</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On June 26, 2024, the Company entered into the June 2024 Purchase Agreement, pursuant to which the Company issued and sold, in the June 2024 Offering, (i) <ix:nonFraction unitRef="shares" contextRef="c-61" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-325">3,529</ix:nonFraction> shares (the June 2024 Shares) of Common Stock, (ii) <ix:nonFraction unitRef="shares" contextRef="c-83" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-326">125,047</ix:nonFraction> pre-funded warrants (the June 2024 Pre-Funded Warrants) exercisable for an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-83" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-327">125,047</ix:nonFraction> shares of Common Stock, (iii) <ix:nonFraction unitRef="shares" contextRef="c-84" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-328">128,577</ix:nonFraction> Series C-1 common warrants (the Series C-1 Common Warrants) exercisable for an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-84" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-329">128,577</ix:nonFraction> shares of Common Stock, and (iv) <ix:nonFraction unitRef="shares" contextRef="c-85" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-330">128,577</ix:nonFraction> Series C-2 common warrants (the Series C-2 Common Warrants, and together with the Series C-1 Common Warrants, the Series C Common Warrants), exercisable for an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-85" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-331">128,577</ix:nonFraction> shares of Common Stock for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="f-332">3,172</ix:nonFraction>, after deducting offering expenses of $<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="ck0001824293:StockIssuanceCostsOfferingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-333">1,057</ix:nonFraction>. The Series C Common Warrants together with the June 2024 Pre-Funded Warrants are referred to in this Quarterly Report as the &#8220;June 2024 Warrants.&#8221; The securities were offered in combinations of (a) <ix:nonFraction unitRef="shares" contextRef="c-86" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-334">one</ix:nonFraction> June 2024 Share or <ix:nonFraction unitRef="shares" contextRef="c-83" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-335">one</ix:nonFraction> June 2024 Pre-Funded Warrant, together with (b) <ix:nonFraction unitRef="shares" contextRef="c-84" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-336">one</ix:nonFraction> Series C-1 Common Warrant and <ix:nonFraction unitRef="shares" contextRef="c-85" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-337">one</ix:nonFraction> Series C-2 Common Warrant, for a combined purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-86" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-338">31.11</ix:nonFraction> (less $<ix:nonFraction unitRef="usdPerShare" contextRef="c-87" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-339">0.0017</ix:nonFraction> for each June 2024 Pre-Funded Warrant).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The June 2024 Pre-Funded Warrants were exercisable for <ix:nonFraction unitRef="shares" contextRef="c-87" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="f-340">one</ix:nonFraction> share of Common Stock at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-87" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-341">0.0017</ix:nonFraction>, were exercisable immediately and have been exercised in full as of June&#160;30, 2025. Each Series C-1 Common Warrant is exercisable into <ix:nonFraction unitRef="shares" contextRef="c-88" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="f-342">one</ix:nonFraction> share of Common Stock at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-88" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-343">31.11</ix:nonFraction> for a <ix:nonNumeric contextRef="c-88" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen" id="f-344">five-year</ix:nonNumeric> period beginning after September 6, 2024. Each Series C-2 Common Warrant is exercisable into <ix:nonFraction unitRef="shares" contextRef="c-89" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="f-345">one</ix:nonFraction> share of Common Stock at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-89" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-346">31.11</ix:nonFraction> for an <ix:nonNumeric contextRef="c-89" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durmonth" id="f-347">18</ix:nonNumeric>-month period beginning after September 6, 2024. The June 2024 Warrants were classified as equity and the allocated fair value of $<ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-348">2,908</ix:nonFraction> is included in additional paid-in capital.</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to an engagement agreement with Wainwright, the Company, in connection with the June 2024 Offering, issued to Wainwright, or its designees, warrants to purchase up to an aggregate of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-91" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-349">9,002</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> shares of Common Stock (the June 2024 PA Warrants). The June 2024 PA Warrants have an exercise price of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-91" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-350">38.89</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> per share, will expire on June 26, 2029 and are exercisable beginning after September 6, 2024. The June 2024 PA Warrants were classified as equity and the fair value of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="3" id="f-351">229</ix:nonFraction> is included in additional paid-in capital.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">October 2024 Repricing Letter Agreement</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On October 21, 2024, the Company entered into the Repricing Letter Agreements with certain Holders of its issued and outstanding Series B Common Warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-92" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-352">44,842</ix:nonFraction> shares of its Common Stock, offering pursuant to which these Holders exercised Series B Common Warrants for cash at a reduced exercise price equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-92" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-353">17.00</ix:nonFraction> per share. In addition, these Holders received new unregistered Series D-1 common warrants (the Series D-1 Common Warrants) exercisable for up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-93" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-354">44,839</ix:nonFraction> shares of Common Stock and new unregistered Series D-2 common warrants (the Series D-2 Common Warrants and, together with the Series D-1 Common Warrants, the Series D Common Warrants) exercisable for up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-94" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-355">44,839</ix:nonFraction> shares of Common Stock. The Series D Common Warrants are immediately exercisable and have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-95" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-356">17.00</ix:nonFraction> per share. The Series D-1 Common Warrants expire on October 22, 2029, and the Series D-2 Common Warrants expire on April 22, 2026. This transaction is referred to as the &#8220;Warrant Repricing Transaction.&#8221;</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Wainwright acted as the exclusive placement agent for the Warrant Repricing Transaction pu</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">rsuant to an engagement agreement between the Company and Wainwright dated as of October 21, 2024. As compensation for such placement agent services, the Company agreed to pay Wainwright an aggregate cash fee equal to <ix:nonFraction unitRef="number" contextRef="c-96" decimals="INF" name="ck0001824293:SaleOfStockAggregateCashFeePercentageOfGrossProceeds" scale="-2" id="f-357">7.0</ix:nonFraction>% of the gross proceeds received by the Company from the Warrant Repricing Transaction, plus a management fee equal to <ix:nonFraction unitRef="number" contextRef="c-96" decimals="INF" name="ck0001824293:SaleOfStockManagementFeePercentageOfGrossProceeds" scale="-2" id="f-358">1.0</ix:nonFraction>% of the gross proceeds received by the Company from the Warrant Repricing Transaction, and reimbursement for accountable expenses of $<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="ck0001824293:SaleOfStockReimbursementOfAccountableExpenses" format="ixt:num-dot-decimal" scale="0" id="f-359">25,000</ix:nonFraction> and non-accountable expenses of $<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="ck0001824293:SaleOfStockReimbursementOfNonAccountableExpenses" format="ixt:num-dot-decimal" scale="0" id="f-360">10,000</ix:nonFraction>. The Company has also issued to Wainwright or its designees the October 2024 PA Warrants to purchase up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-97" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-361">3,140</ix:nonFraction> shares of Common Stock (the October 2024 PA Warrant). The October 2024 PA Warrants are immediately exercisable, expire on October 22, 2029, and have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-97" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-362">21.25</ix:nonFraction> per share.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The net proceeds to the Company from the exercise of the Series B Common Warrants were $<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="ck0001824293:ProceedsFromWarrantExercisesNetOfOfferingExpense" scale="3" id="f-363">202</ix:nonFraction> after deducting placement agent fees and offering expenses of $<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="ck0001824293:ClassOfWarrantOrRightOfferingCost" scale="3" id="f-364">560</ix:nonFraction>. The issuance under the Repricing Letter Agreements represented $<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="3" id="f-365">1,526</ix:nonFraction> in additional value provided to the investors, which was recorded as a deemed dividend to common stockholders.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">April 2025 Securities Purchase Agreement</span></div></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><ix:continuation id="f-288-3" continuedAt="f-288-4"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2025, the Company entered into the April 2025 Purchase Agreement, pursuant to which the Company issued and sold, in the April 2025 Offering, (i) <ix:nonFraction unitRef="shares" contextRef="c-98" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-366">202,000</ix:nonFraction> shares (the April 2025 Shares) of Common Stock, (ii) <ix:nonFraction unitRef="shares" contextRef="c-99" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-367">1,186,888</ix:nonFraction> pre-funded warrants (the April 2025 Pre-Funded Warrants) exercisable for an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-99" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-368">1,186,888</ix:nonFraction> shares of Common Stock, (iii) <ix:nonFraction unitRef="shares" contextRef="c-100" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-369">1,388,888</ix:nonFraction> Series E-1 common stock warrants (the Series E-1 Common Warrants) to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-100" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-370">1,388,888</ix:nonFraction> shares of Common Stock, (iv) <ix:nonFraction unitRef="shares" contextRef="c-101" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-371">1,388,888</ix:nonFraction> Series E-2 common stock warrants (the Series E-2 Common Warrants) to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-101" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-372">1,388,888</ix:nonFraction> shares of Common Stock, and (v) <ix:nonFraction unitRef="shares" contextRef="c-102" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-373">1,388,888</ix:nonFraction> Series E-3 common stock warrants (the Series E-3 Common Warrants, and collectively with the Series E-1 Warrants and the Series E-2 Warrants, the Series E Common Warrants) to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-102" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-374">1,388,888</ix:nonFraction> shares of Common Stock, for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="f-375">4,020</ix:nonFraction>, after deducting offering expenses of $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="ck0001824293:StockIssuanceCostsOfferingExpenses" scale="3" id="f-376">979</ix:nonFraction>. The April 2025 Offering closed on April 2, 2025. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The securities were offered in combinations of (a) <ix:nonFraction unitRef="shares" contextRef="c-104" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-377">one</ix:nonFraction> April 2025 Share or <ix:nonFraction unitRef="shares" contextRef="c-99" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-378">one</ix:nonFraction> April 2025 Pre-Funded Warrant, together with (b) <ix:nonFraction unitRef="shares" contextRef="c-100" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-379">one</ix:nonFraction> Series E-1 Common Warrant, <ix:nonFraction unitRef="shares" contextRef="c-101" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-380">one</ix:nonFraction> Series E-2 Common Warrant and <ix:nonFraction unitRef="shares" contextRef="c-102" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-381">one</ix:nonFraction> Series E-3 Common Warrant, for a combined purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-104" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-382">3.60</ix:nonFraction> (less $<ix:nonFraction unitRef="usdPerShare" contextRef="c-105" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-383">0.0001</ix:nonFraction> for each April 2025 Pre-Funded Warrant). The April 2025 Pre-Funded Warrants had an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-105" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-384">0.0001</ix:nonFraction> per share, became exercisable immediately upon issuance and expired when exercised in full. Each Series E Common Warrant has an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-106" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-385">3.20</ix:nonFraction> per share and became exercisable immediately upon issuance. The Series E-1 Common Warrants expire April 2, 2030. The Series E-2 Common Warrants expire on October 2, 2026. The Series E-3 Common Warrants expire on January 2, 2026. As of June 30, 2025, the April 2025 Pre-Funded Warrants have been exercised in full.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Wainwright acted as the exclusive placement agent for the April 2025 Offering pursuant to an engagement agreement between the Company and Wainwright dated as of March 7, 2025. As compensation for such placement agent services, the Company agreed to pay Wainwright an aggregate cash fee equal to <ix:nonFraction unitRef="number" contextRef="c-103" decimals="INF" name="ck0001824293:SaleOfStockAggregateCashFeePercentageOfGrossProceeds" scale="-2" id="f-386">7.0</ix:nonFraction>% of the gross proceeds received by the Company from the offering, plus a management fee equal to <ix:nonFraction unitRef="number" contextRef="c-103" decimals="INF" name="ck0001824293:SaleOfStockManagementFeePercentageOfGrossProceeds" scale="-2" id="f-387">1.0</ix:nonFraction>% of the gross proceeds received by the Company from the offering,  reimbursement for accountable expenses of $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="ck0001824293:SaleOfStockReimbursementOfAccountableExpenses" format="ixt:num-dot-decimal" scale="3" id="f-388">25,000</ix:nonFraction>,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> reimbursement of up to $<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="ck0001824293:SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses" format="ixt:num-dot-decimal" scale="3" id="f-389">100,000</ix:nonFraction> for legal fees and expenses and other out-of-pocket expenses and up to $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="ck0001824293:SaleOfStockClearingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-390">15,950</ix:nonFraction> for the clearing expenses.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> The Company also issued to Wainwright, or its designees, warrants to purchase up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-108" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-391">97,222</ix:nonFraction> shares of Common Stock (the April 2025 PA Warrants). The April 2025 PA Warrants became exercisable immediately upon issuance, expire on April 1, 2030, and have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-108" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-392">4.50</ix:nonFraction> per share. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The April 2025 PA Warrants were classified as equity and the fair value of $<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="3" id="f-393">123</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> is included in additional paid-in capital.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the amount paid for the April 2025 Pre-Funded Warrants approximates their fair value. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="f-394" continuedAt="f-394-1" escape="true">The Black-Scholes option-pricing model was used to estimate the fair value of the Series E Common Warrants and the April 2025 PA Warrants with the following weighted-average assumptions:</ix:nonNumeric></span></div><ix:continuation id="f-394-1"><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.123%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-109" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-395">156.44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="year" contextRef="c-110" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="f-396">2.48</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-111" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" format="ixt:fixed-zero" scale="-2" id="f-397">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-112" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-398">4.02</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="f-399" continuedAt="f-399-1" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, the Company had the following warrants outstanding to purchase Common Stock: </span></div></ix:nonNumeric></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><ix:continuation id="f-399-1"><ix:continuation id="f-288-4"><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Exercise Price per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-113" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="f-400">210</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-113" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-401">243.10</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">August 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-114" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-402">1,388,888</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-114" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-403">3.20</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">January 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-115" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="f-404">9</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-115" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" format="ixt:num-dot-decimal" scale="0" id="f-405">464,100.00</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">February 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-116" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-406">128,577</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-116" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-407">31.11</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">March 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-117" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-408">44,839</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-117" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-409">17.00</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">April 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-118" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-410">1,388,888</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-118" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-411">3.20</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">October 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-119" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="f-412">16</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-119" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" format="ixt:num-dot-decimal" scale="0" id="f-413">43,548.05</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">May 2027</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-120" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="f-414">1</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-120" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-415">0.01</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">July 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-121" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="f-416">3</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-121" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" format="ixt:num-dot-decimal" scale="0" id="f-417">94,970.33</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">April 2028</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-122" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="f-418">210</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-122" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-419">243.10</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-123" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-420">9,002</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-123" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-421">38.8875</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">June 2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-124" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-422">128,577</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-124" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-423">31.11</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">September 2029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-125" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-424">44,839</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-125" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-425">17.00</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">October 2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-126" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-426">3,140</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-126" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-427">21.25</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">October 2029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-127" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-428">1,388,888</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-127" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-429">3.20</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">April 2030</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-128" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-430">97,222</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-128" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-431">4.50</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">April 2030</span></td></tr></table></div></ix:continuation></ix:continuation><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_70"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-432" continuedAt="f-432-1" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="f-432-1" continuedAt="f-432-2"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amended and Restated 2018 Equity Incentive Plan</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2023, the stockholders of the Company approved the Amended and Restated GRI Bio, Inc. 2018 Equity Incentive Plan (the A&amp;R 2018 Plan). The A&amp;R 2018 Plan provides the Company with the ability to grant stock options, restricted stock and other equity-based awards to employees, directors and consultants. Stock options granted by the Company under the A&amp;R 2018 Plan generally have a contractual life of up to <ix:nonNumeric contextRef="c-129" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="f-433">10</ix:nonNumeric> years. As of June&#160;30, 2025, awards granted under the A&amp;R 2018 Plan representing the right to purchase or contingent right to receive up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-130" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-434">21,270</ix:nonFraction> shares of the Company's Common Stock were outstanding and <ix:nonFraction unitRef="shares" contextRef="c-130" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-435">21,275</ix:nonFraction> shares of the Company&#8217;s Common Stock were reserved for issuance under the A&amp;R 2018 Plan. The number of shares reserved for issuance under the A&amp;R 2018 Plan may be increased pursuant to the A&amp;R 2018 Plan&#8217;s &#8220;evergreen&#8221; provision on the first day of each calendar year beginning January 1, 2024 and ending on and including January 1, 2033, by a number of shares not to exceed <ix:nonFraction unitRef="number" contextRef="c-130" decimals="2" name="ck0001824293:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum" scale="-2" id="f-436">4</ix:nonFraction>% of the aggregate number of shares of the Company&#8217;s Common Stock outstanding on the final day of the immediately preceding calendar year.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-437" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation related to equity-based awards issued under the A&amp;R 2018 Plan in the following expense categories of its accompanying consolidated statements of operations for the three and six months ended June&#160;30, 2025 and 2024:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="f-438">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="f-439">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 4pt 0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-440">25</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="f-441">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-442">41</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-443">37</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-444">236</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-445">74</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-446">41</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-447">37</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-448">261</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-449">74</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures equity-based awards granted to employees and non-employees based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period or performance-based period, which is generally the vesting period of the respective award. The measurement date for service-based equity awards is the date of grant, and </span></div></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><ix:continuation id="f-432-2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">equity-based compensation costs are recognized as expense over the requisite service period. The Company records expense for performance-based awards if the Company concludes that it is probable that the performance condition will be achieved.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="f-450" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table below represents the activity of stock options granted to employees and non-employees for the six months ended June&#160;30, 2025:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average exercise price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-average remaining contractual term&#160;(years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="f-451">142</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" format="ixt:num-dot-decimal" scale="0" id="f-452">4,376.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-139" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-453">8.63</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-454">21,128</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-455">11.66</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="f-456">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-457">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/cancelled</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:fixed-zero" scale="0" id="f-458">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-459">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-460">21,270</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-461">40.80</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-462">9.56</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2025</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-463">21,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-464">30.83</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-465">9.56</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at June 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-466">21,270</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-467">40.80</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-468">9.56</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, all of the outstanding and exercisable stock options were out of the money and therefore had <ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:fixed-zero" scale="0" id="f-469">no</ix:nonFraction> intrinsic value. As of June&#160;30, 2025, the unrecognized compensation cost related to unvested stock options expected to vest was $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="3" id="f-470">174</ix:nonFraction>. This unrecognized compensation is expected to be recognized over a weighted-average amortization period of <ix:nonNumeric contextRef="c-140" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-471">0.78</ix:nonNumeric> years. </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-472">21,128</ix:nonFraction> stock options to its employees and non-employee directors during the six months ended June&#160;30, 2025. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-473" continuedAt="f-473-1" escape="true">The Black-Scholes option-pricing model was used to estimate the grant date fair value of each stock option grant at the time of grant using the following weighted-average assumptions:</ix:nonNumeric></span></div><ix:continuation id="f-473-1"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.205%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.595%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2025</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-140" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-474">110.94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-140" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-475">5.00</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-140" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-476">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-140" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-477">4.45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of option on grant date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-141" decimals="2" name="us-gaap:SharePrice" scale="0" id="f-478">9.43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="f-479">No</ix:nonFraction> equity-based awards were granted during the six-month period ended June&#160;30, 2024.</span></div></ix:continuation><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_587"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">8. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-480" continuedAt="f-480-1" escape="true">SEGMENT REPORTING</ix:nonNumeric></span></div><ix:continuation id="f-480-1" continuedAt="f-480-2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (CODM), or decision-making group, in deciding how to allocate resources in assessing performance. The Company has <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-481">one</ix:nonFraction> reportable segment: biotechnology research. The biotechnology research segment consists of the research and development of products for the treatment of inflammatory disease. The Company&#8217;s CODM is W. Marc Hertz, Ph.D., Chief Executive Officer and Director.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies of the biotechnology research segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance for the biotechnology research segment based on research and development expenses and general and administrative expenses as part of the overall review of the Company&#8217;s consolidated net loss and consolidated cash flows as compared to prior quarters and the Company&#8217;s operating budget.</span></div></ix:continuation><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-480-2">The Company has incurred significant losses since its inception and anticipates incurring continued losses in the future. As such, the CODM uses cash forecast models in deciding how to allocate resources based on the Company&#8217;s available cash resources, as well as its forecasted expenditures.  This information, in conjunction with the assessment of the probability of the success of the Company&#8217;s research and development activities, is used to plan the timing and size of future capital raises.</ix:continuation> </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_76"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-482" continuedAt="f-482-1" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="f-482-1" continuedAt="f-482-2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Employment Agreements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into employment contracts with its officers that provide for severance and continuation of benefits in the event of termination of employment by the Company without cause or by the employee for good reason. In addition, in the event of termination of employment following a change in control, the vesting of certain equity awards may be accelerated.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Separation and Release Agreement</span></div></ix:continuation><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-482-2">In connection with the resignation of David Baker, the Company&#8217;s Former Chief Executive Officer, the Company and Mr. Baker entered into a Separation and Release Agreement on April 21, 2023 (the Separation Agreement). Pursuant to the terms of the Separation Agreement and his employment agreement, Mr. Baker received continuation of his then current salary and certain COBRA benefits for <ix:nonNumeric contextRef="c-142" name="ck0001824293:COBRABenefitsPaymentPeriod" format="ixt-sec:durmonth" id="f-483">18</ix:nonNumeric> months payable in accordance with the Company&#8217;s payroll practices. Mr. Baker also received a lump sum payment equal to <ix:nonFraction unitRef="number" contextRef="c-142" decimals="INF" name="ck0001824293:PercentageOfTargetBonus" scale="-2" id="f-484">150</ix:nonFraction>% of his target bonus and agreed to reduce amounts payable with respect to certain future milestone payments.</ix:continuation> </span></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_79"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-485" continuedAt="f-485-1" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><ix:continuation id="f-485-1"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The One Big Beautiful Bill Act (&#8220;OBBBA&#8221;) was enacted on July 4, 2025. The Company is in the process of assessing the impact of this legislation on its financial statements. The OBBBA is not currently expected to materially impact the Company&#8217;s effective tax rate or cash flows in the current fiscal year.</span></div></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_85"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and the related notes appearing elsewhere in this Quarterly Report on Form 10-Q (the Quarterly Report), the audited financial statements and notes thereto, as well as management&#8217;s discussion and analysis of financial condition and results of operations included in our Annual Report on Form 10-K for the year ended December&#160;31, 2024 filed with the Securities and Exchange Commission (the SEC) on March&#160;14, 2025 (the Annual Report). Some of the information contained in this discussion and analysis, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 12E of the Securities Exchange Act of 1934, as amended (the Exchange Act), that involve risks and uncertainties. As a result of many factors, including those factors set out under the section entitled &#8220;Risk Factors&#8221; included in the Annual Report, our actual results could differ materially from the results described in or implied by these forward-looking statements.</span></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_88"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic and autoimmune disorders. Our goal is to be an industry leader in developing therapies to treat these diseases and to improve the lives of patients suffering from such diseases.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our lead product candidate, GRI-0621, is an oral inhibitor of type 1 invariant Natural Killer T (iNKT) cells. GRI-0621 is also an oral formulation of tazarotene, a synthetic retinoid acid receptor-beta and gamma selective agonist, that is approved in the United States for topical treatment of psoriasis and acne. As of June 30, 2025, it has been evaluated in over 1,700 patients as an oral product for up to 52-weeks. We are developing GRI-0621 for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF), a life-threatening progressive fibrotic disease of the lung that affects approximately 140,000 people in the United States, with up to 40,000 new cases per year in the United States. Some estimate that IPF affects 3 million globally. While there are currently two approved therapies for the treatment of lung fibrosis, neither has been associated with improvements in overall survival, and both therapies have been associated with significant side effects leading to poor therapeutic adherence. In preliminary data from our trials to date with GRI-0621, and earlier trials with oral tazarotene, we have observed GRI-0621 to be well-tolerated and to inhibit iNKT cell activity in subjects. We and others have shown that activated iNKT are upregulated in IPF, primary sclerosing cholangitis, metabolic dysfunction-associated steatohepatitis, alcoholic liver disease, systemic lupus erythematosus (SLE), multiple sclerosis (MS), ulcerative colitis patients as well as other indications. In these patients activated iNKT cells are correlated with more severe disease. The U.S. Food and Drug Administration has cleared our Investigative New Drug (IND) application, and we have received authorization of our clinical trial application from both the United Kingdom Medicines and Healthcare Products Regulatory Agency and the Australian Therapeutic Goods Administration to initiate the Phase 2a biomarker study evaluating GRI-0621 for the treatment of IPF in the, U.S., United Kingdom and Australia, respectively. We are evaluating GRI-0621 in a randomized, double-blind, multi-center Phase 2a biomarker study, for which we commenced enrollment in December 2023.Enrollment was completed in July 2025. No safety concerns have been observed by the Independent Data Monitoring Committee (IDMC) review of the first 12 subjects at two weeks and the first 24 subjects at six weeks of treatment. Changes from baseline of biomarkers in GRI-0621 treated subjects are suggestive of an anti-fibrotic effect, with decreases in biomarkers of fibrosis formation and increases in biomarkers of fibrosis resolution observed. Topline results from the Phase 2a biomarker study are expected in the third quarter of 2025.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidate portfolio also includes GRI-0803 and a proprietary library of 500+ compounds. GRI-0803, the lead molecule selected from the library, is a novel oral agonist of type 2 diverse Natural Killer T (dNKT) cells and would be developed for the treatment of autoimmune disorders, with much of our preclinical work in SLE or lupus and MS. In lupus, the immune system mistakenly attacks its own healthy tissues, especially joints and skin, but can affect almost every organ and tissue of the body. The condition can be fatal and often causes debilitating bouts of fatigue and pain that prevent nearly half of adult patients from working. Lupus affects between 160,000 - 200,000 patients in the United States, with around 80,000 &#8211; 100,000 patients in the United States suffering from kidney nephritis, one of the most serious manifestations of SLE, typically within five years of diagnosis. There is no cure for lupus, but medical interventions and lifestyle changes can help control it. SLE treatment consists primarily of immunosuppressive drugs that inhibit the activity of the immune system. Only two drugs have been approved for lupus in the past 50 years, and new treatment options are sorely needed. In order to focus our resources on our GRI-0621 program, we have limited our development of GRI-0803 pending additional funding. Subject to obtaining the requisite additional funding and IND clearance, we intend to evaluate GRI-0803 in a Phase 1a and 1b trial initially targeting SLE and to file an IND application with respect to this Phase </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1a and 1b trial in 2026. We expect to continue to evaluate indications to select the best fit for further development of the program, but our initial focus would be on lupus.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Recent Developments</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">April 2025 Securities Purchase Agreement </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2025, we entered into a securities purchase agreement (the April 2025 Purchase Agreement), pursuant to which we issued and sold, in a public offering (the April 2025 Offering), (i) 202,000 shares (the April 2025 Shares) of Common Stock, (ii) 1,186,888 pre-funded warrants (the April 2025 Pre-Funded Warrants) exercisable for an aggregate of 1,186,888 shares of Common Stock, (iii) 1,388,888 Series E-1 common stock warrants (the Series E-1 Common Warrants) to purchase up to 1,388,888 shares of Common Stock, (iv) 1,388,888 Series E-2 common stock warrants (the Series E-2 Common Warrants) to purchase up to 1,388,888 shares of Common Stock, and (v) 1,388,888 Series E-3 common stock warrants (the Series E-3 Common Warrants, and collectively with the Series E-1 Warrants and the Series E-2 Warrants, the Series E Common Warrants) to purchase up to 1,388,888 shares of Common Stock, for net proceeds of $4.0 million, before deducting offering expenses of $1.0 million. The securities were offered in combinations of (a) one April 2025 Share or one April 2025 Pre-Funded Warrant, together with (b) one Series E-1 Common Warrant, one Series E-2 Common Warrant and one Series E-3 Common Warrant, for a combined purchase price of $3.60 (less $0.0001 for each April 2025 Pre-Funded Warrant). </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The April 2025 Pre-Funded Warrants were exercisable for one share of Common Stock at a price of $0.0001 per share, were exercisable immediately and expired when exercised in full. Each Series E Common Warrant is exercisable into one share of Common Stock at a price per share of $3.20 and is immediately exercisable. The Series E-1 Common Warrants will expire on the five-year anniversary of the date of issuance. The Series E-2 Common Warrants will expire on the 18-month anniversary of the date of issuance. The Series E-3 Common Warrants will expire on the nine-month anniversary of the date of issuance. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">May 2024 At The Market Offering</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On May 20, 2024, we entered into an At The Market Offering Agreement (the Sales Agreement) with H.C. Wainwright &amp; Co., LLC (Wainwright), pursuant to which we may sell and issue, subject to the limitations in the Sales Agreement, shares up to $10.0 million of our Common Stock from time to time through Wainwright as our sales agent (the ATM Offering). On May 23, 2025, we filed a prospectus supplement to our registration statement on Form S-1 (File No. 333-279348) to increase the amount of shares of Common Stock that we may offer and sell under the Sales Agreement and applicable registration statement to an aggregate offering price of up to $1.8 million, which amount does not include the shares of Common Stock having an aggregate gross sales price of approximately $4.5 million that were sold under the ATM Offering through May 22, 2025, in accordance with the limitations set forth in Instruction I.B.6 of Form S-3. Under the Sales Agreement, Wainwright is entitled to compensation of 3.0% of the gross offering proceeds of all shares of Common Stock sold through it pursuant to the Sales Agreement.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">As of June&#160;30, 2025, we have sold 908,172 shares of our Common Stock in the ATM Offering at a weighted-average price of $5.01 per share, raising $4.5 million of gross proceeds and net proceeds of $4.3 million, after deducting commissions to the sales agent and other ATM Offering related expenses,  of which 582,554 shares of Common Stock were sold during the quarter ended June 30, 2025, for gross proceeds of $941 and net proceeds of $825.</span></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_91"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include personnel costs associated with research and development activities, including third party contractors to perform research, conduct clinical trials and manufacture drug supplies and materials. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses have consisted primarily of costs related to our development program for our lead product candidate GRI-0621. These expenses include:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">employee-related expenses, such as salaries, bonuses and benefits, consultant-related expenses such as consultant fees and bonuses, stock-based compensation, overhead-related expenses and travel-related expenses for our research and development personnel; and</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">expenses incurred under agreements with contract research organizations, contract manufacturing organizations and research laboratories in connection with our preclinical development, process development, manufacturing and clinical development activities as well as consultants that support the implementation of our clinical and non-clinical studies.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Although our direct research and development expenses are tracked by product candidate, we do not allocate employee costs and costs associated with our discovery efforts, laboratory supplies and facilities, including other indirect costs, to specific product candidates as these costs are deployed across multiple programs. We expect our research and development expenses to increase over the next several years as we conduct our planned clinical and preclinical activities for our product candidates.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of compensation and consulting related expenses for executives and other administrative personnel, professional fees and other corporate expenses, including legal and accounting fees, travel expenses, facilities-related expenses, and consulting services relating to corporate matters.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We expect our general and administrative expenses will continue to increase as we incur costs associated with being a public company, including expenses related to services associated with maintaining compliance with The Nasdaq Capital Market and SEC requirements, directors&#8217; and officers&#8217; insurance, legal and accounting costs and investor relations costs, as well as an increase in personnel expenses as we hire additional personnel.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant Liability</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, Vallon Pharmaceuticals, Inc. (Vallon) issued warrants (the May 2022 Warrants) in connection with a securities purchase agreement. Vallon evaluated the May 2022 Warrants in accordance with Accounting Standards Codification (ASC) 815-40, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 815-40), and concluded that a provision in the May 2022 Warrants related to the reduction of the exercise price in certain circumstances precludes the May 2022 Warrants from being accounted for as components of equity. As a result, the May 2022 Warrants were measured at fair value upon issuance using a Black-Scholes valuation model and are recorded as a liability on the consolidated balance sheet. The fair value of the May 2022 Warrants is measured at each reporting date and changes in fair value are recognized in the consolidated statements of operations in the period of change. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists of interest earned on our cash and cash equivalents held with institutional banks.</span></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_94"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended June&#160;30, 2025 and 2024 </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of our operations for the periods indicated (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,879&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,897</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,257</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,897)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,257)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,892)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,250)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $1.9 million and $0.9 million for the three months ended June&#160;30, 2025 and 2024, respectively. The $1.0 million increase in research and development expenses was primarily due to an increase of $0.9 million in expenses related to the registration development program of GRI-0621 and a $0.1 million increase in personnel expenses.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $1.0 million and $1.4 million for the three months ended June&#160;30, 2025 and 2024, respectively. The $0.4 million decrease was primarily related to a $0.4 million decrease in professional fees and public company expenses.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest income was $5,000 and $6,000 for the three months ended June&#160;30, 2025 and 2024, respectively. </span></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_569"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Six Months Ended June&#160;30, 2025 and 2024 </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of our operations for the periods indicated (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,949</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,153</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(5,949)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(4,153)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(5,938)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(4,137)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Research and development expenses were $3.5 million and $1.8 million for the six months ended June&#160;30, 2025 and 2024, respectively. The $1.7 million increase in research and development expenses was primarily due to </span><span style="background-color:#fff7c3;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">i</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">ncreases of $1.6 million in expenses related to the development program of GRI-0621 and a $0.1 million increase in personnel expenses. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $2.4 million and $2.3 million for the six months ended June&#160;30, 2025 and 2024, respectively. The $0.1 million increase was primarily related to an increase of $0.3 million in personnel expenses included stock-based compensation expense, offset by a $0.2 million decrease in public company expenses.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Warrant Liability</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The change in fair value of the warrant liability represents a decrease in the fair value of the May 2022 Warrants during the six months ended June&#160;30, 2024.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Interest income was $11,000 and $13,000 for the six months ended June&#160;30, 2025 and 2024, respectively. </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_97"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred losses and expect to continue to incur losses for the foreseeable future. We incurred net losses of $5.9 million and $4.1 million for the six months ended June&#160;30, 2025 and 2024, respectively. As of June&#160;30, 2025, we had an accumulated deficit of $45.7 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have financed our working capital requirements to date through the issuance of Common Stock, warrants, convertible notes and promissory notes. As of June&#160;30, 2025, we had $5.1 million in cash. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the periods indicated (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(4,902)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(4,344)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8,889&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash and cash equivalents</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,545&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Operating Activities</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June&#160;30, 2025 and 2024, $4.9 million and $4.3 million were used in operating activities, respectively. The $0.6 million increase was primarily due to a $1.8 million increase in net loss and a $0.4 million decrease in cash used for prepaid and other assets and operating lease liabilities, offset by a $0.3 million increase in non-cash adjustments related to stock-based compensation expenses, as well as a $0.8&#160;million increase in cash used for accounts payable and a $0.5&#160;million increase in cash used for accrued expenses.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Financing Activities</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $5.0 million for the six months ended June&#160;30, 2025 and was primarily related to $5.0 million in proceeds from the April 2025 Offering and $0.9 million in proceeds from the ATM Offering, offset by $0.9 million of stock issuance costs. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $8.9 million for the six months ended June&#160;30, 2024 and was primarily related to $9.5 million of proceeds from the February 2024 Offering (defined below) and $1.0 million in proceeds from the ATM Offering. The increase was offset by $1.6 million of stock issuance costs.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">April 2025 Securities Purchase Agreement</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2025, we entered the April 2025 Purchase Agreement, pursuant to which we issued and sold, in the April 2025 Offering, (i)  202,000 April 2025 Shares, (ii) 1,186,888 April 2025 Pre-Funded Warrants exercisable for an aggregate of 1,186,888 shares of Common Stock, (iii) 1,388,888  Series E-1 Common Warrants to purchase up to 1,388,888 shares of Common Stock, (iv) 1,388,888  Series E-2 Common Warrants to purchase up to 1,388,888 shares of Common Stock, and (v) 1,388,888 Series E-3 Common Warrants, to purchase up to 1,388,888 shares of Common Stock, for net proceeds of $4.0&#160;million, after deducting offering expenses of $1.0&#160;million.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">May 2024 At The Market Offering</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, we have sold 908,172 shares of our Common Stock in the ATM Offering at a weighted-average price of $5.01 per share, raising $4.5 million of gross proceeds and net proceeds of $4.3 million, after deducting commissions to the sales agent and other ATM Offering related expenses. On May 23, 2025, we filed a prospectus supplement to our registration statement on Form S-3 (File No. 333-279348) to increase the amount of shares of Common Stock that we may offer and sell under the Sales Agreement and applicable registration statement to an aggregate offering price of up to $1.8 million, which amount does not include the shares of Common Stock having an aggregate gross sales price of approximately $4.5 million that were sold under the ATM Offering through May 22, 2025, in accordance with the limitations set forth in Instruction I.B.6 of Form S-3.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">February 2024 Securities Purchase Agreement</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2024, we entered into  securities purchase agreement , pursuant to which we issued and sold, in a public offering (the February 2024 Offering), (i) 1,495 shares of Common Stock, (ii) 21,131 pre-funded warrants exercisable for an aggregate of 21,131 shares of Common Stock, (iii) 22,631 Series B-1 common warrants exercisable for an aggregate of 22,631 shares of Common Stock, and (iv) 22,631 Series B-2 common warrants exercisable for an aggregate of 22,631 shares of Common Stock for net proceeds of $4.4&#160;million, after deducting offering expenses of $1.1&#160;million.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Funding Requirements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our net losses were $5.9 million and $4.1 million for the six months ended June&#160;30, 2025 and 2024, respectively. As of June&#160;30, 2025, we had $5.1 million in cash and an accumulated deficit of $45.7 million. We expect to devote substantial financial resources to our planned activities, particularly as we prepare for, initiate, and conduct our planned clinical trials of GRI-0621 and GRI-0803, advance our discovery programs and continue our product development efforts. In addition, we expect to incur additional costs associated with operating as a public company. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Based on our current operating plan, we believe that our existing cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements into the fourth quarter of 2025. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. We intend to raise capital through additional issuances of equity securities and/or short-term or long-term debt arrangements, but there can be no assurances any such financing will be available when needed, even if our research and development efforts are successful. If we are unable to secure adequate additional funding, we will need to reevaluate our operating plans and may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, delay, scale back or eliminate some or all of our development programs, or relinquish rights to our technology on less favorable terms than we would otherwise choose or cease operations entirely. These actions could materially impact our business, results of operations and future prospects and the value of shares of our Common Stock. In addition, attempting to secure additional financing may divert the time and attention of management from day-to-day activities and distract from our discovery and product development efforts. As a result, there is substantial doubt about our ability to continue as a going concern. We expect to continue to incur significant and increasing operating losses at least for the foreseeable future. We do not expect to generate product revenue unless and until we successfully complete development, obtain regulatory approval for and successfully commercialize our current, or any future, product candidates.</span></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_100"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are not party to any off-balance sheet transactions. We have no guarantees or obligations other than those which arise out of normal business operations.</span></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_103"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of its financial condition and results of operations is based on its unaudited interim consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States (GAAP). The preparation of these unaudited interim consolidated financial statements requires us to make estimates and assumptions that affect the amounts reported in the unaudited interim consolidated financial statements and accompanying notes. Management evaluates these estimates and judgments on an ongoing basis. Management bases its estimates on historical experience and on various other factors that it believes are reasonable under the circumstances. Actual results could differ from those estimates.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our significant accounting policies are described in more detail in Note 3, &#8220;Summary of Significant Accounting Policies&#8221;, in our Annual Report.</span></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_106"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Emerging Growth Company Status</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS Act) and may remain an emerging growth company for up to five years. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not applicable to emerging growth companies. These exemptions include:</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced disclosure about our executive compensation arrangements;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">no non-binding stockholder advisory votes on executive compensation or golden parachute arrangements; and</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have taken advantage of reduced reporting requirements in this report and may continue to do so until such time that we are no longer an emerging growth company. We will remain an &#8220;emerging growth company&#8221; until the earliest of (a) the last day of the fiscal year in which we have total annual gross revenues of $1.235 billion or more, (b) December 31, 2026, the last day of the fiscal year following the fifth anniversary of the completion of Vallon&#8217;s initial public offering, (c) the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three years or (d) the date on which we are deemed to be a large accelerated filer under the rules of the SEC. Section&#160;107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period for complying with new or revised accounting standards. </span></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_109"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable to a smaller reporting company.</span></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_112"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Evaluation of our Disclosure Controls and Procedures</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our Chief Executive Officer and Chief Financial Officer evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e)) of the Exchange Act as of June&#160;30, 2025. We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in its periodic and current reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Based upon their evaluation, the Chief Executive Officer and the Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of  June&#160;30, 2025 due to the material weakness described in our Annual Report.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the course of preparing the Company&#8217;s financial statements for the Annual Report, management identified a material weakness related to the inaccurate computation of the non-cash deemed dividend associated with the re-pricing of the Series B Common Warrants in the Warrant Repricing Transaction in accordance with applicable GAAP guidance.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Management has implemented a plan to remediate this material weakness which includes the continued engagement of third-party professionals with appropriate expertise in accounting and reporting under GAAP and SEC regulations who have adequate experience related to non-recurring debt and equity transactions and the enhanced documentation related to the accounting treatment for such transactions and who will assist in reviewing the attendant calculations. Management has also refined our processes for communicating with our auditor as to when our financial statements and related materials have passed through the Company&#8217;s internal control processes.</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding this material weakness, we believe that our financial statements contained in this Quarterly Report on Form 10-Q fairly present our financial position, results of operations and cash flows for the periods covered by this report in all material respects.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, we have implemented certain measures to remediate the material weakness identified in the design and operation of our internal controls over financial reporting. There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) other than those noted above that occurred during the fiscal quarter covered by this report that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Limitations of Effectiveness of Control</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">It should be noted that any system of controls, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system are met. The design of any control system is based, in part, upon the benefits of the control system relative to its costs. Control systems can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. In addition, over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of these and other inherent limitations of control systems, there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_115"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PART II&#8212;OTHER INFORMATION</span></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_118"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened legal proceeding against us that we believe could have an adverse effect on our business, operating results or financial condition. </span></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_121"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes from the risk factors previously disclosed in the Annual Report.</span></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_124"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_127"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_130"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_133"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rule 10b5-1 Trading Arrangements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June&#160;30, 2025, none of our directors or officers <ix:nonNumeric contextRef="c-5" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-486"><ix:nonNumeric contextRef="c-5" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-487">adopted</ix:nonNumeric></ix:nonNumeric> or <ix:nonNumeric contextRef="c-5" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-488"><ix:nonNumeric contextRef="c-5" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-489">terminated</ix:nonNumeric></ix:nonNumeric> &#8220;Rule 10b5-1 trading arrangement&#8221; or &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as each term is defined in Item 408 of Regulation S-K.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_136"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="-sec-extract:summary;margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits.</span></div><div style="margin-bottom:8pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:6.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.322%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Filed Herewith</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference File No. </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Date Filed</span></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000182429325000050/gri-202410k_ex31.htm">Amended and Restated Certificate of Incorporation, as amended.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">001-40034</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3/14/2025</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000182429323000129/gribioinc-amendedandrestat.htm">Amended and Restated Bylaws.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">8-K/A</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">001-40034</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">5/26/2023</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828025016066/exhibit41-8xk.htm">Form of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828025016066/exhibit41-8xk.htm">Pre-</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828025016066/exhibit41-8xk.htm">Funded Warrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">001-40034</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">4/2/2025</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828025016066/exhibit42-8xk.htm">Form of Series </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828025016066/exhibit42-8xk.htm">E</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828025016066/exhibit42-8xk.htm"> Warrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">001-40034</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">4/2/2025</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828025016066/exhibit43-8xk1.htm">Form of Placement Agent Warrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">001-40034</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">4/2/2025</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">10.1&#9651;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828025016066/exhibit101-8xk.htm">Form of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828025016066/exhibit101-8xk.htm">Sec</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828025016066/exhibit101-8xk.htm">urities Purchase Agreement.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">001-40034</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">4/2/2025</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">10.2#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex102_directorcomppolicy.htm">Amended and Restated Non-Employee Director Compensa</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex102_directorcomppolicy.htm">tion Policy. </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">X</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">10.3#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000182429325000102/exhibit994-august25sx8.htm">F</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000182429325000102/exhibit994-august25sx8.htm">orm of Rest</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000182429325000102/exhibit994-august25sx8.htm">ricted Stock Unit Agreement under the Amend</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000182429325000102/exhibit994-august25sx8.htm">ed</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000182429325000102/exhibit994-august25sx8.htm"> and Restated 2018 Equity Ince</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000182429325000102/exhibit994-august25sx8.htm">ntive Plan. </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">S-8</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">333-289593</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">8/13/2025</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex311_ceo302cert63025.htm">Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex312_cfo302cert63025.htm">Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex312_cfo302cert63025.htm">.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex321_ceosection906cert630.htm">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex321_ceosection906cert630.htm">.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex322_cfosection906cert630.htm">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex322_cfosection906cert630.htm">.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">iXBRL Instance Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">iXBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">iXBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">iXBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">iXBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">iXBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">____________________________________</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Unless otherwise indicated, exhibits are filed herewith.</span></div><div style="padding-left:18pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:0.1%"/><td style="width:2.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.774%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.933%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.933%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#9651;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K.  The Company undertakes to furnish supplemental copies of any of the omitted schedules upon request by the SEC. </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Indicates a management contract or any compensatory plan, contract or arrangement.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">This certification will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, except to the extent specifically incorporated by reference into such filing.</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="ibeb529ed7e2d4f5fb095c3c93743cecb_139"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibeb529ed7e2d4f5fb095c3c93743cecb_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.352%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.815%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">GRI BIO, INC.</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date: August 14, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Leanne M. Kelly</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Name: Leanne M. Kelly</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Title: Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</span></td></tr></table></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>2
<FILENAME>ex102_directorcomppolicy.htm
<DESCRIPTION>EX-10.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ia109af9c87694f989ed549622794c1c2_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.2</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">GRI BIO, INC.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">(approved on August 11, 2025)</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Non-employee members of the board of directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) of GRI Bio, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Program</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  This Program has been adopted under the Company&#8217;s 2018 Equity Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Equity Plan</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), shall be effective on August 11, 2025 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and amends and restates the Company&#8217;s non-employee director compensation program dated August 10, 2023 in its entirety.  The cash and equity compensation described in this Program shall be paid or be granted, as applicable, automatically and without further action of the Board, to each member of the Board who is not an employee of the Company or any parent or subsidiary of the Company (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Employee Director</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) who is entitled to receive such cash or equity compensation, unless such Non-Employee Director declines the receipt of such cash or equity compensation by written notice to the Company.  This Program shall remain in effect until it is revised or rescinded by further action of the Board.  This Program may be amended, modified or terminated by the Board at any time in its sole discretion.  The terms and conditions of this Program shall supersede any prior cash and&#47;or equity compensation arrangements for service as a member of the Board between the Company and any of its Non-Employee Directors.  No Non-Employee Director shall have any rights hereunder, except with respect to stock options granted pursuant to the Program.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;Cash Compensation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Annual Retainers</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Non-Employee Director shall receive an annual cash retainer of $40,000 for service on the Board.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Additional Annual Retainers</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.  In addition, each Non-Employee Director shall receive the following additional annual cash retainers, as applicable&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Audit Committee</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.  A Non-Employee Director serving as Chairperson of the Audit Committee shall receive an additional annual retainer of $15,000 for such service.  A Non-Employee Director serving as a member of the Audit Committee shall receive an additional annual retainer of $7,500 for such service.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;Compensation Committee</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.  A Non-Employee Director serving as Chairperson of the Compensation Committee shall receive an additional annual retainer of $12,000 for such service.  A Non-Employee Director serving a member of the Compensation Committee shall receive an additional annual retainer of $6,000 for such service.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;Nominating and Corporate Governance Committee</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.  A Non-Employee Director serving as Chairperson of the Nominating and Corporate Governance Committee shall receive an additional annual retainer of $10,000 for such service.  A Non-</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Employee Director serving as a member of the Nominating and Corporate Governance Committee shall receive an additional annual retainer of $5,000 for such service.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;Board Chair</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.  A Non-Employee Director serving as a Board Chair shall receive an additional annual retainer of $30,000 for such service.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Payment of Retainers</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.  The annual retainers described in Sections 1(a) and 1(b) shall be earned on a quarterly basis based on a calendar quarter and shall be paid by the Company in arrears not later than the fifteenth day following the end of each calendar quarter.  In the event a Non-Employee Director does not serve as a Non-Employee Director, or in the applicable positions described in Section 1(b), for an entire calendar quarter, the retainer paid to such Non-Employee Director shall be prorated for the portion of such calendar quarter actually served as a Non-Employee Director, or in such position, as applicable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Election to Receive Stock Option in Lieu of Cash</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.  After January 1, 2026, Non-Employee Directors shall have the ability (provided the Compensation Committee of the Board determines in its discretion that a sufficient number of shares remain available for issuance pursuant to the Equity Plan or pursuant to any then-effective equity incentive plan) to elect to receive the annual retainer set forth in Section 1(a) above in an award of a stock option in lieu of cash pursuant to an election form provided by the Company.  Non-Employee Directors must complete and deliver the election form to the Company (which shall be irrevocable) at least 15 days prior to the end of the calendar quarter that ends immediately prior to the next annual meeting of the Company&#8217;s stockholders&#59; provided that the election cannot be made during a regular or special blackout period within the meaning of the Company&#8217;s Insider Trading and Securities Law Compliance Policy.  In the event that a Non-Employee Director makes an irrevocable election to receive a stock option in lieu of cash, he or she shall be automatically granted, effective immediately following the annual meeting (provided that he or she continues to serve as a Non-Employee Director as of that date), a stock option to purchase that number of shares of the Company&#8217;s common stock determined by dividing (i) the aggregate amount of the annual retainer set forth in Section 1(a) above that would otherwise payable to the Non-Employee Director for the one-year period commencing on July 1 immediately following the annual meeting, by (ii) the per share closing price of the Company&#8217;s common stock on such date, with the resulting quotient rounded down to the nearest whole share (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Retainer Award</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;Equity Compensation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.  Non-Employee Directors shall be granted the equity awards described below.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Initial Awards</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Non-Employee Director who is initially elected or appointed to the Board on or after the Effective Date shall be automatically granted a stock option to purchase a number of shares of the Company&#8217;s common stock equal to the quotient obtained by dividing $100,000 by the closing price of the Company&#8217;s common stock on the date of such initial election or appointment rounded down to the nearest whole share&#59; provided, however, in no event will the number of shares underlying such grant exceed 0.36% of the issued and outstanding shares of common stock on such grant date.  The awards described in this Section 2(a) shall be referred to as &#8220;Initial Awards&#8221;.  No Non-Employee Director shall be granted more than one Initial Award.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Subsequent Awards</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.  A Non-Employee Director, who (i) is serving on the Board as of the date of any annual meeting of the Company&#8217;s stockholders occurring on or after the Effective Date and has been serving as a Non-Employee Director for at least six months as of the date of such meeting, and (ii) will continue to serve as a Non-Employee Director immediately following such meeting, shall be automatically granted a stock option to purchase a number of shares of the Company&#8217;s common stock equal to the quotient obtained by dividing $50,000 (or, for the Chairperson of the Board, $83,333) by the closing price of the Company&#8217;s common stock on the date of such annual meeting rounded down to the nearest whole share&#59; provided, however, in no event will the number of shares underlying such grant exceed 0.18% (or, for the Chairperson of the Board, 0.3%) of the issued and outstanding shares of common stock on such grant date.  The awards described in this Section 2(b) shall be referred to as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Subsequent Awards</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;.  For the avoidance of doubt, a Non-Employee Director elected for the first time to the Board at an annual meeting of the Company&#8217;s stockholders shall only receive an Initial Award in connection with such election and shall not receive any Subsequent Award on the date of such meeting as well.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Termination of Employment of Employee Directors</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.  Members of the Board who are employees of the Company or any parent or subsidiary of the Company who subsequently terminate their employment with the Company and any parent or subsidiary of the Company and remain on the Board will not receive an Initial Award pursuant to Section 2(a) above, but to the extent that they are otherwise entitled, will receive, after termination from employment with the Company and any parent or subsidiary of the Company, Subsequent Awards as described in Section 2(b) above.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Terms of Awards Granted to Non-Employee Directors</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;In General</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.  Each stock option under this Program shall be granted under and shall be subject to the terms and provisions of the Equity Plan, or any other applicable Company equity incentive plan then-maintained by the Company and shall be granted subject to the execution and delivery of award agreements in substantially the forms previously approved by the Board.  All applicable terms of the Equity Plan apply to this Program as if fully set forth herein, and all grants of stock options hereby are subject in all respects to the terms of the Equity Plan and the applicable stock option agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;Exercise Price</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.  The per share exercise price of each stock option granted to a Non-Employee Director shall equal the Fair Market Value (as defined in the Equity Plan) of a share of common stock on the date the option is granted.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;Vesting</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.  Each Initial Award shall vest and become exercisable in substantially equal quarterly installments during the three-year period commencing on the date of grant, and each Retainer Award and each Subsequent Award shall vest and become exercisable in substantially equal quarterly installments during the one-year period commencing on the applicable date of grant, in each case subject to the Non-Employee Director continuing in service on the Board through each such vesting date.  Unless the Board otherwise determines, no portion of a Retainer Award, Initial Award or Subsequent Award which is unvested at the time of a Non-Employee Director&#8217;s termination of service on the Board shall become vested and exercisable </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">thereafter.  Upon a Change in Control, all outstanding equity awards granted under the Equity Plan, and any other equity incentive plan maintained by the Company, that are held by a Non-Employee Director shall become fully vested and exercisable, irrespective of any other provisions of the Plan or any award agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;Term</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.  The term of each stock option granted to a Non-Employee Director shall be ten years from the date the option is granted.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;Compensation Limits</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding anything to the contrary in this Program, all compensation payable under this Program will be subject to any limits on the maximum amount of Non-Employee Director compensation set forth in the Equity Plan, as in effect from time to time.</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">* * * * *</font><img alt="image_0.jpg" src="image_0.jpg" style="height:33px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>ex311_ceo302cert63025.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ieb9a44de00fb40b9851abc9e6775ff66_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 31.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:8pt"><font><br></font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">I, W. Marc Hertz, Ph.D., certify that&#58;</font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended June&#160;30, 2025 of GRI Bio, Inc.&#59;</font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.726%"><tr><td style="width:1.0%"></td><td style="width:31.191%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.352%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; August&#160;14, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; W. Marc Hertz, Ph.D.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">W. Marc Hertz, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>ex312_cfo302cert63025.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i356a1506d6c844ac83f56e2dc43b1df9_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 31.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:8pt"><font><br></font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">I, Leanne M. Kelly, certify that&#58;</font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended June&#160;30, 2025 of GRI Bio, Inc.&#59;</font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.299%"><tr><td style="width:1.0%"></td><td style="width:29.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; August&#160;14, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Leanne M. Kelly</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Leanne M. Kelly</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>ex321_ceosection906cert630.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i7fcb9312d1374f0eaf645195c834f0cb_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 32.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">I, W. Marc Hertz, Ph.D., President and Chief Executive Officer of GRI Bio, Inc. (the &#8220;Company&#8221;), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">the Quarterly Report on Form 10-Q of the Company for the quarter ended June&#160;30, 2025 (the &#8220;Quarterly Report&#8221;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">the information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.281%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.361%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; August&#160;14, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; W. Marc Hertz, Ph.D.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">W. Marc Hertz, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>ex322_cfosection906cert630.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i8ec5740cd0dd434c84e7709570bf28d9_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 32.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">I, Leanne M. Kelly,  Chief Financial Officer of GRI Bio, Inc. (the &#8220;Company&#8221;), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">the Quarterly Report on Form 10-Q of the Company for the quarter ended June&#160;30, 2025 (the &#8220;Quarterly Report&#8221;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">the information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.360%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; August&#160;14, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Leanne M. Kelly</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Leanne M. Kelly</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>ck0001824293-20250630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:63feccd5-3134-497b-93bb-cd3b539b0c1f,g:6dd00c0f-69b4-4831-9595-c67011349d66-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ck0001824293="http://www.vallon-pharma.com/20250630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.vallon-pharma.com/20250630">
  <xs:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ck0001824293-20250630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ck0001824293-20250630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ck0001824293-20250630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ck0001824293-20250630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.vallon-pharma.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets">
        <link:definition>9952151 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>9952152 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations">
        <link:definition>9952153 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofChangesinStockholdersEquity" roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity">
        <link:definition>9952154 - Statement - Consolidated Statements of Changes in Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>9952155 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDDESCRIPTIONOFBUSINESS" roleURI="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS">
        <link:definition>9952156 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LIQUIDITY" roleURI="http://www.vallon-pharma.com/role/LIQUIDITY">
        <link:definition>9952157 - Disclosure - LIQUIDITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>9952158 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENT" roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENT">
        <link:definition>9952159 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSES" roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSES">
        <link:definition>9952160 - Disclosure - ACCRUED EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITY" roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITY">
        <link:definition>9952161 - Disclosure - STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATION" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION">
        <link:definition>9952162 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTREPORTING" roleURI="http://www.vallon-pharma.com/role/SEGMENTREPORTING">
        <link:definition>9952163 - Disclosure - SEGMENT REPORTING</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>9952164 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTS" roleURI="http://www.vallon-pharma.com/role/SUBSEQUENTEVENTS">
        <link:definition>9952165 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>9955511 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>9955512 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTTables" roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTTables">
        <link:definition>9955513 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESTables" roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables">
        <link:definition>9955514 - Disclosure - ACCRUED EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYTables" roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYTables">
        <link:definition>9955515 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONTables" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables">
        <link:definition>9955516 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails" roleURI="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails">
        <link:definition>9955517 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LIQUIDITYDetails" roleURI="http://www.vallon-pharma.com/role/LIQUIDITYDetails">
        <link:definition>9955518 - Disclosure - LIQUIDITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails" roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails">
        <link:definition>9955519 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Diluted Net Loss Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails">
        <link:definition>9955520 - Disclosure - PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTNarrativeDetails" roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTNarrativeDetails">
        <link:definition>9955521 - Disclosure - PROPERTY AND EQUIPMENT - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESDetails" roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails">
        <link:definition>9955522 - Disclosure - ACCRUED EXPENSES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYNarrativeDetails" roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails">
        <link:definition>9955523 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails" roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails">
        <link:definition>9955524 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Schedule of Estimate of the Fair Value of the Warrants and Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails" roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails">
        <link:definition>9955525 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Schedule of Warrants Outstanding to Purchase Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONNarrativeDetails" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails">
        <link:definition>9955526 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails">
        <link:definition>9955527 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails">
        <link:definition>9955528 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Activity of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails">
        <link:definition>9955529 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Assumptions Used to Estimate Fair Value of Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTREPORTINGDetails" roleURI="http://www.vallon-pharma.com/role/SEGMENTREPORTINGDetails">
        <link:definition>9955530 - Disclosure - SEGMENT REPORTING (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESDetails" roleURI="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails">
        <link:definition>9955531 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ck0001824293_ChangeInFairValueOfWarrantLiability" abstract="false" name="ChangeInFairValueOfWarrantLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_CommonStockAndPrefundedWarrantsInFinancingMember" abstract="true" name="CommonStockAndPrefundedWarrantsInFinancingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_CommonStockOtherMember" abstract="true" name="CommonStockOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment" abstract="false" name="StockIssuedDuringPeriodSharesFractionalShareAdjustment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ck0001824293_StockIssuedDuringPeriodValueFractionalShareAdjustment" abstract="false" name="StockIssuedDuringPeriodValueFractionalShareAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise" abstract="false" name="StockIssuedDuringPeriodSharesWarrantExercise" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ck0001824293_ThroughFinancingMember" abstract="true" name="ThroughFinancingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition" abstract="false" name="OperatingLeaseRightOfUseAssetPeriodicAddition" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_PaymentForFractionalSharesReverseStockSplit" abstract="false" name="PaymentForFractionalSharesReverseStockSplit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid" abstract="false" name="DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_WarrantsIssued" abstract="false" name="WarrantsIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_PublicOfferingMember" abstract="true" name="PublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_PublicOfferingsMember" abstract="true" name="PublicOfferingsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_SeriesBCommonWarrantsMember" abstract="true" name="SeriesBCommonWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_StockIssuanceCostsOfferingExpenses" abstract="false" name="StockIssuanceCostsOfferingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_SaleOfStockMaximumValueOfSharesOffered" abstract="false" name="SaleOfStockMaximumValueOfSharesOffered" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_SaleOfStockAgentCompensationPercentage" abstract="false" name="SaleOfStockAgentCompensationPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ck0001824293_ClassOfWarrantsOrRightAgentFeesAndOfferingExpense" abstract="false" name="ClassOfWarrantsOrRightAgentFeesAndOfferingExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" abstract="false" name="AccruedResearchAndDevelopmentCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" abstract="false" name="AccruedGeneralAndAdministrativeExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_PreFundedWarrantsMember" abstract="true" name="PreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_SeriesB1CommonWarrantsMember" abstract="true" name="SeriesB1CommonWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_SeriesB2CommonWarrantsMember" abstract="true" name="SeriesB2CommonWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_SeriesA1WarrantsMember" abstract="true" name="SeriesA1WarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_SeriesC1CommonWarrantsMember" abstract="true" name="SeriesC1CommonWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_SeriesC2CommonWarrantsMember" abstract="true" name="SeriesC2CommonWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_PreFundedAndSeriesCWarrantsMember" abstract="true" name="PreFundedAndSeriesCWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_June2024PAWarrantsMember" abstract="true" name="June2024PAWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_SeriesDWarrantsMember" abstract="true" name="SeriesDWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_SeriesD1WarrantsMember" abstract="true" name="SeriesD1WarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_SeriesD2WarrantsMember" abstract="true" name="SeriesD2WarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_October2024PAWarrantsMember" abstract="true" name="October2024PAWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_SeriesE1CommonWarrantsMember" abstract="true" name="SeriesE1CommonWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_SeriesE2CommonWarrantsMember" abstract="true" name="SeriesE2CommonWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_SeriesE3CommonWarrantsMember" abstract="true" name="SeriesE3CommonWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_SeriesECommonWarrantMember" abstract="true" name="SeriesECommonWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_April2025PAWarrantsMember" abstract="true" name="April2025PAWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction" abstract="false" name="SaleOfStockNumberOfSecuritiesIssuedPerTransaction" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds" abstract="false" name="SaleOfStockAggregateCashFeePercentageOfGrossProceeds" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds" abstract="false" name="SaleOfStockManagementFeePercentageOfGrossProceeds" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ck0001824293_SaleOfStockReimbursementOfAccountableExpenses" abstract="false" name="SaleOfStockReimbursementOfAccountableExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses" abstract="false" name="SaleOfStockReimbursementOfNonAccountableExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense" abstract="false" name="ProceedsFromWarrantExercisesNetOfOfferingExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_ClassOfWarrantOrRightOfferingCost" abstract="false" name="ClassOfWarrantOrRightOfferingCost" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses" abstract="false" name="SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_SaleOfStockClearingExpenses" abstract="false" name="SaleOfStockClearingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_SeriesECommonWarrantsAndApril2025PAWarrantsMember" abstract="true" name="SeriesECommonWarrantsAndApril2025PAWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInAugust2025Member" abstract="true" name="WarrantsExpiringInAugust2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInJanuary2026Member" abstract="true" name="WarrantsExpiringInJanuary2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInFebruary2026Member" abstract="true" name="WarrantsExpiringInFebruary2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInMarch2026Member" abstract="true" name="WarrantsExpiringInMarch2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInApril2026Member" abstract="true" name="WarrantsExpiringInApril2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInOctober2026Member" abstract="true" name="WarrantsExpiringInOctober2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInMay2027Member" abstract="true" name="WarrantsExpiringInMay2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInJuly2027Member" abstract="true" name="WarrantsExpiringInJuly2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInApril2028Member" abstract="true" name="WarrantsExpiringInApril2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInFebruary2029Member" abstract="true" name="WarrantsExpiringInFebruary2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInJune2029Member" abstract="true" name="WarrantsExpiringInJune2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInSeptember2029Member" abstract="true" name="WarrantsExpiringInSeptember2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInOctober2029OneMember" abstract="true" name="WarrantsExpiringInOctober2029OneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInOctober2029TwoMember" abstract="true" name="WarrantsExpiringInOctober2029TwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInApril2030OneMember" abstract="true" name="WarrantsExpiringInApril2030OneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInApril2030TwoMember" abstract="true" name="WarrantsExpiringInApril2030TwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember" abstract="true" name="AmendedAndRestated2018EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ck0001824293_FormerChiefExecutiveOfficerMember" abstract="true" name="FormerChiefExecutiveOfficerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_COBRABenefitsPaymentPeriod" abstract="false" name="COBRABenefitsPaymentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ck0001824293_PercentageOfTargetBonus" abstract="false" name="PercentageOfTargetBonus" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>ck0001824293-20250630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:63feccd5-3134-497b-93bb-cd3b539b0c1f,g:6dd00c0f-69b4-4831-9595-c67011349d66-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_62f9529f-97dd-411a-acea-5698ff95ff4c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_41d5011e-9085-4903-818d-edaf3b8414b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_62f9529f-97dd-411a-acea-5698ff95ff4c" xlink:to="loc_us-gaap_Liabilities_41d5011e-9085-4903-818d-edaf3b8414b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_dc3c0cd1-e095-4ecc-9dc9-5e9688554b76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_62f9529f-97dd-411a-acea-5698ff95ff4c" xlink:to="loc_us-gaap_StockholdersEquity_dc3c0cd1-e095-4ecc-9dc9-5e9688554b76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_ea6b4985-865d-4204-80eb-2140c87a0abb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_62f9529f-97dd-411a-acea-5698ff95ff4c" xlink:to="loc_us-gaap_CommitmentsAndContingencies_ea6b4985-865d-4204-80eb-2140c87a0abb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_59b8d023-134f-48c7-8918-d190d32e8285" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2ac19ad9-411c-4d3f-9d4a-0c76fe171047" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_59b8d023-134f-48c7-8918-d190d32e8285" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2ac19ad9-411c-4d3f-9d4a-0c76fe171047" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_8bb4e92c-e33d-4773-8ca2-5a0e08450da1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_59b8d023-134f-48c7-8918-d190d32e8285" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_8bb4e92c-e33d-4773-8ca2-5a0e08450da1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c869ebd3-029e-46ad-bc36-5540aafc12ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_59b8d023-134f-48c7-8918-d190d32e8285" xlink:to="loc_us-gaap_AssetsCurrent_c869ebd3-029e-46ad-bc36-5540aafc12ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d502a5e9-d725-4c39-acc5-9ccde60d5e75" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_57b0df64-40ac-4c6e-a510-12cae0e0434e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d502a5e9-d725-4c39-acc5-9ccde60d5e75" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_57b0df64-40ac-4c6e-a510-12cae0e0434e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cb9d1c0f-f5ab-473a-9cd6-eede5fcbd1c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d502a5e9-d725-4c39-acc5-9ccde60d5e75" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cb9d1c0f-f5ab-473a-9cd6-eede5fcbd1c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_37f4d6b2-0e90-4809-affd-c28eb53c0209" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_61e0f27d-bc57-4a84-8194-105176f775d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_37f4d6b2-0e90-4809-affd-c28eb53c0209" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_61e0f27d-bc57-4a84-8194-105176f775d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_10854191-7858-4165-a2e8-f2d7e98e73fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_37f4d6b2-0e90-4809-affd-c28eb53c0209" xlink:to="loc_us-gaap_CommonStockValueOutstanding_10854191-7858-4165-a2e8-f2d7e98e73fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_39d96278-6184-42a1-bf7e-88b2fda4fe1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_37f4d6b2-0e90-4809-affd-c28eb53c0209" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_39d96278-6184-42a1-bf7e-88b2fda4fe1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_867dfe99-cae2-4c77-81ec-87646d77db34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0cc224e3-7ba6-401d-be6b-5b3850c9677d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_867dfe99-cae2-4c77-81ec-87646d77db34" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0cc224e3-7ba6-401d-be6b-5b3850c9677d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_df7c51b8-e241-4d2b-8a94-bc3ad6cd4523" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_867dfe99-cae2-4c77-81ec-87646d77db34" xlink:to="loc_us-gaap_LiabilitiesCurrent_df7c51b8-e241-4d2b-8a94-bc3ad6cd4523" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1fb83214-c653-41ca-b9a0-b4f7d544d2eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_4a5b1740-a341-4d51-9157-d02334b87cca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1fb83214-c653-41ca-b9a0-b4f7d544d2eb" xlink:to="loc_us-gaap_AccountsPayableCurrent_4a5b1740-a341-4d51-9157-d02334b87cca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_a4a8b7be-8dc8-4e1e-971e-c7fdec9ebe5f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1fb83214-c653-41ca-b9a0-b4f7d544d2eb" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_a4a8b7be-8dc8-4e1e-971e-c7fdec9ebe5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_313ebd9d-320a-44d3-8602-7d0e1bf40f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1fb83214-c653-41ca-b9a0-b4f7d544d2eb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_313ebd9d-320a-44d3-8602-7d0e1bf40f9b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_8ea4d4fd-d8fa-433b-8deb-0b14fd29d911" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d269da20-67da-4862-ac0e-318851f4b134" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8ea4d4fd-d8fa-433b-8deb-0b14fd29d911" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d269da20-67da-4862-ac0e-318851f4b134" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_4cb9359a-488a-4d9a-bee4-987420bb30dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8ea4d4fd-d8fa-433b-8deb-0b14fd29d911" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_4cb9359a-488a-4d9a-bee4-987420bb30dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6bf04929-1bac-4004-95bc-5b5f24a030df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_cfaaab8a-6b61-4354-8cfc-37461499b180" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_6bf04929-1bac-4004-95bc-5b5f24a030df" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_cfaaab8a-6b61-4354-8cfc-37461499b180" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5867bc84-69f6-4cf4-883c-ca71a9ff7a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_6bf04929-1bac-4004-95bc-5b5f24a030df" xlink:to="loc_us-gaap_OperatingIncomeLoss_5867bc84-69f6-4cf4-883c-ca71a9ff7a9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ChangeInFairValueOfWarrantLiability_37ab8f3d-b292-4ef4-ac76-2c84677a0d61" xlink:href="ck0001824293-20250630.xsd#ck0001824293_ChangeInFairValueOfWarrantLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_6bf04929-1bac-4004-95bc-5b5f24a030df" xlink:to="loc_ck0001824293_ChangeInFairValueOfWarrantLiability_37ab8f3d-b292-4ef4-ac76-2c84677a0d61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3a89e804-8d84-447e-81d0-d99b3820afa6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_af3b42ec-649a-4003-b011-9c1502453acf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_3a89e804-8d84-447e-81d0-d99b3820afa6" xlink:to="loc_us-gaap_OperatingExpenses_af3b42ec-649a-4003-b011-9c1502453acf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_29d314f8-f2c7-40fe-904c-077e1eaa7be5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PaymentForFractionalSharesReverseStockSplit_5a69811c-f4ed-4e56-bb66-d2db204b9e76" xlink:href="ck0001824293-20250630.xsd#ck0001824293_PaymentForFractionalSharesReverseStockSplit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_29d314f8-f2c7-40fe-904c-077e1eaa7be5" xlink:to="loc_ck0001824293_PaymentForFractionalSharesReverseStockSplit_5a69811c-f4ed-4e56-bb66-d2db204b9e76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1b9fd335-4955-4b0a-a170-8b4efe5a97ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_29d314f8-f2c7-40fe-904c-077e1eaa7be5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1b9fd335-4955-4b0a-a170-8b4efe5a97ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_0a4d2573-c7a9-4db8-978d-fda87a90e72b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_29d314f8-f2c7-40fe-904c-077e1eaa7be5" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_0a4d2573-c7a9-4db8-978d-fda87a90e72b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_58cf8196-2e0a-4f9a-b643-ce53cf89697b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8e249420-5de8-4d09-a8d9-91f69a0b9758" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_58cf8196-2e0a-4f9a-b643-ce53cf89697b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8e249420-5de8-4d09-a8d9-91f69a0b9758" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3053a74f-3ba0-46e8-aac4-600e2133c998" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_58cf8196-2e0a-4f9a-b643-ce53cf89697b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3053a74f-3ba0-46e8-aac4-600e2133c998" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e8fea52f-614c-43cc-8970-fd9a3b2f0396" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_958a259d-4697-46d5-a9ec-269d33b4b98f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e8fea52f-614c-43cc-8970-fd9a3b2f0396" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_958a259d-4697-46d5-a9ec-269d33b4b98f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_073bd726-eccf-4f51-b47a-b2c140d7084b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e8fea52f-614c-43cc-8970-fd9a3b2f0396" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_073bd726-eccf-4f51-b47a-b2c140d7084b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_100e928a-cd7c-400b-b226-fb23187cb8b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e8fea52f-614c-43cc-8970-fd9a3b2f0396" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_100e928a-cd7c-400b-b226-fb23187cb8b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_70aed7f3-87c5-4358-ae68-d861d9e24b71" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e8fea52f-614c-43cc-8970-fd9a3b2f0396" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_70aed7f3-87c5-4358-ae68-d861d9e24b71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_de421368-24c0-4bad-a054-9bf0561da6b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e8fea52f-614c-43cc-8970-fd9a3b2f0396" xlink:to="loc_us-gaap_ShareBasedCompensation_de421368-24c0-4bad-a054-9bf0561da6b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bb5dd53c-32d4-40e6-a93a-bfef0727477b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e8fea52f-614c-43cc-8970-fd9a3b2f0396" xlink:to="loc_us-gaap_NetIncomeLoss_bb5dd53c-32d4-40e6-a93a-bfef0727477b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_e3194d09-db51-4031-bba1-478ab591a42c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e8fea52f-614c-43cc-8970-fd9a3b2f0396" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_e3194d09-db51-4031-bba1-478ab591a42c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_6be992ae-f51a-4782-bd8a-a2777a1c937a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e8fea52f-614c-43cc-8970-fd9a3b2f0396" xlink:to="loc_us-gaap_Depreciation_6be992ae-f51a-4782-bd8a-a2777a1c937a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_02ef66f9-aa36-4e37-950e-f418ea304ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e8fea52f-614c-43cc-8970-fd9a3b2f0396" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_02ef66f9-aa36-4e37-950e-f418ea304ec1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition_50597303-1d2d-4249-b336-2e5352cd8a81" xlink:href="ck0001824293-20250630.xsd#ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e8fea52f-614c-43cc-8970-fd9a3b2f0396" xlink:to="loc_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition_50597303-1d2d-4249-b336-2e5352cd8a81" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e92c044d-aca0-4bd8-a779-e650cdb695b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f1d5896d-224c-4176-af63-503e3dbc01cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_e92c044d-aca0-4bd8-a779-e650cdb695b1" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f1d5896d-224c-4176-af63-503e3dbc01cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_ef6207d2-377b-404a-a18e-af48974a6fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_e92c044d-aca0-4bd8-a779-e650cdb695b1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_ef6207d2-377b-404a-a18e-af48974a6fcd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#ACCRUEDEXPENSESDetails"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8fa00834-85a1-4309-a6da-7ef287a6537a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_bad772f6-1e34-44c9-8cac-f7180a0513b4" xlink:href="ck0001824293-20250630.xsd#ck0001824293_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8fa00834-85a1-4309-a6da-7ef287a6537a" xlink:to="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_bad772f6-1e34-44c9-8cac-f7180a0513b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_a6b8a632-ab23-44c9-9883-fac6bdea43ac" xlink:href="ck0001824293-20250630.xsd#ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8fa00834-85a1-4309-a6da-7ef287a6537a" xlink:to="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_a6b8a632-ab23-44c9-9883-fac6bdea43ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_96a8751c-fcf6-4ee7-b2ef-6802cfe32855" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8fa00834-85a1-4309-a6da-7ef287a6537a" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_96a8751c-fcf6-4ee7-b2ef-6802cfe32855" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>ck0001824293-20250630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:63feccd5-3134-497b-93bb-cd3b539b0c1f,g:6dd00c0f-69b4-4831-9595-c67011349d66-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#ConsolidatedStatementsofChangesinStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ecc842bb-7dd1-4f47-a5a5-dc7af1be05aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0a4f62d0-ef5a-406e-9f0f-75a73fd1e39d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_ecc842bb-7dd1-4f47-a5a5-dc7af1be05aa" xlink:to="loc_us-gaap_StatementTable_0a4f62d0-ef5a-406e-9f0f-75a73fd1e39d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_65107d57-84c8-4bf0-acaf-b0bca5cc80d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0a4f62d0-ef5a-406e-9f0f-75a73fd1e39d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_65107d57-84c8-4bf0-acaf-b0bca5cc80d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_65107d57-84c8-4bf0-acaf-b0bca5cc80d3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_65107d57-84c8-4bf0-acaf-b0bca5cc80d3" xlink:to="loc_us-gaap_EquityComponentDomain_65107d57-84c8-4bf0-acaf-b0bca5cc80d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4568436c-8273-4935-9902-e2b5f39557ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_65107d57-84c8-4bf0-acaf-b0bca5cc80d3" xlink:to="loc_us-gaap_EquityComponentDomain_4568436c-8273-4935-9902-e2b5f39557ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7bc88ab1-ca38-4a4d-89c4-d750cb01564a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4568436c-8273-4935-9902-e2b5f39557ae" xlink:to="loc_us-gaap_CommonStockMember_7bc88ab1-ca38-4a4d-89c4-d750cb01564a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ec840060-508d-41ff-9126-66457e5b4f85" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4568436c-8273-4935-9902-e2b5f39557ae" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ec840060-508d-41ff-9126-66457e5b4f85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_31d6d8d0-99c0-4a71-a4e9-a3bb25db24d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4568436c-8273-4935-9902-e2b5f39557ae" xlink:to="loc_us-gaap_RetainedEarningsMember_31d6d8d0-99c0-4a71-a4e9-a3bb25db24d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ef074bc4-0a4b-4dfb-9fd3-5fc992f8d5de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0a4f62d0-ef5a-406e-9f0f-75a73fd1e39d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ef074bc4-0a4b-4dfb-9fd3-5fc992f8d5de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ef074bc4-0a4b-4dfb-9fd3-5fc992f8d5de_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ef074bc4-0a4b-4dfb-9fd3-5fc992f8d5de" xlink:to="loc_us-gaap_ClassOfStockDomain_ef074bc4-0a4b-4dfb-9fd3-5fc992f8d5de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_112c0cff-552a-4126-8a25-ee27b2b27911" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ef074bc4-0a4b-4dfb-9fd3-5fc992f8d5de" xlink:to="loc_us-gaap_ClassOfStockDomain_112c0cff-552a-4126-8a25-ee27b2b27911" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CommonStockAndPrefundedWarrantsInFinancingMember_3c63b352-d924-4c2a-842b-1d26195e249c" xlink:href="ck0001824293-20250630.xsd#ck0001824293_CommonStockAndPrefundedWarrantsInFinancingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_112c0cff-552a-4126-8a25-ee27b2b27911" xlink:to="loc_ck0001824293_CommonStockAndPrefundedWarrantsInFinancingMember_3c63b352-d924-4c2a-842b-1d26195e249c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CommonStockOtherMember_36cb83eb-7a47-4a9d-adab-979349b9233b" xlink:href="ck0001824293-20250630.xsd#ck0001824293_CommonStockOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_112c0cff-552a-4126-8a25-ee27b2b27911" xlink:to="loc_ck0001824293_CommonStockOtherMember_36cb83eb-7a47-4a9d-adab-979349b9233b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ddb9923e-e429-41cc-902d-d9fb278c84ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ecc842bb-7dd1-4f47-a5a5-dc7af1be05aa" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ddb9923e-e429-41cc-902d-d9fb278c84ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9f19587f-85ce-4884-88ea-c93cf2263461" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ddb9923e-e429-41cc-902d-d9fb278c84ad" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9f19587f-85ce-4884-88ea-c93cf2263461" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_de5b7e92-c31c-443c-ad07-28da3d8bb86f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ddb9923e-e429-41cc-902d-d9fb278c84ad" xlink:to="loc_us-gaap_StockholdersEquity_de5b7e92-c31c-443c-ad07-28da3d8bb86f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_92254254-9689-4795-a27f-feb914377ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ddb9923e-e429-41cc-902d-d9fb278c84ad" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_92254254-9689-4795-a27f-feb914377ff4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment_a8c4f6ff-b377-4785-8849-db5db08fbf3f" xlink:href="ck0001824293-20250630.xsd#ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ddb9923e-e429-41cc-902d-d9fb278c84ad" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment_a8c4f6ff-b377-4785-8849-db5db08fbf3f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueFractionalShareAdjustment_77e75e71-bd64-4596-bba9-8931c861102b" xlink:href="ck0001824293-20250630.xsd#ck0001824293_StockIssuedDuringPeriodValueFractionalShareAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ddb9923e-e429-41cc-902d-d9fb278c84ad" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodValueFractionalShareAdjustment_77e75e71-bd64-4596-bba9-8931c861102b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e452905c-4845-4a7f-98e6-950e9eef469b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ddb9923e-e429-41cc-902d-d9fb278c84ad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e452905c-4845-4a7f-98e6-950e9eef469b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_05665425-656d-413e-bb21-a521488f7629" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ddb9923e-e429-41cc-902d-d9fb278c84ad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_05665425-656d-413e-bb21-a521488f7629" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise_bd31d3a4-edf8-41fe-baa0-e209dfe0aa49" xlink:href="ck0001824293-20250630.xsd#ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ddb9923e-e429-41cc-902d-d9fb278c84ad" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise_bd31d3a4-edf8-41fe-baa0-e209dfe0aa49" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f78d7124-dc09-4560-90c0-e1d36115ce05" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ddb9923e-e429-41cc-902d-d9fb278c84ad" xlink:to="loc_us-gaap_NetIncomeLoss_f78d7124-dc09-4560-90c0-e1d36115ce05" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c9d91761-3c30-47de-815f-3aed0374b93b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b466974d-7ebf-4867-844a-5976c690e588" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4787d7f6-57b6-4cd1-8acf-e1f01e8946b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1f8a8aea-d6bc-456b-9ebc-94fea5e2552a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4787d7f6-57b6-4cd1-8acf-e1f01e8946b3" xlink:to="loc_us-gaap_StatementTable_1f8a8aea-d6bc-456b-9ebc-94fea5e2552a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1b064b6c-3705-446d-b7ff-2c61107dcf78" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1f8a8aea-d6bc-456b-9ebc-94fea5e2552a" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1b064b6c-3705-446d-b7ff-2c61107dcf78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1b064b6c-3705-446d-b7ff-2c61107dcf78_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1b064b6c-3705-446d-b7ff-2c61107dcf78" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1b064b6c-3705-446d-b7ff-2c61107dcf78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1e0619a3-2334-4e70-a066-55b822827b97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1b064b6c-3705-446d-b7ff-2c61107dcf78" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1e0619a3-2334-4e70-a066-55b822827b97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ThroughFinancingMember_d38e16a9-38f5-4f7e-bfdd-2286bc9f9c79" xlink:href="ck0001824293-20250630.xsd#ck0001824293_ThroughFinancingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1e0619a3-2334-4e70-a066-55b822827b97" xlink:to="loc_ck0001824293_ThroughFinancingMember_d38e16a9-38f5-4f7e-bfdd-2286bc9f9c79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AtTheMarketOfferingMember_dee98848-acf8-4e14-8a8d-1c9cf2abd3a2" xlink:href="ck0001824293-20250630.xsd#ck0001824293_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1e0619a3-2334-4e70-a066-55b822827b97" xlink:to="loc_ck0001824293_AtTheMarketOfferingMember_dee98848-acf8-4e14-8a8d-1c9cf2abd3a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d3f65d71-e571-44e9-b02b-e878c1b8abd8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4787d7f6-57b6-4cd1-8acf-e1f01e8946b3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d3f65d71-e571-44e9-b02b-e878c1b8abd8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_87044ea8-6388-4c94-83fe-2e21f874a7c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d3f65d71-e571-44e9-b02b-e878c1b8abd8" xlink:to="loc_us-gaap_NetIncomeLoss_87044ea8-6388-4c94-83fe-2e21f874a7c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2db0c234-1519-43a5-b6a2-faaba65e1187" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d3f65d71-e571-44e9-b02b-e878c1b8abd8" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2db0c234-1519-43a5-b6a2-faaba65e1187" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_b1b5cc97-9275-475a-8253-a00f8c78b067" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2db0c234-1519-43a5-b6a2-faaba65e1187" xlink:to="loc_us-gaap_Depreciation_b1b5cc97-9275-475a-8253-a00f8c78b067" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_aad9b696-d8da-4377-a9f5-4561a90819f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2db0c234-1519-43a5-b6a2-faaba65e1187" xlink:to="loc_us-gaap_ShareBasedCompensation_aad9b696-d8da-4377-a9f5-4561a90819f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_9dea3116-6ad7-4cae-b2a9-301651b9a41a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2db0c234-1519-43a5-b6a2-faaba65e1187" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_9dea3116-6ad7-4cae-b2a9-301651b9a41a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_515b93bd-ca1b-44e5-a1f4-36f1e1ca7622" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2db0c234-1519-43a5-b6a2-faaba65e1187" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_515b93bd-ca1b-44e5-a1f4-36f1e1ca7622" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition_e0dbd746-d62b-4545-bf39-33f2e69bfb51" xlink:href="ck0001824293-20250630.xsd#ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2db0c234-1519-43a5-b6a2-faaba65e1187" xlink:to="loc_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition_e0dbd746-d62b-4545-bf39-33f2e69bfb51" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1861b92b-e99d-4d4b-8cae-e180d01e6eae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2db0c234-1519-43a5-b6a2-faaba65e1187" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1861b92b-e99d-4d4b-8cae-e180d01e6eae" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_50ccbb20-dfa5-4ab0-a282-61627a10b75c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1861b92b-e99d-4d4b-8cae-e180d01e6eae" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_50ccbb20-dfa5-4ab0-a282-61627a10b75c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4210a54d-bdf4-4527-ba14-16f163091bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1861b92b-e99d-4d4b-8cae-e180d01e6eae" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4210a54d-bdf4-4527-ba14-16f163091bf6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_9c830b62-5139-4094-ac7a-0bfe5a15c151" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1861b92b-e99d-4d4b-8cae-e180d01e6eae" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_9c830b62-5139-4094-ac7a-0bfe5a15c151" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_1a36a382-afe6-4e70-9ce8-b0d84fa7adf1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1861b92b-e99d-4d4b-8cae-e180d01e6eae" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_1a36a382-afe6-4e70-9ce8-b0d84fa7adf1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c5d5b0f8-718a-4ae4-b73e-10805b67d21d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d3f65d71-e571-44e9-b02b-e878c1b8abd8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c5d5b0f8-718a-4ae4-b73e-10805b67d21d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8685f9fc-58d0-43bd-acc7-baa5149e5d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4787d7f6-57b6-4cd1-8acf-e1f01e8946b3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8685f9fc-58d0-43bd-acc7-baa5149e5d2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_89ef934c-68ff-4c45-a1ec-df4fc24fa25e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8685f9fc-58d0-43bd-acc7-baa5149e5d2c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_89ef934c-68ff-4c45-a1ec-df4fc24fa25e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PaymentForFractionalSharesReverseStockSplit_2cec79bc-9907-4b5a-b289-2a041af71cc6" xlink:href="ck0001824293-20250630.xsd#ck0001824293_PaymentForFractionalSharesReverseStockSplit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8685f9fc-58d0-43bd-acc7-baa5149e5d2c" xlink:to="loc_ck0001824293_PaymentForFractionalSharesReverseStockSplit_2cec79bc-9907-4b5a-b289-2a041af71cc6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_576ccbc2-d6a2-4df9-9e6b-574f8612c7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8685f9fc-58d0-43bd-acc7-baa5149e5d2c" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_576ccbc2-d6a2-4df9-9e6b-574f8612c7a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_071cc2c5-b69a-4837-bc15-2a1343765b45" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8685f9fc-58d0-43bd-acc7-baa5149e5d2c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_071cc2c5-b69a-4837-bc15-2a1343765b45" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a6371fb6-0471-4cca-896d-dccacc1d1579" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4787d7f6-57b6-4cd1-8acf-e1f01e8946b3" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a6371fb6-0471-4cca-896d-dccacc1d1579" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2b1b2048-de72-48e5-9604-16564600fecd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4787d7f6-57b6-4cd1-8acf-e1f01e8946b3" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2b1b2048-de72-48e5-9604-16564600fecd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_07f5a878-7549-431d-9409-78e2394a825f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_280e888a-ab4f-4cba-a00d-8bd4902025c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4787d7f6-57b6-4cd1-8acf-e1f01e8946b3" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_280e888a-ab4f-4cba-a00d-8bd4902025c8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid_b3183231-9636-4f40-8ca3-bcdc34e650e4" xlink:href="ck0001824293-20250630.xsd#ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_280e888a-ab4f-4cba-a00d-8bd4902025c8" xlink:to="loc_ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid_b3183231-9636-4f40-8ca3-bcdc34e650e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsIssued_68ef293f-6df0-479d-b774-982218327cd1" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_280e888a-ab4f-4cba-a00d-8bd4902025c8" xlink:to="loc_ck0001824293_WarrantsIssued_68ef293f-6df0-479d-b774-982218327cd1" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/LIQUIDITYDetails" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#LIQUIDITYDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/LIQUIDITYDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_b9d5748e-3e5d-4d07-ae87-0bda67aa9ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_eab5c4ef-0c7d-4517-93cd-4c7a47dac747" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9d5748e-3e5d-4d07-ae87-0bda67aa9ac5" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_eab5c4ef-0c7d-4517-93cd-4c7a47dac747" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_a52c66b0-de4c-4448-be58-b9f8f9923e71" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_eab5c4ef-0c7d-4517-93cd-4c7a47dac747" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_a52c66b0-de4c-4448-be58-b9f8f9923e71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a52c66b0-de4c-4448-be58-b9f8f9923e71_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a52c66b0-de4c-4448-be58-b9f8f9923e71" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a52c66b0-de4c-4448-be58-b9f8f9923e71_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a6639e37-dd70-4631-a724-33654bcf525a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a52c66b0-de4c-4448-be58-b9f8f9923e71" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a6639e37-dd70-4631-a724-33654bcf525a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PublicOfferingMember_59c7ed0e-50e8-404d-ab94-21227927b177" xlink:href="ck0001824293-20250630.xsd#ck0001824293_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a6639e37-dd70-4631-a724-33654bcf525a" xlink:to="loc_ck0001824293_PublicOfferingMember_59c7ed0e-50e8-404d-ab94-21227927b177" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AtTheMarketOfferingMember_395eed49-5d5a-4dc3-92ba-ada4fb3af72d" xlink:href="ck0001824293-20250630.xsd#ck0001824293_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a6639e37-dd70-4631-a724-33654bcf525a" xlink:to="loc_ck0001824293_AtTheMarketOfferingMember_395eed49-5d5a-4dc3-92ba-ada4fb3af72d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PublicOfferingsMember_8cdbc554-bc2b-44ca-aa0e-e47d9f88cc39" xlink:href="ck0001824293-20250630.xsd#ck0001824293_PublicOfferingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a6639e37-dd70-4631-a724-33654bcf525a" xlink:to="loc_ck0001824293_PublicOfferingsMember_8cdbc554-bc2b-44ca-aa0e-e47d9f88cc39" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0a8fefa9-4231-4e88-baea-d746ec1e2073" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_eab5c4ef-0c7d-4517-93cd-4c7a47dac747" xlink:to="loc_srt_RangeAxis_0a8fefa9-4231-4e88-baea-d746ec1e2073" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0a8fefa9-4231-4e88-baea-d746ec1e2073_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0a8fefa9-4231-4e88-baea-d746ec1e2073" xlink:to="loc_srt_RangeMember_0a8fefa9-4231-4e88-baea-d746ec1e2073_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_09ab51df-c3b9-4ba1-9719-7392e0a90488" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0a8fefa9-4231-4e88-baea-d746ec1e2073" xlink:to="loc_srt_RangeMember_09ab51df-c3b9-4ba1-9719-7392e0a90488" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_4bd080b4-e82c-4b25-9a3e-56ea3c3dcb4c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_09ab51df-c3b9-4ba1-9719-7392e0a90488" xlink:to="loc_srt_WeightedAverageMember_4bd080b4-e82c-4b25-9a3e-56ea3c3dcb4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_fe624655-e68c-42fc-a91c-e13ec8e3864c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_eab5c4ef-0c7d-4517-93cd-4c7a47dac747" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_fe624655-e68c-42fc-a91c-e13ec8e3864c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_fe624655-e68c-42fc-a91c-e13ec8e3864c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_fe624655-e68c-42fc-a91c-e13ec8e3864c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_fe624655-e68c-42fc-a91c-e13ec8e3864c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_7cc24151-5924-48ba-8f42-643ae1fd481a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_fe624655-e68c-42fc-a91c-e13ec8e3864c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_7cc24151-5924-48ba-8f42-643ae1fd481a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesBCommonWarrantsMember_525be305-f928-4f50-982f-ebd74757b63f" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SeriesBCommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7cc24151-5924-48ba-8f42-643ae1fd481a" xlink:to="loc_ck0001824293_SeriesBCommonWarrantsMember_525be305-f928-4f50-982f-ebd74757b63f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f551bb06-295b-44fb-a98e-57fd817c9dec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9d5748e-3e5d-4d07-ae87-0bda67aa9ac5" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f551bb06-295b-44fb-a98e-57fd817c9dec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_977b76a7-9cf0-4b75-b36b-098eff9acbbd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9d5748e-3e5d-4d07-ae87-0bda67aa9ac5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_977b76a7-9cf0-4b75-b36b-098eff9acbbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_282e4333-47bd-41ef-8069-c1b223bff11e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9d5748e-3e5d-4d07-ae87-0bda67aa9ac5" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_282e4333-47bd-41ef-8069-c1b223bff11e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_c0a87688-9fe6-40fa-b1c3-449cd6596f5b" xlink:href="ck0001824293-20250630.xsd#ck0001824293_StockIssuanceCostsOfferingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9d5748e-3e5d-4d07-ae87-0bda67aa9ac5" xlink:to="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_c0a87688-9fe6-40fa-b1c3-449cd6596f5b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockMaximumValueOfSharesOffered_15785aa1-33fa-4881-a881-deb650307810" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SaleOfStockMaximumValueOfSharesOffered"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9d5748e-3e5d-4d07-ae87-0bda67aa9ac5" xlink:to="loc_ck0001824293_SaleOfStockMaximumValueOfSharesOffered_15785aa1-33fa-4881-a881-deb650307810" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockAgentCompensationPercentage_d7988fbb-59ec-4a51-863a-b1357cda1070" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SaleOfStockAgentCompensationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9d5748e-3e5d-4d07-ae87-0bda67aa9ac5" xlink:to="loc_ck0001824293_SaleOfStockAgentCompensationPercentage_d7988fbb-59ec-4a51-863a-b1357cda1070" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_492149f2-ec55-49f3-85d2-7e4d79f4bb33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9d5748e-3e5d-4d07-ae87-0bda67aa9ac5" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_492149f2-ec55-49f3-85d2-7e4d79f4bb33" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_7e289c2f-9488-407d-ab96-544da3a8b05d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9d5748e-3e5d-4d07-ae87-0bda67aa9ac5" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_7e289c2f-9488-407d-ab96-544da3a8b05d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_3606246e-dfa1-4cc4-877c-6c43fb7065e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9d5748e-3e5d-4d07-ae87-0bda67aa9ac5" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_3606246e-dfa1-4cc4-877c-6c43fb7065e9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ClassOfWarrantsOrRightAgentFeesAndOfferingExpense_15c31875-2a34-40bf-8e67-77c63205a6d7" xlink:href="ck0001824293-20250630.xsd#ck0001824293_ClassOfWarrantsOrRightAgentFeesAndOfferingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9d5748e-3e5d-4d07-ae87-0bda67aa9ac5" xlink:to="loc_ck0001824293_ClassOfWarrantsOrRightAgentFeesAndOfferingExpense_15c31875-2a34-40bf-8e67-77c63205a6d7" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_543cdebc-2052-4e66-bf9e-eb8fd06bbc26" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9ba3471a-9692-4ace-a409-3fc58c43e77b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_543cdebc-2052-4e66-bf9e-eb8fd06bbc26" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9ba3471a-9692-4ace-a409-3fc58c43e77b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6fe91bde-0b3f-4c9b-b132-478f32640830" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9ba3471a-9692-4ace-a409-3fc58c43e77b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6fe91bde-0b3f-4c9b-b132-478f32640830" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6fe91bde-0b3f-4c9b-b132-478f32640830_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6fe91bde-0b3f-4c9b-b132-478f32640830" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6fe91bde-0b3f-4c9b-b132-478f32640830_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6b0d8a85-8471-4239-83b3-8a007c983481" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6fe91bde-0b3f-4c9b-b132-478f32640830" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6b0d8a85-8471-4239-83b3-8a007c983481" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1321c49c-7424-48d4-a676-916614d501dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6b0d8a85-8471-4239-83b3-8a007c983481" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1321c49c-7424-48d4-a676-916614d501dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_721f8150-da0f-442f-932a-e07ef7572000" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6b0d8a85-8471-4239-83b3-8a007c983481" xlink:to="loc_us-gaap_WarrantMember_721f8150-da0f-442f-932a-e07ef7572000" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8ffed15c-ee03-4ff0-8c5d-2032247f982c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_543cdebc-2052-4e66-bf9e-eb8fd06bbc26" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8ffed15c-ee03-4ff0-8c5d-2032247f982c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2ff26815-13be-4858-a1d1-4c8268e9afcd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0657fae6-986d-4b23-a37d-3605c5abc913" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2ff26815-13be-4858-a1d1-4c8268e9afcd" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0657fae6-986d-4b23-a37d-3605c5abc913" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_70830ed0-2608-47ba-b8ce-f9b5c7462f94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0657fae6-986d-4b23-a37d-3605c5abc913" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_70830ed0-2608-47ba-b8ce-f9b5c7462f94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_70830ed0-2608-47ba-b8ce-f9b5c7462f94_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_70830ed0-2608-47ba-b8ce-f9b5c7462f94" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_70830ed0-2608-47ba-b8ce-f9b5c7462f94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_eb223681-9c5d-4d6a-b430-4da236586bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_70830ed0-2608-47ba-b8ce-f9b5c7462f94" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_eb223681-9c5d-4d6a-b430-4da236586bb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_8ff34d4f-ab7c-4cf4-877a-b1d089d62c05" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_eb223681-9c5d-4d6a-b430-4da236586bb7" xlink:to="loc_us-gaap_ComputerEquipmentMember_8ff34d4f-ab7c-4cf4-877a-b1d089d62c05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_414cf147-d083-4325-bfd1-bf31f00ab456" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_eb223681-9c5d-4d6a-b430-4da236586bb7" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_414cf147-d083-4325-bfd1-bf31f00ab456" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_9cf8e9a0-3418-46f6-91f7-0c833f8887f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2ff26815-13be-4858-a1d1-4c8268e9afcd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_9cf8e9a0-3418-46f6-91f7-0c833f8887f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b2ba2889-7a9d-44af-b6f3-eb4b163f49da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2ff26815-13be-4858-a1d1-4c8268e9afcd" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b2ba2889-7a9d-44af-b6f3-eb4b163f49da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f7123f16-6558-472f-8ea6-1ae4aaec8d61" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2ff26815-13be-4858-a1d1-4c8268e9afcd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f7123f16-6558-472f-8ea6-1ae4aaec8d61" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#STOCKHOLDERSEQUITYNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_54f54d33-b27d-4f2e-b82c-9a351dcd2c18" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_54f54d33-b27d-4f2e-b82c-9a351dcd2c18" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_0797dc32-06b7-4828-8692-e744059c0c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_54f54d33-b27d-4f2e-b82c-9a351dcd2c18" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_0797dc32-06b7-4828-8692-e744059c0c9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0797dc32-06b7-4828-8692-e744059c0c9a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_0797dc32-06b7-4828-8692-e744059c0c9a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0797dc32-06b7-4828-8692-e744059c0c9a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0a72c619-65a8-404d-8d80-b0eec086f19b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_0797dc32-06b7-4828-8692-e744059c0c9a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0a72c619-65a8-404d-8d80-b0eec086f19b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PublicOfferingMember_0ac741dd-fb30-46ad-b58f-d87b489656d4" xlink:href="ck0001824293-20250630.xsd#ck0001824293_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0a72c619-65a8-404d-8d80-b0eec086f19b" xlink:to="loc_ck0001824293_PublicOfferingMember_0ac741dd-fb30-46ad-b58f-d87b489656d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AtTheMarketOfferingMember_68463b33-4b0b-4f35-949a-a615f80c0a63" xlink:href="ck0001824293-20250630.xsd#ck0001824293_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0a72c619-65a8-404d-8d80-b0eec086f19b" xlink:to="loc_ck0001824293_AtTheMarketOfferingMember_68463b33-4b0b-4f35-949a-a615f80c0a63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_b7474201-8024-467e-a72a-d420619d2cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_54f54d33-b27d-4f2e-b82c-9a351dcd2c18" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_b7474201-8024-467e-a72a-d420619d2cf8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_b7474201-8024-467e-a72a-d420619d2cf8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_b7474201-8024-467e-a72a-d420619d2cf8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_b7474201-8024-467e-a72a-d420619d2cf8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_ecb12587-dde4-4ed0-842a-0bc963d7a2d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_b7474201-8024-467e-a72a-d420619d2cf8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_ecb12587-dde4-4ed0-842a-0bc963d7a2d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PreFundedWarrantsMember_c45d4549-28f4-416f-8a13-c460c82726de" xlink:href="ck0001824293-20250630.xsd#ck0001824293_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ecb12587-dde4-4ed0-842a-0bc963d7a2d1" xlink:to="loc_ck0001824293_PreFundedWarrantsMember_c45d4549-28f4-416f-8a13-c460c82726de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesBCommonWarrantsMember_f7918634-394a-4bc8-b623-13fb20bfd3ca" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SeriesBCommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ecb12587-dde4-4ed0-842a-0bc963d7a2d1" xlink:to="loc_ck0001824293_SeriesBCommonWarrantsMember_f7918634-394a-4bc8-b623-13fb20bfd3ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesB1CommonWarrantsMember_a4a5c285-1585-4937-a13b-5a3b6ffe68cb" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SeriesB1CommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ck0001824293_SeriesBCommonWarrantsMember_f7918634-394a-4bc8-b623-13fb20bfd3ca" xlink:to="loc_ck0001824293_SeriesB1CommonWarrantsMember_a4a5c285-1585-4937-a13b-5a3b6ffe68cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesB2CommonWarrantsMember_053a6bef-4d0a-4883-a84e-c4068f9af2c0" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SeriesB2CommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ck0001824293_SeriesBCommonWarrantsMember_f7918634-394a-4bc8-b623-13fb20bfd3ca" xlink:to="loc_ck0001824293_SeriesB2CommonWarrantsMember_053a6bef-4d0a-4883-a84e-c4068f9af2c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesA1WarrantsMember_9dcb0d7f-d85b-47fa-99b6-4f7d5a030a55" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SeriesA1WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ecb12587-dde4-4ed0-842a-0bc963d7a2d1" xlink:to="loc_ck0001824293_SeriesA1WarrantsMember_9dcb0d7f-d85b-47fa-99b6-4f7d5a030a55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesC1CommonWarrantsMember_760ffc83-8653-487b-9118-d9cda02951b0" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SeriesC1CommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ecb12587-dde4-4ed0-842a-0bc963d7a2d1" xlink:to="loc_ck0001824293_SeriesC1CommonWarrantsMember_760ffc83-8653-487b-9118-d9cda02951b0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesC2CommonWarrantsMember_b9b75110-b6a9-4ada-be22-50691a1af79d" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SeriesC2CommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ecb12587-dde4-4ed0-842a-0bc963d7a2d1" xlink:to="loc_ck0001824293_SeriesC2CommonWarrantsMember_b9b75110-b6a9-4ada-be22-50691a1af79d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PreFundedAndSeriesCWarrantsMember_573b3d49-fa31-4cd3-bd77-34a5988c9de3" xlink:href="ck0001824293-20250630.xsd#ck0001824293_PreFundedAndSeriesCWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ecb12587-dde4-4ed0-842a-0bc963d7a2d1" xlink:to="loc_ck0001824293_PreFundedAndSeriesCWarrantsMember_573b3d49-fa31-4cd3-bd77-34a5988c9de3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_June2024PAWarrantsMember_a9b78bb2-173a-4e67-b00d-35e96a5a4ed9" xlink:href="ck0001824293-20250630.xsd#ck0001824293_June2024PAWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ecb12587-dde4-4ed0-842a-0bc963d7a2d1" xlink:to="loc_ck0001824293_June2024PAWarrantsMember_a9b78bb2-173a-4e67-b00d-35e96a5a4ed9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesDWarrantsMember_0d99db38-5bd4-49ce-ab8b-1fbcea3eb7ea" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SeriesDWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ecb12587-dde4-4ed0-842a-0bc963d7a2d1" xlink:to="loc_ck0001824293_SeriesDWarrantsMember_0d99db38-5bd4-49ce-ab8b-1fbcea3eb7ea" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesD1WarrantsMember_a2fa0a80-0f88-4534-8542-cb48090516e2" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SeriesD1WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ck0001824293_SeriesDWarrantsMember_0d99db38-5bd4-49ce-ab8b-1fbcea3eb7ea" xlink:to="loc_ck0001824293_SeriesD1WarrantsMember_a2fa0a80-0f88-4534-8542-cb48090516e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesD2WarrantsMember_79f62e8f-2f7e-4f93-ac1d-c957f8854501" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SeriesD2WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ck0001824293_SeriesDWarrantsMember_0d99db38-5bd4-49ce-ab8b-1fbcea3eb7ea" xlink:to="loc_ck0001824293_SeriesD2WarrantsMember_79f62e8f-2f7e-4f93-ac1d-c957f8854501" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_October2024PAWarrantsMember_55acee36-674e-478a-9172-740bcf9d8868" xlink:href="ck0001824293-20250630.xsd#ck0001824293_October2024PAWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ecb12587-dde4-4ed0-842a-0bc963d7a2d1" xlink:to="loc_ck0001824293_October2024PAWarrantsMember_55acee36-674e-478a-9172-740bcf9d8868" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesE1CommonWarrantsMember_bb594b59-fa1f-49c4-ae58-a93e78f348a5" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SeriesE1CommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ecb12587-dde4-4ed0-842a-0bc963d7a2d1" xlink:to="loc_ck0001824293_SeriesE1CommonWarrantsMember_bb594b59-fa1f-49c4-ae58-a93e78f348a5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesE2CommonWarrantsMember_597d5266-092d-4da7-84c0-89f773dfbd94" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SeriesE2CommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ecb12587-dde4-4ed0-842a-0bc963d7a2d1" xlink:to="loc_ck0001824293_SeriesE2CommonWarrantsMember_597d5266-092d-4da7-84c0-89f773dfbd94" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesE3CommonWarrantsMember_8e373114-dcfa-45a0-aa28-810f225b4804" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SeriesE3CommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ecb12587-dde4-4ed0-842a-0bc963d7a2d1" xlink:to="loc_ck0001824293_SeriesE3CommonWarrantsMember_8e373114-dcfa-45a0-aa28-810f225b4804" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesECommonWarrantMember_e9397a51-c21c-491f-9ff4-739858a6f3fc" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SeriesECommonWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ecb12587-dde4-4ed0-842a-0bc963d7a2d1" xlink:to="loc_ck0001824293_SeriesECommonWarrantMember_e9397a51-c21c-491f-9ff4-739858a6f3fc" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_April2025PAWarrantsMember_f5871f50-3cc7-4f62-b586-dfff34e43af2" xlink:href="ck0001824293-20250630.xsd#ck0001824293_April2025PAWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ecb12587-dde4-4ed0-842a-0bc963d7a2d1" xlink:to="loc_ck0001824293_April2025PAWarrantsMember_f5871f50-3cc7-4f62-b586-dfff34e43af2" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b1d460a4-7ab6-4d6e-a6e6-9196ac3402f7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_54f54d33-b27d-4f2e-b82c-9a351dcd2c18" xlink:to="loc_srt_RangeAxis_b1d460a4-7ab6-4d6e-a6e6-9196ac3402f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b1d460a4-7ab6-4d6e-a6e6-9196ac3402f7_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b1d460a4-7ab6-4d6e-a6e6-9196ac3402f7" xlink:to="loc_srt_RangeMember_b1d460a4-7ab6-4d6e-a6e6-9196ac3402f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_56ef76e2-2f4f-45ec-b47b-7552241c342c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b1d460a4-7ab6-4d6e-a6e6-9196ac3402f7" xlink:to="loc_srt_RangeMember_56ef76e2-2f4f-45ec-b47b-7552241c342c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_34381a95-5808-45d7-92ae-8f69a5db09b3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_56ef76e2-2f4f-45ec-b47b-7552241c342c" xlink:to="loc_srt_WeightedAverageMember_34381a95-5808-45d7-92ae-8f69a5db09b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_21148ad2-fa44-4b24-a0f6-2cc2af2b8f9d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_56ef76e2-2f4f-45ec-b47b-7552241c342c" xlink:to="loc_srt_MaximumMember_21148ad2-fa44-4b24-a0f6-2cc2af2b8f9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_c37ea21c-691d-4798-a8bd-abb49a380ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_c37ea21c-691d-4798-a8bd-abb49a380ed7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6759bc91-38ba-404f-a3df-a625ce65871e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6759bc91-38ba-404f-a3df-a625ce65871e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_06c9f71d-a7ca-44f9-ae66-24ce77207da2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_06c9f71d-a7ca-44f9-ae66-24ce77207da2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_834208e4-9b7a-443e-8bcf-07641dce30cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_834208e4-9b7a-443e-8bcf-07641dce30cc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_16ea3cf7-4c9f-42c5-87e8-96e5672e0771" xlink:href="ck0001824293-20250630.xsd#ck0001824293_StockIssuanceCostsOfferingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:to="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_16ea3cf7-4c9f-42c5-87e8-96e5672e0771" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction_6d379ac9-faf5-46f3-9486-c877539586fa" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:to="loc_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction_6d379ac9-faf5-46f3-9486-c877539586fa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_210ef656-b49f-466a-8a82-a9adaf2bdf69" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_210ef656-b49f-466a-8a82-a9adaf2bdf69" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_34aa8850-98d5-4b7b-be4a-dde5ae95c23e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_34aa8850-98d5-4b7b-be4a-dde5ae95c23e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_e99dd744-492c-492d-93cc-84813ab36b75" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_e99dd744-492c-492d-93cc-84813ab36b75" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_12453193-f7c5-4025-b121-e79dbd05b486" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_12453193-f7c5-4025-b121-e79dbd05b486" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_1cc7e94b-c6ac-449a-af0a-50be50f9973b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_1cc7e94b-c6ac-449a-af0a-50be50f9973b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockMaximumValueOfSharesOffered_7e69a8ca-6235-4355-a712-7ff39fee5f98" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SaleOfStockMaximumValueOfSharesOffered"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:to="loc_ck0001824293_SaleOfStockMaximumValueOfSharesOffered_7e69a8ca-6235-4355-a712-7ff39fee5f98" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockAgentCompensationPercentage_ef7f90e0-951a-4d76-81fb-c83a67379d61" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SaleOfStockAgentCompensationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:to="loc_ck0001824293_SaleOfStockAgentCompensationPercentage_ef7f90e0-951a-4d76-81fb-c83a67379d61" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_59e14906-7ca1-43e8-a1cc-4bd36e541f77" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_59e14906-7ca1-43e8-a1cc-4bd36e541f77" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds_b84bf33d-4041-489e-a18d-ef8a47ec7ef7" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:to="loc_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds_b84bf33d-4041-489e-a18d-ef8a47ec7ef7" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds_e12fad4c-ebf0-4b41-ab14-1df482132f37" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:to="loc_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds_e12fad4c-ebf0-4b41-ab14-1df482132f37" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses_76097c4b-42ce-4c67-89fb-738cd3bcb27f" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SaleOfStockReimbursementOfAccountableExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:to="loc_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses_76097c4b-42ce-4c67-89fb-738cd3bcb27f" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses_77f6a894-2e22-4d50-9e34-229b645aa148" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:to="loc_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses_77f6a894-2e22-4d50-9e34-229b645aa148" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense_d890a8ec-0258-4ce9-ac5d-d62b6f6cfb33" xlink:href="ck0001824293-20250630.xsd#ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:to="loc_ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense_d890a8ec-0258-4ce9-ac5d-d62b6f6cfb33" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ClassOfWarrantOrRightOfferingCost_c13d82a3-5890-4d45-8c52-6c736a59d758" xlink:href="ck0001824293-20250630.xsd#ck0001824293_ClassOfWarrantOrRightOfferingCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:to="loc_ck0001824293_ClassOfWarrantOrRightOfferingCost_c13d82a3-5890-4d45-8c52-6c736a59d758" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_133617d9-06b5-4661-88ad-d8b5cf19bb55" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_133617d9-06b5-4661-88ad-d8b5cf19bb55" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses_4caa0f49-0acc-49ff-94ac-5a78daf3d946" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:to="loc_ck0001824293_SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses_4caa0f49-0acc-49ff-94ac-5a78daf3d946" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockClearingExpenses_a7a47bf5-f0ad-4b4c-bcf1-c6a26908c119" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SaleOfStockClearingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:to="loc_ck0001824293_SaleOfStockClearingExpenses_a7a47bf5-f0ad-4b4c-bcf1-c6a26908c119" xlink:type="arc" order="22"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_7892a359-56b9-4d3f-af5a-b89ef5227bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_d720841e-7a89-46a9-870f-4da6bd16884d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_7892a359-56b9-4d3f-af5a-b89ef5227bf7" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_d720841e-7a89-46a9-870f-4da6bd16884d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_45b1798c-857c-424d-90e6-6be30ce42ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d720841e-7a89-46a9-870f-4da6bd16884d" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_45b1798c-857c-424d-90e6-6be30ce42ff9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_45b1798c-857c-424d-90e6-6be30ce42ff9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_45b1798c-857c-424d-90e6-6be30ce42ff9" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_45b1798c-857c-424d-90e6-6be30ce42ff9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_e9a90f08-9478-48ce-8ca9-6eb5850f7454" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_45b1798c-857c-424d-90e6-6be30ce42ff9" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_e9a90f08-9478-48ce-8ca9-6eb5850f7454" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember_b18f5631-61a0-433f-8b03-1311dd03e613" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputOptionVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_e9a90f08-9478-48ce-8ca9-6eb5850f7454" xlink:to="loc_us-gaap_MeasurementInputOptionVolatilityMember_b18f5631-61a0-433f-8b03-1311dd03e613" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_e90c2e58-69b5-48d4-95a6-345d70481c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_e9a90f08-9478-48ce-8ca9-6eb5850f7454" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_e90c2e58-69b5-48d4-95a6-345d70481c5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_ccadac89-b402-4ede-bb5e-e3bcb9003740" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_e9a90f08-9478-48ce-8ca9-6eb5850f7454" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_ccadac89-b402-4ede-bb5e-e3bcb9003740" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_7c6382d5-6245-4243-8039-e4a3842729c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_e9a90f08-9478-48ce-8ca9-6eb5850f7454" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_7c6382d5-6245-4243-8039-e4a3842729c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_aa0a16fd-95e9-4f39-b141-a6de23934017" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d720841e-7a89-46a9-870f-4da6bd16884d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_aa0a16fd-95e9-4f39-b141-a6de23934017" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_aa0a16fd-95e9-4f39-b141-a6de23934017_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_aa0a16fd-95e9-4f39-b141-a6de23934017" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_aa0a16fd-95e9-4f39-b141-a6de23934017_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_95f7a7d8-f255-4f51-ab62-79d7fbe25b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_aa0a16fd-95e9-4f39-b141-a6de23934017" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_95f7a7d8-f255-4f51-ab62-79d7fbe25b0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesECommonWarrantsAndApril2025PAWarrantsMember_9d5fc306-2e94-475c-a1b7-b5931aa8560a" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SeriesECommonWarrantsAndApril2025PAWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_95f7a7d8-f255-4f51-ab62-79d7fbe25b0c" xlink:to="loc_ck0001824293_SeriesECommonWarrantsAndApril2025PAWarrantsMember_9d5fc306-2e94-475c-a1b7-b5931aa8560a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_7551edc4-7b7e-4767-8e4b-598678d9d45c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7892a359-56b9-4d3f-af5a-b89ef5227bf7" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_7551edc4-7b7e-4767-8e4b-598678d9d45c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_9358c0c0-977d-499b-aca7-71b9c77f3fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_f5c07a95-9d10-4de5-a512-372f751a49f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_9358c0c0-977d-499b-aca7-71b9c77f3fb7" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_f5c07a95-9d10-4de5-a512-372f751a49f0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_2ae52d6b-994e-4386-8264-62c077d57b53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f5c07a95-9d10-4de5-a512-372f751a49f0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_2ae52d6b-994e-4386-8264-62c077d57b53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_2ae52d6b-994e-4386-8264-62c077d57b53_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2ae52d6b-994e-4386-8264-62c077d57b53" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_2ae52d6b-994e-4386-8264-62c077d57b53_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_ed84f39c-8cb5-45a8-b108-dbf26687b61b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2ae52d6b-994e-4386-8264-62c077d57b53" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_ed84f39c-8cb5-45a8-b108-dbf26687b61b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInAugust2025Member_a1b6e84e-ee58-4bee-a775-7d53bc834f6b" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsExpiringInAugust2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ed84f39c-8cb5-45a8-b108-dbf26687b61b" xlink:to="loc_ck0001824293_WarrantsExpiringInAugust2025Member_a1b6e84e-ee58-4bee-a775-7d53bc834f6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInJanuary2026Member_924afc1e-54eb-40a1-a213-31dcbe6db5ae" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsExpiringInJanuary2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ed84f39c-8cb5-45a8-b108-dbf26687b61b" xlink:to="loc_ck0001824293_WarrantsExpiringInJanuary2026Member_924afc1e-54eb-40a1-a213-31dcbe6db5ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInFebruary2026Member_82f48073-5bbe-4fc8-bb1e-aa319e7bd256" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsExpiringInFebruary2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ed84f39c-8cb5-45a8-b108-dbf26687b61b" xlink:to="loc_ck0001824293_WarrantsExpiringInFebruary2026Member_82f48073-5bbe-4fc8-bb1e-aa319e7bd256" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInMarch2026Member_572d18db-e39a-41c3-9929-cc03f0c5d33e" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsExpiringInMarch2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ed84f39c-8cb5-45a8-b108-dbf26687b61b" xlink:to="loc_ck0001824293_WarrantsExpiringInMarch2026Member_572d18db-e39a-41c3-9929-cc03f0c5d33e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInApril2026Member_423c0718-27f0-4739-ba57-17df9552ba32" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsExpiringInApril2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ed84f39c-8cb5-45a8-b108-dbf26687b61b" xlink:to="loc_ck0001824293_WarrantsExpiringInApril2026Member_423c0718-27f0-4739-ba57-17df9552ba32" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInOctober2026Member_d633c1db-e9e3-48cf-9932-bbb4dd74d673" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsExpiringInOctober2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ed84f39c-8cb5-45a8-b108-dbf26687b61b" xlink:to="loc_ck0001824293_WarrantsExpiringInOctober2026Member_d633c1db-e9e3-48cf-9932-bbb4dd74d673" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInMay2027Member_8e781d7f-2d67-4436-9bc9-51722c307703" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsExpiringInMay2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ed84f39c-8cb5-45a8-b108-dbf26687b61b" xlink:to="loc_ck0001824293_WarrantsExpiringInMay2027Member_8e781d7f-2d67-4436-9bc9-51722c307703" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInJuly2027Member_d6afd618-b81f-4e5a-8523-3fc84d4eeed4" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsExpiringInJuly2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ed84f39c-8cb5-45a8-b108-dbf26687b61b" xlink:to="loc_ck0001824293_WarrantsExpiringInJuly2027Member_d6afd618-b81f-4e5a-8523-3fc84d4eeed4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInApril2028Member_f2085efa-fca3-496e-841c-14af4ba1208b" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsExpiringInApril2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ed84f39c-8cb5-45a8-b108-dbf26687b61b" xlink:to="loc_ck0001824293_WarrantsExpiringInApril2028Member_f2085efa-fca3-496e-841c-14af4ba1208b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInFebruary2029Member_b305603b-f07b-4ede-9f39-43f0aefde18b" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsExpiringInFebruary2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ed84f39c-8cb5-45a8-b108-dbf26687b61b" xlink:to="loc_ck0001824293_WarrantsExpiringInFebruary2029Member_b305603b-f07b-4ede-9f39-43f0aefde18b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInJune2029Member_8c0db434-fc16-418d-95b4-5121c62e770f" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsExpiringInJune2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ed84f39c-8cb5-45a8-b108-dbf26687b61b" xlink:to="loc_ck0001824293_WarrantsExpiringInJune2029Member_8c0db434-fc16-418d-95b4-5121c62e770f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInSeptember2029Member_9ec0396c-3625-4ae1-917c-66e8540f4686" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsExpiringInSeptember2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ed84f39c-8cb5-45a8-b108-dbf26687b61b" xlink:to="loc_ck0001824293_WarrantsExpiringInSeptember2029Member_9ec0396c-3625-4ae1-917c-66e8540f4686" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInOctober2029OneMember_6c81a780-f96a-419b-b896-4e6b9d929d74" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsExpiringInOctober2029OneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ed84f39c-8cb5-45a8-b108-dbf26687b61b" xlink:to="loc_ck0001824293_WarrantsExpiringInOctober2029OneMember_6c81a780-f96a-419b-b896-4e6b9d929d74" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInOctober2029TwoMember_47bb9e27-9dd1-4bd9-a92e-8f0956977349" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsExpiringInOctober2029TwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ed84f39c-8cb5-45a8-b108-dbf26687b61b" xlink:to="loc_ck0001824293_WarrantsExpiringInOctober2029TwoMember_47bb9e27-9dd1-4bd9-a92e-8f0956977349" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInApril2030OneMember_8eb6b77b-d0ce-4894-a9a3-7be31686df78" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsExpiringInApril2030OneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ed84f39c-8cb5-45a8-b108-dbf26687b61b" xlink:to="loc_ck0001824293_WarrantsExpiringInApril2030OneMember_8eb6b77b-d0ce-4894-a9a3-7be31686df78" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInApril2030TwoMember_9ac831a6-d364-471e-bc9f-4f7cf390160a" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsExpiringInApril2030TwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ed84f39c-8cb5-45a8-b108-dbf26687b61b" xlink:to="loc_ck0001824293_WarrantsExpiringInApril2030TwoMember_9ac831a6-d364-471e-bc9f-4f7cf390160a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_987f5f48-85aa-415c-acde-4542e86f1280" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9358c0c0-977d-499b-aca7-71b9c77f3fb7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_987f5f48-85aa-415c-acde-4542e86f1280" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_18d1f9f2-cc84-40d3-9292-c32b848027b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_9358c0c0-977d-499b-aca7-71b9c77f3fb7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_18d1f9f2-cc84-40d3-9292-c32b848027b7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#STOCKBASEDCOMPENSATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0c0ef969-437e-4ffc-9d1c-0bac82b512cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_997f385e-bd8b-446c-984f-4c3bb334fe9b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0c0ef969-437e-4ffc-9d1c-0bac82b512cc" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_997f385e-bd8b-446c-984f-4c3bb334fe9b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_f1ebebb4-6b73-496c-a867-43b35a40a7c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_997f385e-bd8b-446c-984f-4c3bb334fe9b" xlink:to="loc_us-gaap_PlanNameAxis_f1ebebb4-6b73-496c-a867-43b35a40a7c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f1ebebb4-6b73-496c-a867-43b35a40a7c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_f1ebebb4-6b73-496c-a867-43b35a40a7c3" xlink:to="loc_us-gaap_PlanNameDomain_f1ebebb4-6b73-496c-a867-43b35a40a7c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6fcc1869-ce2a-4153-a48e-771038e8a452" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_f1ebebb4-6b73-496c-a867-43b35a40a7c3" xlink:to="loc_us-gaap_PlanNameDomain_6fcc1869-ce2a-4153-a48e-771038e8a452" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember_4feee8cb-0b87-4c46-9aa5-27a29cc2e2e6" xlink:href="ck0001824293-20250630.xsd#ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6fcc1869-ce2a-4153-a48e-771038e8a452" xlink:to="loc_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember_4feee8cb-0b87-4c46-9aa5-27a29cc2e2e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4199bb70-eb6c-4022-b467-21a4cb59cb65" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_997f385e-bd8b-446c-984f-4c3bb334fe9b" xlink:to="loc_srt_RangeAxis_4199bb70-eb6c-4022-b467-21a4cb59cb65" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4199bb70-eb6c-4022-b467-21a4cb59cb65_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4199bb70-eb6c-4022-b467-21a4cb59cb65" xlink:to="loc_srt_RangeMember_4199bb70-eb6c-4022-b467-21a4cb59cb65_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1122e202-21ce-4678-9721-6668d52c4458" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4199bb70-eb6c-4022-b467-21a4cb59cb65" xlink:to="loc_srt_RangeMember_1122e202-21ce-4678-9721-6668d52c4458" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c952d014-34b0-4780-9683-d2cad3a64844" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1122e202-21ce-4678-9721-6668d52c4458" xlink:to="loc_srt_MaximumMember_c952d014-34b0-4780-9683-d2cad3a64844" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_76ea04fc-7c1e-46ec-86c3-0e3ff8eb1950" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_997f385e-bd8b-446c-984f-4c3bb334fe9b" xlink:to="loc_us-gaap_AwardTypeAxis_76ea04fc-7c1e-46ec-86c3-0e3ff8eb1950" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76ea04fc-7c1e-46ec-86c3-0e3ff8eb1950_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_76ea04fc-7c1e-46ec-86c3-0e3ff8eb1950" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76ea04fc-7c1e-46ec-86c3-0e3ff8eb1950_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8e46cbb8-d554-4443-8ebf-ead02635dc0d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_76ea04fc-7c1e-46ec-86c3-0e3ff8eb1950" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8e46cbb8-d554-4443-8ebf-ead02635dc0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_db2153e3-6461-4cfb-a435-cc68a756a541" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8e46cbb8-d554-4443-8ebf-ead02635dc0d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_db2153e3-6461-4cfb-a435-cc68a756a541" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_544c35bb-95ee-48c6-8443-ebb5d4623068" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0c0ef969-437e-4ffc-9d1c-0bac82b512cc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_544c35bb-95ee-48c6-8443-ebb5d4623068" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4cc4ca85-95de-4dd5-81e3-17e3ec8d8251" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0c0ef969-437e-4ffc-9d1c-0bac82b512cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4cc4ca85-95de-4dd5-81e3-17e3ec8d8251" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b0607e69-a97f-469b-818e-fe889ae43617" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0c0ef969-437e-4ffc-9d1c-0bac82b512cc" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b0607e69-a97f-469b-818e-fe889ae43617" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum_c3a1d58f-3b0c-4054-b46c-359f5c34797a" xlink:href="ck0001824293-20250630.xsd#ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0c0ef969-437e-4ffc-9d1c-0bac82b512cc" xlink:to="loc_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum_c3a1d58f-3b0c-4054-b46c-359f5c34797a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e1043246-9d7c-4a78-a0d3-169251b3e3a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0c0ef969-437e-4ffc-9d1c-0bac82b512cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e1043246-9d7c-4a78-a0d3-169251b3e3a3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_89cfc33c-b43e-4a76-9a6d-847e2f95dd55" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0c0ef969-437e-4ffc-9d1c-0bac82b512cc" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_89cfc33c-b43e-4a76-9a6d-847e2f95dd55" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_be04871d-90be-4bae-9f59-404b2ee2c0a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0c0ef969-437e-4ffc-9d1c-0bac82b512cc" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_be04871d-90be-4bae-9f59-404b2ee2c0a8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3d39698a-fb86-45c9-a70e-1b3de3057ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0c0ef969-437e-4ffc-9d1c-0bac82b512cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3d39698a-fb86-45c9-a70e-1b3de3057ea1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_90eadbff-0643-41cd-9c5a-bd575a421a49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0c0ef969-437e-4ffc-9d1c-0bac82b512cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_90eadbff-0643-41cd-9c5a-bd575a421a49" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d2bdf903-5377-41a8-b781-fc8c2bc9b3b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f37969f7-0e29-4e4a-8fbd-b6d30d0abd9c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d2bdf903-5377-41a8-b781-fc8c2bc9b3b2" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f37969f7-0e29-4e4a-8fbd-b6d30d0abd9c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6c0b43fc-4a49-4e4a-b943-fa09af6e7640" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f37969f7-0e29-4e4a-8fbd-b6d30d0abd9c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6c0b43fc-4a49-4e4a-b943-fa09af6e7640" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6c0b43fc-4a49-4e4a-b943-fa09af6e7640_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6c0b43fc-4a49-4e4a-b943-fa09af6e7640" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6c0b43fc-4a49-4e4a-b943-fa09af6e7640_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9bdf10f7-e3bc-49fb-9dc3-1cc1be2fc816" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6c0b43fc-4a49-4e4a-b943-fa09af6e7640" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9bdf10f7-e3bc-49fb-9dc3-1cc1be2fc816" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e97a21ac-d569-40fc-b251-7278bb1c65f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9bdf10f7-e3bc-49fb-9dc3-1cc1be2fc816" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e97a21ac-d569-40fc-b251-7278bb1c65f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_b1ef0503-061f-4b8b-a29f-ad27a5db13fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9bdf10f7-e3bc-49fb-9dc3-1cc1be2fc816" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_b1ef0503-061f-4b8b-a29f-ad27a5db13fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_ddb3731d-6a18-46ba-9682-20208a8ebd5b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d2bdf903-5377-41a8-b781-fc8c2bc9b3b2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_ddb3731d-6a18-46ba-9682-20208a8ebd5b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7586e510-2e3e-4f3d-a5f2-adb09ac5d816" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40cbd760-36ee-42d3-bdac-3a304cd2b42b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7586e510-2e3e-4f3d-a5f2-adb09ac5d816" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40cbd760-36ee-42d3-bdac-3a304cd2b42b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c96a2ada-d911-43e9-b372-5a748c3eba1d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40cbd760-36ee-42d3-bdac-3a304cd2b42b" xlink:to="loc_us-gaap_AwardTypeAxis_c96a2ada-d911-43e9-b372-5a748c3eba1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c96a2ada-d911-43e9-b372-5a748c3eba1d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c96a2ada-d911-43e9-b372-5a748c3eba1d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c96a2ada-d911-43e9-b372-5a748c3eba1d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f1ac4525-46a7-49cc-9d2c-b274fc0f23ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c96a2ada-d911-43e9-b372-5a748c3eba1d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f1ac4525-46a7-49cc-9d2c-b274fc0f23ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_61f053e7-ed7d-47c8-9db8-a9c761a7423a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f1ac4525-46a7-49cc-9d2c-b274fc0f23ee" xlink:to="loc_us-gaap_EmployeeStockOptionMember_61f053e7-ed7d-47c8-9db8-a9c761a7423a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1131aca8-bfd4-460a-a075-ae3f6a11ea14" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7586e510-2e3e-4f3d-a5f2-adb09ac5d816" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1131aca8-bfd4-460a-a075-ae3f6a11ea14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_272c6252-e3b7-4bab-8b50-1ce5360922b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7586e510-2e3e-4f3d-a5f2-adb09ac5d816" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_272c6252-e3b7-4bab-8b50-1ce5360922b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f4426e86-a2f3-4b55-b569-8bc081cb0a73" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7586e510-2e3e-4f3d-a5f2-adb09ac5d816" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f4426e86-a2f3-4b55-b569-8bc081cb0a73" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_112adb28-314c-4d61-9544-7fd55692570f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7586e510-2e3e-4f3d-a5f2-adb09ac5d816" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_112adb28-314c-4d61-9544-7fd55692570f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_2d114dee-f58c-4c1c-a92d-446285ebf3f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7586e510-2e3e-4f3d-a5f2-adb09ac5d816" xlink:to="loc_us-gaap_SharePrice_2d114dee-f58c-4c1c-a92d-446285ebf3f3" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_0a755d28-06e5-4e31-ba7b-b1a353e69d92" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_d919134a-8031-4bc9-8d0c-4d0d4faf96d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_0a755d28-06e5-4e31-ba7b-b1a353e69d92" xlink:to="loc_us-gaap_LossContingenciesTable_d919134a-8031-4bc9-8d0c-4d0d4faf96d8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_b43fceb9-d305-42dc-a3a4-df2680c96725" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_d919134a-8031-4bc9-8d0c-4d0d4faf96d8" xlink:to="loc_srt_TitleOfIndividualAxis_b43fceb9-d305-42dc-a3a4-df2680c96725" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b43fceb9-d305-42dc-a3a4-df2680c96725_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_b43fceb9-d305-42dc-a3a4-df2680c96725" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b43fceb9-d305-42dc-a3a4-df2680c96725_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6e3ccb98-2ee3-43ab-b9fe-96063d8037ef" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_b43fceb9-d305-42dc-a3a4-df2680c96725" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6e3ccb98-2ee3-43ab-b9fe-96063d8037ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_FormerChiefExecutiveOfficerMember_449985e1-6dc6-4ea0-ba97-e00c56eba611" xlink:href="ck0001824293-20250630.xsd#ck0001824293_FormerChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6e3ccb98-2ee3-43ab-b9fe-96063d8037ef" xlink:to="loc_ck0001824293_FormerChiefExecutiveOfficerMember_449985e1-6dc6-4ea0-ba97-e00c56eba611" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_COBRABenefitsPaymentPeriod_a46ea572-65b3-498d-a275-befcc1d0f94d" xlink:href="ck0001824293-20250630.xsd#ck0001824293_COBRABenefitsPaymentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_0a755d28-06e5-4e31-ba7b-b1a353e69d92" xlink:to="loc_ck0001824293_COBRABenefitsPaymentPeriod_a46ea572-65b3-498d-a275-befcc1d0f94d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PercentageOfTargetBonus_09ff05ab-c450-478d-8d0a-8ed7bd354886" xlink:href="ck0001824293-20250630.xsd#ck0001824293_PercentageOfTargetBonus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_0a755d28-06e5-4e31-ba7b-b1a353e69d92" xlink:to="loc_ck0001824293_PercentageOfTargetBonus_09ff05ab-c450-478d-8d0a-8ed7bd354886" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>ck0001824293-20250630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:63feccd5-3134-497b-93bb-cd3b539b0c1f,g:6dd00c0f-69b4-4831-9595-c67011349d66-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_ck0001824293_SeriesECommonWarrantsAndApril2025PAWarrantsMember_77f779a9-2798-4e51-9900-d0e4cb31022e_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesECommonWarrantsAndApril2025PAWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series E Common Warrants and April 2025 PA Warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesECommonWarrantsAndApril2025PAWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesECommonWarrantsAndApril2025PAWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series E Common Warrants And April 2025 PA Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesECommonWarrantsAndApril2025PAWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesECommonWarrantsAndApril2025PAWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series E Common Warrants And April 2025 PA Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesECommonWarrantsAndApril2025PAWarrantsMember" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SeriesECommonWarrantsAndApril2025PAWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesECommonWarrantsAndApril2025PAWarrantsMember" xlink:to="lab_ck0001824293_SeriesECommonWarrantsAndApril2025PAWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_ba9c47fd-c520-434e-87a3-4cb89bd53688_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_cac03e42-89a3-419c-bc66-790d9f3f056b_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesD1WarrantsMember_0dec1025-1650-4ef3-98cd-74b2f7bbf83d_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesD1WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series D-1 Warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesD1WarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesD1WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series D-1 Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesD1WarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesD1WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series D-1 Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesD1WarrantsMember" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SeriesD1WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesD1WarrantsMember" xlink:to="lab_ck0001824293_SeriesD1WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_ddf13bc1-5aae-476b-9a70-b13dafcaad84_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional&#160; Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ClassOfWarrantOrRightOfferingCost_1122ddb8-1875-4136-8fbb-72016e1f3cee_terseLabel_en-US" xlink:label="lab_ck0001824293_ClassOfWarrantOrRightOfferingCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right, offering cost</link:label>
    <link:label id="lab_ck0001824293_ClassOfWarrantOrRightOfferingCost_label_en-US" xlink:label="lab_ck0001824293_ClassOfWarrantOrRightOfferingCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Offering Cost</link:label>
    <link:label id="lab_ck0001824293_ClassOfWarrantOrRightOfferingCost_documentation_en-US" xlink:label="lab_ck0001824293_ClassOfWarrantOrRightOfferingCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Offering Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ClassOfWarrantOrRightOfferingCost" xlink:href="ck0001824293-20250630.xsd#ck0001824293_ClassOfWarrantOrRightOfferingCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ClassOfWarrantOrRightOfferingCost" xlink:to="lab_ck0001824293_ClassOfWarrantOrRightOfferingCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_587863b8-90a4-42d4-a354-f0901c0ccf1c_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_3153e499-ed99-49b7-a23c-9796a63462a6_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesB2CommonWarrantsMember_df3c5f06-e253-436d-91c4-484b7c8a4a20_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesB2CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series B-2 Common Warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesB2CommonWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesB2CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series B-2 Common Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesB2CommonWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesB2CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series B-2 Common Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesB2CommonWarrantsMember" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SeriesB2CommonWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesB2CommonWarrantsMember" xlink:to="lab_ck0001824293_SeriesB2CommonWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_01d4eeb7-ee60-41c8-bf00-41ea43f7c29c_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_76ed119f-6044-4f54-859d-a5777aca7a8a_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_fd29e434-b62c-4e99-814e-b43cd7fe5e8b_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of Shares (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_384a40fd-9a26-434c-b6aa-1082d3a8b2e8_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share of common stock, basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_43dc9522-4e64-409d-9529-cae192858bb0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common shares reserved for future awards (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueFractionalShareAdjustment_87109c1d-3dd2-47de-8357-16bc10dc2855_negatedTerseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueFractionalShareAdjustment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Fractional share adjustment</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueFractionalShareAdjustment_label_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueFractionalShareAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Fractional Share Adjustment</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueFractionalShareAdjustment_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueFractionalShareAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Fractional Share Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueFractionalShareAdjustment" xlink:href="ck0001824293-20250630.xsd#ck0001824293_StockIssuedDuringPeriodValueFractionalShareAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedDuringPeriodValueFractionalShareAdjustment" xlink:to="lab_ck0001824293_StockIssuedDuringPeriodValueFractionalShareAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_cc2107b7-2bcd-458a-b956-4a2e2381d9d4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_969c4b44-6147-4b39-a3da-2ca0a426f2d9_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_bb2fc910-f298-4813-a018-b524cc6a06c8_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_6e5d930b-7651-4d42-a5b3-a2ce29ce53b5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInSeptember2029Member_1aac98b9-e2c3-411f-b18f-4a72e43f94a9_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInSeptember2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In September 2029</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInSeptember2029Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInSeptember2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In September 2029 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInSeptember2029Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInSeptember2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In September 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInSeptember2029Member" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsExpiringInSeptember2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInSeptember2029Member" xlink:to="lab_ck0001824293_WarrantsExpiringInSeptember2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_bfe86c9f-135b-4784-88d7-aa77a584af06_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_aee1a272-33ed-4d34-a204-d886fec70a3c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_68164239-11dc-4b8f-84de-1af68ef268ee_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_64684a80-e7a5-40f5-85bc-735eeeffb1b8_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_fb469e8e-a3d1-4824-8303-6ced29d31951_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_30837c7d-c3b1-449c-8507-bd6510acedc8_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_dd5cba10-259a-480b-86a2-c8fc745213a0_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_8b804472-dbd2-4ea5-917d-9005fbbddd94_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_55d1c613-ba6e-4ce4-b810-cf34ec329779_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_b237d472-c5a0-473b-8a39-094e3111a9db_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8eeeeff0-afa2-4d28-a16c-1f4f68e9d513_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock and prefunded warrants in financing (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_c032a887-3b7a-436d-b23f-9637faa1f013_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3a497253-5c92-4a38-ae22-8a5cb8afa500_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited/cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_b6e2730e-c44f-486d-b817-cb3c6742b47b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8c5ba06f-4f78-4983-944a-9b32047faf59_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_94000c8c-281e-4cb9-bf83-2bf642266ecb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_50cc12ef-8314-43ff-918d-8b77d708abfe_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_30fdff02-011c-4a5c-b974-82338dbc5ccf_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_df962bef-a7cf-4113-8507-9abc2622534a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Exercisable, Ending balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_f3ecf4a3-1619-4fa6-b677-a9fb1c13064d_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInApril2028Member_c7f31570-06cd-400c-98ac-ea1bb7659790_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInApril2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In April 2028</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInApril2028Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInApril2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In April 2028 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInApril2028Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInApril2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In April 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInApril2028Member" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsExpiringInApril2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInApril2028Member" xlink:to="lab_ck0001824293_WarrantsExpiringInApril2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3d3f15e2-72a6-433a-a4a6-1f887ad8bff0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInApril2030TwoMember_b7b69d52-40be-4013-b652-1ddda55d5e73_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInApril2030TwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In April 2030, Two</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInApril2030TwoMember_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInApril2030TwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In April 2030, Two [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInApril2030TwoMember_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInApril2030TwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In April 2030, Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInApril2030TwoMember" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsExpiringInApril2030TwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInApril2030TwoMember" xlink:to="lab_ck0001824293_WarrantsExpiringInApril2030TwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_1a966d64-298c-45af-acc2-c0d78e3357de_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_3707afe1-54c9-4cf7-94b0-26af3f92e78f_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_33a08363-750c-40e9-8d5b-0fa371a2a3bc_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_39d98ab6-975a-4b81-b45f-a62b338b6c44_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_32962d82-497b-4c7c-b35f-5a5e19dd9655_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_a327c33a-d26e-4a63-b92a-e6c4a4151c51_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_393ee1e0-f036-4348-8497-74c028e2d475_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInApril2026Member_23a96b6f-fbb7-4673-92ca-192de464be41_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInApril2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In April 2026</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInApril2026Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInApril2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In April 2026 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInApril2026Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInApril2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In April 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInApril2026Member" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsExpiringInApril2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInApril2026Member" xlink:to="lab_ck0001824293_WarrantsExpiringInApril2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_4bf69def-92fe-4fa0-83c6-145326d2c0cb_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_6444f806-2b33-4cea-b357-4012c63bed70_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_9b62e6f1-b02a-43ae-b664-fb7c49919945_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_3ee48e59-9e70-400a-8fc8-0e41b0d9c301_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_PublicOfferingsMember_f67245f4-0e93-410a-bf5e-b6f5abd99dc8_terseLabel_en-US" xlink:label="lab_ck0001824293_PublicOfferingsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Public offerings</link:label>
    <link:label id="lab_ck0001824293_PublicOfferingsMember_label_en-US" xlink:label="lab_ck0001824293_PublicOfferingsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Public offerings [Member]</link:label>
    <link:label id="lab_ck0001824293_PublicOfferingsMember_documentation_en-US" xlink:label="lab_ck0001824293_PublicOfferingsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Public offerings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PublicOfferingsMember" xlink:href="ck0001824293-20250630.xsd#ck0001824293_PublicOfferingsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_PublicOfferingsMember" xlink:to="lab_ck0001824293_PublicOfferingsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_7c556691-0e45-4219-93cb-8421c15b6e62_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_bf68b4c6-ae19-4224-b5a4-42dafa42b4ea_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_1262757c-89cd-40e2-a2de-f0f16844d4e6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_704ea0b1-82d5-40fb-a173-bc5f3f9806d6_terseLabel_en-US" xlink:label="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_label_en-US" xlink:label="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Research And Development Costs, Current</link:label>
    <link:label id="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_documentation_en-US" xlink:label="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Research And Development Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:href="ck0001824293-20250630.xsd#ck0001824293_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:to="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_f6abcb50-6a0d-4b04-ac19-8d750a704b37_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_b0e3f284-4611-4d85-986b-2243901c8f06_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_beaf0535-95c7-4daf-8b4c-559ad9cde256_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_61ce9424-9422-4787-87bf-1db350d30f74_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3f7b3f25-0f40-43ff-9644-56fd4f8f306b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment_d7788a6e-14b1-46c0-8d01-db6c9bb19101_negatedLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Fractional share adjustment (in shares)</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment_label_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Fractional Share Adjustment</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Fractional Share Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment" xlink:href="ck0001824293-20250630.xsd#ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment" xlink:to="lab_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid_9e719114-365f-44f4-9757-0fac7d3cc6c5_terseLabel_en-US" xlink:label="lab_ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred stock issuance costs in accounts payable and accrued expenses</link:label>
    <link:label id="lab_ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid_label_en-US" xlink:label="lab_ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs And Financing Costs Incurred But Not Yet Paid</link:label>
    <link:label id="lab_ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid_documentation_en-US" xlink:label="lab_ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs And Financing Costs Incurred But Not Yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid" xlink:href="ck0001824293-20250630.xsd#ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid" xlink:to="lab_ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_8bad6626-d696-43a2-910c-b13c9acf3773_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_fc69391f-e993-46b6-bf53-ddaf2a1c496e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_72fd1d93-86ad-4a85-83d4-6b5ac6adbcd9_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_b5d4704a-b8a9-42a1-8b9b-a6bd095d9e90_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrant liability</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_b5e5d789-5346-4884-8e27-cf93b41b56d2_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_PercentageOfTargetBonus_d79fdd98-316a-4432-9454-bf813a0b041f_terseLabel_en-US" xlink:label="lab_ck0001824293_PercentageOfTargetBonus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of target bonus</link:label>
    <link:label id="lab_ck0001824293_PercentageOfTargetBonus_label_en-US" xlink:label="lab_ck0001824293_PercentageOfTargetBonus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Target Bonus</link:label>
    <link:label id="lab_ck0001824293_PercentageOfTargetBonus_documentation_en-US" xlink:label="lab_ck0001824293_PercentageOfTargetBonus" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Of Target Bonus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PercentageOfTargetBonus" xlink:href="ck0001824293-20250630.xsd#ck0001824293_PercentageOfTargetBonus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_PercentageOfTargetBonus" xlink:to="lab_ck0001824293_PercentageOfTargetBonus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e2c77fca-cc98-43eb-b014-35de5c45dab8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_16287896-7c95-47f4-8ae0-3eaa3de2dd1c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesD2WarrantsMember_4ba2abab-f963-437c-9943-8f8d895035df_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesD2WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series D-2 Warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesD2WarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesD2WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series D-2 Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesD2WarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesD2WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series D-2 Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesD2WarrantsMember" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SeriesD2WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesD2WarrantsMember" xlink:to="lab_ck0001824293_SeriesD2WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_8cc86434-d79c-430e-a520-ce1f284b523c_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0eb00ec6-edd8-4c62-a4b6-23aa59527447_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_d053039b-f396-429d-97b4-b19918703e35_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_98553257-7d90-4ce7-9694-58e77e6f835a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4ad180e8-fd99-4a9c-8279-955035b1e5ae_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b80dafcb-068e-440e-9d2d-513194b5cde2_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_13a7a34c-97bd-4039-8662-acf574e99935_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_bc0a70ad-1070-4b4d-bb98-d04a291655d1_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_b2c6f8ed-3332-4c84-bba6-faf1c4ee931e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_96a96bdd-1e9a-4c04-9b34-adc38123c903_terseLabel_en-US" xlink:label="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_label_en-US" xlink:label="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued General And Administrative Expenses, Current</link:label>
    <link:label id="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_documentation_en-US" xlink:label="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued General And Administrative Expenses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:href="ck0001824293-20250630.xsd#ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:to="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_PreFundedWarrantsMember_fef7a500-7081-426c-b892-2eaaeafdf031_terseLabel_en-US" xlink:label="lab_ck0001824293_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrants</link:label>
    <link:label id="lab_ck0001824293_PreFundedWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_PreFundedWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PreFundedWarrantsMember" xlink:href="ck0001824293-20250630.xsd#ck0001824293_PreFundedWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_PreFundedWarrantsMember" xlink:to="lab_ck0001824293_PreFundedWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_08942e47-4baa-4100-8f63-c4b2041bf2b6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_df85b1f9-b9dc-4efd-8037-d5c6780d487f_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_ea03377d-d2a8-49b8-9667-15e05e935657_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_993bf2c0-7200-4902-8dd2-8fa647bcc75f_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_3de12f1b-558c-498d-8cb8-495eaf2024da_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_CommonStockAndPrefundedWarrantsInFinancingMember_c7dcc465-4060-474f-bc34-02061b271f66_terseLabel_en-US" xlink:label="lab_ck0001824293_CommonStockAndPrefundedWarrantsInFinancingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock and prefunded warrants in financing</link:label>
    <link:label id="lab_ck0001824293_CommonStockAndPrefundedWarrantsInFinancingMember_label_en-US" xlink:label="lab_ck0001824293_CommonStockAndPrefundedWarrantsInFinancingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock And Prefunded Warrants In Financing [Member]</link:label>
    <link:label id="lab_ck0001824293_CommonStockAndPrefundedWarrantsInFinancingMember_documentation_en-US" xlink:label="lab_ck0001824293_CommonStockAndPrefundedWarrantsInFinancingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock And Prefunded Warrants In Financing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CommonStockAndPrefundedWarrantsInFinancingMember" xlink:href="ck0001824293-20250630.xsd#ck0001824293_CommonStockAndPrefundedWarrantsInFinancingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_CommonStockAndPrefundedWarrantsInFinancingMember" xlink:to="lab_ck0001824293_CommonStockAndPrefundedWarrantsInFinancingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_d21ea8ef-bcb8-48ff-9697-dac9c03d6a5c_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_5df998ae-acd9-4d3e-9064-1da79fdc6298_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_4977e5a9-6f8e-4531-9488-bfbe76eba415_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesDWarrantsMember_24622823-2e83-433b-8a61-20c09353ee42_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesDWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series D Warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesDWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesDWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series D Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesDWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesDWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series D Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesDWarrantsMember" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SeriesDWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesDWarrantsMember" xlink:to="lab_ck0001824293_SeriesDWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_d0869a6e-4597-4891-a7c3-2de3a082cc3e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInJanuary2026Member_a511c8bb-8b55-4693-a2f5-b3d03f710f45_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInJanuary2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In January 2026</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInJanuary2026Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInJanuary2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In January 2026 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInJanuary2026Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInJanuary2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In January 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInJanuary2026Member" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsExpiringInJanuary2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInJanuary2026Member" xlink:to="lab_ck0001824293_WarrantsExpiringInJanuary2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_5aacd372-a7ab-47bf-8084-b20a9f74055f_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_3e5b0bf6-6608-4739-bb1c-ab86261c1c9c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_4d0b117d-4a39-4728-b787-d4ab884a29f5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_36741378-346b-4da0-a983-66d635908d95_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_e740aa04-f729-4426-85ab-7b0beb6b09ba_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum_83a85bca-0bb1-4e4b-8c9a-ae642329f836_terseLabel_en-US" xlink:label="lab_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum increase in shares reserved for issuance as a percentage of aggregate common stock outstanding</link:label>
    <link:label id="lab_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum_label_en-US" xlink:label="lab_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Increase In Shares Reserved For Issuance As Percentage Of Aggregate Common Stock Outstanding, Maximum</link:label>
    <link:label id="lab_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum_documentation_en-US" xlink:label="lab_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Increase In Shares Reserved For Issuance As Percentage Of Aggregate Common Stock Outstanding, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum" xlink:href="ck0001824293-20250630.xsd#ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum" xlink:to="lab_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_ca97e511-8793-4e76-8cb3-8a79db6810aa_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ORGANIZATION AND DESCRIPTION OF BUSINESS</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_3d14e450-d7c0-48f5-966b-6cd1ca5b53c8_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise_9f0b1ebe-acd5-4a97-a876-c75bbf765603_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prefunded warrant exercise (in shares)</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise_label_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Warrant Exercise</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Warrant Exercise</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise" xlink:href="ck0001824293-20250630.xsd#ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise" xlink:to="lab_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_410a2838-d5f4-43c2-ac30-b34a5cefe300_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, outstanding term</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_6fc2e6d0-d139-4f11-9662-dcb85701df74_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of non-cash financing activities:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0c5eba59-b134-4068-bcea-3ffa4d1576fd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_4017349e-d252-41ed-80be-1f8aad86ed7f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_bdab8cf0-761a-4404-a352-652aa3257584_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_0fd35403-3db9-4e51-b934-67b906dff7d7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_October2024PAWarrantsMember_c5ac2c66-ea74-42e2-9f3a-0f63685422d9_terseLabel_en-US" xlink:label="lab_ck0001824293_October2024PAWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">October 2024 PA Warrants</link:label>
    <link:label id="lab_ck0001824293_October2024PAWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_October2024PAWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">October 2024 PA Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_October2024PAWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_October2024PAWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">October 2024 PA Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_October2024PAWarrantsMember" xlink:href="ck0001824293-20250630.xsd#ck0001824293_October2024PAWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_October2024PAWarrantsMember" xlink:to="lab_ck0001824293_October2024PAWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_f86cd1c3-fac5-4918-b94c-98f418fa3dd8_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesBCommonWarrantsMember_cc19a12a-cf06-4d67-9f4c-3c3952105c91_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesBCommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series B Common Warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesBCommonWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesBCommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series B Common Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesBCommonWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesBCommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series B Common Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesBCommonWarrantsMember" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SeriesBCommonWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesBCommonWarrantsMember" xlink:to="lab_ck0001824293_SeriesBCommonWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SaleOfStockMaximumValueOfSharesOffered_774eeb83-6301-44ed-856a-2d50ff191329_terseLabel_en-US" xlink:label="lab_ck0001824293_SaleOfStockMaximumValueOfSharesOffered" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, maximum value of shares offered</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockMaximumValueOfSharesOffered_label_en-US" xlink:label="lab_ck0001824293_SaleOfStockMaximumValueOfSharesOffered" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Maximum Value Of Shares Offered</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockMaximumValueOfSharesOffered_documentation_en-US" xlink:label="lab_ck0001824293_SaleOfStockMaximumValueOfSharesOffered" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Maximum Value Of Shares Offered</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockMaximumValueOfSharesOffered" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SaleOfStockMaximumValueOfSharesOffered"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SaleOfStockMaximumValueOfSharesOffered" xlink:to="lab_ck0001824293_SaleOfStockMaximumValueOfSharesOffered" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_824aa449-6b51-4e03-b60d-e7c8f897efd5_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_36ce0937-7ec6-4594-9971-431b20a8702d_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_April2025PAWarrantsMember_44c24a5d-f087-4140-b831-19629a86ebf6_terseLabel_en-US" xlink:label="lab_ck0001824293_April2025PAWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">April 2025 PA Warrants</link:label>
    <link:label id="lab_ck0001824293_April2025PAWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_April2025PAWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">April 2025 PA Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_April2025PAWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_April2025PAWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">April 2025 PA Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_April2025PAWarrantsMember" xlink:href="ck0001824293-20250630.xsd#ck0001824293_April2025PAWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_April2025PAWarrantsMember" xlink:to="lab_ck0001824293_April2025PAWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_dc792128-ef44-4bbd-8d67-b3933794ac05_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_c14afd26-8b41-45b5-928b-3b4344c28e94_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Accounting</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_3e82b0da-851d-4577-9c46-7c2be0a04de2_terseLabel_en-US" xlink:label="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIQUIDITY</link:label>
    <link:label id="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_label_en-US" xlink:label="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Substantial Doubt about Going Concern [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_d4089326-0f64-41c6-98c1-3b63e8595c66_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_9c19166c-e990-49ee-8f8b-d2bd30f93ece_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_271ac894-3fac-4a30-92af-408b0936d590_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0e6c8dca-8887-4620-bf16-762dc4a11df1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation, weighted average amortization period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_adc1b8af-c4c6-4dcc-95a7-6feebecdaa08_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_June2024PAWarrantsMember_422f2eca-20d4-4ca5-8b41-6c9f1d8f0257_terseLabel_en-US" xlink:label="lab_ck0001824293_June2024PAWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">June 2024 PA Warrants</link:label>
    <link:label id="lab_ck0001824293_June2024PAWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_June2024PAWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">June 2024 PA Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_June2024PAWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_June2024PAWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">June 2024 PA Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_June2024PAWarrantsMember" xlink:href="ck0001824293-20250630.xsd#ck0001824293_June2024PAWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_June2024PAWarrantsMember" xlink:to="lab_ck0001824293_June2024PAWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInJuly2027Member_0d25c88a-3476-48a1-9d31-857df0fef324_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInJuly2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In July 2027</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInJuly2027Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInJuly2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In July 2027 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInJuly2027Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInJuly2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In July 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInJuly2027Member" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsExpiringInJuly2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInJuly2027Member" xlink:to="lab_ck0001824293_WarrantsExpiringInJuly2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_79318f86-93fe-44c2-b2ee-0a5769811956_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Activity of Stock Options Granted</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_2cd91695-308c-4666-ad63-e18b191eb387_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEGMENT REPORTING</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_01f0fecc-a0bf-4afc-8b37-a5bf0d2d727e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_54012db3-35ec-4e2b-b879-900c18b7eda0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_da7ed73e-6d7f-44c9-a9bb-97bed47919da_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_82f36c94-af13-4b19-9945-293e821cb572_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_b0c5a936-b7fb-4822-9d73-2bf7c623684f_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from sale of stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_33526fff-7c75-4e73-886c-a5bd3d6d1c18_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesE2CommonWarrantsMember_ecc98cdf-3eb9-4584-a9df-0c08f9318ee5_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesE2CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series E-2 Common Warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesE2CommonWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesE2CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series E-2 Common Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesE2CommonWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesE2CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series E-2 Common Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesE2CommonWarrantsMember" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SeriesE2CommonWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesE2CommonWarrantsMember" xlink:to="lab_ck0001824293_SeriesE2CommonWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9c54b27e-db13-4e66-9253-1977110a2cc8_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant exercise price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f5aafbb5-a88a-4bff-9f1e-63f4693d0eb8_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price per Share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_cdab5388-5441-48a4-a5c5-fb89e1329400_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_f01a0f64-0a3e-4e61-869f-2332be64b448_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_2ca5ab95-95db-4d70-a215-ae355205f209_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_0e23a642-d3ab-46a8-ac72-aac0cc5b1e53_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_d35f7a4d-16f4-4940-97d5-1dcb1ad587d2_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of option on grant date (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_268b5629-d6ec-4ee7-aecc-869103cf71bc_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_44084b67-cbc5-43d9-b1d3-ba3b19c7965d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_e013f79c-b66e-40d8-b1d6-e95552f23421_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_1421c86c-c40d-4752-a3bf-848d6d084276_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_3d356e1c-5683-4dc2-a1a9-62db6479b8e8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_c8364b2c-aac0-4307-92c3-20c390d2ae84_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesC1CommonWarrantsMember_1c7feb84-7866-4032-a644-9b8f0eeb1ab9_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesC1CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series C-1 Common Warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesC1CommonWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesC1CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series C-1 Common Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesC1CommonWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesC1CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series C-1 Common Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesC1CommonWarrantsMember" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SeriesC1CommonWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesC1CommonWarrantsMember" xlink:to="lab_ck0001824293_SeriesC1CommonWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_4e2a3d35-b19a-4c5f-9f16-b24d919f75da_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_1234ae01-cfb6-4495-b181-67d705a64928_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Stock Issuance Costs</link:label>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:to="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_c5db227b-6d1d-4b44-a012-ac91bf470f6d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, non-current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputOptionVolatilityMember_6a460668-afb0-45fe-9c9f-4dce3789f1da_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputOptionVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputOptionVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputOptionVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Option Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputOptionVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputOptionVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputOptionVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInOctober2029OneMember_e3ad8265-c191-4968-ac5e-534b30af932f_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInOctober2029OneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In October 2029, One</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInOctober2029OneMember_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInOctober2029OneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In October 2029, One [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInOctober2029OneMember_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInOctober2029OneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In October 2029, One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInOctober2029OneMember" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsExpiringInOctober2029OneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInOctober2029OneMember" xlink:to="lab_ck0001824293_WarrantsExpiringInOctober2029OneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_f9d63bbf-e010-49a1-ac55-ac632cad2e46_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_faca726a-0d55-4d52-ae44-60f31854bda0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from warrant exercise</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_59b2a306-0628-43fa-81c8-9ddf1807116e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity based award granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_a86d9e69-1650-4fea-923e-0b4c61e5a219_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title and Position [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_bccb8682-e41f-4b6c-a902-8883e32b05cc_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_f7203c77-e8dd-47ea-91b7-a3f740115299_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_77cdff82-45c9-4759-9875-ee5b53c78132_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of the Fair Value of the Warrants</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_9cc5c372-2b14-4997-97cc-4f27dee9d18e_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reverse stock split</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_e72f367f-3ff9-46f0-8010-ba3691e9a176_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInMay2027Member_ffee93d8-2687-4a6c-80a7-fed3c34e5ffc_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInMay2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In May 2027</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInMay2027Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInMay2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In May 2027 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInMay2027Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInMay2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In May 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInMay2027Member" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsExpiringInMay2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInMay2027Member" xlink:to="lab_ck0001824293_WarrantsExpiringInMay2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ChangeInFairValueOfWarrantLiability_750887c6-55a9-4d81-bfcf-c30a60aa94c8_terseLabel_en-US" xlink:label="lab_ck0001824293_ChangeInFairValueOfWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrant liability</link:label>
    <link:label id="lab_ck0001824293_ChangeInFairValueOfWarrantLiability_label_en-US" xlink:label="lab_ck0001824293_ChangeInFairValueOfWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value Of Warrant Liability</link:label>
    <link:label id="lab_ck0001824293_ChangeInFairValueOfWarrantLiability_documentation_en-US" xlink:label="lab_ck0001824293_ChangeInFairValueOfWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change In Fair Value Of Warrant Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ChangeInFairValueOfWarrantLiability" xlink:href="ck0001824293-20250630.xsd#ck0001824293_ChangeInFairValueOfWarrantLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ChangeInFairValueOfWarrantLiability" xlink:to="lab_ck0001824293_ChangeInFairValueOfWarrantLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_8b6d2414-5b64-41eb-b726-9e7407a7a2d6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable, intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInAugust2025Member_0d8716d7-6512-4df1-a891-6e4103193b52_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInAugust2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In August 2025</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInAugust2025Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInAugust2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In August 2025 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInAugust2025Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInAugust2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In August 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInAugust2025Member" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsExpiringInAugust2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInAugust2025Member" xlink:to="lab_ck0001824293_WarrantsExpiringInAugust2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_cfb7aa2c-5bdb-4f55-b491-8eaa0ffb3602_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c3cbb17c-165c-4d91-acff-8a0798248365_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Award Types</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_54bbf002-f300-43a4-9eea-29d3bcc9816e_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants outstanding, measurement input</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_fdd2f45d-8018-4a08-b7d2-0c55d9dac33e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c1135421-ff7c-42ff-84bb-938acb9e0fd7_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInOctober2029TwoMember_95ee9fba-2850-42bb-ad04-a7f7db37ada3_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInOctober2029TwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In October 2029, Two</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInOctober2029TwoMember_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInOctober2029TwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In October 2029, Two [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInOctober2029TwoMember_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInOctober2029TwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In October 2029, Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInOctober2029TwoMember" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsExpiringInOctober2029TwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInOctober2029TwoMember" xlink:to="lab_ck0001824293_WarrantsExpiringInOctober2029TwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_ea1f6bdf-9071-460e-95f5-61d2e56c21f5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_d3093026-9def-4f90-b8e5-5d066a891ac1_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a49629af-78e3-4854-9fc9-2f666a391c5f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_8465fcbb-a9e8-428a-a348-0a4da6245177_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses_25884d54-a3d1-4d2a-abdc-c867205754f9_terseLabel_en-US" xlink:label="lab_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reimbursement of accountable expenses</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses_label_en-US" xlink:label="lab_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Reimbursement Of Accountable Expenses</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses_documentation_en-US" xlink:label="lab_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Reimbursement Of Accountable Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SaleOfStockReimbursementOfAccountableExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses" xlink:to="lab_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_fa48c854-d4f1-475e-8eae-5ad864b753c8_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8d32a678-84db-4027-8c0e-09d14a3827f5_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_d9b35fd3-6045-4400-b05f-566c099086cf_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title and Position [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f8467ee6-d04e-40a0-9f0b-b86ffe6cc39f_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_53b9532b-8692-4c56-a8e0-11f87dd7f126_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 9)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_73dff53a-43d9-46d4-b36a-4d339fdecbfc_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_571f8e7a-dbb4-447d-b85b-4749e85f991a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of stock issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_e2eb5d75-cf98-4e6d-8fe8-507c81330bbd_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_99560c36-2af7-41df-a2f4-f894c800ec51_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants not settleable in cash, fair value disclosure</link:label>
    <link:label id="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Not Settleable in Cash, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:to="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SaleOfStockClearingExpenses_05fbc214-c979-4192-a9c1-b62e583672f3_terseLabel_en-US" xlink:label="lab_ck0001824293_SaleOfStockClearingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clearing expenses</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockClearingExpenses_label_en-US" xlink:label="lab_ck0001824293_SaleOfStockClearingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Clearing Expenses</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockClearingExpenses_documentation_en-US" xlink:label="lab_ck0001824293_SaleOfStockClearingExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Clearing Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockClearingExpenses" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SaleOfStockClearingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SaleOfStockClearingExpenses" xlink:to="lab_ck0001824293_SaleOfStockClearingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_95872890-8e9d-4fd1-8c89-c6c39f6178be_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_6a587cdb-0915-45da-b955-491b4dba3632_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_COBRABenefitsPaymentPeriod_021903d0-09e7-4fa5-bec1-02b78e28e6bd_terseLabel_en-US" xlink:label="lab_ck0001824293_COBRABenefitsPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COBRA benefits, payment period</link:label>
    <link:label id="lab_ck0001824293_COBRABenefitsPaymentPeriod_label_en-US" xlink:label="lab_ck0001824293_COBRABenefitsPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">COBRA Benefits, Payment Period</link:label>
    <link:label id="lab_ck0001824293_COBRABenefitsPaymentPeriod_documentation_en-US" xlink:label="lab_ck0001824293_COBRABenefitsPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">COBRA Benefits, Payment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_COBRABenefitsPaymentPeriod" xlink:href="ck0001824293-20250630.xsd#ck0001824293_COBRABenefitsPaymentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_COBRABenefitsPaymentPeriod" xlink:to="lab_ck0001824293_COBRABenefitsPaymentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInMarch2026Member_f05b245e-0209-4540-a41e-0248eb45ad1d_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInMarch2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In March 2026</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInMarch2026Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInMarch2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In March 2026 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInMarch2026Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInMarch2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In March 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInMarch2026Member" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsExpiringInMarch2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInMarch2026Member" xlink:to="lab_ck0001824293_WarrantsExpiringInMarch2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses_e8c2306f-e409-49a0-ac64-a0790c8882f3_terseLabel_en-US" xlink:label="lab_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reimbursement of non-accountable expenses</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses_label_en-US" xlink:label="lab_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Reimbursement Of Non-Accountable Expenses</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses_documentation_en-US" xlink:label="lab_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Reimbursement Of Non-Accountable Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses" xlink:to="lab_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f55aef0c-5e3c-4bb1-af19-578582dbfc23_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInFebruary2026Member_882166cb-48c0-4cc9-9ca8-a9cb2a5d0f58_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInFebruary2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In February 2026</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInFebruary2026Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInFebruary2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In February 2026 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInFebruary2026Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInFebruary2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In February 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInFebruary2026Member" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsExpiringInFebruary2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInFebruary2026Member" xlink:to="lab_ck0001824293_WarrantsExpiringInFebruary2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_f381f227-570f-40e4-a323-f76b2c6b698d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_40d4c556-60d1-4911-bacd-44543d0407af_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInFebruary2029Member_4e839f5c-ebba-4fe9-a045-1cb33312cb48_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In February 2029</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInFebruary2029Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In February 2029 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInFebruary2029Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In February 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInFebruary2029Member" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsExpiringInFebruary2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInFebruary2029Member" xlink:to="lab_ck0001824293_WarrantsExpiringInFebruary2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_5244f5cf-7416-427c-a880-5182d1404a6b_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_680d43cf-42c0-4db9-8f47-6bca6c044a4a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInApril2030OneMember_37d80d3f-addf-4e54-afd8-5df97ba50a90_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInApril2030OneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In April 2030, One</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInApril2030OneMember_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInApril2030OneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In April 2030, One [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInApril2030OneMember_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInApril2030OneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In April 2030, One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInApril2030OneMember" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsExpiringInApril2030OneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInApril2030OneMember" xlink:to="lab_ck0001824293_WarrantsExpiringInApril2030OneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_573b01cd-b78e-4901-be2c-c848936311b8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5d8dbdbf-5557-4a2c-8a80-d0a2c6865e90_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock awards, contractual life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_73be9fa7-a4ca-4e60-b32d-f4aa02caff94_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_b586a5dc-81ea-4b7a-9c4a-8a59b06084d6_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_d48db407-c57e-4199-b254-d16a957a8191_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5edb36d0-0866-4caa-b390-34fafe33ebea_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining contractual term&#160;(years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_7dbae92d-0013-418c-8d54-a36a8d4c6add_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_b3d837cb-80d7-4912-9bd1-8f0184e43726_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_5f816e6c-01d4-4dee-9fed-c29d74287b27_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_76caa5fd-a7cd-4745-8cbb-2846aca0a48e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_f388faad-ad3b-4d25-8597-dc4416b3e823_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share of common stock, diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_dc1b8262-7e5b-4b50-a181-0997ab778239_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuanceCostsOfferingExpenses_e522a6cb-aaa9-4a58-8e1b-53612b86cb6b_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offering expenses</link:label>
    <link:label id="lab_ck0001824293_StockIssuanceCostsOfferingExpenses_label_en-US" xlink:label="lab_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issuance Costs, Offering Expenses</link:label>
    <link:label id="lab_ck0001824293_StockIssuanceCostsOfferingExpenses_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issuance Costs, Offering Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:href="ck0001824293-20250630.xsd#ck0001824293_StockIssuanceCostsOfferingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:to="lab_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_fbe55142-ca20-463e-80fe-a6a3529f2c97_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesA1WarrantsMember_d8194d98-4500-41df-8b13-d3df901877e5_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesA1WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A-1 Warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesA1WarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesA1WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A-1 Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesA1WarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesA1WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series A-1 Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesA1WarrantsMember" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SeriesA1WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesA1WarrantsMember" xlink:to="lab_ck0001824293_SeriesA1WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds_15432a58-1865-43fe-b2bc-1da6153115df_terseLabel_en-US" xlink:label="lab_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash fee (as a percent)</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds_label_en-US" xlink:label="lab_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Aggregate Cash Fee, Percentage Of Gross Proceeds</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds_documentation_en-US" xlink:label="lab_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Aggregate Cash Fee, Percentage Of Gross Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds" xlink:to="lab_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SaleOfStockAgentCompensationPercentage_e3a64062-fe7f-4792-89e6-f9dd01d2d188_terseLabel_en-US" xlink:label="lab_ck0001824293_SaleOfStockAgentCompensationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, agent compensation, percentage</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockAgentCompensationPercentage_label_en-US" xlink:label="lab_ck0001824293_SaleOfStockAgentCompensationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Agent Compensation, Percentage</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockAgentCompensationPercentage_documentation_en-US" xlink:label="lab_ck0001824293_SaleOfStockAgentCompensationPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Agent Compensation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockAgentCompensationPercentage" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SaleOfStockAgentCompensationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SaleOfStockAgentCompensationPercentage" xlink:to="lab_ck0001824293_SaleOfStockAgentCompensationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_dae9fcc6-41f4-4a10-91d7-6abcdb254c28_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Common Stock Equivalents Excluded From Diluted Net Loss Per Share Calculation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses_b70f6fa5-94bd-4955-8575-7492f08e77df_terseLabel_en-US" xlink:label="lab_ck0001824293_SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal fees and expenses and other out of pocket expenses</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses_label_en-US" xlink:label="lab_ck0001824293_SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Legal Fees And expenses And Other Out Of Pocket Expenses</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses_documentation_en-US" xlink:label="lab_ck0001824293_SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Legal Fees And expenses And Other Out Of Pocket Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses" xlink:to="lab_ck0001824293_SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_d93b5975-e754-48b6-af33-b9bbe4bd4919_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ACCRUED EXPENSES</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ClassOfWarrantsOrRightAgentFeesAndOfferingExpense_f82e1793-d87e-4971-a6f4-3db2eb7a3e94_terseLabel_en-US" xlink:label="lab_ck0001824293_ClassOfWarrantsOrRightAgentFeesAndOfferingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Placement agent fees and offering expenses</link:label>
    <link:label id="lab_ck0001824293_ClassOfWarrantsOrRightAgentFeesAndOfferingExpense_label_en-US" xlink:label="lab_ck0001824293_ClassOfWarrantsOrRightAgentFeesAndOfferingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrants Or Right, Agent Fees and Offering Expense</link:label>
    <link:label id="lab_ck0001824293_ClassOfWarrantsOrRightAgentFeesAndOfferingExpense_documentation_en-US" xlink:label="lab_ck0001824293_ClassOfWarrantsOrRightAgentFeesAndOfferingExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrants Or Right, Agent Fees and Offering Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ClassOfWarrantsOrRightAgentFeesAndOfferingExpense" xlink:href="ck0001824293-20250630.xsd#ck0001824293_ClassOfWarrantsOrRightAgentFeesAndOfferingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ClassOfWarrantsOrRightAgentFeesAndOfferingExpense" xlink:to="lab_ck0001824293_ClassOfWarrantsOrRightAgentFeesAndOfferingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds_f0ccafbb-0716-4d0b-a602-0070f6c85d5f_terseLabel_en-US" xlink:label="lab_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Management fee (as a percent)</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds_label_en-US" xlink:label="lab_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Management Fee, Percentage Of Gross Proceeds</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds_documentation_en-US" xlink:label="lab_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Management Fee, Percentage Of Gross Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds" xlink:to="lab_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_dc744445-6a17-4ec0-af38-829c4c40c24a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a6c4f603-6dc8-4c1a-b5c1-991abcd9bd4f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_3b1860dc-ade5-4207-89af-0bb83e87588e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payroll and related</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_8c1975da-22b2-4e26-82ca-497e440410c8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_87391bb7-ae45-4e71-a7bb-6ecf4ba45651_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesB1CommonWarrantsMember_2dce4681-e9bc-429f-8097-c4eaaea7a355_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesB1CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series B-1 Common Warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesB1CommonWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesB1CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series B-1 Common Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesB1CommonWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesB1CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series B-1 Common Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesB1CommonWarrantsMember" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SeriesB1CommonWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesB1CommonWarrantsMember" xlink:to="lab_ck0001824293_SeriesB1CommonWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_890f7892-44aa-42f9-93c3-7550d0bd3aa4_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_c49c8420-18e0-4cd9-98fd-3cac2cb416d7_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_856ed590-81f8-41d6-9c7b-f38ebabb26b5_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense_326eee49-fa7d-4a4e-ab81-4c4e5745eaed_terseLabel_en-US" xlink:label="lab_ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from warrant exercise, net of offering cost</link:label>
    <link:label id="lab_ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense_label_en-US" xlink:label="lab_ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Warrant Exercises, Net Of Offering Expense</link:label>
    <link:label id="lab_ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense_documentation_en-US" xlink:label="lab_ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Warrant Exercises, Net Of Offering Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense" xlink:href="ck0001824293-20250630.xsd#ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense" xlink:to="lab_ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_FormerChiefExecutiveOfficerMember_050a78fb-4527-4d32-afde-247d2d1cc7db_terseLabel_en-US" xlink:label="lab_ck0001824293_FormerChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Former Chief Executive Officer</link:label>
    <link:label id="lab_ck0001824293_FormerChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_ck0001824293_FormerChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Former Chief Executive Officer [Member]</link:label>
    <link:label id="lab_ck0001824293_FormerChiefExecutiveOfficerMember_documentation_en-US" xlink:label="lab_ck0001824293_FormerChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Former Chief Executive Officer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_FormerChiefExecutiveOfficerMember" xlink:href="ck0001824293-20250630.xsd#ck0001824293_FormerChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_FormerChiefExecutiveOfficerMember" xlink:to="lab_ck0001824293_FormerChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_PublicOfferingMember_744d9cdc-c151-4c1c-887b-9df4d66f1335_terseLabel_en-US" xlink:label="lab_ck0001824293_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Public Offering</link:label>
    <link:label id="lab_ck0001824293_PublicOfferingMember_label_en-US" xlink:label="lab_ck0001824293_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Public Offering [Member]</link:label>
    <link:label id="lab_ck0001824293_PublicOfferingMember_documentation_en-US" xlink:label="lab_ck0001824293_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PublicOfferingMember" xlink:href="ck0001824293-20250630.xsd#ck0001824293_PublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_PublicOfferingMember" xlink:to="lab_ck0001824293_PublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsIssued_b30a5729-7493-4b4d-8d49-59c2f8284f67_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of warrants for payment of stock issuance costs</link:label>
    <link:label id="lab_ck0001824293_WarrantsIssued_label_en-US" xlink:label="lab_ck0001824293_WarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Issued</link:label>
    <link:label id="lab_ck0001824293_WarrantsIssued_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsIssued" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsIssued" xlink:to="lab_ck0001824293_WarrantsIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember_085a53f6-10c2-49f3-99fa-3282988144fb_terseLabel_en-US" xlink:label="lab_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">A&amp;R 2918 Plan</link:label>
    <link:label id="lab_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember_label_en-US" xlink:label="lab_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amended and Restated 2018 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember_documentation_en-US" xlink:label="lab_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amended and Restated 2018 Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember" xlink:href="ck0001824293-20250630.xsd#ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember" xlink:to="lab_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_15bb8359-675b-4aa5-bba5-793519051659_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_3edf4fe0-7df9-48e5-9426-62497919c0b9_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_PaymentForFractionalSharesReverseStockSplit_c3fe8962-ba4a-43bf-a22a-2cae9a4abe26_negatedTerseLabel_en-US" xlink:label="lab_ck0001824293_PaymentForFractionalSharesReverseStockSplit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment for fractional shares in connection with reverse stock split</link:label>
    <link:label id="lab_ck0001824293_PaymentForFractionalSharesReverseStockSplit_label_en-US" xlink:label="lab_ck0001824293_PaymentForFractionalSharesReverseStockSplit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment For Fractional Shares, Reverse Stock Split</link:label>
    <link:label id="lab_ck0001824293_PaymentForFractionalSharesReverseStockSplit_documentation_en-US" xlink:label="lab_ck0001824293_PaymentForFractionalSharesReverseStockSplit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment For Fractional Shares, Reverse Stock Split</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PaymentForFractionalSharesReverseStockSplit" xlink:href="ck0001824293-20250630.xsd#ck0001824293_PaymentForFractionalSharesReverseStockSplit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_PaymentForFractionalSharesReverseStockSplit" xlink:to="lab_ck0001824293_PaymentForFractionalSharesReverseStockSplit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_99606bac-4a9c-4ecb-a84e-e81c3df84a9d_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_4bdb186e-cf6f-4bd5-a64a-fff3397fd69c_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term in years</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_ef88aab8-fbb7-4793-9699-95262a1ca7f7_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_55a21633-76be-42a6-8665-f157fee47e9e_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesE3CommonWarrantsMember_8c15ed86-07ad-48eb-9a1d-e6d0f1707330_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesE3CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series E-3 Common Warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesE3CommonWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesE3CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series E-3 Common Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesE3CommonWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesE3CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series E-3 Common Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesE3CommonWarrantsMember" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SeriesE3CommonWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesE3CommonWarrantsMember" xlink:to="lab_ck0001824293_SeriesE3CommonWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_0d4fa813-1f1b-4051-a6c5-d11ce4a85be6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_45657ef9-860d-4394-b1e6-be7f5055c2c0_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_5058824b-21a6-4806-9cdb-773b99411695_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares called by each warrant</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_678d2a8e-bb23-4719-ba8b-d2c696a4e219_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_425f2c72-3068-411b-972d-c091195348a7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_39bf1fe3-3896-4c56-9261-70f8dfc6cd8b_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e4937dfa-6e4b-45c3-b55e-fb7139e98016_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_dd1cfddd-aabd-438b-9890-26955b47421c_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant issuance</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_91596440-4b3d-4bb2-9be9-8a86d4d3a0e7_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInOctober2026Member_a54011b7-2fa0-4ee2-941f-76142ea01cdb_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInOctober2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In October 2026</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInOctober2026Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInOctober2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In October 2026 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInOctober2026Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInOctober2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In October 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInOctober2026Member" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsExpiringInOctober2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInOctober2026Member" xlink:to="lab_ck0001824293_WarrantsExpiringInOctober2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ThroughFinancingMember_287c0f51-0c3d-4efe-b05e-9492b89d87ff_terseLabel_en-US" xlink:label="lab_ck0001824293_ThroughFinancingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Through Financing</link:label>
    <link:label id="lab_ck0001824293_ThroughFinancingMember_label_en-US" xlink:label="lab_ck0001824293_ThroughFinancingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Through Financing [Member]</link:label>
    <link:label id="lab_ck0001824293_ThroughFinancingMember_documentation_en-US" xlink:label="lab_ck0001824293_ThroughFinancingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Through Financing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ThroughFinancingMember" xlink:href="ck0001824293-20250630.xsd#ck0001824293_ThroughFinancingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ThroughFinancingMember" xlink:to="lab_ck0001824293_ThroughFinancingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesE1CommonWarrantsMember_99a80d71-085c-4466-b243-0ecf8067ddc6_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesE1CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series E-1 Common Warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesE1CommonWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesE1CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series E-1 Common Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesE1CommonWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesE1CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series E-1 Common Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesE1CommonWarrantsMember" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SeriesE1CommonWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesE1CommonWarrantsMember" xlink:to="lab_ck0001824293_SeriesE1CommonWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction_56064faf-212f-4b48-85cd-231642745790_terseLabel_en-US" xlink:label="lab_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of securities issued (in shares)</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction_label_en-US" xlink:label="lab_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Number Of Securities Issued Per Transaction</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction_documentation_en-US" xlink:label="lab_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Number Of Securities Issued Per Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction" xlink:to="lab_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6f0beb7e-37ea-442f-9e35-1978f05d2f99_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_4cd26e6c-c582-434d-819f-df748eeb3923_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_8b728077-2c3d-495f-80c7-fe0add56437b_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, price per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_88ef829d-0b93-46ef-8900-6a49cc86074c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_dc217d57-9413-4637-8ae4-c3531488b18b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition_387e1067-90d1-4247-92e7-47c3b121ed39_negatedTerseLabel_en-US" xlink:label="lab_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in operating lease right-of-use assets</link:label>
    <link:label id="lab_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition_label_en-US" xlink:label="lab_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-Of-Use Asset, Periodic Addition</link:label>
    <link:label id="lab_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition_documentation_en-US" xlink:label="lab_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-Of-Use Asset, Periodic Addition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition" xlink:href="ck0001824293-20250630.xsd#ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition" xlink:to="lab_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_PreFundedAndSeriesCWarrantsMember_4cf3e931-c03b-41c7-bea9-46c3e8220437_terseLabel_en-US" xlink:label="lab_ck0001824293_PreFundedAndSeriesCWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-Funded And Series C Warrants</link:label>
    <link:label id="lab_ck0001824293_PreFundedAndSeriesCWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_PreFundedAndSeriesCWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-Funded And Series C Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_PreFundedAndSeriesCWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_PreFundedAndSeriesCWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre-Funded And Series C Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PreFundedAndSeriesCWarrantsMember" xlink:href="ck0001824293-20250630.xsd#ck0001824293_PreFundedAndSeriesCWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_PreFundedAndSeriesCWarrantsMember" xlink:to="lab_ck0001824293_PreFundedAndSeriesCWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_19a28833-1713-43e2-bacc-04a591ea03b3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Warrants Outstanding to Purchase Common Stock</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_c24c835c-578e-4839-93f0-32c1a74c205b_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_8d3d02ae-9154-491d-b655-8e3a2f22c795_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1ca81e16-6179-4877-9ff8-57f7dac6bf8a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f94b5132-9eec-4753-8df9-776b8fbe7ad9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_38346c8e-dfd2-4c3a-9648-4ddd7803f83d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_fdaa9706-bd39-498e-8773-105788057609_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_f828e9b2-83b4-4320-8b6d-1c9e1c9d6642_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_AtTheMarketOfferingMember_2f54f93d-9c0a-4366-9642-9c4b23641b9c_terseLabel_en-US" xlink:label="lab_ck0001824293_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ATM</link:label>
    <link:label id="lab_ck0001824293_AtTheMarketOfferingMember_label_en-US" xlink:label="lab_ck0001824293_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At The Market Offering [Member]</link:label>
    <link:label id="lab_ck0001824293_AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_ck0001824293_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At The Market Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AtTheMarketOfferingMember" xlink:href="ck0001824293-20250630.xsd#ck0001824293_AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_AtTheMarketOfferingMember" xlink:to="lab_ck0001824293_AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_688fd496-da89-42b3-9882-91708be66f82_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, Beginning balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_93ee3ea5-5ccb-484a-b01d-65043394bb97_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, Ending balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7f930900-e718-44fe-acf4-d06a293eaafd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_12189acb-3b66-4076-ba5a-727df490f011_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_6e806d3f-d67d-48b3-bb36-1c4d1de3736d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_CommonStockOtherMember_8bafea26-79f1-4c8f-a6c4-c914b231fa70_terseLabel_en-US" xlink:label="lab_ck0001824293_CommonStockOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock</link:label>
    <link:label id="lab_ck0001824293_CommonStockOtherMember_label_en-US" xlink:label="lab_ck0001824293_CommonStockOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Other [Member]</link:label>
    <link:label id="lab_ck0001824293_CommonStockOtherMember_documentation_en-US" xlink:label="lab_ck0001824293_CommonStockOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CommonStockOtherMember" xlink:href="ck0001824293-20250630.xsd#ck0001824293_CommonStockOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_CommonStockOtherMember" xlink:to="lab_ck0001824293_CommonStockOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5b9826f3-9bc0-4d27-a379-87de7d7e9041_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesC2CommonWarrantsMember_de8e271a-6991-4f60-bfbd-c8bc0c9bc005_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesC2CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series C-2 Common Warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesC2CommonWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesC2CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series C-2 Common Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesC2CommonWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesC2CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series C-2 Common Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesC2CommonWarrantsMember" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SeriesC2CommonWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesC2CommonWarrantsMember" xlink:to="lab_ck0001824293_SeriesC2CommonWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_4ee96195-e7ea-40d7-bd8d-9806e3b9f604_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_a213cd51-f64d-491d-8b60-8805c5984844_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_8c3e55a7-e2f6-4b49-a744-11a56db76a4a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_084efb82-e647-4e0b-8529-124ca676dce6_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_3d7ae7f9-88a7-4ff3-8ef0-0d461228d821_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited/cancelled (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInJune2029Member_0afe296f-708f-4e55-8f8b-acbc271a03b3_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInJune2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In June 2029</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInJune2029Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInJune2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In June 2029 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInJune2029Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInJune2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In June 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInJune2029Member" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsExpiringInJune2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInJune2029Member" xlink:to="lab_ck0001824293_WarrantsExpiringInJune2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_d50db6fe-8df9-4a82-aeef-925dccc116bb_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_6db349f1-8ebc-4423-a8e0-391eaf5e56bb_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_76fb6710-7b3c-4952-bde1-e0ee27b5f00e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, 0.0001 par value; 250,000,000 shares authorized as of June&#160;30, 2025 and December&#160;31, 2024; 2,496,800 and 525,485 shares issued and outstanding as of June&#160;30, 2025 and December&#160;31, 2024, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_f9f1a497-2e6a-4954-816b-4d8169d9c7d7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesECommonWarrantMember_9b7232a4-c47c-4329-9d5b-f80bba656ec6_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesECommonWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series E Common Warrant</link:label>
    <link:label id="lab_ck0001824293_SeriesECommonWarrantMember_label_en-US" xlink:label="lab_ck0001824293_SeriesECommonWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series E Common Warrant [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesECommonWarrantMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesECommonWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series E Common Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesECommonWarrantMember" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SeriesECommonWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesECommonWarrantMember" xlink:to="lab_ck0001824293_SeriesECommonWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_ada7a630-80b1-4bab-a517-f6fb529b039f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock and prefunded warrants in financing</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_579b1bd4-77cf-4316-b95d-d1e4a1bfa579_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7e391227-66ef-48cc-b588-8ce7a053d224_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_2a2203de-0f8c-44a0-b2dd-0c366f3c73d3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common&#160;Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_df013657-c70b-4d1d-8c9f-930430f71f8f_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9f92752f-438f-4141-b189-4c5e25343325_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>ck0001824293-20250630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:63feccd5-3134-497b-93bb-cd3b539b0c1f,g:6dd00c0f-69b4-4831-9595-c67011349d66-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/Cover" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_feb56e9b-667c-4d63-b02d-9f0ddad0f40c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_28aad030-fcf9-4d1f-9604-5988af8a5750" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_feb56e9b-667c-4d63-b02d-9f0ddad0f40c" xlink:to="loc_dei_DocumentType_28aad030-fcf9-4d1f-9604-5988af8a5750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_7add4be0-e0ab-4329-b0cb-290cd17d43cb" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_feb56e9b-667c-4d63-b02d-9f0ddad0f40c" xlink:to="loc_dei_DocumentQuarterlyReport_7add4be0-e0ab-4329-b0cb-290cd17d43cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_4590a454-0415-485c-9c9c-f388e973e517" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_feb56e9b-667c-4d63-b02d-9f0ddad0f40c" xlink:to="loc_dei_DocumentPeriodEndDate_4590a454-0415-485c-9c9c-f388e973e517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_68667110-562c-47a4-b35f-318052406504" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_feb56e9b-667c-4d63-b02d-9f0ddad0f40c" xlink:to="loc_dei_DocumentTransitionReport_68667110-562c-47a4-b35f-318052406504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_db1fb61e-0bd1-431f-b8e4-86e4a6aad95d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_feb56e9b-667c-4d63-b02d-9f0ddad0f40c" xlink:to="loc_dei_EntityFileNumber_db1fb61e-0bd1-431f-b8e4-86e4a6aad95d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_6545ee2a-b77c-4243-a213-e89a577511b3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_feb56e9b-667c-4d63-b02d-9f0ddad0f40c" xlink:to="loc_dei_EntityRegistrantName_6545ee2a-b77c-4243-a213-e89a577511b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_2969a657-b932-4aef-aa85-dff92e615537" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_feb56e9b-667c-4d63-b02d-9f0ddad0f40c" xlink:to="loc_dei_EntityIncorporationStateCountryCode_2969a657-b932-4aef-aa85-dff92e615537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_84001f1c-1889-4efa-b74d-8f1def7e31e8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_feb56e9b-667c-4d63-b02d-9f0ddad0f40c" xlink:to="loc_dei_EntityTaxIdentificationNumber_84001f1c-1889-4efa-b74d-8f1def7e31e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_72fb18f7-449d-4bc5-a093-cf9437daf240" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_feb56e9b-667c-4d63-b02d-9f0ddad0f40c" xlink:to="loc_dei_EntityAddressAddressLine1_72fb18f7-449d-4bc5-a093-cf9437daf240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_1a79e9ea-9e39-4c44-8756-1a4d7bbe776a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_feb56e9b-667c-4d63-b02d-9f0ddad0f40c" xlink:to="loc_dei_EntityAddressAddressLine2_1a79e9ea-9e39-4c44-8756-1a4d7bbe776a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_50d080b2-63ba-4218-a7d7-382d0503e7d3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_feb56e9b-667c-4d63-b02d-9f0ddad0f40c" xlink:to="loc_dei_EntityAddressCityOrTown_50d080b2-63ba-4218-a7d7-382d0503e7d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_d800e9b2-fdf8-4460-9af4-adc6be460195" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_feb56e9b-667c-4d63-b02d-9f0ddad0f40c" xlink:to="loc_dei_EntityAddressStateOrProvince_d800e9b2-fdf8-4460-9af4-adc6be460195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_48463212-fd31-43bb-ad12-10eae2186273" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_feb56e9b-667c-4d63-b02d-9f0ddad0f40c" xlink:to="loc_dei_EntityAddressPostalZipCode_48463212-fd31-43bb-ad12-10eae2186273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_ce3a1a07-d92e-4162-b2a9-45a14afa90a9" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_feb56e9b-667c-4d63-b02d-9f0ddad0f40c" xlink:to="loc_dei_CityAreaCode_ce3a1a07-d92e-4162-b2a9-45a14afa90a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_ba1b4a0d-3e50-4b12-8775-4cb8c51bbe93" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_feb56e9b-667c-4d63-b02d-9f0ddad0f40c" xlink:to="loc_dei_LocalPhoneNumber_ba1b4a0d-3e50-4b12-8775-4cb8c51bbe93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_d17d717a-9b51-490b-b9d4-b9af457038fa" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_feb56e9b-667c-4d63-b02d-9f0ddad0f40c" xlink:to="loc_dei_Security12bTitle_d17d717a-9b51-490b-b9d4-b9af457038fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_bac16452-c2d9-4864-9dbb-49ed7491d9fa" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_feb56e9b-667c-4d63-b02d-9f0ddad0f40c" xlink:to="loc_dei_TradingSymbol_bac16452-c2d9-4864-9dbb-49ed7491d9fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_46d589ab-cb4a-4844-8c34-8e681602262b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_feb56e9b-667c-4d63-b02d-9f0ddad0f40c" xlink:to="loc_dei_SecurityExchangeName_46d589ab-cb4a-4844-8c34-8e681602262b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_f79cef18-61c2-4f60-a038-f048eefefe95" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_feb56e9b-667c-4d63-b02d-9f0ddad0f40c" xlink:to="loc_dei_EntityCurrentReportingStatus_f79cef18-61c2-4f60-a038-f048eefefe95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_5de8b1b9-3565-4508-af40-5445786447e8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_feb56e9b-667c-4d63-b02d-9f0ddad0f40c" xlink:to="loc_dei_EntityInteractiveDataCurrent_5de8b1b9-3565-4508-af40-5445786447e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_351d15dc-9193-427c-a4ec-5f784fa173f2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_feb56e9b-667c-4d63-b02d-9f0ddad0f40c" xlink:to="loc_dei_EntityFilerCategory_351d15dc-9193-427c-a4ec-5f784fa173f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_d96f9299-4651-475f-bb24-6e461745050d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_feb56e9b-667c-4d63-b02d-9f0ddad0f40c" xlink:to="loc_dei_EntitySmallBusiness_d96f9299-4651-475f-bb24-6e461745050d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_d0f2e259-e280-432f-a4a6-f676bc730aa2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_feb56e9b-667c-4d63-b02d-9f0ddad0f40c" xlink:to="loc_dei_EntityEmergingGrowthCompany_d0f2e259-e280-432f-a4a6-f676bc730aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_4fdf5be9-6ee5-4d33-ad29-d2f7e75a24b3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_feb56e9b-667c-4d63-b02d-9f0ddad0f40c" xlink:to="loc_dei_EntityExTransitionPeriod_4fdf5be9-6ee5-4d33-ad29-d2f7e75a24b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_2fad76a5-0e04-4197-8d14-1ba450ee94f7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_feb56e9b-667c-4d63-b02d-9f0ddad0f40c" xlink:to="loc_dei_EntityShellCompany_2fad76a5-0e04-4197-8d14-1ba450ee94f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_268395c4-a0fc-42e1-b6b9-7907ea895706" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_feb56e9b-667c-4d63-b02d-9f0ddad0f40c" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_268395c4-a0fc-42e1-b6b9-7907ea895706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_45a3a611-303c-47ee-b6c0-7a8e80b9da0e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_feb56e9b-667c-4d63-b02d-9f0ddad0f40c" xlink:to="loc_dei_EntityCentralIndexKey_45a3a611-303c-47ee-b6c0-7a8e80b9da0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_86dd28aa-72b4-41fd-a1e7-093a1f0b0aa9" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_feb56e9b-667c-4d63-b02d-9f0ddad0f40c" xlink:to="loc_dei_CurrentFiscalYearEndDate_86dd28aa-72b4-41fd-a1e7-093a1f0b0aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_899fa11f-10ff-4546-824e-2eeb06ae644b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_feb56e9b-667c-4d63-b02d-9f0ddad0f40c" xlink:to="loc_dei_DocumentFiscalYearFocus_899fa11f-10ff-4546-824e-2eeb06ae644b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_a8a07121-f249-42bd-9ecc-e9f3c2715278" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_feb56e9b-667c-4d63-b02d-9f0ddad0f40c" xlink:to="loc_dei_DocumentFiscalPeriodFocus_a8a07121-f249-42bd-9ecc-e9f3c2715278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_254eb1b1-7f90-4279-9cf7-8fdff26fb8ed" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_feb56e9b-667c-4d63-b02d-9f0ddad0f40c" xlink:to="loc_dei_AmendmentFlag_254eb1b1-7f90-4279-9cf7-8fdff26fb8ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_97e7ab59-d7ee-407c-8ff9-0710889649db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_19f03500-c026-4184-9651-849bbd32d03c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_97e7ab59-d7ee-407c-8ff9-0710889649db" xlink:to="loc_us-gaap_AssetsAbstract_19f03500-c026-4184-9651-849bbd32d03c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_7681af2e-a78f-4fbd-8d1f-25fff176e39a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_19f03500-c026-4184-9651-849bbd32d03c" xlink:to="loc_us-gaap_AssetsCurrentAbstract_7681af2e-a78f-4fbd-8d1f-25fff176e39a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b83ddbe5-d274-434d-b1da-b3e2582a5fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7681af2e-a78f-4fbd-8d1f-25fff176e39a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b83ddbe5-d274-434d-b1da-b3e2582a5fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b8bbf287-6d84-428a-99b3-cb9674c1a7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7681af2e-a78f-4fbd-8d1f-25fff176e39a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b8bbf287-6d84-428a-99b3-cb9674c1a7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_253ee853-ed2a-4466-8237-72f7479d15ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7681af2e-a78f-4fbd-8d1f-25fff176e39a" xlink:to="loc_us-gaap_AssetsCurrent_253ee853-ed2a-4466-8237-72f7479d15ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3bc33bca-8e05-420c-8485-6a48bf88d2cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_19f03500-c026-4184-9651-849bbd32d03c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3bc33bca-8e05-420c-8485-6a48bf88d2cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_43d85e0e-a1c9-4b32-830a-dd16985f327d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_19f03500-c026-4184-9651-849bbd32d03c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_43d85e0e-a1c9-4b32-830a-dd16985f327d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_c9d9eadb-de0e-49d1-bccc-1414d3337ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_19f03500-c026-4184-9651-849bbd32d03c" xlink:to="loc_us-gaap_Assets_c9d9eadb-de0e-49d1-bccc-1414d3337ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_296a3f70-8439-4e9b-b42f-86e0cf689247" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_97e7ab59-d7ee-407c-8ff9-0710889649db" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_296a3f70-8439-4e9b-b42f-86e0cf689247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_df07ae7d-1b9f-483b-a0cb-d4f796096f73" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_296a3f70-8439-4e9b-b42f-86e0cf689247" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_df07ae7d-1b9f-483b-a0cb-d4f796096f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_deba246e-802e-41cb-9c5a-a366b7be640a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_df07ae7d-1b9f-483b-a0cb-d4f796096f73" xlink:to="loc_us-gaap_AccountsPayableCurrent_deba246e-802e-41cb-9c5a-a366b7be640a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_fc78f817-b717-45ae-83fd-0707a3b066e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_df07ae7d-1b9f-483b-a0cb-d4f796096f73" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_fc78f817-b717-45ae-83fd-0707a3b066e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_a17ad095-cb0e-46bf-b08d-31929a6757aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_df07ae7d-1b9f-483b-a0cb-d4f796096f73" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_a17ad095-cb0e-46bf-b08d-31929a6757aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_47d562d5-11ef-4238-8ffe-80ca64b007a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_df07ae7d-1b9f-483b-a0cb-d4f796096f73" xlink:to="loc_us-gaap_LiabilitiesCurrent_47d562d5-11ef-4238-8ffe-80ca64b007a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f1a7ecb9-c551-4541-86c5-df0c407ec717" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_296a3f70-8439-4e9b-b42f-86e0cf689247" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f1a7ecb9-c551-4541-86c5-df0c407ec717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d13544ce-a605-43cf-857b-d37045040079" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_296a3f70-8439-4e9b-b42f-86e0cf689247" xlink:to="loc_us-gaap_Liabilities_d13544ce-a605-43cf-857b-d37045040079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_e6f1f74b-a094-4145-a6cd-ae05ebee17ac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_296a3f70-8439-4e9b-b42f-86e0cf689247" xlink:to="loc_us-gaap_CommitmentsAndContingencies_e6f1f74b-a094-4145-a6cd-ae05ebee17ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_4128d2db-13aa-4bc5-82a5-4dea6c3aec43" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_296a3f70-8439-4e9b-b42f-86e0cf689247" xlink:to="loc_us-gaap_StockholdersEquityAbstract_4128d2db-13aa-4bc5-82a5-4dea6c3aec43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_082284b8-e28f-4086-b951-9f301b4293f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4128d2db-13aa-4bc5-82a5-4dea6c3aec43" xlink:to="loc_us-gaap_CommonStockValueOutstanding_082284b8-e28f-4086-b951-9f301b4293f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_bf6b17be-419e-4543-bfd3-6a09c277ad26" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4128d2db-13aa-4bc5-82a5-4dea6c3aec43" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_bf6b17be-419e-4543-bfd3-6a09c277ad26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a6421dd4-94c4-43a0-a548-a26a97942a5c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4128d2db-13aa-4bc5-82a5-4dea6c3aec43" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a6421dd4-94c4-43a0-a548-a26a97942a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2411bf2e-23d7-4073-b618-b3b3bb266a88" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4128d2db-13aa-4bc5-82a5-4dea6c3aec43" xlink:to="loc_us-gaap_StockholdersEquity_2411bf2e-23d7-4073-b618-b3b3bb266a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b53d5a9f-1405-4621-82a2-d3dfe150216c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_296a3f70-8439-4e9b-b42f-86e0cf689247" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_b53d5a9f-1405-4621-82a2-d3dfe150216c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1feb1ade-b00a-489b-b66f-8c85ec6e38e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_0955b3e8-7aae-4b38-980f-e6999f7a3167" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1feb1ade-b00a-489b-b66f-8c85ec6e38e0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_0955b3e8-7aae-4b38-980f-e6999f7a3167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_54a639f4-1694-4097-9a8b-8ac9660c4cfc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1feb1ade-b00a-489b-b66f-8c85ec6e38e0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_54a639f4-1694-4097-9a8b-8ac9660c4cfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_c5897d16-5c3c-49e4-b3c2-213b5f759d47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1feb1ade-b00a-489b-b66f-8c85ec6e38e0" xlink:to="loc_us-gaap_CommonStockSharesIssued_c5897d16-5c3c-49e4-b3c2-213b5f759d47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ffdcd8fc-458e-42c5-afe1-403850cda9bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1feb1ade-b00a-489b-b66f-8c85ec6e38e0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ffdcd8fc-458e-42c5-afe1-403850cda9bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_94e812ce-d236-4fc9-b722-4e784884e763" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_0d2e6cf7-a9ed-4d12-b0d0-c4747f5e779a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_94e812ce-d236-4fc9-b722-4e784884e763" xlink:to="loc_us-gaap_OperatingExpensesAbstract_0d2e6cf7-a9ed-4d12-b0d0-c4747f5e779a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_261aad96-232e-44d6-8adb-8f23963bc3cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0d2e6cf7-a9ed-4d12-b0d0-c4747f5e779a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_261aad96-232e-44d6-8adb-8f23963bc3cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_ac536a54-ea83-49c6-987a-64b4db90260c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0d2e6cf7-a9ed-4d12-b0d0-c4747f5e779a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_ac536a54-ea83-49c6-987a-64b4db90260c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_b73a19a0-045a-4e3d-8ba8-690421d76801" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0d2e6cf7-a9ed-4d12-b0d0-c4747f5e779a" xlink:to="loc_us-gaap_OperatingExpenses_b73a19a0-045a-4e3d-8ba8-690421d76801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d44d61da-6225-44c7-81e7-4738ab2a0235" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_94e812ce-d236-4fc9-b722-4e784884e763" xlink:to="loc_us-gaap_OperatingIncomeLoss_d44d61da-6225-44c7-81e7-4738ab2a0235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ChangeInFairValueOfWarrantLiability_40b68351-247f-4960-baa5-cb01106e5e7d" xlink:href="ck0001824293-20250630.xsd#ck0001824293_ChangeInFairValueOfWarrantLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_94e812ce-d236-4fc9-b722-4e784884e763" xlink:to="loc_ck0001824293_ChangeInFairValueOfWarrantLiability_40b68351-247f-4960-baa5-cb01106e5e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_8fa37c83-ce63-43a0-9ff9-9006b59782a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_94e812ce-d236-4fc9-b722-4e784884e763" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_8fa37c83-ce63-43a0-9ff9-9006b59782a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_462d6443-67d3-4651-a7ec-520107749e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_94e812ce-d236-4fc9-b722-4e784884e763" xlink:to="loc_us-gaap_NetIncomeLoss_462d6443-67d3-4651-a7ec-520107749e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_4a59338a-702b-4e2e-ae81-f7e395a26770" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_94e812ce-d236-4fc9-b722-4e784884e763" xlink:to="loc_us-gaap_EarningsPerShareBasic_4a59338a-702b-4e2e-ae81-f7e395a26770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_58c074bc-100f-4346-9bdd-c10fea383db9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_94e812ce-d236-4fc9-b722-4e784884e763" xlink:to="loc_us-gaap_EarningsPerShareDiluted_58c074bc-100f-4346-9bdd-c10fea383db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7863ba96-05fe-4083-84c5-c142d0cc0a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_94e812ce-d236-4fc9-b722-4e784884e763" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7863ba96-05fe-4083-84c5-c142d0cc0a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a85bea97-5e1e-4bbc-9413-f70129f38b04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_94e812ce-d236-4fc9-b722-4e784884e763" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a85bea97-5e1e-4bbc-9413-f70129f38b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#ConsolidatedStatementsofChangesinStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_59eee489-e5ba-4a25-a7d6-a05643fcbf37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0a4f62d0-ef5a-406e-9f0f-75a73fd1e39d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_59eee489-e5ba-4a25-a7d6-a05643fcbf37" xlink:to="loc_us-gaap_StatementTable_0a4f62d0-ef5a-406e-9f0f-75a73fd1e39d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_65107d57-84c8-4bf0-acaf-b0bca5cc80d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0a4f62d0-ef5a-406e-9f0f-75a73fd1e39d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_65107d57-84c8-4bf0-acaf-b0bca5cc80d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4568436c-8273-4935-9902-e2b5f39557ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_65107d57-84c8-4bf0-acaf-b0bca5cc80d3" xlink:to="loc_us-gaap_EquityComponentDomain_4568436c-8273-4935-9902-e2b5f39557ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7bc88ab1-ca38-4a4d-89c4-d750cb01564a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4568436c-8273-4935-9902-e2b5f39557ae" xlink:to="loc_us-gaap_CommonStockMember_7bc88ab1-ca38-4a4d-89c4-d750cb01564a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ec840060-508d-41ff-9126-66457e5b4f85" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4568436c-8273-4935-9902-e2b5f39557ae" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ec840060-508d-41ff-9126-66457e5b4f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_31d6d8d0-99c0-4a71-a4e9-a3bb25db24d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4568436c-8273-4935-9902-e2b5f39557ae" xlink:to="loc_us-gaap_RetainedEarningsMember_31d6d8d0-99c0-4a71-a4e9-a3bb25db24d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ef074bc4-0a4b-4dfb-9fd3-5fc992f8d5de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0a4f62d0-ef5a-406e-9f0f-75a73fd1e39d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ef074bc4-0a4b-4dfb-9fd3-5fc992f8d5de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_112c0cff-552a-4126-8a25-ee27b2b27911" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ef074bc4-0a4b-4dfb-9fd3-5fc992f8d5de" xlink:to="loc_us-gaap_ClassOfStockDomain_112c0cff-552a-4126-8a25-ee27b2b27911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CommonStockAndPrefundedWarrantsInFinancingMember_3c63b352-d924-4c2a-842b-1d26195e249c" xlink:href="ck0001824293-20250630.xsd#ck0001824293_CommonStockAndPrefundedWarrantsInFinancingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_112c0cff-552a-4126-8a25-ee27b2b27911" xlink:to="loc_ck0001824293_CommonStockAndPrefundedWarrantsInFinancingMember_3c63b352-d924-4c2a-842b-1d26195e249c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CommonStockOtherMember_36cb83eb-7a47-4a9d-adab-979349b9233b" xlink:href="ck0001824293-20250630.xsd#ck0001824293_CommonStockOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_112c0cff-552a-4126-8a25-ee27b2b27911" xlink:to="loc_ck0001824293_CommonStockOtherMember_36cb83eb-7a47-4a9d-adab-979349b9233b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ecc842bb-7dd1-4f47-a5a5-dc7af1be05aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0a4f62d0-ef5a-406e-9f0f-75a73fd1e39d" xlink:to="loc_us-gaap_StatementLineItems_ecc842bb-7dd1-4f47-a5a5-dc7af1be05aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ddb9923e-e429-41cc-902d-d9fb278c84ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ecc842bb-7dd1-4f47-a5a5-dc7af1be05aa" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ddb9923e-e429-41cc-902d-d9fb278c84ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9f19587f-85ce-4884-88ea-c93cf2263461" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ddb9923e-e429-41cc-902d-d9fb278c84ad" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9f19587f-85ce-4884-88ea-c93cf2263461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_de5b7e92-c31c-443c-ad07-28da3d8bb86f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ddb9923e-e429-41cc-902d-d9fb278c84ad" xlink:to="loc_us-gaap_StockholdersEquity_de5b7e92-c31c-443c-ad07-28da3d8bb86f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_92254254-9689-4795-a27f-feb914377ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ddb9923e-e429-41cc-902d-d9fb278c84ad" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_92254254-9689-4795-a27f-feb914377ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment_a8c4f6ff-b377-4785-8849-db5db08fbf3f" xlink:href="ck0001824293-20250630.xsd#ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ddb9923e-e429-41cc-902d-d9fb278c84ad" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment_a8c4f6ff-b377-4785-8849-db5db08fbf3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueFractionalShareAdjustment_77e75e71-bd64-4596-bba9-8931c861102b" xlink:href="ck0001824293-20250630.xsd#ck0001824293_StockIssuedDuringPeriodValueFractionalShareAdjustment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ddb9923e-e429-41cc-902d-d9fb278c84ad" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodValueFractionalShareAdjustment_77e75e71-bd64-4596-bba9-8931c861102b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e452905c-4845-4a7f-98e6-950e9eef469b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ddb9923e-e429-41cc-902d-d9fb278c84ad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e452905c-4845-4a7f-98e6-950e9eef469b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_05665425-656d-413e-bb21-a521488f7629" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ddb9923e-e429-41cc-902d-d9fb278c84ad" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_05665425-656d-413e-bb21-a521488f7629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise_bd31d3a4-edf8-41fe-baa0-e209dfe0aa49" xlink:href="ck0001824293-20250630.xsd#ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ddb9923e-e429-41cc-902d-d9fb278c84ad" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise_bd31d3a4-edf8-41fe-baa0-e209dfe0aa49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f78d7124-dc09-4560-90c0-e1d36115ce05" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ddb9923e-e429-41cc-902d-d9fb278c84ad" xlink:to="loc_us-gaap_NetIncomeLoss_f78d7124-dc09-4560-90c0-e1d36115ce05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c9d91761-3c30-47de-815f-3aed0374b93b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ddb9923e-e429-41cc-902d-d9fb278c84ad" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c9d91761-3c30-47de-815f-3aed0374b93b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b466974d-7ebf-4867-844a-5976c690e588" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ddb9923e-e429-41cc-902d-d9fb278c84ad" xlink:to="loc_us-gaap_StockholdersEquity_b466974d-7ebf-4867-844a-5976c690e588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_46d2d077-9ad1-46cf-a214-406a3038c631" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1f8a8aea-d6bc-456b-9ebc-94fea5e2552a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_46d2d077-9ad1-46cf-a214-406a3038c631" xlink:to="loc_us-gaap_StatementTable_1f8a8aea-d6bc-456b-9ebc-94fea5e2552a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1b064b6c-3705-446d-b7ff-2c61107dcf78" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1f8a8aea-d6bc-456b-9ebc-94fea5e2552a" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1b064b6c-3705-446d-b7ff-2c61107dcf78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1e0619a3-2334-4e70-a066-55b822827b97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1b064b6c-3705-446d-b7ff-2c61107dcf78" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1e0619a3-2334-4e70-a066-55b822827b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ThroughFinancingMember_d38e16a9-38f5-4f7e-bfdd-2286bc9f9c79" xlink:href="ck0001824293-20250630.xsd#ck0001824293_ThroughFinancingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1e0619a3-2334-4e70-a066-55b822827b97" xlink:to="loc_ck0001824293_ThroughFinancingMember_d38e16a9-38f5-4f7e-bfdd-2286bc9f9c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AtTheMarketOfferingMember_dee98848-acf8-4e14-8a8d-1c9cf2abd3a2" xlink:href="ck0001824293-20250630.xsd#ck0001824293_AtTheMarketOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1e0619a3-2334-4e70-a066-55b822827b97" xlink:to="loc_ck0001824293_AtTheMarketOfferingMember_dee98848-acf8-4e14-8a8d-1c9cf2abd3a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4787d7f6-57b6-4cd1-8acf-e1f01e8946b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1f8a8aea-d6bc-456b-9ebc-94fea5e2552a" xlink:to="loc_us-gaap_StatementLineItems_4787d7f6-57b6-4cd1-8acf-e1f01e8946b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d3f65d71-e571-44e9-b02b-e878c1b8abd8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4787d7f6-57b6-4cd1-8acf-e1f01e8946b3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d3f65d71-e571-44e9-b02b-e878c1b8abd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_87044ea8-6388-4c94-83fe-2e21f874a7c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d3f65d71-e571-44e9-b02b-e878c1b8abd8" xlink:to="loc_us-gaap_NetIncomeLoss_87044ea8-6388-4c94-83fe-2e21f874a7c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2db0c234-1519-43a5-b6a2-faaba65e1187" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d3f65d71-e571-44e9-b02b-e878c1b8abd8" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2db0c234-1519-43a5-b6a2-faaba65e1187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_b1b5cc97-9275-475a-8253-a00f8c78b067" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2db0c234-1519-43a5-b6a2-faaba65e1187" xlink:to="loc_us-gaap_Depreciation_b1b5cc97-9275-475a-8253-a00f8c78b067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_aad9b696-d8da-4377-a9f5-4561a90819f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2db0c234-1519-43a5-b6a2-faaba65e1187" xlink:to="loc_us-gaap_ShareBasedCompensation_aad9b696-d8da-4377-a9f5-4561a90819f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_9dea3116-6ad7-4cae-b2a9-301651b9a41a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2db0c234-1519-43a5-b6a2-faaba65e1187" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_9dea3116-6ad7-4cae-b2a9-301651b9a41a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_515b93bd-ca1b-44e5-a1f4-36f1e1ca7622" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2db0c234-1519-43a5-b6a2-faaba65e1187" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_515b93bd-ca1b-44e5-a1f4-36f1e1ca7622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition_e0dbd746-d62b-4545-bf39-33f2e69bfb51" xlink:href="ck0001824293-20250630.xsd#ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2db0c234-1519-43a5-b6a2-faaba65e1187" xlink:to="loc_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition_e0dbd746-d62b-4545-bf39-33f2e69bfb51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1861b92b-e99d-4d4b-8cae-e180d01e6eae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2db0c234-1519-43a5-b6a2-faaba65e1187" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1861b92b-e99d-4d4b-8cae-e180d01e6eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_50ccbb20-dfa5-4ab0-a282-61627a10b75c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1861b92b-e99d-4d4b-8cae-e180d01e6eae" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_50ccbb20-dfa5-4ab0-a282-61627a10b75c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4210a54d-bdf4-4527-ba14-16f163091bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1861b92b-e99d-4d4b-8cae-e180d01e6eae" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4210a54d-bdf4-4527-ba14-16f163091bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_9c830b62-5139-4094-ac7a-0bfe5a15c151" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1861b92b-e99d-4d4b-8cae-e180d01e6eae" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_9c830b62-5139-4094-ac7a-0bfe5a15c151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_1a36a382-afe6-4e70-9ce8-b0d84fa7adf1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1861b92b-e99d-4d4b-8cae-e180d01e6eae" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_1a36a382-afe6-4e70-9ce8-b0d84fa7adf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c5d5b0f8-718a-4ae4-b73e-10805b67d21d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d3f65d71-e571-44e9-b02b-e878c1b8abd8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c5d5b0f8-718a-4ae4-b73e-10805b67d21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8685f9fc-58d0-43bd-acc7-baa5149e5d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4787d7f6-57b6-4cd1-8acf-e1f01e8946b3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8685f9fc-58d0-43bd-acc7-baa5149e5d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_89ef934c-68ff-4c45-a1ec-df4fc24fa25e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8685f9fc-58d0-43bd-acc7-baa5149e5d2c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_89ef934c-68ff-4c45-a1ec-df4fc24fa25e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PaymentForFractionalSharesReverseStockSplit_2cec79bc-9907-4b5a-b289-2a041af71cc6" xlink:href="ck0001824293-20250630.xsd#ck0001824293_PaymentForFractionalSharesReverseStockSplit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8685f9fc-58d0-43bd-acc7-baa5149e5d2c" xlink:to="loc_ck0001824293_PaymentForFractionalSharesReverseStockSplit_2cec79bc-9907-4b5a-b289-2a041af71cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_576ccbc2-d6a2-4df9-9e6b-574f8612c7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8685f9fc-58d0-43bd-acc7-baa5149e5d2c" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_576ccbc2-d6a2-4df9-9e6b-574f8612c7a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_071cc2c5-b69a-4837-bc15-2a1343765b45" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8685f9fc-58d0-43bd-acc7-baa5149e5d2c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_071cc2c5-b69a-4837-bc15-2a1343765b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a6371fb6-0471-4cca-896d-dccacc1d1579" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4787d7f6-57b6-4cd1-8acf-e1f01e8946b3" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a6371fb6-0471-4cca-896d-dccacc1d1579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2b1b2048-de72-48e5-9604-16564600fecd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4787d7f6-57b6-4cd1-8acf-e1f01e8946b3" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2b1b2048-de72-48e5-9604-16564600fecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_07f5a878-7549-431d-9409-78e2394a825f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4787d7f6-57b6-4cd1-8acf-e1f01e8946b3" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_07f5a878-7549-431d-9409-78e2394a825f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_280e888a-ab4f-4cba-a00d-8bd4902025c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4787d7f6-57b6-4cd1-8acf-e1f01e8946b3" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_280e888a-ab4f-4cba-a00d-8bd4902025c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid_b3183231-9636-4f40-8ca3-bcdc34e650e4" xlink:href="ck0001824293-20250630.xsd#ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_280e888a-ab4f-4cba-a00d-8bd4902025c8" xlink:to="loc_ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid_b3183231-9636-4f40-8ca3-bcdc34e650e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsIssued_68ef293f-6df0-479d-b774-982218327cd1" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_280e888a-ab4f-4cba-a00d-8bd4902025c8" xlink:to="loc_ck0001824293_WarrantsIssued_68ef293f-6df0-479d-b774-982218327cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#ORGANIZATIONANDDESCRIPTIONOFBUSINESS"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ff7a6b1a-24bf-4fea-af78-cfa4f0952c97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_b75dc2f6-85c8-4218-997d-1713403a84a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ff7a6b1a-24bf-4fea-af78-cfa4f0952c97" xlink:to="loc_us-gaap_NatureOfOperations_b75dc2f6-85c8-4218-997d-1713403a84a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/LIQUIDITY" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#LIQUIDITY"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/LIQUIDITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6683d62e-d093-4376-ace9-a10576f95139" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_bb4b83df-dbe5-417c-97c6-3dd45bccc9a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6683d62e-d093-4376-ace9-a10576f95139" xlink:to="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_bb4b83df-dbe5-417c-97c6-3dd45bccc9a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_dae88abf-9cfd-4c76-b708-9cc73d1f76cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_7dc61bef-3182-47b3-99ef-793d89e633c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dae88abf-9cfd-4c76-b708-9cc73d1f76cc" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_7dc61bef-3182-47b3-99ef-793d89e633c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENT" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#PROPERTYANDEQUIPMENT"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f7a062ce-4091-43a1-83a3-a657fc036b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_f21db2f1-7d89-40d4-90b2-f93ea7c9479a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f7a062ce-4091-43a1-83a3-a657fc036b5b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_f21db2f1-7d89-40d4-90b2-f93ea7c9479a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSES" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#ACCRUEDEXPENSES"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ACCRUEDEXPENSES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_b16f78b9-0867-4dd2-b929-e24d276291ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_1d70d6b1-3366-4341-ba7f-b00e6cdbd8d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_b16f78b9-0867-4dd2-b929-e24d276291ea" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_1d70d6b1-3366-4341-ba7f-b00e6cdbd8d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#STOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_443f9975-abd5-4cbb-af30-6f4da2809bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8c85baea-4d65-45d4-9c84-2450c9f4b60d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_443f9975-abd5-4cbb-af30-6f4da2809bf0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8c85baea-4d65-45d4-9c84-2450c9f4b60d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#STOCKBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f2366a92-9292-4b99-bb0a-33a31a07680e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3eaf8fdb-b496-40ff-bee7-0ceff286786d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f2366a92-9292-4b99-bb0a-33a31a07680e" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3eaf8fdb-b496-40ff-bee7-0ceff286786d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/SEGMENTREPORTING" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#SEGMENTREPORTING"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/SEGMENTREPORTING" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_259c6f73-cc53-4eb7-84cc-8f182e28a11c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_bee0565d-6c87-4c90-9d0a-f93f72692d75" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_259c6f73-cc53-4eb7-84cc-8f182e28a11c" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_bee0565d-6c87-4c90-9d0a-f93f72692d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_adb59291-dbf4-4fcf-9276-674b2e59a42d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ba283e2f-9ca7-4772-969f-229e01d91b80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_adb59291-dbf4-4fcf-9276-674b2e59a42d" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ba283e2f-9ca7-4772-969f-229e01d91b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#SUBSEQUENTEVENTS"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/SUBSEQUENTEVENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_9fcf4910-b207-4d2f-ba50-96eb35512aab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_6df54b6a-1a2f-4147-83c6-c07260569a48" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_9fcf4910-b207-4d2f-ba50-96eb35512aab" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_6df54b6a-1a2f-4147-83c6-c07260569a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_fa06deb6-e8e3-49e4-9a40-8f3d925fe935" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_5c524c25-8031-4a6c-81af-6fa1a3e63a5c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fa06deb6-e8e3-49e4-9a40-8f3d925fe935" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_5c524c25-8031-4a6c-81af-6fa1a3e63a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_d5411699-9105-4e55-bf3e-fbef34048dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fa06deb6-e8e3-49e4-9a40-8f3d925fe935" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_d5411699-9105-4e55-bf3e-fbef34048dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_f9272c8e-7288-4889-9525-f6ac69130550" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fa06deb6-e8e3-49e4-9a40-8f3d925fe935" xlink:to="loc_us-gaap_UseOfEstimates_f9272c8e-7288-4889-9525-f6ac69130550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_c9bae075-63e3-4c62-9812-b29cc786bc1c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fa06deb6-e8e3-49e4-9a40-8f3d925fe935" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_c9bae075-63e3-4c62-9812-b29cc786bc1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock_038286b0-1269-4da0-a471-b2360e27a330" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fa06deb6-e8e3-49e4-9a40-8f3d925fe935" xlink:to="loc_us-gaap_DeferredChargesPolicyTextBlock_038286b0-1269-4da0-a471-b2360e27a330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_bdc9bbb2-6dc8-46f0-ad04-6164c8f00dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fa06deb6-e8e3-49e4-9a40-8f3d925fe935" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_bdc9bbb2-6dc8-46f0-ad04-6164c8f00dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_99426fdb-7c7a-424c-a6c2-f4e7423d09f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fa06deb6-e8e3-49e4-9a40-8f3d925fe935" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_99426fdb-7c7a-424c-a6c2-f4e7423d09f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_04322019-468d-4e9c-b21d-1f240ec40486" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_500b4282-88c4-45af-8214-73d40a2a03ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_04322019-468d-4e9c-b21d-1f240ec40486" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_500b4282-88c4-45af-8214-73d40a2a03ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#PROPERTYANDEQUIPMENTTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7a81975c-750d-4327-aac0-8af9804e860e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_6f879ce6-226b-4cf3-baa6-0b3c14a2263a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7a81975c-750d-4327-aac0-8af9804e860e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_6f879ce6-226b-4cf3-baa6-0b3c14a2263a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#ACCRUEDEXPENSESTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_89b77265-2b55-4e8b-8265-d8ac793e966d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_e4c97428-9cc7-45d9-86c1-8e14fe7311b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_89b77265-2b55-4e8b-8265-d8ac793e966d" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_e4c97428-9cc7-45d9-86c1-8e14fe7311b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYTables" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#STOCKHOLDERSEQUITYTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f05fba1b-bf15-4ff2-92fa-7d5e03f42c93" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_a7b1ba44-14a5-4127-880a-1d9f40f659fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f05fba1b-bf15-4ff2-92fa-7d5e03f42c93" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_a7b1ba44-14a5-4127-880a-1d9f40f659fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1a970d12-5b07-405e-a91c-905245ff189a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f05fba1b-bf15-4ff2-92fa-7d5e03f42c93" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1a970d12-5b07-405e-a91c-905245ff189a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#STOCKBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9a711b15-fbb2-4afa-9a3a-1f42216e57b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_36984c57-e8b6-4be4-ba22-04612f6e96e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9a711b15-fbb2-4afa-9a3a-1f42216e57b2" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_36984c57-e8b6-4be4-ba22-04612f6e96e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_e0bae59a-f569-4bc5-8a64-b8dc620b3933" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9a711b15-fbb2-4afa-9a3a-1f42216e57b2" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_e0bae59a-f569-4bc5-8a64-b8dc620b3933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0826964b-64ce-401d-85ea-266f134533b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9a711b15-fbb2-4afa-9a3a-1f42216e57b2" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0826964b-64ce-401d-85ea-266f134533b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_944a7fbb-ac57-484a-9e0d-822b12e5ed42" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_8b8a593d-887c-467b-8d2b-7a9ffb1c8155" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_944a7fbb-ac57-484a-9e0d-822b12e5ed42" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_8b8a593d-887c-467b-8d2b-7a9ffb1c8155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_f85a5d92-95c2-4f0e-aa94-116d10ee63c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_944a7fbb-ac57-484a-9e0d-822b12e5ed42" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_f85a5d92-95c2-4f0e-aa94-116d10ee63c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/LIQUIDITYDetails" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#LIQUIDITYDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/LIQUIDITYDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bf4cfc5d-fd92-45dc-967c-9f316c587606" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_eab5c4ef-0c7d-4517-93cd-4c7a47dac747" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bf4cfc5d-fd92-45dc-967c-9f316c587606" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_eab5c4ef-0c7d-4517-93cd-4c7a47dac747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_a52c66b0-de4c-4448-be58-b9f8f9923e71" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_eab5c4ef-0c7d-4517-93cd-4c7a47dac747" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_a52c66b0-de4c-4448-be58-b9f8f9923e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a6639e37-dd70-4631-a724-33654bcf525a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a52c66b0-de4c-4448-be58-b9f8f9923e71" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a6639e37-dd70-4631-a724-33654bcf525a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PublicOfferingMember_59c7ed0e-50e8-404d-ab94-21227927b177" xlink:href="ck0001824293-20250630.xsd#ck0001824293_PublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a6639e37-dd70-4631-a724-33654bcf525a" xlink:to="loc_ck0001824293_PublicOfferingMember_59c7ed0e-50e8-404d-ab94-21227927b177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AtTheMarketOfferingMember_395eed49-5d5a-4dc3-92ba-ada4fb3af72d" xlink:href="ck0001824293-20250630.xsd#ck0001824293_AtTheMarketOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a6639e37-dd70-4631-a724-33654bcf525a" xlink:to="loc_ck0001824293_AtTheMarketOfferingMember_395eed49-5d5a-4dc3-92ba-ada4fb3af72d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PublicOfferingsMember_8cdbc554-bc2b-44ca-aa0e-e47d9f88cc39" xlink:href="ck0001824293-20250630.xsd#ck0001824293_PublicOfferingsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a6639e37-dd70-4631-a724-33654bcf525a" xlink:to="loc_ck0001824293_PublicOfferingsMember_8cdbc554-bc2b-44ca-aa0e-e47d9f88cc39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0a8fefa9-4231-4e88-baea-d746ec1e2073" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_eab5c4ef-0c7d-4517-93cd-4c7a47dac747" xlink:to="loc_srt_RangeAxis_0a8fefa9-4231-4e88-baea-d746ec1e2073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_09ab51df-c3b9-4ba1-9719-7392e0a90488" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0a8fefa9-4231-4e88-baea-d746ec1e2073" xlink:to="loc_srt_RangeMember_09ab51df-c3b9-4ba1-9719-7392e0a90488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_4bd080b4-e82c-4b25-9a3e-56ea3c3dcb4c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_09ab51df-c3b9-4ba1-9719-7392e0a90488" xlink:to="loc_srt_WeightedAverageMember_4bd080b4-e82c-4b25-9a3e-56ea3c3dcb4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_fe624655-e68c-42fc-a91c-e13ec8e3864c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_eab5c4ef-0c7d-4517-93cd-4c7a47dac747" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_fe624655-e68c-42fc-a91c-e13ec8e3864c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_7cc24151-5924-48ba-8f42-643ae1fd481a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_fe624655-e68c-42fc-a91c-e13ec8e3864c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_7cc24151-5924-48ba-8f42-643ae1fd481a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesBCommonWarrantsMember_525be305-f928-4f50-982f-ebd74757b63f" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SeriesBCommonWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7cc24151-5924-48ba-8f42-643ae1fd481a" xlink:to="loc_ck0001824293_SeriesBCommonWarrantsMember_525be305-f928-4f50-982f-ebd74757b63f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_b9d5748e-3e5d-4d07-ae87-0bda67aa9ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_eab5c4ef-0c7d-4517-93cd-4c7a47dac747" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_b9d5748e-3e5d-4d07-ae87-0bda67aa9ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f551bb06-295b-44fb-a98e-57fd817c9dec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9d5748e-3e5d-4d07-ae87-0bda67aa9ac5" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f551bb06-295b-44fb-a98e-57fd817c9dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_977b76a7-9cf0-4b75-b36b-098eff9acbbd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9d5748e-3e5d-4d07-ae87-0bda67aa9ac5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_977b76a7-9cf0-4b75-b36b-098eff9acbbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_282e4333-47bd-41ef-8069-c1b223bff11e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9d5748e-3e5d-4d07-ae87-0bda67aa9ac5" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_282e4333-47bd-41ef-8069-c1b223bff11e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_c0a87688-9fe6-40fa-b1c3-449cd6596f5b" xlink:href="ck0001824293-20250630.xsd#ck0001824293_StockIssuanceCostsOfferingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9d5748e-3e5d-4d07-ae87-0bda67aa9ac5" xlink:to="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_c0a87688-9fe6-40fa-b1c3-449cd6596f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockMaximumValueOfSharesOffered_15785aa1-33fa-4881-a881-deb650307810" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SaleOfStockMaximumValueOfSharesOffered"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9d5748e-3e5d-4d07-ae87-0bda67aa9ac5" xlink:to="loc_ck0001824293_SaleOfStockMaximumValueOfSharesOffered_15785aa1-33fa-4881-a881-deb650307810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockAgentCompensationPercentage_d7988fbb-59ec-4a51-863a-b1357cda1070" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SaleOfStockAgentCompensationPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9d5748e-3e5d-4d07-ae87-0bda67aa9ac5" xlink:to="loc_ck0001824293_SaleOfStockAgentCompensationPercentage_d7988fbb-59ec-4a51-863a-b1357cda1070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_492149f2-ec55-49f3-85d2-7e4d79f4bb33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9d5748e-3e5d-4d07-ae87-0bda67aa9ac5" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_492149f2-ec55-49f3-85d2-7e4d79f4bb33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_7e289c2f-9488-407d-ab96-544da3a8b05d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9d5748e-3e5d-4d07-ae87-0bda67aa9ac5" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_7e289c2f-9488-407d-ab96-544da3a8b05d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_3606246e-dfa1-4cc4-877c-6c43fb7065e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9d5748e-3e5d-4d07-ae87-0bda67aa9ac5" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_3606246e-dfa1-4cc4-877c-6c43fb7065e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ClassOfWarrantsOrRightAgentFeesAndOfferingExpense_15c31875-2a34-40bf-8e67-77c63205a6d7" xlink:href="ck0001824293-20250630.xsd#ck0001824293_ClassOfWarrantsOrRightAgentFeesAndOfferingExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b9d5748e-3e5d-4d07-ae87-0bda67aa9ac5" xlink:to="loc_ck0001824293_ClassOfWarrantsOrRightAgentFeesAndOfferingExpense_15c31875-2a34-40bf-8e67-77c63205a6d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e923b485-273c-4a5a-a9b1-fb9d2f7c8cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9ba3471a-9692-4ace-a409-3fc58c43e77b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e923b485-273c-4a5a-a9b1-fb9d2f7c8cf0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9ba3471a-9692-4ace-a409-3fc58c43e77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6fe91bde-0b3f-4c9b-b132-478f32640830" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9ba3471a-9692-4ace-a409-3fc58c43e77b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6fe91bde-0b3f-4c9b-b132-478f32640830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6b0d8a85-8471-4239-83b3-8a007c983481" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6fe91bde-0b3f-4c9b-b132-478f32640830" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6b0d8a85-8471-4239-83b3-8a007c983481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1321c49c-7424-48d4-a676-916614d501dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6b0d8a85-8471-4239-83b3-8a007c983481" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1321c49c-7424-48d4-a676-916614d501dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_721f8150-da0f-442f-932a-e07ef7572000" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6b0d8a85-8471-4239-83b3-8a007c983481" xlink:to="loc_us-gaap_WarrantMember_721f8150-da0f-442f-932a-e07ef7572000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_543cdebc-2052-4e66-bf9e-eb8fd06bbc26" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_9ba3471a-9692-4ace-a409-3fc58c43e77b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_543cdebc-2052-4e66-bf9e-eb8fd06bbc26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8ffed15c-ee03-4ff0-8c5d-2032247f982c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_543cdebc-2052-4e66-bf9e-eb8fd06bbc26" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8ffed15c-ee03-4ff0-8c5d-2032247f982c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_da5a9a8f-8b04-42ad-8b79-1fba9fbb23d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0657fae6-986d-4b23-a37d-3605c5abc913" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_da5a9a8f-8b04-42ad-8b79-1fba9fbb23d5" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0657fae6-986d-4b23-a37d-3605c5abc913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_70830ed0-2608-47ba-b8ce-f9b5c7462f94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0657fae6-986d-4b23-a37d-3605c5abc913" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_70830ed0-2608-47ba-b8ce-f9b5c7462f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_eb223681-9c5d-4d6a-b430-4da236586bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_70830ed0-2608-47ba-b8ce-f9b5c7462f94" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_eb223681-9c5d-4d6a-b430-4da236586bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_8ff34d4f-ab7c-4cf4-877a-b1d089d62c05" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_eb223681-9c5d-4d6a-b430-4da236586bb7" xlink:to="loc_us-gaap_ComputerEquipmentMember_8ff34d4f-ab7c-4cf4-877a-b1d089d62c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_414cf147-d083-4325-bfd1-bf31f00ab456" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_eb223681-9c5d-4d6a-b430-4da236586bb7" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_414cf147-d083-4325-bfd1-bf31f00ab456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2ff26815-13be-4858-a1d1-4c8268e9afcd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0657fae6-986d-4b23-a37d-3605c5abc913" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2ff26815-13be-4858-a1d1-4c8268e9afcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_9cf8e9a0-3418-46f6-91f7-0c833f8887f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2ff26815-13be-4858-a1d1-4c8268e9afcd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_9cf8e9a0-3418-46f6-91f7-0c833f8887f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b2ba2889-7a9d-44af-b6f3-eb4b163f49da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2ff26815-13be-4858-a1d1-4c8268e9afcd" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b2ba2889-7a9d-44af-b6f3-eb4b163f49da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f7123f16-6558-472f-8ea6-1ae4aaec8d61" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2ff26815-13be-4858-a1d1-4c8268e9afcd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f7123f16-6558-472f-8ea6-1ae4aaec8d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#PROPERTYANDEQUIPMENTNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_509f226a-1c1e-4bc7-a62e-fd5130b273a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_c85100f6-0c32-4f73-90ba-fb3a5b91d975" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_509f226a-1c1e-4bc7-a62e-fd5130b273a2" xlink:to="loc_us-gaap_Depreciation_c85100f6-0c32-4f73-90ba-fb3a5b91d975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#ACCRUEDEXPENSESDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_bdd5dbf3-4024-46b6-81c7-7ea51699e091" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_9a7ce572-d91a-475c-87ea-7e9c0fc550c7" xlink:href="ck0001824293-20250630.xsd#ck0001824293_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_bdd5dbf3-4024-46b6-81c7-7ea51699e091" xlink:to="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_9a7ce572-d91a-475c-87ea-7e9c0fc550c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_65863b20-1ea0-4e32-87e0-d8126fce3ca5" xlink:href="ck0001824293-20250630.xsd#ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_bdd5dbf3-4024-46b6-81c7-7ea51699e091" xlink:to="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_65863b20-1ea0-4e32-87e0-d8126fce3ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b2e3479b-b702-4d01-a6e8-4bea1a6f82f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_bdd5dbf3-4024-46b6-81c7-7ea51699e091" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b2e3479b-b702-4d01-a6e8-4bea1a6f82f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_11fdf608-5d8d-49cb-a264-f1aae3092c17" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_bdd5dbf3-4024-46b6-81c7-7ea51699e091" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_11fdf608-5d8d-49cb-a264-f1aae3092c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#STOCKHOLDERSEQUITYNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ce517b98-0b2f-493e-9410-8784939603cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_54f54d33-b27d-4f2e-b82c-9a351dcd2c18" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ce517b98-0b2f-493e-9410-8784939603cd" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_54f54d33-b27d-4f2e-b82c-9a351dcd2c18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_0797dc32-06b7-4828-8692-e744059c0c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_54f54d33-b27d-4f2e-b82c-9a351dcd2c18" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_0797dc32-06b7-4828-8692-e744059c0c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0a72c619-65a8-404d-8d80-b0eec086f19b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_0797dc32-06b7-4828-8692-e744059c0c9a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0a72c619-65a8-404d-8d80-b0eec086f19b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PublicOfferingMember_0ac741dd-fb30-46ad-b58f-d87b489656d4" xlink:href="ck0001824293-20250630.xsd#ck0001824293_PublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0a72c619-65a8-404d-8d80-b0eec086f19b" xlink:to="loc_ck0001824293_PublicOfferingMember_0ac741dd-fb30-46ad-b58f-d87b489656d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AtTheMarketOfferingMember_68463b33-4b0b-4f35-949a-a615f80c0a63" xlink:href="ck0001824293-20250630.xsd#ck0001824293_AtTheMarketOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0a72c619-65a8-404d-8d80-b0eec086f19b" xlink:to="loc_ck0001824293_AtTheMarketOfferingMember_68463b33-4b0b-4f35-949a-a615f80c0a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_b7474201-8024-467e-a72a-d420619d2cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_54f54d33-b27d-4f2e-b82c-9a351dcd2c18" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_b7474201-8024-467e-a72a-d420619d2cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_ecb12587-dde4-4ed0-842a-0bc963d7a2d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_b7474201-8024-467e-a72a-d420619d2cf8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_ecb12587-dde4-4ed0-842a-0bc963d7a2d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PreFundedWarrantsMember_c45d4549-28f4-416f-8a13-c460c82726de" xlink:href="ck0001824293-20250630.xsd#ck0001824293_PreFundedWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ecb12587-dde4-4ed0-842a-0bc963d7a2d1" xlink:to="loc_ck0001824293_PreFundedWarrantsMember_c45d4549-28f4-416f-8a13-c460c82726de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesBCommonWarrantsMember_f7918634-394a-4bc8-b623-13fb20bfd3ca" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SeriesBCommonWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ecb12587-dde4-4ed0-842a-0bc963d7a2d1" xlink:to="loc_ck0001824293_SeriesBCommonWarrantsMember_f7918634-394a-4bc8-b623-13fb20bfd3ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesB1CommonWarrantsMember_a4a5c285-1585-4937-a13b-5a3b6ffe68cb" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SeriesB1CommonWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ck0001824293_SeriesBCommonWarrantsMember_f7918634-394a-4bc8-b623-13fb20bfd3ca" xlink:to="loc_ck0001824293_SeriesB1CommonWarrantsMember_a4a5c285-1585-4937-a13b-5a3b6ffe68cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesB2CommonWarrantsMember_053a6bef-4d0a-4883-a84e-c4068f9af2c0" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SeriesB2CommonWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ck0001824293_SeriesBCommonWarrantsMember_f7918634-394a-4bc8-b623-13fb20bfd3ca" xlink:to="loc_ck0001824293_SeriesB2CommonWarrantsMember_053a6bef-4d0a-4883-a84e-c4068f9af2c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesA1WarrantsMember_9dcb0d7f-d85b-47fa-99b6-4f7d5a030a55" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SeriesA1WarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ecb12587-dde4-4ed0-842a-0bc963d7a2d1" xlink:to="loc_ck0001824293_SeriesA1WarrantsMember_9dcb0d7f-d85b-47fa-99b6-4f7d5a030a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesC1CommonWarrantsMember_760ffc83-8653-487b-9118-d9cda02951b0" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SeriesC1CommonWarrantsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ecb12587-dde4-4ed0-842a-0bc963d7a2d1" xlink:to="loc_ck0001824293_SeriesC1CommonWarrantsMember_760ffc83-8653-487b-9118-d9cda02951b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesC2CommonWarrantsMember_b9b75110-b6a9-4ada-be22-50691a1af79d" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SeriesC2CommonWarrantsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ecb12587-dde4-4ed0-842a-0bc963d7a2d1" xlink:to="loc_ck0001824293_SeriesC2CommonWarrantsMember_b9b75110-b6a9-4ada-be22-50691a1af79d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PreFundedAndSeriesCWarrantsMember_573b3d49-fa31-4cd3-bd77-34a5988c9de3" xlink:href="ck0001824293-20250630.xsd#ck0001824293_PreFundedAndSeriesCWarrantsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ecb12587-dde4-4ed0-842a-0bc963d7a2d1" xlink:to="loc_ck0001824293_PreFundedAndSeriesCWarrantsMember_573b3d49-fa31-4cd3-bd77-34a5988c9de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_June2024PAWarrantsMember_a9b78bb2-173a-4e67-b00d-35e96a5a4ed9" xlink:href="ck0001824293-20250630.xsd#ck0001824293_June2024PAWarrantsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ecb12587-dde4-4ed0-842a-0bc963d7a2d1" xlink:to="loc_ck0001824293_June2024PAWarrantsMember_a9b78bb2-173a-4e67-b00d-35e96a5a4ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesDWarrantsMember_0d99db38-5bd4-49ce-ab8b-1fbcea3eb7ea" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SeriesDWarrantsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ecb12587-dde4-4ed0-842a-0bc963d7a2d1" xlink:to="loc_ck0001824293_SeriesDWarrantsMember_0d99db38-5bd4-49ce-ab8b-1fbcea3eb7ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesD1WarrantsMember_a2fa0a80-0f88-4534-8542-cb48090516e2" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SeriesD1WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ck0001824293_SeriesDWarrantsMember_0d99db38-5bd4-49ce-ab8b-1fbcea3eb7ea" xlink:to="loc_ck0001824293_SeriesD1WarrantsMember_a2fa0a80-0f88-4534-8542-cb48090516e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesD2WarrantsMember_79f62e8f-2f7e-4f93-ac1d-c957f8854501" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SeriesD2WarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ck0001824293_SeriesDWarrantsMember_0d99db38-5bd4-49ce-ab8b-1fbcea3eb7ea" xlink:to="loc_ck0001824293_SeriesD2WarrantsMember_79f62e8f-2f7e-4f93-ac1d-c957f8854501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_October2024PAWarrantsMember_55acee36-674e-478a-9172-740bcf9d8868" xlink:href="ck0001824293-20250630.xsd#ck0001824293_October2024PAWarrantsMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ecb12587-dde4-4ed0-842a-0bc963d7a2d1" xlink:to="loc_ck0001824293_October2024PAWarrantsMember_55acee36-674e-478a-9172-740bcf9d8868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesE1CommonWarrantsMember_bb594b59-fa1f-49c4-ae58-a93e78f348a5" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SeriesE1CommonWarrantsMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ecb12587-dde4-4ed0-842a-0bc963d7a2d1" xlink:to="loc_ck0001824293_SeriesE1CommonWarrantsMember_bb594b59-fa1f-49c4-ae58-a93e78f348a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesE2CommonWarrantsMember_597d5266-092d-4da7-84c0-89f773dfbd94" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SeriesE2CommonWarrantsMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ecb12587-dde4-4ed0-842a-0bc963d7a2d1" xlink:to="loc_ck0001824293_SeriesE2CommonWarrantsMember_597d5266-092d-4da7-84c0-89f773dfbd94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesE3CommonWarrantsMember_8e373114-dcfa-45a0-aa28-810f225b4804" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SeriesE3CommonWarrantsMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ecb12587-dde4-4ed0-842a-0bc963d7a2d1" xlink:to="loc_ck0001824293_SeriesE3CommonWarrantsMember_8e373114-dcfa-45a0-aa28-810f225b4804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesECommonWarrantMember_e9397a51-c21c-491f-9ff4-739858a6f3fc" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SeriesECommonWarrantMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ecb12587-dde4-4ed0-842a-0bc963d7a2d1" xlink:to="loc_ck0001824293_SeriesECommonWarrantMember_e9397a51-c21c-491f-9ff4-739858a6f3fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_April2025PAWarrantsMember_f5871f50-3cc7-4f62-b586-dfff34e43af2" xlink:href="ck0001824293-20250630.xsd#ck0001824293_April2025PAWarrantsMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ecb12587-dde4-4ed0-842a-0bc963d7a2d1" xlink:to="loc_ck0001824293_April2025PAWarrantsMember_f5871f50-3cc7-4f62-b586-dfff34e43af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b1d460a4-7ab6-4d6e-a6e6-9196ac3402f7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_54f54d33-b27d-4f2e-b82c-9a351dcd2c18" xlink:to="loc_srt_RangeAxis_b1d460a4-7ab6-4d6e-a6e6-9196ac3402f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_56ef76e2-2f4f-45ec-b47b-7552241c342c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b1d460a4-7ab6-4d6e-a6e6-9196ac3402f7" xlink:to="loc_srt_RangeMember_56ef76e2-2f4f-45ec-b47b-7552241c342c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_34381a95-5808-45d7-92ae-8f69a5db09b3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_56ef76e2-2f4f-45ec-b47b-7552241c342c" xlink:to="loc_srt_WeightedAverageMember_34381a95-5808-45d7-92ae-8f69a5db09b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_21148ad2-fa44-4b24-a0f6-2cc2af2b8f9d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_56ef76e2-2f4f-45ec-b47b-7552241c342c" xlink:to="loc_srt_MaximumMember_21148ad2-fa44-4b24-a0f6-2cc2af2b8f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_54f54d33-b27d-4f2e-b82c-9a351dcd2c18" xlink:to="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_c37ea21c-691d-4798-a8bd-abb49a380ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_c37ea21c-691d-4798-a8bd-abb49a380ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6759bc91-38ba-404f-a3df-a625ce65871e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6759bc91-38ba-404f-a3df-a625ce65871e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_06c9f71d-a7ca-44f9-ae66-24ce77207da2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_06c9f71d-a7ca-44f9-ae66-24ce77207da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_834208e4-9b7a-443e-8bcf-07641dce30cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_834208e4-9b7a-443e-8bcf-07641dce30cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_16ea3cf7-4c9f-42c5-87e8-96e5672e0771" xlink:href="ck0001824293-20250630.xsd#ck0001824293_StockIssuanceCostsOfferingExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:to="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_16ea3cf7-4c9f-42c5-87e8-96e5672e0771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction_6d379ac9-faf5-46f3-9486-c877539586fa" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:to="loc_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction_6d379ac9-faf5-46f3-9486-c877539586fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_210ef656-b49f-466a-8a82-a9adaf2bdf69" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_210ef656-b49f-466a-8a82-a9adaf2bdf69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_34aa8850-98d5-4b7b-be4a-dde5ae95c23e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_34aa8850-98d5-4b7b-be4a-dde5ae95c23e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_e99dd744-492c-492d-93cc-84813ab36b75" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_e99dd744-492c-492d-93cc-84813ab36b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_12453193-f7c5-4025-b121-e79dbd05b486" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_12453193-f7c5-4025-b121-e79dbd05b486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_1cc7e94b-c6ac-449a-af0a-50be50f9973b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_1cc7e94b-c6ac-449a-af0a-50be50f9973b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockMaximumValueOfSharesOffered_7e69a8ca-6235-4355-a712-7ff39fee5f98" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SaleOfStockMaximumValueOfSharesOffered"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:to="loc_ck0001824293_SaleOfStockMaximumValueOfSharesOffered_7e69a8ca-6235-4355-a712-7ff39fee5f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockAgentCompensationPercentage_ef7f90e0-951a-4d76-81fb-c83a67379d61" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SaleOfStockAgentCompensationPercentage"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:to="loc_ck0001824293_SaleOfStockAgentCompensationPercentage_ef7f90e0-951a-4d76-81fb-c83a67379d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_59e14906-7ca1-43e8-a1cc-4bd36e541f77" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_59e14906-7ca1-43e8-a1cc-4bd36e541f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds_b84bf33d-4041-489e-a18d-ef8a47ec7ef7" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:to="loc_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds_b84bf33d-4041-489e-a18d-ef8a47ec7ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds_e12fad4c-ebf0-4b41-ab14-1df482132f37" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:to="loc_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds_e12fad4c-ebf0-4b41-ab14-1df482132f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses_76097c4b-42ce-4c67-89fb-738cd3bcb27f" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SaleOfStockReimbursementOfAccountableExpenses"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:to="loc_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses_76097c4b-42ce-4c67-89fb-738cd3bcb27f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses_77f6a894-2e22-4d50-9e34-229b645aa148" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:to="loc_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses_77f6a894-2e22-4d50-9e34-229b645aa148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense_d890a8ec-0258-4ce9-ac5d-d62b6f6cfb33" xlink:href="ck0001824293-20250630.xsd#ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:to="loc_ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense_d890a8ec-0258-4ce9-ac5d-d62b6f6cfb33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ClassOfWarrantOrRightOfferingCost_c13d82a3-5890-4d45-8c52-6c736a59d758" xlink:href="ck0001824293-20250630.xsd#ck0001824293_ClassOfWarrantOrRightOfferingCost"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:to="loc_ck0001824293_ClassOfWarrantOrRightOfferingCost_c13d82a3-5890-4d45-8c52-6c736a59d758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_133617d9-06b5-4661-88ad-d8b5cf19bb55" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_133617d9-06b5-4661-88ad-d8b5cf19bb55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses_4caa0f49-0acc-49ff-94ac-5a78daf3d946" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:to="loc_ck0001824293_SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses_4caa0f49-0acc-49ff-94ac-5a78daf3d946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockClearingExpenses_a7a47bf5-f0ad-4b4c-bcf1-c6a26908c119" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SaleOfStockClearingExpenses"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5fd5d9ab-beec-4c2c-807f-14696b68faf5" xlink:to="loc_ck0001824293_SaleOfStockClearingExpenses_a7a47bf5-f0ad-4b4c-bcf1-c6a26908c119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_212b0889-0fb6-4fc5-8cd4-63bf95aa2ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_d720841e-7a89-46a9-870f-4da6bd16884d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_212b0889-0fb6-4fc5-8cd4-63bf95aa2ad7" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_d720841e-7a89-46a9-870f-4da6bd16884d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_45b1798c-857c-424d-90e6-6be30ce42ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d720841e-7a89-46a9-870f-4da6bd16884d" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_45b1798c-857c-424d-90e6-6be30ce42ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_e9a90f08-9478-48ce-8ca9-6eb5850f7454" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_45b1798c-857c-424d-90e6-6be30ce42ff9" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_e9a90f08-9478-48ce-8ca9-6eb5850f7454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember_b18f5631-61a0-433f-8b03-1311dd03e613" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputOptionVolatilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_e9a90f08-9478-48ce-8ca9-6eb5850f7454" xlink:to="loc_us-gaap_MeasurementInputOptionVolatilityMember_b18f5631-61a0-433f-8b03-1311dd03e613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_e90c2e58-69b5-48d4-95a6-345d70481c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_e9a90f08-9478-48ce-8ca9-6eb5850f7454" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_e90c2e58-69b5-48d4-95a6-345d70481c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_ccadac89-b402-4ede-bb5e-e3bcb9003740" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_e9a90f08-9478-48ce-8ca9-6eb5850f7454" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_ccadac89-b402-4ede-bb5e-e3bcb9003740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_7c6382d5-6245-4243-8039-e4a3842729c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_e9a90f08-9478-48ce-8ca9-6eb5850f7454" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_7c6382d5-6245-4243-8039-e4a3842729c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_aa0a16fd-95e9-4f39-b141-a6de23934017" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d720841e-7a89-46a9-870f-4da6bd16884d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_aa0a16fd-95e9-4f39-b141-a6de23934017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_95f7a7d8-f255-4f51-ab62-79d7fbe25b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_aa0a16fd-95e9-4f39-b141-a6de23934017" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_95f7a7d8-f255-4f51-ab62-79d7fbe25b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesECommonWarrantsAndApril2025PAWarrantsMember_9d5fc306-2e94-475c-a1b7-b5931aa8560a" xlink:href="ck0001824293-20250630.xsd#ck0001824293_SeriesECommonWarrantsAndApril2025PAWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_95f7a7d8-f255-4f51-ab62-79d7fbe25b0c" xlink:to="loc_ck0001824293_SeriesECommonWarrantsAndApril2025PAWarrantsMember_9d5fc306-2e94-475c-a1b7-b5931aa8560a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_7892a359-56b9-4d3f-af5a-b89ef5227bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d720841e-7a89-46a9-870f-4da6bd16884d" xlink:to="loc_us-gaap_ClassOfStockLineItems_7892a359-56b9-4d3f-af5a-b89ef5227bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_7551edc4-7b7e-4767-8e4b-598678d9d45c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7892a359-56b9-4d3f-af5a-b89ef5227bf7" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_7551edc4-7b7e-4767-8e4b-598678d9d45c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_6ef79f44-5828-4fea-ad18-93613dc56d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_f5c07a95-9d10-4de5-a512-372f751a49f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6ef79f44-5828-4fea-ad18-93613dc56d1b" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_f5c07a95-9d10-4de5-a512-372f751a49f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_2ae52d6b-994e-4386-8264-62c077d57b53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f5c07a95-9d10-4de5-a512-372f751a49f0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_2ae52d6b-994e-4386-8264-62c077d57b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_ed84f39c-8cb5-45a8-b108-dbf26687b61b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2ae52d6b-994e-4386-8264-62c077d57b53" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_ed84f39c-8cb5-45a8-b108-dbf26687b61b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInAugust2025Member_a1b6e84e-ee58-4bee-a775-7d53bc834f6b" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsExpiringInAugust2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ed84f39c-8cb5-45a8-b108-dbf26687b61b" xlink:to="loc_ck0001824293_WarrantsExpiringInAugust2025Member_a1b6e84e-ee58-4bee-a775-7d53bc834f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInJanuary2026Member_924afc1e-54eb-40a1-a213-31dcbe6db5ae" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsExpiringInJanuary2026Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ed84f39c-8cb5-45a8-b108-dbf26687b61b" xlink:to="loc_ck0001824293_WarrantsExpiringInJanuary2026Member_924afc1e-54eb-40a1-a213-31dcbe6db5ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInFebruary2026Member_82f48073-5bbe-4fc8-bb1e-aa319e7bd256" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsExpiringInFebruary2026Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ed84f39c-8cb5-45a8-b108-dbf26687b61b" xlink:to="loc_ck0001824293_WarrantsExpiringInFebruary2026Member_82f48073-5bbe-4fc8-bb1e-aa319e7bd256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInMarch2026Member_572d18db-e39a-41c3-9929-cc03f0c5d33e" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsExpiringInMarch2026Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ed84f39c-8cb5-45a8-b108-dbf26687b61b" xlink:to="loc_ck0001824293_WarrantsExpiringInMarch2026Member_572d18db-e39a-41c3-9929-cc03f0c5d33e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInApril2026Member_423c0718-27f0-4739-ba57-17df9552ba32" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsExpiringInApril2026Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ed84f39c-8cb5-45a8-b108-dbf26687b61b" xlink:to="loc_ck0001824293_WarrantsExpiringInApril2026Member_423c0718-27f0-4739-ba57-17df9552ba32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInOctober2026Member_d633c1db-e9e3-48cf-9932-bbb4dd74d673" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsExpiringInOctober2026Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ed84f39c-8cb5-45a8-b108-dbf26687b61b" xlink:to="loc_ck0001824293_WarrantsExpiringInOctober2026Member_d633c1db-e9e3-48cf-9932-bbb4dd74d673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInMay2027Member_8e781d7f-2d67-4436-9bc9-51722c307703" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsExpiringInMay2027Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ed84f39c-8cb5-45a8-b108-dbf26687b61b" xlink:to="loc_ck0001824293_WarrantsExpiringInMay2027Member_8e781d7f-2d67-4436-9bc9-51722c307703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInJuly2027Member_d6afd618-b81f-4e5a-8523-3fc84d4eeed4" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsExpiringInJuly2027Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ed84f39c-8cb5-45a8-b108-dbf26687b61b" xlink:to="loc_ck0001824293_WarrantsExpiringInJuly2027Member_d6afd618-b81f-4e5a-8523-3fc84d4eeed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInApril2028Member_f2085efa-fca3-496e-841c-14af4ba1208b" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsExpiringInApril2028Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ed84f39c-8cb5-45a8-b108-dbf26687b61b" xlink:to="loc_ck0001824293_WarrantsExpiringInApril2028Member_f2085efa-fca3-496e-841c-14af4ba1208b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInFebruary2029Member_b305603b-f07b-4ede-9f39-43f0aefde18b" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsExpiringInFebruary2029Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ed84f39c-8cb5-45a8-b108-dbf26687b61b" xlink:to="loc_ck0001824293_WarrantsExpiringInFebruary2029Member_b305603b-f07b-4ede-9f39-43f0aefde18b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInJune2029Member_8c0db434-fc16-418d-95b4-5121c62e770f" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsExpiringInJune2029Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ed84f39c-8cb5-45a8-b108-dbf26687b61b" xlink:to="loc_ck0001824293_WarrantsExpiringInJune2029Member_8c0db434-fc16-418d-95b4-5121c62e770f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInSeptember2029Member_9ec0396c-3625-4ae1-917c-66e8540f4686" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsExpiringInSeptember2029Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ed84f39c-8cb5-45a8-b108-dbf26687b61b" xlink:to="loc_ck0001824293_WarrantsExpiringInSeptember2029Member_9ec0396c-3625-4ae1-917c-66e8540f4686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInOctober2029OneMember_6c81a780-f96a-419b-b896-4e6b9d929d74" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsExpiringInOctober2029OneMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ed84f39c-8cb5-45a8-b108-dbf26687b61b" xlink:to="loc_ck0001824293_WarrantsExpiringInOctober2029OneMember_6c81a780-f96a-419b-b896-4e6b9d929d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInOctober2029TwoMember_47bb9e27-9dd1-4bd9-a92e-8f0956977349" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsExpiringInOctober2029TwoMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ed84f39c-8cb5-45a8-b108-dbf26687b61b" xlink:to="loc_ck0001824293_WarrantsExpiringInOctober2029TwoMember_47bb9e27-9dd1-4bd9-a92e-8f0956977349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInApril2030OneMember_8eb6b77b-d0ce-4894-a9a3-7be31686df78" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsExpiringInApril2030OneMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ed84f39c-8cb5-45a8-b108-dbf26687b61b" xlink:to="loc_ck0001824293_WarrantsExpiringInApril2030OneMember_8eb6b77b-d0ce-4894-a9a3-7be31686df78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInApril2030TwoMember_9ac831a6-d364-471e-bc9f-4f7cf390160a" xlink:href="ck0001824293-20250630.xsd#ck0001824293_WarrantsExpiringInApril2030TwoMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ed84f39c-8cb5-45a8-b108-dbf26687b61b" xlink:to="loc_ck0001824293_WarrantsExpiringInApril2030TwoMember_9ac831a6-d364-471e-bc9f-4f7cf390160a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_9358c0c0-977d-499b-aca7-71b9c77f3fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f5c07a95-9d10-4de5-a512-372f751a49f0" xlink:to="loc_us-gaap_ClassOfStockLineItems_9358c0c0-977d-499b-aca7-71b9c77f3fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_987f5f48-85aa-415c-acde-4542e86f1280" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9358c0c0-977d-499b-aca7-71b9c77f3fb7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_987f5f48-85aa-415c-acde-4542e86f1280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_18d1f9f2-cc84-40d3-9292-c32b848027b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9358c0c0-977d-499b-aca7-71b9c77f3fb7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_18d1f9f2-cc84-40d3-9292-c32b848027b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#STOCKBASEDCOMPENSATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b93c1f43-3381-43e1-8cc1-58c8221d9e53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_997f385e-bd8b-446c-984f-4c3bb334fe9b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b93c1f43-3381-43e1-8cc1-58c8221d9e53" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_997f385e-bd8b-446c-984f-4c3bb334fe9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_f1ebebb4-6b73-496c-a867-43b35a40a7c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_997f385e-bd8b-446c-984f-4c3bb334fe9b" xlink:to="loc_us-gaap_PlanNameAxis_f1ebebb4-6b73-496c-a867-43b35a40a7c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6fcc1869-ce2a-4153-a48e-771038e8a452" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_f1ebebb4-6b73-496c-a867-43b35a40a7c3" xlink:to="loc_us-gaap_PlanNameDomain_6fcc1869-ce2a-4153-a48e-771038e8a452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember_4feee8cb-0b87-4c46-9aa5-27a29cc2e2e6" xlink:href="ck0001824293-20250630.xsd#ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_6fcc1869-ce2a-4153-a48e-771038e8a452" xlink:to="loc_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember_4feee8cb-0b87-4c46-9aa5-27a29cc2e2e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4199bb70-eb6c-4022-b467-21a4cb59cb65" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_997f385e-bd8b-446c-984f-4c3bb334fe9b" xlink:to="loc_srt_RangeAxis_4199bb70-eb6c-4022-b467-21a4cb59cb65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1122e202-21ce-4678-9721-6668d52c4458" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4199bb70-eb6c-4022-b467-21a4cb59cb65" xlink:to="loc_srt_RangeMember_1122e202-21ce-4678-9721-6668d52c4458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c952d014-34b0-4780-9683-d2cad3a64844" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1122e202-21ce-4678-9721-6668d52c4458" xlink:to="loc_srt_MaximumMember_c952d014-34b0-4780-9683-d2cad3a64844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_76ea04fc-7c1e-46ec-86c3-0e3ff8eb1950" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_997f385e-bd8b-446c-984f-4c3bb334fe9b" xlink:to="loc_us-gaap_AwardTypeAxis_76ea04fc-7c1e-46ec-86c3-0e3ff8eb1950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8e46cbb8-d554-4443-8ebf-ead02635dc0d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_76ea04fc-7c1e-46ec-86c3-0e3ff8eb1950" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8e46cbb8-d554-4443-8ebf-ead02635dc0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_db2153e3-6461-4cfb-a435-cc68a756a541" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8e46cbb8-d554-4443-8ebf-ead02635dc0d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_db2153e3-6461-4cfb-a435-cc68a756a541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0c0ef969-437e-4ffc-9d1c-0bac82b512cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_997f385e-bd8b-446c-984f-4c3bb334fe9b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0c0ef969-437e-4ffc-9d1c-0bac82b512cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_544c35bb-95ee-48c6-8443-ebb5d4623068" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0c0ef969-437e-4ffc-9d1c-0bac82b512cc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_544c35bb-95ee-48c6-8443-ebb5d4623068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4cc4ca85-95de-4dd5-81e3-17e3ec8d8251" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0c0ef969-437e-4ffc-9d1c-0bac82b512cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4cc4ca85-95de-4dd5-81e3-17e3ec8d8251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b0607e69-a97f-469b-818e-fe889ae43617" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0c0ef969-437e-4ffc-9d1c-0bac82b512cc" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b0607e69-a97f-469b-818e-fe889ae43617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum_c3a1d58f-3b0c-4054-b46c-359f5c34797a" xlink:href="ck0001824293-20250630.xsd#ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0c0ef969-437e-4ffc-9d1c-0bac82b512cc" xlink:to="loc_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum_c3a1d58f-3b0c-4054-b46c-359f5c34797a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e1043246-9d7c-4a78-a0d3-169251b3e3a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0c0ef969-437e-4ffc-9d1c-0bac82b512cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e1043246-9d7c-4a78-a0d3-169251b3e3a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_89cfc33c-b43e-4a76-9a6d-847e2f95dd55" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0c0ef969-437e-4ffc-9d1c-0bac82b512cc" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_89cfc33c-b43e-4a76-9a6d-847e2f95dd55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_be04871d-90be-4bae-9f59-404b2ee2c0a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0c0ef969-437e-4ffc-9d1c-0bac82b512cc" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_be04871d-90be-4bae-9f59-404b2ee2c0a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3d39698a-fb86-45c9-a70e-1b3de3057ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0c0ef969-437e-4ffc-9d1c-0bac82b512cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3d39698a-fb86-45c9-a70e-1b3de3057ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_90eadbff-0643-41cd-9c5a-bd575a421a49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0c0ef969-437e-4ffc-9d1c-0bac82b512cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_90eadbff-0643-41cd-9c5a-bd575a421a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_34d5e9b1-4e53-4dd9-9db8-426b55191fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f37969f7-0e29-4e4a-8fbd-b6d30d0abd9c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_34d5e9b1-4e53-4dd9-9db8-426b55191fc0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f37969f7-0e29-4e4a-8fbd-b6d30d0abd9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6c0b43fc-4a49-4e4a-b943-fa09af6e7640" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f37969f7-0e29-4e4a-8fbd-b6d30d0abd9c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6c0b43fc-4a49-4e4a-b943-fa09af6e7640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9bdf10f7-e3bc-49fb-9dc3-1cc1be2fc816" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6c0b43fc-4a49-4e4a-b943-fa09af6e7640" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9bdf10f7-e3bc-49fb-9dc3-1cc1be2fc816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e97a21ac-d569-40fc-b251-7278bb1c65f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9bdf10f7-e3bc-49fb-9dc3-1cc1be2fc816" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e97a21ac-d569-40fc-b251-7278bb1c65f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_b1ef0503-061f-4b8b-a29f-ad27a5db13fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9bdf10f7-e3bc-49fb-9dc3-1cc1be2fc816" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_b1ef0503-061f-4b8b-a29f-ad27a5db13fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d2bdf903-5377-41a8-b781-fc8c2bc9b3b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f37969f7-0e29-4e4a-8fbd-b6d30d0abd9c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d2bdf903-5377-41a8-b781-fc8c2bc9b3b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_ddb3731d-6a18-46ba-9682-20208a8ebd5b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d2bdf903-5377-41a8-b781-fc8c2bc9b3b2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_ddb3731d-6a18-46ba-9682-20208a8ebd5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f92a06c1-c31e-428d-bbf2-db11271106c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b91679b9-6eca-4661-bb6a-6b59bd29ca81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f92a06c1-c31e-428d-bbf2-db11271106c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b91679b9-6eca-4661-bb6a-6b59bd29ca81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60d85b09-f342-4def-ba6d-8badacdc41a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b91679b9-6eca-4661-bb6a-6b59bd29ca81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60d85b09-f342-4def-ba6d-8badacdc41a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7224e68f-698c-479a-994f-e07d5e6a05c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b91679b9-6eca-4661-bb6a-6b59bd29ca81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7224e68f-698c-479a-994f-e07d5e6a05c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_532c0ad7-82cc-4157-aff4-4e988f6d2270" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b91679b9-6eca-4661-bb6a-6b59bd29ca81" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_532c0ad7-82cc-4157-aff4-4e988f6d2270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_dfb9ca04-75ac-479b-a28d-052ab278a90c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b91679b9-6eca-4661-bb6a-6b59bd29ca81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_dfb9ca04-75ac-479b-a28d-052ab278a90c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1e41d42c-8dec-4ad0-8203-38f63ceb73a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b91679b9-6eca-4661-bb6a-6b59bd29ca81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1e41d42c-8dec-4ad0-8203-38f63ceb73a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_66fac194-fd1c-42a5-8647-9322539ce3a6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f92a06c1-c31e-428d-bbf2-db11271106c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_66fac194-fd1c-42a5-8647-9322539ce3a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_febcc9a9-420b-4b57-9a00-caee0bbb82ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f92a06c1-c31e-428d-bbf2-db11271106c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_febcc9a9-420b-4b57-9a00-caee0bbb82ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5b637455-fde3-469f-a055-beda56da0d41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f92a06c1-c31e-428d-bbf2-db11271106c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5b637455-fde3-469f-a055-beda56da0d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5e4f768c-944f-4471-ab8c-035156eb8691" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5b637455-fde3-469f-a055-beda56da0d41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5e4f768c-944f-4471-ab8c-035156eb8691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_cf694971-91f3-4485-bb4f-09f0bd157156" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5b637455-fde3-469f-a055-beda56da0d41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_cf694971-91f3-4485-bb4f-09f0bd157156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8597de64-b019-470e-a561-4494036c0c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5b637455-fde3-469f-a055-beda56da0d41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8597de64-b019-470e-a561-4494036c0c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_f200dbcc-11ee-48a7-af8b-40b03e307f19" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5b637455-fde3-469f-a055-beda56da0d41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_f200dbcc-11ee-48a7-af8b-40b03e307f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8d3fd367-1f8d-4fae-a004-fdefbcb1eb09" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_5b637455-fde3-469f-a055-beda56da0d41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8d3fd367-1f8d-4fae-a004-fdefbcb1eb09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2c6ccebc-c449-49c4-8ecd-90e7bccd747d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f92a06c1-c31e-428d-bbf2-db11271106c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2c6ccebc-c449-49c4-8ecd-90e7bccd747d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c9d62c0c-23da-4049-9743-7e3794b3c6f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f92a06c1-c31e-428d-bbf2-db11271106c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c9d62c0c-23da-4049-9743-7e3794b3c6f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c5b29731-36ef-498b-ad77-6c7fc2ae068d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f92a06c1-c31e-428d-bbf2-db11271106c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c5b29731-36ef-498b-ad77-6c7fc2ae068d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_122293e7-2150-4fce-bde3-9cfcb6ec1734" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c5b29731-36ef-498b-ad77-6c7fc2ae068d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_122293e7-2150-4fce-bde3-9cfcb6ec1734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_97416cfc-b6d1-452b-a3e6-78713cfe0928" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c5b29731-36ef-498b-ad77-6c7fc2ae068d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_97416cfc-b6d1-452b-a3e6-78713cfe0928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_4a641c46-0d9a-441e-aa8f-b0ba9c0004c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c5b29731-36ef-498b-ad77-6c7fc2ae068d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_4a641c46-0d9a-441e-aa8f-b0ba9c0004c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1d3da5b8-d274-4a5e-aa32-a7419e11b9bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40cbd760-36ee-42d3-bdac-3a304cd2b42b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1d3da5b8-d274-4a5e-aa32-a7419e11b9bd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40cbd760-36ee-42d3-bdac-3a304cd2b42b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c96a2ada-d911-43e9-b372-5a748c3eba1d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40cbd760-36ee-42d3-bdac-3a304cd2b42b" xlink:to="loc_us-gaap_AwardTypeAxis_c96a2ada-d911-43e9-b372-5a748c3eba1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f1ac4525-46a7-49cc-9d2c-b274fc0f23ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c96a2ada-d911-43e9-b372-5a748c3eba1d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f1ac4525-46a7-49cc-9d2c-b274fc0f23ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_61f053e7-ed7d-47c8-9db8-a9c761a7423a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f1ac4525-46a7-49cc-9d2c-b274fc0f23ee" xlink:to="loc_us-gaap_EmployeeStockOptionMember_61f053e7-ed7d-47c8-9db8-a9c761a7423a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7586e510-2e3e-4f3d-a5f2-adb09ac5d816" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_40cbd760-36ee-42d3-bdac-3a304cd2b42b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7586e510-2e3e-4f3d-a5f2-adb09ac5d816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1131aca8-bfd4-460a-a075-ae3f6a11ea14" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7586e510-2e3e-4f3d-a5f2-adb09ac5d816" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1131aca8-bfd4-460a-a075-ae3f6a11ea14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_272c6252-e3b7-4bab-8b50-1ce5360922b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7586e510-2e3e-4f3d-a5f2-adb09ac5d816" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_272c6252-e3b7-4bab-8b50-1ce5360922b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f4426e86-a2f3-4b55-b569-8bc081cb0a73" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7586e510-2e3e-4f3d-a5f2-adb09ac5d816" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f4426e86-a2f3-4b55-b569-8bc081cb0a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_112adb28-314c-4d61-9544-7fd55692570f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7586e510-2e3e-4f3d-a5f2-adb09ac5d816" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_112adb28-314c-4d61-9544-7fd55692570f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_2d114dee-f58c-4c1c-a92d-446285ebf3f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7586e510-2e3e-4f3d-a5f2-adb09ac5d816" xlink:to="loc_us-gaap_SharePrice_2d114dee-f58c-4c1c-a92d-446285ebf3f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/SEGMENTREPORTINGDetails" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#SEGMENTREPORTINGDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/SEGMENTREPORTINGDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_773a7e49-5e06-4ab2-abbc-232a7e3fa243" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_a2714763-46cf-4285-bb67-bc0ed3cf4d93" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_773a7e49-5e06-4ab2-abbc-232a7e3fa243" xlink:to="loc_us-gaap_NumberOfReportableSegments_a2714763-46cf-4285-bb67-bc0ed3cf4d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="ck0001824293-20250630.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c502d896-4ce0-49d5-81b8-44bcbbe877d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_d919134a-8031-4bc9-8d0c-4d0d4faf96d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c502d896-4ce0-49d5-81b8-44bcbbe877d8" xlink:to="loc_us-gaap_LossContingenciesTable_d919134a-8031-4bc9-8d0c-4d0d4faf96d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_b43fceb9-d305-42dc-a3a4-df2680c96725" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_d919134a-8031-4bc9-8d0c-4d0d4faf96d8" xlink:to="loc_srt_TitleOfIndividualAxis_b43fceb9-d305-42dc-a3a4-df2680c96725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6e3ccb98-2ee3-43ab-b9fe-96063d8037ef" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_b43fceb9-d305-42dc-a3a4-df2680c96725" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6e3ccb98-2ee3-43ab-b9fe-96063d8037ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_FormerChiefExecutiveOfficerMember_449985e1-6dc6-4ea0-ba97-e00c56eba611" xlink:href="ck0001824293-20250630.xsd#ck0001824293_FormerChiefExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_6e3ccb98-2ee3-43ab-b9fe-96063d8037ef" xlink:to="loc_ck0001824293_FormerChiefExecutiveOfficerMember_449985e1-6dc6-4ea0-ba97-e00c56eba611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_0a755d28-06e5-4e31-ba7b-b1a353e69d92" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_d919134a-8031-4bc9-8d0c-4d0d4faf96d8" xlink:to="loc_us-gaap_LossContingenciesLineItems_0a755d28-06e5-4e31-ba7b-b1a353e69d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_COBRABenefitsPaymentPeriod_a46ea572-65b3-498d-a275-befcc1d0f94d" xlink:href="ck0001824293-20250630.xsd#ck0001824293_COBRABenefitsPaymentPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_0a755d28-06e5-4e31-ba7b-b1a353e69d92" xlink:to="loc_ck0001824293_COBRABenefitsPaymentPeriod_a46ea572-65b3-498d-a275-befcc1d0f94d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PercentageOfTargetBonus_09ff05ab-c450-478d-8d0a-8ed7bd354886" xlink:href="ck0001824293-20250630.xsd#ck0001824293_PercentageOfTargetBonus"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_0a755d28-06e5-4e31-ba7b-b1a353e69d92" xlink:to="loc_ck0001824293_PercentageOfTargetBonus_09ff05ab-c450-478d-8d0a-8ed7bd354886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ck0001824293-20250630_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ck0001824293-20250630_g1.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M
M   18W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP=
M @0    4<EA96@   A@    49UA96@   BP    48EA96@   D     49&UN
M9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D
M;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P
M  @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@
M*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M$G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR
M+C$
M         %A96B        #S40 !     1;,6%E:(
M  !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:
M(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI
M96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                                    9&5S8P
M       N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@
M+2!S4D="               N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C
M;VQO=7(@<W!A8V4@+2!S4D="                             &1E<V,
M        +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV
M-BTR+C$              "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@
M:6X@245#-C$Y-C8M,BXQ                                  !V:65W
M       3I/X %%\N !#/%  #[<P !!,+  -<G@    %865H@      !,"58
M4    %<?YVUE87,          0                        */     G-I
M9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M #(
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M(@LY"U$+:0N "Y@+L O("^$+^0P2#"H,0PQ<#'4,C@RG#, ,V0SS#0T-)@U
M#5H-= V.#:D-PPW>#?@.$PXN#DD.9 Y_#IL.M@[2#NX/"0\E#T$/7@]Z#Y8/
MLP_/#^P0"1 F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H$@<2)A)%
M$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P%1(5
M-!56%7@5FQ6]%> 6 Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2%_<8&QA
M&&48BABO&-48^AD@&449:QF1&;<9W1H$&BH:41IW&IX:Q1KL&Q0;.QMC&XH;
MLAO:' (<*AQ2''L<HQS,'/4='AU''7 =F1W#'>P>%AY 'FH>E!Z^'ND?$Q\^
M'VD?E!^_'^H@%2!!(&P@F"#$(/ A'"%((74AH2'.(?LB)R)5(H(BKR+=(PHC
M."-F(Y0CPB/P)!\D321\)*LDVB4))3@E:"67)<<E]R8G)E<FAR:W)N@G&"=)
M)WHGJR?<* TH/RAQ**(HU"D&*3@I:RF=*= J BHU*F@JFRK/*P(K-BMI*YTK
MT2P%+#DL;BRB+-<M#"U!+78MJRWA+A8N3"Z"+K<N[B\D+UHOD2_'+_XP-3!L
M,*0PVS$2,4HQ@C&Z,?(R*C)C,ILRU#,-,T8S?S.X,_$T*S1E-)XTV#43-4TU
MAS7"-?TV-S9R-JXVZ3<D-V WG#?7.!0X4#B,.,@Y!3E".7\YO#GY.C8Z=#JR
M.N\[+3MK.ZH[Z#PG/&4\I#SC/2(]83VA/> ^(#Y@/J ^X#\A/V$_HC_B0"-
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M)*75\.*CY6;"@T2D)?%D_]H # ,!  (1 Q$ /P"_P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MF8X8IKIG#BJARY?5<Q=OT6ZJ:.355$<$3T?#7Q$8:X
M
M
M
M
M                      %8KTM'ZK;7OE6<2_F;RJW.YB?SV7?@/->RY92M
M8]J1Z./$EFGIB5L                 )'O!_P#K2>@+Y5G#7YY8UB'?]\R>
MU/P'F_8JG:R?MNWZ./%; Z 9>0
M
M
M
M
M     "L5Z6C]5MKWRK.)?S-Y5;G<Q/Y[+OP'FO9<LI6L>U(]''B2S3TQ*V
M               $CW@__6D] 7RK.&OSRQK$._[YD]J?@/-^Q5.UD_;=OT<>
M*V!T R\@
M
M
M
M                                               %8KTM'ZK;7OE6
M<2_F;RJW.YB?SV7?@/->RY92M8]J1Z./$EFGIB5L                 )'O
M!_\ K2>@+Y5G#7YY8UB'?]\R>U/P'F_8JG:R?MNWZ./%; Z 9>0
M
M
M
M
M                              "L5Z6C]5MKWRK.)?S-Y5;G<Q/Y[+OP
M'FO9<LI6L>U(]''B2S3TQ*V                 $CW@_P#UI/0%\JSAK\\L
M:Q#O^^9/:GX#S?L53M9/VW;]''BM@= ,O(
M
M
M
M
M             !6*]+1^JVU[Y5G$OYF\JMSN8G\]EWX#S7LN64K6/:D>CCQ)
M9IZ8E;                 "1[P?_K2>@+Y5G#7YY8UB'?\ ?,GM3\!YOV*I
MVLG[;M^CCQ6P.@&7D
M
M
M
M                                                         K%>
MEH_5;:]\JSB7\S>56YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@
M      !(]X/_ -:3T!?*LX:_/+&L0[_OF3VI^ \W[%4[63]MV_1QXK8'0#+R
M
M
M
M
M                                        5BO2T?JMM>^59Q+^9O*K
M<[F)_/9=^ \U[+EE*UCVI'HX\26:>F)6P                 D>\'_ZTGH"
M^59PU^>6-8AW_?,GM3\!YOV*IVLG[;M^CCQ6P.@&7D
M
M
M
M
M                      K%>EH_5;:]\JSB7\S>56YW,3^>R[\!YKV7+*5K
M'M2/1QXDLT],2M@                !(]X/_P!:3T!?*LX:_/+&L0[_ +YD
M]J?@/-^Q5.UD_;=OT<>*V!T R\@
M
M
M
M
M      %8KTM'ZK;7OE6<2_F;RJW.YB?SV7?@/->RY92M8]J1Z./$EFGIB5L
M                )'O!_P#K2>@+Y5G#7YY8UB'?]\R>U/P'F_8JG:R?MNWZ
M./%; Z 9>0
M
M
M
M                                                 "L5Z6C]5MKW
MRK.)?S-Y5;G<Q/Y[+OP'FO9<LI6L>U(]''B2S3TQ*V                 $
MCW@__6D] 7RK.&OSRQK$._[YD]J?@/-^Q5.UD_;=OT<>*V!T R\@
M
M
M
M
M                               %8KTM'ZK;7OE6<2_F;RJW.YB?SV7?
M@/->RY92M8]J1Z./$EFGIB5L                 )'O!_\ K2>@+Y5G#7YY
M8UB'?]\R>U/P'F_8JG:R?MNWZ./%; Z 9>0
M
M
M
M
M              "L5Z6C]5MKWRK.)?S-Y5;G<Q/Y[+OP'FO9<LI6L>U(]''B
M2S3TQ*V                 $CW@_P#UI/0%\JSAK\\L:Q#O^^9/:GX#S?L5
M3M9/VW;]''BM@= ,O(
M
M
M
M                                                         !6*
M]+1^JVU[Y5G$OYF\JMSN8G\]EWX#S7LN64K6/:D>CCQ)9IZ8E;
M       "1[P?_K2>@+Y5G#7YY8UB'?\ ?,GM3\!YOV*IVLG[;M^CCQ6P.@&7
MD
M
M
M
M                                         K%>EH_5;:]\JSB7\S>5
M6YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@                !(]X/_ -:3
MT!?*LX:_/+&L0[_OF3VI^ \W[%4[63]MV_1QXK8'0#+R
M
M
M
M
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MHF>%H2HHUQ@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M0]:TR)G4LGFLO$1$_7;5RWP3.$>;ICCG@CIRY(KHJ\S,3X;GJEOH
M
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M/%)\_P!ZK/?EW+V2/D!W)_%;0_>EKU)VYF_7*^O)],!XI/G^]5GOR[E[)'R
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MY[^,D].>2,81A&$81A'LB_:='TBFJ*J<KEHJB<8F+5&,3Z4Y573EPE4GR
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MF*J:HFFJF8XXJIG"8F.C$QB[<3$QC'$^@XGZ
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MQ,3$\3L92]>G-6XFNJ8FN.C/3:NR#5=P
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M:JIGJNC<OWKOV2NJKP9EY@7HX0
M
M &A]Z'E\1_J<^577^"+C9$WWP#YR=%^ X_&LPN31OL%?H_&A;G:&*P
M           I3>F6_P!FO03[>>H#\0<4I&>]Z_EC:CW-D?J\RH>M^9M^#/C*
M&:3Y;X
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M3T!?*LX:_/+&L0[_ +YD]J?@/-^Q5.UD_;=OT<>*V!T R\@
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M.,N/NV_
M                                              &A]Z'E\1_J<^57
M7^"+C9$WWP#YR=%^ X_&LPN31OL%?H_&A;G:&*P                 I3>F
M6_V:]!/MYZ@/Q!Q2D9[WK^6-J/<V1^KS*AZWYFWX,^,H9I/EO@
M
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MR9>>+&:X[%RIBFB]7*OY;/V,SP4SR;G2GQNGXO43)->W=
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M7*O*]*."/_'@XHT68W5
M
M :'WH>7Q'^ISY5=?X(N-D3?? /G)T7X#C\:S"Y-&^P5^C\:%N=H8K
M          "E-Z9;_9KT$^WGJ _$'%*1GO>OY8VH]S9'ZO,J'K?F;?@SXRAF
MD^6^
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MPKHF,:;ENK#&BY1-5%<<--4QPKBMW+=VB*[<Q-$NZ%NOL
M      !6*]+1^JVU[Y5G$OYF\JMSN8G\]EWX#S7LN64K6/:D>CCQ)9IZ8E;
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M'$<C&[R9FFN]7"W,UG[^:X)GDVNE'C]/Q.HAD;#NB
M
M                         T/O0\OB/]3GRJZ_P1<;(F^^ ?.3HOP''XUF
M%R:-]@K]'XT+<[0Q6                 %*;TRW^S7H)]O/4!^(.*4C/>]?
MRQM1[FR/U>94/6_,V_!GQE#-)\M\
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M=FN>5&$U437;PKFZ,KG+6;HQHX*XXXZ,>3'52A,+.V
M   K%>EH_5;:]\JSB7\S>56YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@
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MJJF9JGHRXH[SY
M                                                          :'
MWH>7Q'^ISY5=?X(N-D3?? /G)T7X#C\:S"Y-&^P5^C\:%N=H8K
M       "E-Z9;_9KT$^WGJ _$'%*1GO>OY8VH]S9'ZO,J'K?F;?@SXRAFD^6
M^
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M +YD]J?@/-^Q5.UD_;=OT<>*V!T R\@
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M\51'+O1]-F)B)C'DVHIIY55RV<[J->8F;=O&FQ]&?!ZG4ZZMHW!4L
M
M                                       !H?>AY?$?ZG/E5U_@BXV1
M-]\ ^<G1?@./QK,+DT;[!7Z/QH6YVABL                 *4WIEO]FO03
M[>>H#\0<4I&>]Z_EC:CW-D?J\RH>M^9M^#/C*&:3Y;X
M
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M9NS$133F+43$5Q$1%=,TW*(B*IIHNW)9RC-V\>*Y'''CQU)2[L".X
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M.*/'GJ^(AK;".B
M
M  T/O0\OB/\ 4Y\JNO\ !%QLB;[X!\Y.B_ <?C687)HWV"OT?C0MSM#%8
M              4IO3+?[->@GV\]0'X@XI2,][U_+&U'N;(_5YE0];\S;\&?
M&4,TGRWP
M                                 'J_HHZRN:>@OJ+T3J2X*SE3&;9J
M%W"VS.#N+B[IZYR!IE[<6M39./MSL[6K2CD]8V.C:4_*21CW[>YI4+NA&G<V
M]"K)8N\;=[L[O0V2S6Q^TUJ*\CF*<:*XB.R6+T1/8[]F9B>3<MS,X3Q54S51
M5C1753/-8OUY>[%VWQQ]&.E+6QZ#^MSASQ!NFG0NI7A:_P#_ .3;3:0L=JU.
M[NJ5QL'&V_8^WMH[1Q_L\M*2CV97 W5Q+Y.M"G)2O[*K0O*,(T+BG&,$6\_=
MOM!NIVQS6QVT5/\ S%BKE6KL1,6\Q8JF>QW[?'Y6N(X8QF:*XJMU>6HE>&7O
MT9FU%VCBGZ$])[%8_<P                 "L5Z6C]5MKWRK.)?S-Y5;G<Q
M/Y[+OP'FO9<LI6L>U(]''B2S3TQ*V                 $CW@__ %I/0%\J
MSAK\\L:Q#O\ OF3VI^ \W[%4[63]MV_1QXK8'0#+R
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M2
M                                                  :'WH>7Q'^I
MSY5=?X(N-D3?? /G)T7X#C\:S"Y-&^P5^C\:%N=H8K                 "
ME-Z9;_9KT$^WGJ _$'%*1GO>OY8VH]S9'ZO,J'K?F;?@SXRAFD^6^
M
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MJVU[Y5G$OYF\JMSN8G\]EWX#S7LN64K6/:D>CCQ)9IZ8E;
M   "1[P?_K2>@+Y5G#7YY8UB'?\ ?,GM3\!YOV*IVLG[;M^CCQ6P.@&7D
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M7M;7*:
M                                                        T/O0
M\OB/]3GRJZ_P1<;(F^^ ?.3HOP''XUF%R:-]@K]'XT+<[0Q6
M     %*;TRW^S7H)]O/4!^(.*4C/>]?RQM1[FR/U>94/6_,V_!GQE#-)\M\
M
M                          !H!^BM>*36Y3X]O_#FYIV.:YWWB/"76R=-
MN7RUUW[K9>)K*;RFP\9PN+NO&M=Y3C.M7A=8NC)WYHZ_6J4I):=#%0[T5_/>
MW)TZ)JU.]S9VSAI>?N1;U"FF."WFI^QYC"(PBG,1')N3.'U^(JF9JO\ !<6D
MYOET]K5SY:/,^!TO"\3P%R)'PK0                "L5Z6C]5MKWRK.)?S
M-Y5;G<Q/Y[+OP'FO9<LI6L>U(]''B2S3TQ*V                 $CW@_\
MUI/0%\JSAK\\L:Q#O^^9/:GX#S?L53M9/VW;]''BM@= ,O(
M                         !1%])]\8N?/Y//>&CTU[7V8+"W<E'JXW; W
M<)OPQG;*XH75EP+C<A;S?R=CK]W0EN-K\E-&:M?0I8N>:G"VR5O7DXYE_-^C
M*V;6^/;"Q_S5RG'2[-<>8HF)B<[53/TUR)Y.6QXJ.5?B)Y=FNF@:KG<9[5M3
MP?33XWD];IJ2B1]0@
M
M       &A]Z'E\1_J<^577^"+C9$WWP#YR=%^ X_&LPN31OL%?H_&A;G:&*P
M                 I3>F6_V:]!/MYZ@/Q!Q2D9[WK^6-J/<V1^KS*AZWYFW
MX,^,H9I/EO@
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M >;]BJ=K)^V[?HX\5L#H!EY
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M1$1$80M.9F9QGC?@<K\
M
M          :'WH>7Q'^ISY5=?X(N-D3?? /G)T7X#C\:S"Y-&^P5^C\:%N=H
M8K                 "E-Z9;_9KT$^WGJ _$'%*1GO>OY8VH]S9'ZO,J'K?
MF;?@SXRAFD^6^
M                                          NJ^B+==\VO[WR[X>^\
MYJ?\%;_0ON<."*-]=TH4;;<=>QUM9\JZABZ=:::YJU]BU*RM,W1MZ791H28+
M(UHR]^O/-&.?GZ;L8S>EY#>MIEN.SY6:<GG9IB<9M7*IG+7:L."(MW9JLS5/
M#,WK5..%,0KFCYC"JK+5<4\,>#T8ZW#X4KZ",!<                "L5Z6
MC]5MKWRK.)?S-Y5;G<Q/Y[+OP'FO9<LI6L>U(]''B2S3TQ*V
M     $CW@_\ UI/0%\JSAK\\L:Q#O^^9/:GX#S?L53M9/VW;]''BM@= ,O(
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MW3V3,WHC"<QFJXCLMV>CAC$46XGAIM46Z)F>3BLW-9BK,WINU<70CI1T(_\
M'1>#&4'7
M
M:'WH>7Q'^ISY5=?X(N-D3?? /G)T7X#C\:S"Y-&^P5^C\:%N=H8K
M         "E-Z9;_ &:]!/MYZ@/Q!Q2D9[WK^6-J/<V1^KS*AZWYFWX,^,H9
MI/EO@
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M^59Q+^9O*K<[F)_/9=^ \U[+EE*UCVI'HX\26:>F)6P
MD>\'_P"M)Z OE6<-?GEC6(=_WS)[4_ >;]BJ=K)^V[?HX\5L#H!EY
M                              *.'I9GB33R2ZEX:G%6=[):TF Y6ZH+
MO'7$(]Z2%23*<4\3WLU.O&,.RI2I[3E+>I2A'U,)/3J?_P 1325<Q7<_$]GW
MQ:Y:X8FO+:=%4?Z.9S4<'5G+6ZHG\)B8\Q*@ZOFN+*T>#5XT>/UE&E):H(
M
M                                                  #0^]#R^(_U
M.?*KK_!%QLB;[X!\Y.B_ <?C687)HWV"OT?C0MSM#%8
M4IO3+?[->@GV\]0'X@XI2,][U_+&U'N;(_5YE0];\S;\&?&4,TGRWP
M
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MRLNY75=KFY7YJ9Q=3JZ^
M
M             &A]Z'E\1_J<^577^"+C9$WWP#YR=%^ X_&LPN31OL%?H_&A
M;G:&*P                 I3>F6_P!FO03[>>H#\0<4I&>]Z_EC:CW-D?J\
MRH>M^9M^#/C*&:3Y;X
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ME6<-?GEC6(=_WS)[4_ >;]BJ=K)^V[?HX\5L#H!EY
M                 *(OI=/7E5RFT<0^'GH><J0QVL4+'G+GVC9S3227&PY6
MVN;+B33;ZK)4ISS?@C!5[W.75K/+/0J1R6+K0CY6AV22<<PO=A38R6?WL:I:
MCLUZ:LGD9GH6Z9B<U=IC^O7%%FFJ)BJ.QWJ>*KAH&L9C&:<M3Q1PSXT>/UE)
M1(^H0
M                                                          #0
M^]#R^(_U.?*KK_!%QLB;[X!\Y.B_ <?C687)HWV"OT?C0MSM#%8
M        4IO3+?[->@GV\]0'X@XI2,][U_+&U'N;(_5YE0];\S;\&?&4,TGR
MWP
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ME1_R.G92W9B<,)KJICZY<JC&<*KMR:KE7#YJJ<%E7KE5Z[5=JXZIQ>?%UN(
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MA>&I_EY=#7S2^ _< ?+1OB^-FTO^*9W[^=JY7UNWZ6/(/HPO#4_R\NAKYI?
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MH?>AY?$?ZG/E5U_@BXV1-]\ ^<G1?@./QK,+DT;[!7Z/QH6YVABL
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M:]\JSB7\S>56YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@
M !(]X/\ ]:3T!?*LX:_/+&L0[_OF3VI^ \W[%4[63]MV_1QXK8'0#+R
M                              5:/2O>L2;@[H1U7IGUO*S6>Z]7>\2X
MK+T;:K&E=4^(.++C#;;NM6%:G3GJ6\N5VRZUW'321GI0N[*YNZ?;/)"K)'=G
MF-;OXVEWG7]LLY1RM.T#+<JB9C&.VLS%=JSP='DVHS%S'">373;G@GDRI.KW
MNQY>+4>:KGZ$<?C,W%+\MD                     ![CZ'?#FZN?$1Y JZ
M'TP\6Y#::&*JVTNX\A9F>?7^+>/J%U":>C7W/=[JA4QUA<UZ,D]2WQ]O"ZRU
M[)3GC:VM?N3]F--Y6]S8/=-I4:IMIG:+%5<3V*Q1Y?,WYCCBS9B>55$3A%5=
M7)M43,<NNG&'8L9:]F:N3:C'IST(\&5Z_P /WT6/HWZ;Y<-O?5KDINL#EFVE
MH7<=<R]C7UW@+7+^$):D:-IHLEU5RG($UM///2FK;!=5,;>4X2SQQ-O4AZD9
M>]3GM[P=KYN:9L)1W T*<8[)15%S/7*>G-["*;&/!.%BF+E$XQV>N%>R^DV;
M7EKWEZ_H=;H^'UEG/5=2U71-=Q.H:1K.OZ;J> M);#!:OJN&QVO:[A;&2:>>
M2RQ.$Q%M9XW&VDL]2:,*=&E))",T8]GJM,L]G\]J>;N9_4KUW,9^[5RJ[EVN
MJY<KJZ=5=<S55/5F9E58B*8Y-,1$0Y ZC]
M                                            9&/CA_6T==O[<\M^
M)L*GGYMGS$[,?!E/U=:S\_[<N>B14,X.F                 T/O0\OB/\
M4Y\JNO\ !%QLB;[X!\Y.B_ <?C687)HWV"OT?C0MSM#%8
M  4IO3+?[->@GV\]0'X@XI2,][U_+&U'N;(_5YE0];\S;\&?&4,TGRWP
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M%VC&.53C,3$TUT556ZJ*ZK6O6;F7N3;N1A5'T>K'4>7%ZN$
M     !KY^#/N,^]>%7T#YN>M+6FL>F?C;3H3RUJ%Q"63CO$2\?TZ/?MY*=.6
M:WIZQ"G&2,._3C+W)XS3RS1C 9SA=/C3-]^U.6B,.5K.8N\4Q]GJ[/CP]/LF
M./%/'&$3"\LE5RLI;G^K$=;@29,-NT              K%>EH_5;:]\JSB7\
MS>56YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@                !(]X/\
M]:3T!?*LX:_/+&L0[_OF3VI^ \W[%4[63]MV_1QXK8'0#+R
M                      9:_I*O5E4ZFO%$Y4U7$Y.:^T3I>Q>+Z>-8HR34
MX6\FP:O/<9;E2XGHTHS22Y"CR9FLEC*E2:::I4H8NA";N]V%.2;#F>;"QL9N
M5R.>OT<G4]:KJS]R>CR+F%.6C&?I9R]%NY$<457*L,<<9M34[W9<W,1YFC@\
MGZ* )M.IP                    "TCX+WHZ'(O6W2UGJ2ZNZ&R<1]*-SZR
MS6HZI2A6PO)G/V/J2T;NTN\--6I>7T[C#)4)X1CFIY87N2HS0_!TD*=27(4M
M*.<3SM])W;U7MC]@ILY_;F,:+MV<*\OD:N&)BO"<+N9IG_8QY2W/V:<8FU55
MLCIM5_"[>QIL]#ISY$=7K=-H?<)\&</].'&NM\/<$\<ZIQ7QGJ-I"TP.GZ=B
MJ&*Q=KWNR-S>W/DX3765S.2K0C6O;^[J5[Z^N)IJUQ5JU9YIXQ-[1[3:_M?K
M%[:#:?-W\]K-^K&N[=JFJJ>E$="FBF."BBF*:**<*:*8IB(7';MT6J8HMQ$4
MQT(=K*&^P
M                    &1CXX?UM'7;^W/+?B;"IY^;9\Q.S'P93]76L_/\
MMRYZ)%0S@Z8                #0^]#R^(_U.?*KK_!%QLB;[X!\Y.B_ <?
MC687)HWV"OT?C0MSM#%8                 4IO3+?[->@GV\]0'X@XI2,]
M[U_+&U'N;(_5YE0];\S;\&?&4,TGRWP                $Y7HVOUTW1C_>
M)_PH<ZM:>>!_#KM%_8/TGDG?TSV]1X?U,M5M!\NT
M                              !$)XR?A6Z!XH73)D]4DM<5@>HWC.QS
M.R=.W)%S3I4)\=LT]M)5N]!V7(2TYKF/'_(4;*C:W\(=_P!8W,MOD)*=6>U\
MC6SYS>]]^J[EMLZ,]-5=W9'.546\_EXX>5;QPB_;IXNSV,9JHXN73-=J9IBO
ME4]/.Y2G-6L/]K'%/C>!/]+)YW'4-HX^VW9]#W?!9+5]RTO8,QJFUZWF+:>S
MRV V/7\A<8K-8;)VM3[^WOL;D;2I1JR1]66>2,$Y^GY_):KD+.J:;=HO:?F;
M5%VU<HG&FNW<IBJBNF>C353,3$]*5HU1-,S35P51+C;N/D
M   !JZ^CI9FKG?!FZ*KVM1IT)Z&&YGPT)*<TTTLU+7>H_F'7Z%:,9O5\I<T<
M9+4GA]R$TT80]3L0;<[;+TY;G#;1VZ9F8FYE*_#N:?E+DQX4U81U(7=ILXY*
MCP_JI38-<7>              5BO2T?JMM>^59Q+^9O*K<[F)_/9=^ \U[+E
ME*UCVI'HX\26:>F)6P                 D>\'_ .M)Z OE6<-?GEC6(=_W
MS)[4_ >;]BJ=K)^V[?HX\5L#H!EY
M  .C.ISG' ],W3ISEU"[/+3JX3A;BG>^2[VTJ3QIQR<VH:YD,U:8:C-+&$T;
MO-WMI3M*,L/OIZU:66'JQ@N;8S9K-;9;6Z9LGDL8S.HYZSEXGSO9;E-$USU*
M(F:IZ41,N.[<BU:JN3Q4Q,]9BX[CMN>W[;MJWK:K^IE=HW38\YMNR9.K"$*N
M1SVQY.ZS&8OZD(>I"I>9"\J5(]GJ=LST2Z?D,KI>0L:9D:8HR66LT6K=,<5-
M%NF***?"IB(635,U535/',N-NX^0                   %R/T>KP"\?SO;
M:QUT]<&D5+GAN-2VS73_ ,%[3CH0LN8)/)T[BPY2W_&77WUSQ9)/-";#XNM3
MA)LD\L+JO";$PI4\I'QSKN=)=V8KO;L]VV9B-H<)HSV=M5<.4Z%66L51Q9GH
M7;D3CEX\I3A?Y4V:WIVGQ<PS%^/*=".GU9ZG2Z?@<=_VA0H6M"C:VM&E;6UM
M2IT+>WH4Y*-"A0HR0IT:-&C3A+3I4J5.6$LLLL(0EA#LAZB+&JJJNJ:ZYF:Y
MG&9GAF9GCF9Z,RN%_5\@
M                                #(Q\</ZVCKM_;GEOQ-A4\_-L^8G9
MCX,I^KK6?G_;EST2*AG!TP                &A]Z'E\1_J<^577^"+C9$W
MWP#YR=%^ X_&LPN31OL%?H_&A;G:&*P                 I3>F6_V:]!/M
MYZ@/Q!Q2D9[WK^6-J/<V1^KS*AZWYFWX,^,H9I/EO@                )R
MO1M?KINC'^\3_A0YU:T\\#^'7:+^P?I/)._IGMZCP_J9:K:#Y=H
M                                          #/$]+-Z#L?PYU(<<=;
M?'^"DQVG]35I<:CRK+C[2%''V7.&D8ZA-99RX\C3I6MM=\CZ'3IU/)RPC4N+
MW W]W5FFJ5YXI8^8KO/N[0;(9S=OJMV:]0T:J+N6Y4XU3D[U4XT1CC,QE[^,
M8\5-%^U13$13"W-7R_(NQ?ICRM?'X,>3'B2J*M]%&                  :
MKGHVOU+/1C_>)_Q7\ZH/N>!_$5M%_8/T9DEVZ9[1H\/ZJ4Y+6EWP
M     %8KTM'ZK;7OE6<2_F;RJW.YB?SV7?@/->RY92M8]J1Z./$EFGIB5L
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MKU55=ZNJ:JJJIF:JJIG&9F9X9F9X9F>&9X973Q<$<3];C
M                                                           &
M1CXX?UM'7;^W/+?B;"IY^;9\Q.S'P93]76L_/^W+GHD5#.#I@
M     -#[T/+XC_4Y\JNO\$7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,5@
M              !2F],M_LUZ"?;SU ?B#BE(SWO7\L;4>YLC]7F5#UOS-OP9
M\90S2?+?                 3E>C:_73=&/]XG_  H<ZM:>>!_#KM%_8/TG
MDG?TSV]1X?U,M5M!\NT
M          !"]Z01TW6/4KX475'C?P?+>;)PUK5#J-TVYC#O5,5DN&YZNQ;3
M>4)/^W5N^,)L_8]GW>[>1C#MC"$&Q'-5VPN;';\M$O<ODY/4;TY"['GJ<WA;
MMQ/4C,]@K_T'1U&UV7*5QT:8Y4>%_1BR>TYZT0                 &JYZ-
MK]2ST8_WB?\ %?SJ@^YX'\16T7]@_1F27;IGM&CP_JI3DM:7?
M   5BO2T?JMM>^59Q+^9O*K<[F)_/9=^ \U[+EE*UCVI'HX\26:>F)6P
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M;5%BW%JCS,1_XGPWH9:;D
M                                    9&/CA_6T==O[<\M^)L*GGYMG
MS$[,?!E/U=:S\_[<N>B14,X.F                 T/O0\OB/\ 4Y\JNO\
M!%QLB;[X!\Y.B_ <?C687)HWV"OT?C0MSM#%8                 4IO3+?
M[->@GV\]0'X@XI2,][U_+&U'N;(_5YE0];\S;\&?&4,TGRWP
M    $Y7HVOUTW1C_ 'B?\*'.K6GG@?PZ[1?V#])Y)W],]O4>']3+5;0?+M
M                                                  <&Y/T?'\G<
M:<A\;9:G0JXKD+1MMT?)TKJG"M;5,?MF R&!O:=Q2FEGEJT)[:_FA/+&6,)I
M>V'9%4]%U*[HNLY36+$S%_*9FU>IF.">5:KIKC">A.-/ ^:Z8KHFF>*8F&(W
M=6MS8W-Q97MO7L[RSKUK6[M+JC4M[FUN;>I-2KV]Q0JRR5:%>A5DC+/)-"$T
MLT(PC"$8/2#171<HBY;F*K=41,3$XQ,3PQ,3'!,3'%*QGYWV_
M      &JYZ-K]2ST8_WB?\5_.J#[G@?Q%;1?V#]&9)=NF>T:/#^JE.2UI=\
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MG'@PNW;U%48T1*Y-(RW(MSF*O-5<7@?TSXD+<C0U6
M                                                         &1C
MXX?UM'7;^W/+?B;"IY^;9\Q.S'P93]76L_/^W+GHD5#.#I@
M   -#[T/+XC_ %.?*KK_  1<;(F^^ ?.3HOP''XUF%R:-]@K]'XT+<[0Q6
M               %*;TRW^S7H)]O/4!^(.*4C/>]?RQM1[FR/U>94/6_,V_!
MGQE#-)\M\                !.5Z-K]=-T8_P!XG_"ASJUIYX'\.NT7]@_2
M>2=_3/;U'A_4RU6T'R[0
M            &(GR?_:5R'[>=M_'^0>D31?R/E/<UKZBE8M7FI\%P94WR
M              U7/1M?J6>C'^\3_BOYU0?<\#^(K:+^P?HS)+MTSVC1X?U4
MIR6M+O@             *Q7I:/U6VO?*LXE_,WE5N=S$_GLN_ >:]ERRE:Q[
M4CT<>)+-/3$K8                 2/>#_]:3T!?*LX:_/+&L0[_OF3VI^
M\W[%4[63]MV_1QXK8'0#+R                                 <0Y!W
M3#\;Z%N_(FPU/(X#0M0V7=,Y5[TLGDL/JV&O<YDZG?F^]D[EE8SQ[8^I#L=_
M2M.S&L:IEM)RD8YK-9BW9HCIUW*XHI^C5#YJJBFF:IXHC%B7[IMN:W[<=LWO
M9+B6[V+==ESNVY^ZEA/++<YK8\I=9C*W$LM2>K4A+6OKRI-"$TTT?5]6,?NO
M1WIV0RVEZ?8TS)QR<IEK-%JB.E1;IBBF.AQ4Q"QZIFJJ:IXYEQEW7R
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M,44Q33P4Q&$.6N@_0
M                                &1CXX?UM'7;^W/+?B;"IY^;9\Q.S
M'P93]76L_/\ MRYZ)%0S@Z8                #0^]#R^(_U.?*KK_!%QLB
M;[X!\Y.B_ <?C687)HWV"OT?C0MSM#%8                 4IO3+?[->@G
MV\]0'X@XI2,][U_+&U'N;(_5YE0];\S;\&?&4,TGRWP                $
MY7HVOUTW1C_>)_PH<ZM:>>!_#KM%_8/TGDG?TSV]1X?U,M5M!\NT
M                                            !B)\G_VE<A^WG;?Q
M_D'I$T7\CY3W-:^HI6+5YJ?!<&5-\@                -5ST;7ZEGHQ_O$
M_P"*_G5!]SP/XBMHO[!^C,DNW3/:-'A_52G):TN^              K%>EH_
M5;:]\JSB7\S>56YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@
M   !(]X/_P!:3T!?*LX:_/+&L0[_ +YD]J?@/-^Q5.UD_;=OT<>*V!T R\@
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M+@
M                   9&/CA_6T==O[<\M^)L*GGYMGS$[,?!E/U=:S\_P"W
M+GHD5#.#I@                -#[T/+XC_4Y\JNO\$7&R)OO@'SDZ+\!Q^-
M9A<FC?8*_1^-"W.T,5@                !2F],M_LUZ"?;SU ?B#BE(SWO
M7\L;4>YLC]7F5#UOS-OP9\90S2?+?                 3E>C:_73=&/]XG
M_"ASJUIYX'\.NT7]@_2>2=_3/;U'A_4RU6T'R[0
M                               &(GR?_:5R'[>=M_'^0>D31?R/E/<U
MKZBE8M7FI\%P94WR                 U7/1M?J6>C'^\3_ (K^=4'W/ _B
M*VB_L'Z,R2[=,]HT>']5*<EK2[X             "L5Z6C]5MKWRK.)?S-Y5
M;G<Q/Y[+OP'FO9<LI6L>U(]''B2S3TQ*V                 $CW@__ %I/
M0%\JSAK\\L:Q#O\ OF3VI^ \W[%4[63]MV_1QXK8'0#+R
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M,.">7CU5WZ=:[%E*(Z,QC/A_T8)E&O;N@
M                                                 ,C'QP_K:.NW
M]N>6_$V%3S\VSYB=F/@RGZNM9^?]N7/1(J&<'3                 :'WH>
M7Q'^ISY5=?X(N-D3?? /G)T7X#C\:S"Y-&^P5^C\:%N=H8K
M    "E-Z9;_9KT$^WGJ _$'%*1GO>OY8VH]S9'ZO,J'K?F;?@SXRAFD^6^
M               G*]&U^NFZ,?[Q/^%#G5K3SP/X==HO[!^D\D[^F>WJ/#^I
MEJMH/EV@
M,1/D_P#M*Y#]O.V_C_(/2)HOY'RGN:U]12L6KS4^"X,J;Y
M   :KGHVOU+/1C_>)_Q7\ZH/N>!_$5M%_8/T9DEVZ9[1H\/ZJ4Y+6EWP
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MF[]RJY75/'5775-554]69F97Q$13&$<4/MNL_0
M                                                      &1CXX?
MUM'7;^W/+?B;"IY^;9\Q.S'P93]76L_/^W+GHD5#.#I@
M-#[T/+XC_4Y\JNO\$7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,5@
M         !2F],M_LUZ"?;SU ?B#BE(SWO7\L;4>YLC]7F5#UOS-OP9\90S2
M?+?                 3E>C:_73=&/]XG_"ASJUIYX'\.NT7]@_2>2=_3/;
MU'A_4RU6T'R[0
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M/+&L0[_OF3VI^ \W[%4[63]MV_1QXK8'0#+R
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MQ1PQWM-HY><HCH1,SUH\EJ](-%W
M                                             ,C'QP_K:.NW]N>6
M_$V%3S\VSYB=F/@RGZNM9^?]N7/1(J&<'3                 :'WH>7Q'^
MISY5=?X(N-D3?? /G)T7X#C\:S"Y-&^P5^C\:%N=H8K
M"E-Z9;_9KT$^WGJ _$'%*1GO>OY8VH]S9'ZO,J'K?F;?@SXRAFD^6^
M           G*]&U^NFZ,?[Q/^%#G5K3SP/X==HO[!^D\D[^F>WJ/#^IEJMH
M/EV@
M                               *Q7I:/U6VO?*LXE_,WE5N=S$_GLN_
M >:]ERRE:Q[4CT<>)+-/3$K8                 2/>#_\ 6D] 7RK.&OSR
MQK$._P"^9/:GX#S?L53M9/VW;]''BM@= ,O(
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MCF:JNE1XLPT9T1RY0
M                                  &1CXX?UM'7;^W/+?B;"IY^;9\Q
M.S'P93]76L_/^W+GHD5#.#I@                -#[T/+XC_4Y\JNO\$7&R
M)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,5@                !2F],M_LUZ"
M?;SU ?B#BE(SWO7\L;4>YLC]7F5#UOS-OP9\90S2?+?
M3E>C:_73=&/]XG_"ASJUIYX'\.NT7]@_2>2=_3/;U'A_4RU6T'R[0
M
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M57J%VJ.'Z6,G11/2X>5<ZL8=")X:]HE/#<J]#'BKT:,Y7@
M
M   &1CXX?UM'7;^W/+?B;"IY^;9\Q.S'P93]76L_/^W+GHD5#.#I@
M         -#[T/+XC_4Y\JNO\$7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,
M5@                !2F],M_LUZ"?;SU ?B#BE(SWO7\L;4>YLC]7F5#UOS
M-OP9\90S2?+?                 3E>C:_73=&/]XG_  H<ZM:>>!_#KM%_
M8/TGDG?TSV]1X?U,M5M!\NT
M                                                  !6*]+1^JVU
M[Y5G$OYF\JMSN8G\]EWX#S7LN64K6/:D>CCQ)9IZ8E;
M"1[P?_K2>@+Y5G#7YY8UB'?]\R>U/P'F_8JG:R?MNWZ./%; Z 9>0
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MG^M'B+DR/=6@
M                             &1CXX?UM'7;^W/+?B;"IY^;9\Q.S'P9
M3]76L_/^W+GHD5#.#I@                -#[T/+XC_ %.?*KK_  1<;(F^
M^ ?.3HOP''XUF%R:-]@K]'XT+<[0Q6                 %*;TRW^S7H)]O
M/4!^(.*4C/>]?RQM1[FR/U>94/6_,V_!GQE#-)\M\                !.5
MZ-K]=-T8_P!XG_"ASJUIYX'\.NT7]@_2>2=_3/;U'A_4RU6T'R[0
M
M                   %8KTM'ZK;7OE6<2_F;RJW.YB?SV7?@/->RY92M8]J
M1Z./$EFGIB5L                 )'O!_\ K2>@+Y5G#7YY8UB'?]\R>U/P
M'F_8JG:R?MNWZ./%; Z 9>0                                #+<])
MV^N(Y_\ :-P+\#6FIKN9C_#_ *5[ISOXW=6IJGMVKP(\2%?UM2IP
M         #0^]#R^(_U.?*KK_!%QLB;[X!\Y.B_ <?C687)HWV"OT?C0MSM#
M%8
M                    9&/CA_6T==O[<\M^)L*GGYMGS$[,?!E/U=:S\_[<
MN>B14,X.F                 T/O0\OB/\ 4Y\JNO\ !%QLB;[X!\Y.B_ <
M?C687)HWV"OT?C0MSM#%8                 4IO3+?[->@GV\]0'X@XI2,
M][U_+&U'N;(_5YE0];\S;\&?&4,TGRWP                $Y7HVOUTW1C_
M 'B?\*'.K6GG@?PZ[1?V#])Y)W],]O4>']3+5;0?+M
M
M          5BO2T?JMM>^59Q+^9O*K<[F)_/9=^ \U[+EE*UCVI'HX\26:>F
M)6P                 D>\'_P"M)Z OE6<-?GEC6(=_WS)[4_ >;]BJ=K)^
MV[?HX\5L#H!EY                                 ,MSTG;ZXCG_P!H
MW OP-::FNYF/\/\ I7NG._C=U:FJ>W:O CQ(5_6U*G
M-#[T/+XC_4Y\JNO\$7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,5@
M
M          !D8^.'];1UV_MSRWXFPJ>?FV?,3LQ\&4_5UK/S_MRYZ)%0S@Z8
M                #0^]#R^(_P!3GRJZ_P $7&R)OO@'SDZ+\!Q^-9A<FC?8
M*_1^-"W.T,5@                !2F],M_LUZ"?;SU ?B#BE(SWO7\L;4>Y
MLC]7F5#UOS-OP9\90S2?+?                 3E>C:_73=&/\ >)_PH<ZM
M:>>!_#KM%_8/TGDG?TSV]1X?U,M5M!\NT
M
M!6*]+1^JVU[Y5G$OYF\JMSN8G\]EWX#S7LN64K6/:D>CCQ)9IZ8E;
M          "1[P?_ *TGH"^59PU^>6-8AW_?,GM3\!YOV*IVLG[;M^CCQ6P.
M@&7D                                 RZ_2@L;>V/C <UW5U1\E0S/
M''!.2QL_E*4_KFRI<6Z]AZE;NTZD\]'NY'%7%/NU(23Q\GWH0[LTLT9JN9;>
MMW=P.FT43C5;SF=IJX^"9S-RO#J^5JIG@QCAPXXF%J:K&&=J\"/$5[FUJG
M                - 7T.+.>N.FKK)UKU_Y3\$\Y:'G/P9V__P '_2'0:]AZ
M_P"[W?4_"7]&/)]O;'M]:_<AV>K%=WP7+<C;'9[.<G#LFF7Z.5T^QWXJY/\
MH]DQ_P!)<6BS]:KC^M'B+D"/E6@
M                                            &1CXX?UM'7;^W/+?
MB;"IY^;9\Q.S'P93]76L_/\ MRYZ)%0S@Z8                #0^]#R^(_
MU.?*KK_!%QLB;[X!\Y.B_ <?C687)HWV"OT?C0MSM#%8
M 4IO3+?[->@GV\]0'X@XI2,][U_+&U'N;(_5YE0];\S;\&?&4,TGRWP
M           $Y7HVOUTW1C_>)_PH<ZM:>>!_#KM%_8/TGDG?TSV]1X?U,M5M
M!\NT
M                               !6*]+1^JVU[Y5G$OYF\JMSN8G\]EW
MX#S7LN64K6/:D>CCQ)9IZ8E;                 "1[P?\ ZTGH"^59PU^>
M6-8AW_?,GM3\!YOV*IVLG[;M^CCQ6P.@&7D
M        S+_2M\-5Q?BMWM]4K4ZLFQ].G#F9H222S0FMJ5"OM^O1HU8S>I/4
MFK8&>I",/4[M2$/NPBF3YCF8IO;C:;<1,39U?-T3U9F+5S&/"KB/!A:^KQAF
M_!IA6J;B*6                  O&^AF[;W:_B"Z+7JS1C4H]-.VXNA"E1A
M++Y&?G'#YVK4K]Z%Q--/ZXQT)).R:2$)9H]LL8_?1J]\,R&-.RFITQQ3J%JJ
M<9Z/:==$8<70N8SQ\7'T*]HD_9*?0^.O,(TE>
M                                                       9&/CA
M_6T==O[<\M^)L*GGYMGS$[,?!E/U=:S\_P"W+GHD5#.#I@
M  -#[T/+XC_4Y\JNO\$7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,5@
M           !2F],M_LUZ"?;SU ?B#BE(SWO7\L;4>YLC]7F5#UOS-OP9\90
MS2?+?                 3E>C:_73=&/]XG_"ASJUIYX'\.NT7]@_2>2=_3
M/;U'A_4RU6T'R[0
M                                          %8KTM'ZK;7OE6<2_F;
MRJW.YB?SV7?@/->RY92M8]J1Z./$EFGIB5L                 )'O!_P#K
M2>@+Y5G#7YY8UB'?]\R>U/P'F_8JG:R?MNWZ./%; Z 9>0
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M3/#P81RL:QHU6&8JIZ='B3#1;1)+D
M                                               9&/CA_6T==O[<
M\M^)L*GGYMGS$[,?!E/U=:S\_P"W+GHD5#.#I@                -#[T/+
MXC_4Y\JNO\$7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,5@
M   !2F],M_LUZ"?;SU ?B#BE(SWO7\L;4>YLC]7F5#UOS-OP9\90S2?+?
M              3E>C:_73=&/]XG_"ASJUIYX'\.NT7]@_2>2=_3/;U'A_4R
MU6T'R[0
M                                  %8KTM'ZK;7OE6<2_F;RJW.YB?S
MV7?@/->RY92M8]J1Z./$EFGIB5L                 )'O!_P#K2>@+Y5G#
M7YY8UB'?]\R>U/P'F_8JG:R?MNWZ./%; Z 9>0
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MD9RCI3C'7CR6K0@Z7:
M                                    R,?'#^MHZ[?VYY;\385//S;/
MF)V8^#*?JZUGY_VY<]$BH9P=,                !H?>AY?$?ZG/E5U_@BX
MV1-]\ ^<G1?@./QK,+DT;[!7Z/QH6YVABL                 *4WIEO]FO
M03[>>H#\0<4I&>]Z_EC:CW-D?J\RH>M^9M^#/C*&:3Y;X
M "<KT;7ZZ;HQ_O$_X4.=6M// _AUVB_L'Z3R3OZ9[>H\/ZF6JV@^7:
M
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M9C+WLIF*\KF:9HS%JNJBJF>.FJF9BJ)ZL3$Q*]XF)C&.)])POT
M
M      !D8^.'];1UV_MSRWXFPJ>?FV?,3LQ\&4_5UK/S_MRYZ)%0S@Z8
M            #0^]#R^(_P!3GRJZ_P $7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^
M-"W.T,5@                !2F],M_LUZ"?;SU ?B#BE(SWO7\L;4>YLC]7
MF5#UOS-OP9\90S2?+?                 3E>C:_73=&/\ >)_PH<ZM:>>!
M_#KM%_8/TGDG?TSV]1X?U,M5M!\NT
M                                                        !6*]
M+1^JVU[Y5G$OYF\JMSN8G\]EWX#S7LN64K6/:D>CCQ)9IZ8E;
M      "1[P?_ *TGH"^59PU^>6-8AW_?,GM3\!YOV*IVLG[;M^CCQ6P.@&7D
M                                 K5>E;\>S;IX4EYLD)._#B/J+X<Y
M"FF[9X>2ER5#;^*._P#>75O+'MFY.A+]])7E^^_U(1[*E/</F-ZM&G;\:<GC
M[?TC-V/2S:S/2G\&Z<>#T)I>KT\K*8]*J)\6/'9EZ91:X
M   #6Q\"?J1I=3_A7=).Y7%[Z[V30^/Z/!>Y25*TMQ>T,]PE<5>/+.ODJLL9
MHS7V?U7"8W+31FC&I-)D)9I_OHQ01<YO9"K8O?=KVGTT\G)YK-SG;7!A$T9R
M.SS%,>=HNUW+7!P8VYB.!>&0N]ERE%71B,)\+@\3A2Z,"NX
M
M    R,?'#^MHZ[?VYY;\385//S;/F)V8^#*?JZUGY_VY<]$BH9P=,
M         !H?>AY?$?ZG/E5U_@BXV1-]\ ^<G1?@./QK,+DT;[!7Z/QH6YVA
MBL                 *4WIEO]FO03[>>H#\0<4I&>]Z_EC:CW-D?J\RH>M^
M9M^#/C*&:3Y;X                "<KT;7ZZ;HQ_O$_X4.=6M// _AUVB_L
M'Z3R3OZ9[>H\/ZF6JV@^7:
M                                                  K%>EH_5;:]
M\JSB7\S>56YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@                !
M(]X/_P!:3T!?*LX:_/+&L0[_ +YD]J?@/-^Q5.UD_;=OT<>*V!T R\@
M                           $5OC>\71Y@\)OKLU&6WFNIL9P7F.3)*,D
MTLDT:G"F6PW,U.I+WJ=7OS4)]"A/"2$.]/W>[+&6:,)H9OYMNM]P-^NS&?QY
M,5ZG1E\?=E->4ZG'V?#'H<<X\3J9^CEY.Y']7'K</C,BQ/0LX
M       !=R]#UZLY,?L74_T2;#E>Y2V&TQ/49QACZUQ&G1_"V(EQ^A<L6]M2
MJ=M.O?9+$U=8N))*<99X4,;<3QA/++&-.-[G_P"PDW<IHN\C*48U6JJLAF:H
MCAY-?*OY69GH4TU1F*9F>#&Y3'!,\-=T:]A-=B>CY:/$GQE[-&2KX
M
M         #(Q\</ZVCKM_;GEOQ-A4\_-L^8G9CX,I^KK6?G_ &Y<]$BH9P=,
M                !H?>AY?$?ZG/E5U_@BXV1-]\ ^<G1?@./QK,+DT;[!7Z
M/QH6YVABL                 *4WIEO]FO03[>>H#\0<4I&>]Z_EC:CW-D?
MJ\RH>M^9M^#/C*&:3Y;X                "<KT;7ZZ;HQ_O$_X4.=6M//
M_AUVB_L'Z3R3OZ9[>H\/ZF6JV@^7:
M                                                         K%>
MEH_5;:]\JSB7\S>56YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@
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MT[.7M/S]NJUGK%VJW<HJC"JBNBJ::Z*HZ%5-43$QT)A>D3%4153PQ+[KK/T
M
M              !D8^.'];1UV_MSRWXFPJ>?FV?,3LQ\&4_5UK/S_MRYZ)%0
MS@Z8                #0^]#R^(_P!3GRJZ_P $7&R)OO@'SDZ+\!Q^-9A<
MFC?8*_1^-"W.T,5@                !2F],M_LUZ"?;SU ?B#BE(SWO7\L
M;4>YLC]7F5#UOS-OP9\90S2?+?                 3E>C:_73=&/\ >)_P
MH<ZM:>>!_#KM%_8/TGDG?TSV]1X?U,M5M!\NT
M
M    !6*]+1^JVU[Y5G$OYF\JMSN8G\]EWX#S7LN64K6/:D>CCQ)9IZ8E;
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M.9[)9[!5YNCB\#^CBZRUBT=5<
M                                        !D8^.'];1UV_MSRWXFPJ
M>?FV?,3LQ\&4_5UK/S_MRYZ)%0S@Z8                #0^]#R^(_U.?*K
MK_!%QLB;[X!\Y.B_ <?C687)HWV"OT?C0MSM#%8                 4IO3
M+?[->@GV\]0'X@XI2,][U_+&U'N;(_5YE0];\S;\&?&4,TGRWP
M      $Y7HVOUTW1C_>)_P *'.K6GG@?PZ[1?V#])Y)W],]O4>']3+5;0?+M
M
M                            5BO2T?JMM>^59Q+^9O*K<[F)_/9=^ \U
M[+EE*UCVI'HX\26:>F)6P                 D>\'_ZTGH"^59PU^>6-8AW
M_?,GM3\!YOV*IVLG[;M^CCQ6P.@&7D
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MRB[;BY1.-,P[F6\^P
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M77,4Q%,355.$1$<40CT_BOZI?.4Y^]^/D3W1KP[@:#^!93[C;]2VI^1#<O\
M%#9?_"LC]X/XK^J7SE.?O?CY$]T9W T'\"RGW&WZD^1#<O\ %#9?_"LC]X/X
MK^J7SE.?O?CY$]T9W T'\"RGW&WZD^1#<O\ %#9?_"LC]X/XK^J7SE.?O?CY
M$]T9W T'\"RGW&WZD^1#<O\ %#9?_"LC]X/XK^J7SE.?O?CY$]T9W T'\"RG
MW&WZD^1#<O\ %#9?_"LC]X/XK^J7SE.?O?CY$]T9W T'\"RGW&WZD^1#<O\
M%#9?_"LC]X6B?1X.4N3>3M.ZI:_)/(V]\A5\/LW%5+$UMXV[8-LJXNE>8O>I
M[RECJF>R%_/94[J>WIQJ2THRPGC3EC-V]V'9@K?#D,CD<SD(R5FU9BJB[CR*
M*:,<)HPQY,1CAT,4,O?6-B]CMCM?V+M[(Z3IFE6\QD]2F[&3RMC+1<FBYDXI
MFY%FBB*YIBJJ*9JQPY4X88RL>L,HE
M                                           %8KTM'ZK;7OE6<2_F
M;RJW.YB?SV7?@/->RY92M8]J1Z./$EFGIB5L                 )'O!_\
MK2>@+Y5G#7YY8UB'?]\R>U/P'F_8JG:R?MNWZ./%; Z 9>0
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M&,)I9H1[81A]U$!,3$X3QKF?Z?@
M                                         R,?'#^MHZ[?VYY;\385
M//S;/F)V8^#*?JZUGY_VY<]$BH9P=,                !H?>AY?$?ZG/E5
MU_@BXV1-]\ ^<G1?@./QK,+DT;[!7Z/QH6YVABL                 *4WI
MEO\ 9KT$^WGJ _$'%*1GO>OY8VH]S9'ZO,J'K?F;?@SXRAFD^6^
M        G*]&U^NFZ,?[Q/\ A0YU:T\\#^'7:+^P?I/)._IGMZCP_J9:K:#Y
M=H    #/B\7[ZR#JC]M6J?!KI3;W=W^I>0^UU^R5O4US#?X2-B_<69_2&;1L
M+T;=@    +9GHU']2>K;VU<0_BCD!K_OK]M:?]KO>+;0==][_6+87W%JGLN1
M6>&#D-X
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MCA5T
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M\4<@-?\ ?7[:T_[7>\6V@Z[[W^L6PON+5/9<BL\,'(;P
M                                                         %8K
MTM'ZK;7OE6<2_F;RJW.YB?SV7?@/->RY92M8]J1Z./$EFGIB5L
M       )'O!_^M)Z OE6<-?GEC6(=_WS)[4_ >;]BJ=K)^V[?HX\5L#H!EY
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MJ9B:9<B=1^@
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MV]M7$/XHY :_[Z_;6G_:[WBVT'7?>_UBV%]Q:I[+D5GA@Y#>
M
M  K%>EH_5;:]\JSB7\S>56YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@
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M?@
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MZ_;6G_:[WBVT'7?>_P!8MA?<6J>RY%9X8.0W@
M                                                  *Q7I:/U6VO
M?*LXE_,WE5N=S$_GLN_ >:]ERRE:Q[4CT<>)+-/3$K8
M2/>#_P#6D] 7RK.&OSRQK$._[YD]J?@/-^Q5.UD_;=OT<>*V!T R\@
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M_1PXS3%=,3-%6'T]NK&BN."::Z:HF(F,%E7;=5JY5;J\U3.#I1<;C
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M;TRW^S7H)]O/4!^(.*4C/>]?RQM1[FR/U>94/6_,V_!GQE#-)\M\
M        !.5Z-K]=-T8_WB?\*'.K6GG@?PZ[1?V#])Y)W],]O4>']3+5;0?+
MM     9\7B_?60=4?MJU3X-=*;>[N_U+R'VNOV2MZFN8;_"1L7[BS/Z0S:-A
M>C;L    !;,]&H_J3U;>VKB'\4<@-?\ ?7[:T_[7>\6V@Z[[W^L6PON+5/9<
MBL\,'(;P
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MQ;ICBPM7JJ;D=&>V*^A0M[6,OR:XS%/%5P3X,<77CQ%,A(<H@
M
M                                          #0^]#R^(_U.?*KK_!%
MQLB;[X!\Y.B_ <?C687)HWV"OT?C0MSM#%8                 4IO3+?[-
M>@GV\]0'X@XI2,][U_+&U'N;(_5YE0];\S;\&?&4,TGRWP
M  $Y7HVOUTW1C_>)_P *'.K6GG@?PZ[1?V#])Y)W],]O4>']3+5;0?+M
M 9\7B_?60=4?MJU3X-=*;>[N_P!2\A]KK]DK>IKF&_PD;%^XLS^D,VC87HV[
M     6S/1J/ZD]6WMJXA_%'(#7_?7[:T_P"UWO%MH.N^]_K%L+[BU3V7(K/#
M!R&\
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M%43A+KY57R
M
M   T/O0\OB/]3GRJZ_P1<;(F^^ ?.3HOP''XUF%R:-]@K]'XT+<[0Q6
M            %*;TRW^S7H)]O/4!^(.*4C/>]?RQM1[FR/U>94/6_,V_!GQE
M#-)\M\                !.5Z-K]=-T8_WB?\*'.K6GG@?PZ[1?V#])Y)W]
M,]O4>']3+5;0?+M     9\7B_?60=4?MJU3X-=*;>[N_U+R'VNOV2MZFN8;_
M  D;%^XLS^D,VC87HV[     6S/1J/ZD]6WMJXA_%'(#7_?7[:T_[7>\6V@Z
M[[W^L6PON+5/9<BL\,'(;P
M                                   %8KTM'ZK;7OE6<2_F;RJW.YB?
MSV7?@/->RY92M8]J1Z./$EFGIB5L                 )'O!_\ K2>@+Y5G
M#7YY8UB'?]\R>U/P'F_8JG:R?MNWZ./%; Z 9>0
M               "AOZ63X;,^N[7JGB3<5X'LP>XSX+B_J8ML=;PA)CMNM+6
M3&<8\G7=.A0FFEH;)B+277LC<U)Y*-*ZL<5)+":M>U)HR>\Q;?!&;R-_<_K=
MW_F<O%>9TZ:I\U:F>5F<O&,\=NJ>SVZ8B9FFN_,X4VXA;^KY7"8S5'%/!5X/
M0GQNLI1)&E#
M
M    :'WH>7Q'^ISY5=?X(N-D3?? /G)T7X#C\:S"Y-&^P5^C\:%N=H8K
M             "E-Z9;_ &:]!/MYZ@/Q!Q2D9[WK^6-J/<V1^KS*AZWYFWX,
M^,H9I/EO@                )RO1M?KINC'^\3_ (4.=6M// _AUVB_L'Z3
MR3OZ9[>H\/ZF6JV@^7:     SXO%^^L@ZH_;5JGP:Z4V]W=_J7D/M=?LE;U-
M<PW^$C8OW%F?TAFT;"]&W8    "V9Z-1_4GJV]M7$/XHY :_[Z_;6G_:[WBV
MT'7?>_UBV%]Q:I[+D5GA@Y#>
M                                      K%>EH_5;:]\JSB7\S>56YW
M,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@                !(]X/_P!:3T!?
M*LX:_/+&L0[_ +YD]J?@/-^Q5.UD_;=OT<>*V!T R\@
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M75HJ\S,Q'+MS1<B,*X6;F+%67O3:KZ'T8Z$O&;(;@
M
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M)ZMO;5Q#^*.0&O\ OK]M:?\ :[WBVT'7?>_UBV%]Q:I[+D5GA@Y#>
M
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MF.&)B>*8GHQ*U7\7T_
M
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MVN]XMM!UWWO]8MA?<6J>RY%9X8.0W@
M                                           *Q7I:/U6VO?*LXE_,
MWE5N=S$_GLN_ >:]ERRE:Q[4CT<>)+-/3$K8                 2/>#_\
M6D] 7RK.&OSRQK$._P"^9/:GX#S?L53M9/VW;]''BM@= ,O(
M                          !GY^DX^#K5X=W/->(OTXZSV<3\BYVE-U*Z
M;AK6;R7'7).=NI*-OREC[:WIQDHZ;R-DJT*>5A&$L+#8*LM2$T]/)0DM)4^9
MGS@:=H-.M[I-KKW_ /=REJ>Y]VN>',9>B,9RU4SQW<O3&-KS]B)C")LXW+=U
M3)<BKMFU'E)GRT=*>GX$^+X*G,D$44
M
M                    !H?>AY?$?ZG/E5U_@BXV1-]\ ^<G1?@./QK,+DT;
M[!7Z/QH6YVABL                 *4WIEO]FO03[>>H#\0<4I&>]Z_EC:C
MW-D?J\RH>M^9M^#/C*&:3Y;X                "<KT;7ZZ;HQ_O$_X4.=6
MM// _AUVB_L'Z3R3OZ9[>H\/ZF6JV@^7:     SXO%^^L@ZH_;5JGP:Z4V]W
M=_J7D/M=?LE;U-<PW^$C8OW%F?TAFT;"]&W8    "V9Z-1_4GJV]M7$/XHY
M:_[Z_;6G_:[WBVT'7?>_UBV%]Q:I[+D5GA@Y#>
M                                                    K%>EH_5;
M:]\JSB7\S>56YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@
M !(]X/\ ]:3T!?*LX:_/+&L0[_OF3VI^ \W[%4[63]MV_1QXK8'0#+R
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MH,&S#H
M                                                        -#[T
M/+XC_4Y\JNO\$7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,5@
M     !2F],M_LUZ"?;SU ?B#BE(SWO7\L;4>YLC]7F5#UOS-OP9\90S2?+?
M                3E>C:_73=&/]XG_"ASJUIYX'\.NT7]@_2>2=_3/;U'A_
M4RU6T'R[0    &?%XOWUD'5'[:M4^#72FWN[O]2\A]KK]DK>IKF&_P )&Q?N
M+,_I#-HV%Z-NP    %LST:C^I/5M[:N(?Q1R U_WU^VM/^UWO%MH.N^]_K%L
M+[BU3V7(K/#!R&\
M                            !6*]+1^JVU[Y5G$OYF\JMSN8G\]EWX#S
M7LN64K6/:D>CCQ)9IZ8E;                 "1[P?_ *TGH"^59PU^>6-8
MAW_?,GM3\!YOV*IVLG[;M^CCQ6P.@&7D
M            Z%ZFNF?AGJ^X2WKI\Y\TZQW;C3D#%5<=EL=<R4Y+_&7DL(SX
MK9=:R4U*K6P6UZ[?=VZQ]_1A"K;7%.6:';#O2S71L;MEM#L#M)E=J]ELQ5EM
M8RM?*IJCS-4?36[E.,17:N1C3<HG@JIF8Z4QQW;5%ZW-NY&-,LIOQ6_"TYE\
M+7J"J\:;M/<[EQ-N4M_G>#^9K7&5K/#;[J]"ZC2K8O*2RPJ6>&Y"U>%2E3S.
M+A5GC1\K1N:49[2ZMZL\XFXW?9L]OLV4C6--B,OKN7Y-&<RDU1-=BY,8Q53T
M:[%SAFU<PC'"JBK"NBNF+2S>4KRESDU<-$\4]/\ IZ:+AFMU
M
M                                     &A]Z'E\1_J<^577^"+C9$WW
MP#YR=%^ X_&LPN31OL%?H_&A;G:&*P                 I3>F6_P!FO03[
M>>H#\0<4I&>]Z_EC:CW-D?J\RH>M^9M^#/C*&:3Y;X                "<
MKT;7ZZ;HQ_O$_P"%#G5K3SP/X==HO[!^D\D[^F>WJ/#^IEJMH/EV@    ,^+
MQ?OK(.J/VU:I\&NE-O=W?ZEY#[77[)6]37,-_A(V+]Q9G](9M&PO1MV
MMF>C4?U)ZMO;5Q#^*.0&O^^OVUI_VN]XMM!UWWO]8MA?<6J>RY%9X8.0W@
M
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M9NV*Y\Q=BF(Q\I7%-<32M/-Y2YE*^35PT3Q3T_Z>HBM9O=0
M
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MHU']2>K;VU<0_BCD!K_OK]M:?]KO>+;0==][_6+87W%JGLN16>&#D-X
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M?@/-^Q5.UD_;=OT<>*V!T R\@
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MFJNS,S=M1$S]<MTS<6QG<A<RL\NGRUGI]+P?)XD"#:)3@
M
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MK;VU<0_BCD!K_OK]M:?]KO>+;0==][_6+87W%JGLN16>&#D-X
M                                  "GYZ0)\<GC3Y,NF_"GS.V"W4?J
M[>]VU^Q64XW>S_F(U;]K<U^C]+08,GI$     $Y_H_?QR>2_DR[E\*?##&&]
M?]7;/NVCV*\CO[YA\Q&D_M;E?T?JBX&U]0<@                  *Q7I:/
MU6VO?*LXE_,WE5N=S$_GLN_ >:]ERRE:Q[4CT<>)+-/3$K8
M    2/>#_P#6D] 7RK.&OSRQK$._[YD]J?@/-^Q5.UD_;=OT<>*V!T R\@
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MJIJB8F*HF8F)QB5#F)B<)X)A\ESOP
M
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MG_:[WBVT'7?>_P!8MA?<6J>RY%9X8.0W@
M                  *?GI GQR>-/DRZ;\*?,[8+=1^KM[W;7[%93C=[/^8C
M5OVMS7Z/TM!@R>D0     3G^C]_')Y+^3+N7PI\,,8;U_P!7;/NVCV*\CO[Y
MA\Q&D_M;E?T?JBX&U]0<@                  *Q7I:/U6VO?*LXE_,WE5N
M=S$_GLN_ >:]ERRE:Q[4CT<>)+-/3$K8                 2/>#_\ 6D]
M7RK.&OSRQK$._P"^9/:GX#S?L53M9/VW;]''BM@= ,O(
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MT=..+^CPT73-;J
M                                                          -#
M[T/+XC_4Y\JNO\$7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,5@
M       !2F],M_LUZ"?;SU ?B#BE(SWO7\L;4>YLC]7F5#UOS-OP9\90S2?+
M?                 3E>C:_73=&/]XG_"ASJUIYX'\.NT7]@_2>2=_3/;U'
MA_4RU6T'R[0    &?%XOWUD'5'[:M4^#72FWN[O]2\A]KK]DK>IKF&_PD;%^
MXLS^D,VC87HV[     6S/1J/ZD]6WMJXA_%'(#7_ 'U^VM/^UWO%MH.N^]_K
M%L+[BU3V7(K/#!R&\
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M,\C,VOMMBO"Y3&/!%?)FW5/F*ZHX5"OY:]EYPNTS'5Z$^&\3LCN
M
M                                 !H?>AY?$?ZG/E5U_@BXV1-]\ ^<
MG1?@./QK,+DT;[!7Z/QH6YVABL                 *4WIEO]FO03[>>H#\
M0<4I&>]Z_EC:CW-D?J\RH>M^9M^#/C*&:3Y;X                "<KT;7Z
MZ;HQ_O$_X4.=6M// _AUVB_L'Z3R3OZ9[>H\/ZF6JV@^7:     SXO%^^L@Z
MH_;5JGP:Z4V]W=_J7D/M=?LE;U-<PW^$C8OW%F?TAFT;"]&W8    "V9Z-1_
M4GJV]M7$/XHY :_[Z_;6G_:[WBVT'7?>_P!8MA?<6J>RY%9X8.0W@
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M1.,3''$CPOS7X87AX]1'KZMS!T9=.^UY7)=OKW:*'&6N:ON]QV]G^MO>H6>
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MK\\L:M'?]\R>U/P'F_8JG+D_;=OT<>*V!T R\@
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M8X8F."8='BX)?F?;\
M                                                        :'WH
M>7Q'^ISY5=?X(N-D3?? /G)T7X#C\:S"Y-&^P5^C\:%N=H8K
M     "E-Z9;_ &:]!/MYZ@/Q!Q2D9[WK^6-J/<V1^KS*AZWYFWX,^,H9I/EO
M@                )RO1M?KINC'^\3_ (4.=6M// _AUVB_L'Z3R3OZ9[>H
M\/ZF6JV@^7:     SXO%^^L@ZH_;5JGP:Z4V]W=_J7D/M=?LE;U-<PW^$C8O
MW%F?TAFT;"]&W8    "V9Z-1_4GJV]M7$/XHY :_[Z_;6G_:[WBVT'7?>_UB
MV%]Q:I[+D5GA@Y#>
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M<]PX5YB]7=F,>A3RZIBBGI4TQ%,1$1$1$/JBW;M1R;=,4QU(P=S+>?8
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MJ(Y-=,Q/!Q<'4XNM@F8:\NZ
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M;2[.[39;MS9S/Y+/Y28\WEK]N_1Z:W55'T71KMUVYPKIFF>K&#JU6WP
M
M                               T/O0\OB/]3GRJZ_P1<;(F^^ ?.3HO
MP''XUF%R:-]@K]'XT+<[0Q6                 %*;TRW^S7H)]O/4!^(.*
M4C/>]?RQM1[FR/U>94/6_,V_!GQE#-)\M\                !.5Z-K]=-T
M8_WB?\*'.K6GG@?PZ[1?V#])Y)W],]O4>']3+5;0?+M     9\7B_?60=4?M
MJU3X-=*;>[N_U+R'VNOV2MZFN8;_  D;%^XLS^D,VC87HV[     6S/1J/ZD
M]6WMJXA_%'(#7_?7[:T_[7>\6V@Z[[W^L6PON+5/9<BL\,'(;P
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MT5U3%,353$S,88S$8XS"VFP*A6
M
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M0C&G7MKB2G6HU(0C]R:6$7?M7;=ZW%VS537:JC&)IF)B8ZDQP2_.+C?D<C\
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M7_?7[:T_[7>\6V@Z[[W^L6PON+5/9<BL\,'(;P
M
M
M
M                         &1CXX?UM'7;^W/+?B;"IY^;9\Q.S'P93]76
ML_/^W+GHD5#.#I@                -#[T/+XC_ %.?*KK_  1<;(F^^ ?.
M3HOP''XUF%R:-]@K]'XT+<[0Q6
M         &?%XOWUD'5'[:M4^#72FWN[O]2\A]KK]DK>IKF&_P )&Q?N+,_I
M#-HV%Z-NP    %LST:C^I/5M[:N(?Q1R U_WU^VM/^UWO%MH.N^]_K%L+[BU
M3V7(K/#!R&\
M
M
M                                                          !D
M8^.'];1UV_MSRWXFPJ>?FV?,3LQ\&4_5UK/S_MRYZ)%0S@Z8
M    #0^]#R^(_P!3GRJZ_P $7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,5@
M                                          !GQ>+]]9!U1^VK5/@U
MTIM[N[_4O(?:Z_9*WJ:YAO\ "1L7[BS/Z0S:-A>C;L    !;,]&H_J3U;>VK
MB'\4<@-?]]?MK3_M=[Q;:#KOO?ZQ;"^XM4]ER*SPP<AO
M
M
M
M                                8_'C 9C\.>*3U^WOX0_"?D.JSF7#
M^N?+>7\G_1[<LE@/P?W^V/=_!/X,]:]S_P#Q^1[GJ=U/SN"R_:VY/9:WR.1C
MH>4KPPP^R6J:^5_I<KE8]'''HK-SDXYNYZ.?%1PLO.J
MT6?0^<--0\/SJ'V&-Q+-)E.L;9\-+:PIQA-1FP/"G"-]/<1J]^,)Y;F&QRRP
ME[L.[Y*,>V/>]2)+G^YB*MZNDY3#AHV?MUX]/EYS.1AAU.Q_1ZBY=&C_ )>J
M?Z_C0MF-%57                                           9\7B_?
M60=4?MJU3X-=*;>[N_U+R'VNOV2MZFN8;_"1L7[BS/Z0S:-A>C;L    !;,]
M&H_J3U;>VKB'\4<@-?\ ?7[:T_[7>\6V@Z[[W^L6PON+5/9<BL\,'(;P
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M0
M
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MQ?OK(.J/VU:I\&NE-O=W?ZEY#[77[)6]37,-_A(V+]Q9G](9M&PO1MV
MMF>C4?U)ZMO;5Q#^*.0&O^^OVUI_VN]XMM!UWWO]8MA?<6J>RY%9X8.0W@
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MFJM MX_\_D\,YDN3&'EJ[MCE3EXF9PB,U18JF8X*9C"9]TK5:U@
M
M
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M]2>K;VU<0_BCD!K_ +Z_;6G_ &N]XMM!UWWO]8MA?<6J>RY%9X8.0W@
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M^J11FKU-7!PV+,T4Y;+83CR*[5F+\4SR:KU?#,QF+V;A
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MI%CAH/,33/)JX)A_T?@
M
M                           "'+Q^.=;?@/PENL#-0N_(9?D?0[;@K VT
MM2%*MD[CFG-8_0,_:49H^I-ZWTC,Y6[J2_\ :H6T\(>K&#8+FM;,U[4[]M R
MW)QR^3S4YVN>.*8RE%5^B9\&]1:ICI550Z6H7.QY.N>C,8=?@\1DSIU5H
M               -:SP$]%CQWX0G0W@(T9J'X0XOS6]=R;RW;-#E#D;=N2X5
MH>7KW$_=N8;;Y2'9-"3LF^\EDE[))8(^=#J?=;?YM+FL<>1G:+/0_P#QLO9R
M^'!$<78L.GP<,S/#-X:?3R<G;CJ8]>9E+RP([@
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M.#9?<U^K%_W?7[%8>A7O37\.FM?MKG/T9HZ 5EI*      L1^C?_ !IN<_V
M5OA%TEAW?/\ D+*^Z_\ AUHI>^V?,MLW^U$?B&<7(6N" 0
M  !'EUJ^)ITR=$./N<=OFQS[CRM5LH76&X<TFK:Y#;[CR]*::QN]CKSU(8W2
M\+7G[L8W%_/+7J48S3VMO=1DC(O#9G8C7-J*XKRE'8\ACA5>KQBCJQ3T:ZNI
M3P1/FIIXVU7-XYGF^+G&9JC-[,Y2,AL33<Y-W5<W%5&5IY,^7IL1$=DS=Z(Q
M\I9B:*:L*;UVS%45*?76GXK?5-UGU<GKV;V*/&/#UY&-*EQ#H%]>66%O[.$T
MLTDF[9KMHY?>:\TU.2:>2ZC3QT*LD)Z5G1F;%[,[ Z#LU%-ZU1V?48_VUR(F
MJ)_J4\5'A>6PX)JE/3S>N9'N6YOE%G5=.RG=G;ZWPSJF=HHKO45]&<I9X;63
MCAF(FWRK_)F::[]R$9J]FX0                    "3SHN\67JJZ-:V-U[
M&[%/ROP]:STJ5?B7D._O+_'8^QD[LL:6C['-ZYS>BU9*7>\E2MXUL7"I/&I5
ML:TW9&%C[3;O]!VDBJ]71VOJ,_[6W$1,S_7IX*:^K,X5="*H:;\X3F.[D^<!
M;O:KF\I&B;>UQ,QJ>1HHHN5UST<Y8\K9SD3.'*JKY&8Y,131F;=.*X!T6^)A
MTQ];N,MK+0=F_HCRE3M)J^8X<W>O9XW=;:-O3[UY=Z_W*TUAN>%H]D9O7./G
MJ5*5+NS75&UGFA3:Z[3;$ZYLO7-6;H[)D,>"]1C-$]**NC15U*N"9\S-7&@9
MYPO,_P!\?-SSE>8VHR?;^Q<UX6M5R<5W,I5RI\I3?QB*\I>G@CL=^*::JL8L
MW+U,<I(0M!JP
M
M                    H\^F&=6%K+C^EWHDP&2FGO:MYE>I/DNQHUX2RVUK
M;T,OQWQ/0N):?>FJS7M6ZVFO4I5(R0IPH6]3NS]^2:22?F ;"US=UO>1FJ,+
M<4TZ?EZICCF9HOYJ8Z6$1EHB8QQY5<8QA,30M9O>8L1Z*?$CQU&!)@H
M             #:/Z+^-YN'.CWI3XDJ4?6];C'IPX1T&YI1A2[\+O4>--9P-
MY-5C1J5J4]>I=6$\U2>$\_?GC&;O3=O;'SL[Q-8C:#;_ %S7HG&G.ZOG+\3P
M\5W,7*XPQPG#"J,(PC".#"%[V*>19HHZ5,1]!Z66<Y0
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MTW.?[ *WPBZ2P[OG_(65]U_\.M%+WVSYEMF_VHC\0SBY"UP0"
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M\=%RW7%-5%4=&*HB7WG$I@
M
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M<Q<F;E^[PQ$X57:JN1%7#3;Y%'%3"S,S>G,7JKL]&>#J1T/H/%S(K@
M           >B^D#B*?G_JOZ:.#I;?UU)RYSSQ+QU=THTX5:<N.V_>\%@\I7
MN))I9I/6EICKVK5K1FA&66E)-&/J0BM';[7HV6V&UG:69Y,Y#2\UF(GB\M:L
MUUTQ'5FJ(B.K,.6S1V2]3;\]5$=>6TT\ZR]P
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M&*,Q.
M
M        _E7KT+6A6NKJM2MK:VI5*]Q<5ZDE&A0H49(U*U:M6J1EITJ5*G+&
M::::,(2PAVQ]1]4TU5U111$S7,X1$<,S,\41'1F1GB>DA^-GB>J?-9#H1Z5-
MJI97IYTC8J%SS9R;@,A"OA^;]YUZ[M[K%ZIK=S;PEI9'C+0<W;1KSW<)ZMMG
M<S1HW%O#UK8VMS>2Q<T+FXW]B,O1O.VXL31M9F;,QD\O73A7D[-R)BJ[<B>&
MG,7Z)Y,4X159LS517Y>[71;MS4\]%V>U[,_6XGAGISY$?1E4:;YJ,
M           GR]&AX.FYG\6_@S*7%E+?8/@W5N2^<<_2F[>RE+K^JW.GZK>P
MFA_JS6'(F]86M#_\QD[/]+5SGC;2QL[N'U.Q15R<SJ=_+Y.B>GR[L7;L?Z5B
MS>CPU1TNWR\Y3/0IB9\;Q9AJ9H2UU@
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M.6:6>66:6:$TLT(32S2QA&6:6,.V$TL8=L(PC"/J18 0?S$TSR:N"8?]'X
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M:V*W?92+.6C"K,9BO"K,YR_$83?S-W")KKGAY-,13:M4SR+5%%$12\S*VS"
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MEFJW=K]R+6:W@
M
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M<<,38IKB*KMVF>&+]RFF:9B)MV[=4<J;=SFIW,Q$V[6--GZ,^#Y"M W'4L
M                !>D]#CZ>)Z6(ZQNK#)V';3OLCH_3QI64[D(=V?%VT>2>
M3[#RD>V:/?ES&H5.R'9"'=[8]O;#NQG=\%VLBJ_L_L+9KX::+V?O4^BGM?+5
M?ZF:C_QPU_1;?!7>GJ1'BSXR\"C95T
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M73+5,1&;B(FJ[G<I1'!&:B,:\Q8IC#-1C=MQVSRJ<S;<:^(+P
M%+7TC3X[G%OR5](^%OG!LON:_5B_[OK]BL/0KWIK^'36OVUSGZ,T= *RTE
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M9'):;E:,CIUFUE\E:C"BW;HIHHHCI4T4Q%-,=2(B'0F9JG&J<9? =I^
M               -:KP(NE^KTH>%MTMZ3E<?^#]QW_4:G.N]R3RS27<=@YDN
M9MTQMID:,\E.:WR6OZ5?XG%5Z<8=LE2PC+&,8PC&,$G.<VTC;G?9K>I6*^7I
M^5S':5GI<C*1V&J:9Z--=ZF[=IGHQ7BO#3[78<I13/FIC&?#X?$2]L!NX
M                                         SXO%^^L@ZH_;5JGP:Z4
MV]W=_J7D/M=?LE;U-<PW^$C8OW%F?TAFT;"]&W8    "V9Z-1_4GJV]M7$/X
MHY :_P"^OVUI_P!KO>+;0==][_6+87W%JGLN16>&#D-X
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M4PT"[7-S6<E:IX,M<KJ\MJ-BBG_\>Y5,=MVZ8^L7)G,1]9KN]@LT,(H>0
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MP]GD9.Q'*OWZHI[/G,Q5$1<S.8JIB.5<KPB(CS-NW31:MQ3;HIB/-JM,N
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M:[F8_P /^E>Z<[^-W5J:I[=J\"/$A7];4J<
M
M                       ]T>&CTHWO6WUU]-'393LJ]Y@=^Y+P]QR#-0[\
MDUEQ9J<*NX<GWL*\)8R6]>GHV"OY+:,\999[N>E3[>]/+".,]\>W-O=ONRUG
M;":HIS65R=<6,>CF;N%K+1AT8[-71-6'%3%4\42[&5L]GS%-KH3/#X''/T&Q
MQ0H4+6A1M;6C2MK:VI4Z%O;T*<E&A0H49(4Z-&C1IPEITJ5*G+"6666$(2PA
MV0]1Y]JJJJZIKKF9KF<9F>&9F>.9GHS*]']7R
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MBS.\#4J;=[5<W3'!7>B)Y&6LU3'*[5RO*JHM8X3<KJNYB::)N]CHCH7DVP
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M:TU-=S,?X?\ 2O=.=_&[JU-4]NU>!'B0K^MJ5.
M
M                          7F?1!>BB>G1Y]Z^]NQ522%QW^G;AFM=T(2
MRU*-.?#[;RWLEE+7AWZDD:TN#Q5K=T80D[U/)6_>C&%266-'G\[QHFK2]UN0
MKC@_Y_-Q$]'R]K*VYPZG9KE5,\/#9KPXIFO:-8\UF)]#'BSXWT5XQ&LKP
M                                         #/B\7[ZR#JC]M6J?!KI
M3;W=W^I>0^UU^R5O4US#?X2-B_<69_2&;1L+T;=@    +9GHU']2>K;VU<0_
MBCD!K_OK]M:?]KO>+;0==][_ %BV%]Q:I[+D5GA@Y#>
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MCM+I=B*=7M6Z>',Y*B,*,[A3PU7LE3Y6]5,535E,*JJJ:,I$56_&NR!P
M                        !EN>D[?7$<_^T;@7X&M-37<S'^'_ $KW3G?Q
MNZM35/;M7@1XD*_K:E3@
M
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M-JGBIC__ &?#EZD62Y0
M   &?%XOWUD'5'[:M4^#72FWN[O]2\A]KK]DK>IKF&_PD;%^XLS^D,VC87HV
M[     6S/1J/ZD]6WMJXA_%'(#7_ 'U^VM/^UWO%MH.N^]_K%L+[BU3V7(K/
M#!R&\                        !\/9=9UW<]?S.I[=@L3L^L;%CKK$9[7
ML]C[7*X;,XN^I34+S'Y/&WU*M:7MG<T9XRSTZDDTLT(^K!RV+][+7J<QEZZJ
M+]%43353,Q5$QQ3$QPQ,*EH^L:ML_JF7US0LS?R>LY2[3=LW[-=5N[:N43C1
M7;N43%5%=,QC%5,Q,2IP^*?X-6:Z=I=AZ@^F#&Y39^"*<;K+[KH,LU7);)PY
M:0A3J5\E8UJU>MD=GX^HU)YYIZL99[W#T(0FN8UK>2K=T]C]@]Y%K6>1I&N5
M4V]5X(HN<5-Z>E/0IN=3S-<^9PF8IF?GF5]\ T[>O.5W6[Y;UG)[RYY-K*9W
M@MY?5:N&*;=<13%O+YZ8B(BG&+6:KF8LQ;NU46*Z^K+J4H      !.UX&O7=
M/T[\YPZ=N0,SZWX<Y^S5G9XJO>U9H6.F<NUZ5'&:[EY9II_)VF/W6G2H8>^F
M[L8>7A859YJ=&WJS1Q7O2V5C6-*[L92G'4LI3,SAQUV>.J.K-'#73U.7$8S,
M(T^^1<VFG>MNV^5?9;+\O;_9?+UUW(HCR^;TN)FY?M888U5Y29KS5F,?,3F:
M*::[EVB(NU-8GG6         4M?2-/CN<6_)7TCX6^<&R^YK]6+_ +OK]BL/
M0KWIK^'36OVUSGZ,T= *RTE      6(_1O\ XTW.?[ *WPBZ2P[OG_(65]U_
M\.M%+WVSYEMF_P!J(_$,XN0M<$ @        "-3Q3NN"SZ(NFC+[!@KRV_3+
MR5&^TGAS&5/)5:E#-5+62;.;M7M9YX35,7HF,NI;F,W<J4I\C6LK>I"$EQ&:
M%[;![+U;4:W39NQ/<VQA7>G^KCY6C'IW)C#H3R8JF.&&WO,LYN-_G&;X+&EZ
ME;K^3_2.1F]5N1C$56HJGL.4IJB."YG+E,V\,::HL49B[1/*M1$Y^-_?WV4O
MKS)Y.\NLCDLC=7%_D,A?W%:[OKZ^NZT]Q=WEY=W$]2O=75U7J33U*D\TT\\\
MT8QC&,8Q;=444VZ8HHB*:*8PB(X(B(XHB.A$/4CELMELEEK>3R=NBUE+5%-%
M%%%,4T444Q%--%%-,133333$133$1$1$1$8/R/US@     ._>FOIGY@ZL>5,
M'Q%POJ]SL.QY:I)6R60GIUZ6NZA@I:]*C?[5N&8IT*]+":]C?+2]^K/":I6J
MS24*$E:YJT:-2DZUK>G;/Y"O4=3N119IXH^FKJZ%%$?353TNA&,S,4Q,QC#>
M]O@V#W'[%9G;O>#G:,KI-B)BW1$TS?S5["9HRV5M3-,WK]S"<*8F*::8JNW:
MK=JBY<IO6^'[X;/"_0=I<D<';6^Z\U;!C;>WW_EW*6<DN3O8QA)5N->U"VJQ
MJ_T5TVE=P[T+>E-&XO9I)*EY5K34Z,M'5;:[;74]J\S]=F;6F45?6[,3P1TJ
MJY^FKPZ,\%/#%,1C./FKYTG.ZWA<YG:&8U*NK3MWF5O559+2[=<]CHXXIOYJ
MJ,.V<W-/!RZH[':B:J;%%N*[DW)&EFM30                  $=W7YX;_"
MO7CI4]'8[:AI?,."L:U+0^7\1CZ-7,XN>$M2>AA-GMI9K>.U:=6N9N]4LZM2
M2M;QC-/:UJ$\]3REX[);::GLIFL;,S=TZN?KEF9X)_K4SP\BO#HQP3Q51,88
M;6\V#G;;P^;/M%%S2:ZM1V"S-V)SNEW:YBU<C@BJ]EZL*NULU%,81=IIFFN(
MBF];N4TT\FB=U,],',?21RIF.(N:M8J8#8\?#UYB\A;U/7NN[=K]:O6HX_:=
M3S$LDE+*X/(^0F[LW93KV]66>A<TJ-S2JT9-J=$US3=H<A3J.F5\NS/!,3P5
M45=&FN.A5'6F.&F9IF)GTK;GM\FP._38K+[=[O,Y&:TF[Y2Y15'(OY6_$1->
M6S-K&9MWK>,8QC-%=,TW;5=RU71<J\^JNRD      _397MYC;RTR..N[FPR%
MA<T+VQOK*O5M;RRO+6K)7MKNTN:$].M;W-O6IRSTZDDT)I)H0C",(P?E5--=
M,T5Q$T3&$Q/#$Q/'$QT8EPYC+Y?-Y>O*9NBB[E;M%5%=%=,545T51,54U4S$
MQ535$S%5,Q,3$S$Q@T ?"FZY;7K:Z:L5DMCR%O/S;Q;)C=+YAL(1IR7&1R$E
MM4EU[?Z=O3[D)++?<=8SUZG=DI4J>4H7M&G)"E1DC-J/M]LM5LQK=5%F)[EW
M\:[,]*,?+6_!MS.'1F:9IF>&9>7;GM\VZ_S==[U_*:3:JC=UK4W,WI=?#--N
MB:H[/DIJG'&O)7*XHIQFJJK+UY>Y75RZZHB3I8[3D
M        !EN>D[?7$<_^T;@7X&M-37<S'^'_ $KW3G?QNZM35/;M7@1XD*_K
M:E3@
M                                                  %S;T37PY:^
M\<F[CXC')F%__P"2XHJ9CC'I[M[^VDFIYODS,XOUKR!O=K"K/+/ZTT74\I#%
M6M2%.I1N+[,W,9)Y*^-FA&/+GU;W*=-T;+[H]&N?\_GHHS.>FF?,9>BK&Q9G
M#HWKM/9:HQB::+5&,33>A6](RW*KG,U>9C@CP>C/A>/U%^]%JN$
M                                    !GQ>+]]9!U1^VK5/@UTIM[N[
M_4O(?:Z_9*WJ:YAO\)&Q?N+,_I#-HV%Z-NP    %LST:C^I/5M[:N(?Q1R U
M_P!]?MK3_M=[Q;:#KOO?ZQ;"^XM4]ER*SPP<AO
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MUQ'/_M&X%^!K34UW,Q_A_P!*]TYW\;NK4U3V[5X$>)"OZVI4X
M
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M&H_J3U;>VKB'\4<@-?\ ?7[:T_[7>\6V@Z[[W^L6PON+5/9<BL\,'(;P
M                      'XLEC<=F<=D,/F,?99;$9:RNL;E,7DK6A?8[)8
MZ^H5+6^Q^0L;JG5MKRRO+:K-3JTJDLU.I3FC+-",(Q@^J*Z[5<7+<S3<IF)B
M8G"8F.&)B8X8F)X8F'8R><S>GYNUG\A=N6,]8N4W+=RW551<MW**HJHKHKIF
M*J*Z*HBJFJF8JIJB)B8F%%WQ>/#7NNB_DV3DOC#&W=QTV\H96XCKW=EJ5_T9
M;;7A7O;SCO)7,T]6>IBJM"G/<X2YJQEGJVLM2VG[]6TFKU]I]WFVM.TN1[2S
MU41K5BGRW^]HXHN1'3Z%<1Q3A5&$581Z3>8CSN['.$V.G9#;*[11O<T:Q3V?
MBCNAE8Y-%.>MTX1$7(JF+>;MTXQ3<FB]3R:+\6[4-3)"0      !*3X0_5]<
M=)G5[I\V;S$F.XGYBN+'C+E"G=U84L;:6V6NHTM2VVXJ30FIVL^H[-<TJM6X
MC#[S&U[R3MEA5C-"Q-X>SM.T&SMSL5..H9:)NVL..9B/+T=7ETQ,1'GHIGH-
M+^?=N'M;\=P^?C3LO-W;?0**]0TZ:8QN556J<<SEJ8CAJC-9>FJFFB/-9BC+
MU83R(B;_ &U)>7H       !2U](T^.YQ;\E?2/A;YP;+[FOU8O\ N^OV*P]"
MO>FOX=-:_;7.?HS1T K+24     !8C]&_P#C3<Y_L K?"+I+#N^?\A97W7_P
MZT4O?;/F6V;_ &HC\0SBY"UP0"        (1/'2ZP/X?>EB?AS5,IZUY+ZD_
MPGI\GK:MW;S#<765*A^D3+1[D9HTOPY;7M#!TY:DLOEJ.1N9Z<W?MH]F3]U>
MSO=?7NZ68IQR.2PKX>*;L_8X_P!&8FN>E--,3P5)&.]L;AOE2WU1M_K=GE['
M[(]CS4\J,:+NHUS5VC:X>/L-5%><JF)GDU6+--<<F[&-'9M$]'H     #F/'
MV@;CRKN^J\;\?8"_VC=MUSEAKNLX#&R2SW>3RV2KRT+:C+-4FIT+>C+&:,]:
MO5GDH6]&6:I5GDIR330Z^<S>6R&5N9W.5Q;RMJF:JJIXHB./^B(X9G@CA4#:
MG:C0-B=G,[M;M3FK62V=T[+5W\Q?N3A3;M6XY54\&,U3/%313$UUU3311355
M5$3H$>''T"Z1T'<*V^KVLMAG.7=SH8W+\P[[0DC/'-9VWHU8VNO86M6I4;FC
MIVJQNZU&QIS2R35IZE6YJ2RU*\TDFHVV>UN:VKU.;]6-&G6IF+-OSM,\=57]
M>O")JZ7!3'!#RY<[3G/;1\YG>'7K-Z;N6V$T^JY:TK)3.'8K-4QRK]Z(F:9S
M69Y--5ZJ)F*(BBS3,T6XJJD+6>U6                       1_>(IT%:-
MUX\)7FG9"&.P'*VJ4[S,<0<AW%O--5UW8)Z4D:V$RU:VEC=U].VF6A);Y"C"
M%7R484KNG3GKVU*6-W;';69K934XS-'*KR%S"+UO'S5/GHZ'+IXZ9X,>&F9B
M*I;1\U'G-[2<V?>+;U_*]ES6Q.>FBUJF1IJC"_8B9PO6HJ\K&:RW*FNQ7/)Y
M7E[%5=-N]7,9^?)/'&Z\0[[MG&/(VOWNK;QI&:O-?V7 Y"66%Q89*RG[L\):
ME.:>A=6MQ3C+5M[BE-/0N*%22K2FFISRS1VZR6=RNHY2WGLE7%S*W:8JIJCH
MQ/B3T)B>&)QB>&'J/V1VMV=V\V8R.V.R>:MYW9S4<O1?R]ZCS-=NN.#@G"::
MJ9QIKHJB*[==-5%=--5,Q'"'97&      NZ>!!U@?IWZ8JO!>V93USR/TW_@
M_7;/UU6[UYF>*,EY?^@U])WXRS5OZ,36U?"U):<L9;>UM;*,\W?KP[=8=ZVS
MO<K7.ZN7IPR6=QJG#BB['FX_TL8KZLS5AQ/.?WR_<-\FF^.G>3H=GD;);7<N
M_5R8\I:U*WAVY1.'%VQRJ,W3-4XUW+F8BF.3:3H,6(V@
M          &6YZ3M]<1S_P"T;@7X&M-37<S'^'_2O=.=_&[JU-4]NU>!'B0K
M^MJ5.
M                                                  ?ZEEFGFEDD
MEFGGGFA+))+",TTTTT>R6666';&:::,>R$(?=?DS$1C/$-.+T=+PE*W0'T\5
M^>.;=9EQ_5CU&X3'7N>QN3LH4\SP]Q5/4I936N+YO+QFN,?L68JRT<MLM/NT
M)Y+V%M85:<9\9"K4AFYVV_>G>EM9&R^S=[E["Z1<JBBJF?*9O,\--S,\'!5;
MHC&UEYX8FCEW:9PO<F+ITW)]KV^R7(^O5?0CI>3_ $+(+4)4P
M                                   &?%XOWUD'5'[:M4^#72FWN[O]
M2\A]KK]DK>IKF&_PD;%^XLS^D,VC87HV[     6S/1J/ZD]6WMJXA_%'(#7_
M 'U^VM/^UWO%MH.N^]_K%L+[BU3V7(K/#!R&\
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M .E=MU>5SNHVY^P3,>:L9"K&F:<>37G(KJFF>U[%Q8A8=13
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MP-::FNYF/\/^E>Z<[^-W5J:I[=J\"/$A7];4J<
M
M                       N/>C0^"]<\N[;K/B)]3^I5:?$VBY>7*=,^AY^
MQEEH\F[WAKN:6CRQE+.ZEC-6T?0LI;QCAY8R0ER>;HPK][UM8QDO(^N>-SB*
M- R%[=+L7?B==S5ODZC>HJX<O9KCARM,QQ7K],_79Q^MV9Y.'+NXVZUI>1Y<
MQF;L>4CS,=.>GX$=#JM =%:N(
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M%%-.;JKG,VJ>#DTQ:SE.8IHMT\%%F;7!3$Q"458K3$
M       !EN>D[?7$<_\ M&X%^!K34UW,Q_A_TKW3G?QNZM35/;M7@1XD*_K:
ME3@
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MJIF9F9F9G%=$1%,81P1#[+KOT
M            !GQ>+]]9!U1^VK5/@UTIM[N[_4O(?:Z_9*WJ:YAO\)&Q?N+,
M_I#-HV%Z-NP    %LST:C^I/5M[:N(?Q1R U_P!]?MK3_M=[Q;:#KOO?ZQ;"
M^XM4]ER*SPP<AO                             ?XJ4Y*LD]*K))4IU)
M)J=2G4EA/)4DGA&6>2>2:$99I)I8]D81]2,")F)QCC?5-55%45T3,5Q.,3'!
M,3'%,3T)AGR>*STA_P 'W5YNVK8''>LN+^0^_P G<4^1I]RSLM:V*]N_PCJU
M#NPC3I?T-V&A=6%*E&::KZPIVM6?_OH-O=@=HO\ ,>SMJ_=JQSUGZU=Z<U4Q
M&%7^G3A5,\7*Y41Q/4SS)-^_R];B-.UK4[O9-L]*PT_4L9QKKS%BBGL>9GHS
MVU8FW>JJPBGLU5ZBG['*-E>C;H    !S;C7?]BXIY#T7D[4KJ-EM''NW:[NF
MOW,(S0A2R^M9:TS%A&IW8PC/0FN;.66I+]R>2,98]L(Q@ZV=REG/Y.[D<Q&-
MB];JHJCJ51,3]"5N[7[+Z5MMLIJ6QVNT=DT;5<A?RE^GIVLQ:JM5X=*>35,T
MSQQ.$QPPTT^+>0\!RYQIQ_RGJM6-;6N1],UG>,%//-)-5ABMIPUGFK*E7[D8
MRRW-&A>RR59?NR5)9I8]D81@TBS^3O:?G;V0S'V>S=JHJ\&F9IGPN#@>/';/
M975-A=K]4V*UNGDZOI.H9C)WHC'#LF6NUV:YIQ^EFJB9IGHTS$QP2YVZBV@
M    %+7TC3X[G%OR5](^%OG!LON:_5B_[OK]BL/0KWIK^'36OVUSGZ,T= *R
MTE      6(_1O_C3<Y_L K?"+I+#N^?\A97W7_PZT4O?;/F6V;_:B/Q#.+D+
M7! (       IM>D2=0<^Z=1G'73SB;Z-3"<*:9+L>R6DDTDLLN_<E2VV2A0N
M9).V:K''Z/88JM0FGC",GX2K0EEA":,T^R&YW1XRVC7M8N1]=S5WDTS_ +NW
MC'!X-<UQ/H83^]ZDW64[/;IM6WJYZUAJ.T6H=@R]4X^TM/FJWC3,\7+SE>9I
MKB./L%$S,S$137@9A2L     /]TZ<]6>2E2DGJ5*D\M.G3IRQGGJ3SQA+)))
M)+",TT\TT>R$(>K&),Q$8SQ/FJJFBF:ZYB*(C&9G@B(CCF9Z$0T)_"UZ/+?H
MUZ3-*T_,8R2SY5WRE0Y%Y@KU)8^O:6W9ZSH3VNKUIIHSQITM'P<MOC(TY)HT
M)KRC<W$D(1N)HQU!V[VCG:3:"[F;=6.0M?6[/2Y%,\-7^G5C5CQX33$\3RO<
M]'?W=YP&_'4=>R%Z;FQ6F53D-+ICS$Y6S5,59B.+&<Y>Y>8BJ8BN+5=FU5P6
MJ<)&EF-30                          $>OB=](%GUE])V\Z%C["2XY*T
M^E5Y$XBNI)8>NH;QKMA>1IX"6I"'>C:[EBJ]QBYY)H^2EJW-*O&$9J%/LO#8
M?:*K9O:"UFZYPR5SZW>CH<BJ8\MX-$X5=/")CHRVHYG&_F_S?M^&F[39J[-.
MR&?JC(ZI3,^5[3OUT8WYCBY64N1;S,3'EIIMUVHF*;M6.>14ISTIYZ562>G4
MISS4ZE.I+&2>G/)&,L\D\DT(32SRS0[(PCZL(MP8F)C&.)ZJZ:J:Z8KHF)HF
M,8F.&)B>*8GHQ+_ ^@    %A#T>'J"FT7J:WW@'+7\:6#YTTF?*Z_:5;B/DY
MN0.-)+W-6U*TMZD?)TZE_I-]F9Z\\G9/4]8T99H30EEC)B'?#I';>AVM7MQ]
M=RMW"J?]W<PIG'P*XHP]%/AQ8]]7W6QM+N=TS>AD;7*U+9K48MWZHIX>TM0F
MBU5-54<,Q1FZ,I%$3P4]FN3$Q-4Q5<T:V//P
M  RW/2=OKB.?_:-P+\#6FIKN9C_#_I7NG._C=U:FJ>W:O CQ(5_6U*G
M
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M>C4?U)ZMO;5Q#^*.0&O^^OVUI_VN]XMM!UWWO]8MA?<6J>RY%9X8.0W@
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M<AJEV;NU.S-<:7F9JG&NNU:HIJR5Z>&9F*\K-%J:ZIY5=ZQ>JGIS$@R"WH
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MNG._C=U:FJ>W:O CQ(5_6U*G
M
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MZZYFJJNNJJ9JJJJJF9JJF9F9G&5Q1$4QA'!$/MNL_0
M                               &?%XOWUD'5'[:M4^#72FWN[O]2\A]
MKK]DK>IKF&_PD;%^XLS^D,VC87HV[     6S/1J/ZD]6WMJXA_%'(#7_ 'U^
MVM/^UWO%MH.N^]_K%L+[BU3V7(K/#!R&\
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MD[G*T39/(TV,(G&F<[FZ;>9S5<<.&,6^U;%7!$Q78JB9GH3HL6(V0
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M5MW+]=J(C@B;<TQP0D%6@U:                         9;GI.WUQ'/\
M[1N!?@:TU-=S,?X?]*]TYW\;NK4U3V[5X$>)"OZVI4X
M
M                      !W;T]].'.759RCK_#'3QQEM/*W).RU>YCM;U:P
MC<SV]K+/3DN<QF\C6GH8G6]=QT*L)KO)9"O;6-I3CWJU627U5M[5[7[-;#Z+
M=VBVLSMC(Z/9CRURY5AC/0HHIC&JY<JP\K;MTU5U3P4TS+DMVKEVN*+<3-4M
M"_P@_1MN&>BROK7/O5U'5NH'J@L9K7,:YKDMK-E>&.%<K1GA7L[S7;#+V=O4
MWW>\;4A+4DS.0MJ=MC[F$LV/M:=>A3OZD4&_SG@;0[Q:;VRVP79]*V+JQHN7
M,>3F\Y3/!,7*J9GL%FKBFS;JFJY3C%VN::IM1<>3TRBQA<O857?H1Y,]7K=-
M:):5JJ                                                    SX
MO%^^L@ZH_;5JGP:Z4V]W=_J7D/M=?LE;U-<PW^$C8OW%F?TAFT;"]&W8
M"V9Z-1_4GJV]M7$/XHY :_[Z_;6G_:[WBVT'7?>_UBV%]Q:I[+D5GA@Y#>
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MTU_#IK7[:YS]&:.@%9:2@     +$?HW_ ,:;G/\ 8!6^$726'=\_Y"RONO\
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MNG._C=U:FJ>W:O CQ(5_6U*G
M
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MO:R]'(M1A'T9\&7KQ8+F
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MIMN.+E1G[]O+WX]Z59BKJ\G#@B<8T#VHKRW
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MK::>5=T_:*K+8X3,TT9W*7KE4XQ&$4S7DK=,S,QY::(C&97%VN* H
M                 !EN>D[?7$<_^T;@7X&M-37<S'^'_2O=.=_&[JU-4]NU
M>!'B0K^MJ5.
M                                               <DU'3MNY V/$Z
M=H>J[)NVW9Z[IV&"U;4<'D]DV/-7U6/92LL3@\-:WN3R-W5CZDM.C2GGF_T0
M=//ZAD-*RES4-4OV<MD+5/*KNW:Z;=NBF..:JZYBFF(Z<S$/J*9JGDTQ,U2L
ME=#/HM77EU*3X;;.HZKBNC?BR^IR7DTN[V=/;.:<E9S2R3TI<?Q/BLI80URI
M7FA/2JR['D\/?6D80J>LJ\L82S:?[R^>QNPV.BYD-D(KVAUNF</K,]BR=,]'
ME9JJFKLF'!,=KV[M%7%V2F>*IV-*S%WAN^4HZO'UO)P76>@7P7.@GP[K;&9G
MB#BJAN7,%I0EEN^>^6O6.Z<HSW,:?<KUM=O*MA:X'C^A5A--)&G@+''35:48
M2W$]>:'?C'/O2YQ.]#>S77E]?STY?0*IX,EE>59RV'0BY$537?F./&_7<PGA
MHBF.!6\OD<OEN&B,:^G/#/\ 1X25Y@QW
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M7NG._C=U:FJ>W:O CQ(5_6U*G
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M$XTTW+D]BHF>/L5BGDV;6/1[';IB>BJMJQ9L1A:IBGQ>OQO4RR'*
M                                                 SXO%^^L@ZH_
M;5JGP:Z4V]W=_J7D/M=?LE;U-<PW^$C8OW%F?TAFT;"]&W8    "V9Z-1_4G
MJV]M7$/XHY :_P"^OVUI_P!KO>+;0==][_6+87W%JGLN16>&#D-X
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MGO\ \I3^8?\ _#_^J_\ MIW$_P![_J_^8^QA_P#V1_\ )[_\I3^8?_\ #_\
MJO\ [:=Q/][_ *O_ )C[&'_]D?\ R>__ "E/YA__ ,/_ .J_^VG<3_>_ZO\
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MOKSZD^R!>)7^N_H:]\KGS_IG/W^]SOYMVE][Y+_N)W&S7GK?7GU)]D"\2O\
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MI\.7:IIIIC"F(B.HY:Z#Z
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M\AR>&ULC9N<K'C[+J.HTX8=3L4SCCP\KJ<-A!B!%B
M            K]^D;V-K4Z,>)<E/2[;VTZGM5L;>MWZD/)VN0XJYAKWE+R<)
MX4I_+5<90CWII8S2]SLEC"$9NW+FYFJJ-I<Q1]+.1KGPXNV</%E*/WIC,WJ>
M<'KN4IG_ )>O8W,UU1A'#51J6E4TSCAC&$7*XPB<)QX8G",*7[95Z#@    '
MM+PY/CY](G[?^-/SEL5M;9_JGJ/N2Y]3+7KG9_PS;=_LOJ'XO6T<FF;R7@
M
M
M                                                           ,
M_#QC\=<8OQ*.I^VN8TXU*N<T#(R^2FC-+ZWR_$7'^6M(1C&66,*D+6]D[\.S
MLA/VPA&,(=L=NMV]<5[%9&JGBY-R.M>N1/T8>I'F!9JUG.:'L;>LX\B,MG:.
M'@\M:U3/6JO"Y5$X=.,)X.)&4O=N(     MF>C4?U)ZMO;5Q#^*.0&O^^OVU
MI_VN]XMM!UWWO]8MA?<6J>RY%9X8.0W@
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M-%X!][76_P#T1_G/:S\XYO[I5Y)^]GSFOCWM1_B&8]6?1Q]!GFB\ ^]KK?\
MZ(_SGM9^<<W]TJ\D_>SYS7Q[VH_Q#,>K/HX^@SS1> ?>UUO_ -$?YSVL_..;
M^Z5>2?O9\YKX][4?XAF/5O0G$_"O$G!&NWNH\,\<ZAQCJ^1S5SL=_@=*P=E@
M,5=YZ\L<;C+K+W%G84J5&ID+C'X>UHSU8P[T:=O)+V]DL%'U#4]0U6]&8U*]
M<OWZ:8IBJNJ:IBF)F8C&>AC,SATYEBS;C>'MUO+U:WKN\#5L_K.LVLO38HO9
MN]7?N4V::[ERFU377,S%%-=VY7%/%%5=4\<R[/=%9H
M            " ;TC3XD?%ORJ-(^"3G!EO<U^L]_W!7[+82@=Z:_B+UK]BLY
M^D]'4M&RST*@    /:7AR?'SZ1/V_P#&GYRV*VML_P!4]1]R7/J9:]<[/^&;
M;O\ 9?4/Q>MHY-,WDO
M
M
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M)Y4S7&FUVXQPPPCL=V<)F)QJX(G&J8M7,"(30
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M]YMGR67GN\K0U3CKCK7)[7^EO)6[WMK<WMK@,/&\GDM,=86=C9UKO(Y&X_\
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MGB:*S3AY00
M
M
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ME;69RF;IJGI?9;=BGACZ;@F.*;G[6IY\0
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MV3'H<6/'"JZ1RNVIPXN1./T/':5*'A<X
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M3Y[#C7]&I3R_
M
M
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M9HY>;R61MZA1.$S-$:??M9N]5&'_ /S6K],S/!%-4SP<<:#[4)Y9
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MIJJI\I-%44S%-<S$Q''E<]8S<S3;QBN.A/\ XE+JP*[@
M             "BEX\?)DN_^(1M^ HUZ=>UXBX\X[XVH3T9H34_*U<7<<BY&
MGWI8QEFKVV3Y K4*G^F6>E&2/JRMJ=U.1[4V0MWIC"K,7KESZ/8XZ\6XF/!>
ME3O9VQ\[+\UC(:I<IFF_KNJY[/S$\>$7*<C1/@56\C173TXJBJ."4-#)"0$
M   !/1Z/!ID^?ZV]QVFI3CZTT/@7;[^G7[)XRRY;/;5I&O6=O'N5Z4(1KXR^
MOIX1FEJR_P E&'=A-&6>7%&^',]BV8MV(\U=S=$>%3175/T8IZ7&C*[ZQM!3
MIG-UT_1:)^OZGM/E:)C@^Q6<MG+]=7#$\5RBS'!-,^6X\(FF;KC65YWP
M
M
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M5=)U',Y.]&&'UW+7J[-S@X>#E43APSP=&7-W56X
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M%<VW;7:#E]CNT[/9NQ;JX,:;V<MSD[$QCP8Q>S%$QCCP]">*='5IF\EH
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M)M6-0SUVG'C[+7E\OEZII_J]AS,1/#CRIB,,)QM&,%(8P
M
M
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M0B*[M41$<$1A$1$<"\<C7->4MU5<?)PZW!XR4MA-VP
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MJ?\ 0S.;OT3Q>6IGP9E]8[:'
M
M
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ME?G/T<F)FJK)UTQ;U"W&'%33;BWFZY\[E,(X^&\^U9>;0
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M1'!$1$1P1#LETEH@
M
M
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M9N-IVUUFQV/:S:ZNWG*N5&%=&0HIF-/MSTHKHKN9O@XZ<U135PT81">R:D1
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M7C<KM7+<533%RJNNBJW5RKE454Q35=-SU>9B;=W[)3&./3CR5FIIJJ@
M                    #S=U==1VM=)O3KRCSSLL+>XDTC7:]77\-7JQI_TE
MW/)SR8K3M:D\G-"OW,QL5Y;TJ\].$TUO:^5KQAW:4T85K9[1K^T&LV-)L8Q-
MVORT^=HCAKJ\*F)F,>.<(Z++FXG=+J^_#>QHN[+1^715J.;B+]VF,>U\I;B;
MF:S$X^5QM6*:ZJ(JPBNYR+>/*KAFY[MN6R\B[CM>_P"Y96XSFV[ML69VO9LS
M=1A&XRF>V#(W&5RU_6[L(2RSW5]=3S]DL(2R]O9"$(0A!NAE<M8R>6MY3+4Q
M1E[5%-%,1Q133&$1X40]<&SNS^D;)Z!DME]G[%&6T+3LI:RV7M4^9MV;%%-N
MU1'4IHIB,9X9PQGA<8<ZL@    )6_!<X$FYTZ^>*[B\LY+K6>&:61YLV.-6E
M"I3IU-,FM:&G=R-22>CZXAR#EL35A+'[Z-*E4FE]67MA8.\O5NY6R5^FF<+^
M9PLT_P"GCR__ $XKCP9AI'WPG>=3NVYL.MVLO<FC6-H*K>D6,)PF8S?*G-8X
M3$\GM&UF:<8X.551$\$X3?I:F/,,
M
M
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M<C&BJ:Z8HJGDU2K&EY.Y8Y5Z[&%5481'1PZJW T.5@
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MM,V9R79,Q$3P=OY^*+M5-41P53:RE&6FF<9FFJ_>HPIGE<JPBQ BP
M
M
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MPQPBN_<JN333CQ44<KD41]+1333'!#L-TUJ
M
M
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M3R]>&,3V?,4U9BJF<*J>U;%7#3=X;;;7Q!B
M
M
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M(X8GCIKHJC&FY:N4S%=J[1-5NY;JIKHJFF8EV2Z2T0
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M^7L[LS<FYG9HJQHNZG<HPY$X8Q/:-FJ;7'$TW[V9MUQC;C"PPP^BL
M 4M?2-/CN<6_)7TCX6^<&R^YK]6+_N^OV*P]"O>FOX=-:_;7.?HS1T K+24
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MZ)GA['E[%%NS1,\,TT1-6-4S+O-2F-@
M
M
M                                     %?SQY.AJ?FWANRZH^/L1&ZY
M,X'Q-Q0W6TL+:2>]VKAZ:YJ7^0KU)I98UJ]SQQ?5ZV2I2]L)9<?<Y":/>GEI
M2LN;J-J8TS4IT+.589'-U>4F9X*+V&$>%<C"F?ZT4=5*-WLWG(T[NMO[FYC:
MJ_R-C]IK]-64JKJF*,MJG)BBB(QG"FG/T4T9>J<)F;]O*Q&%,URI?-E7H/
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M_P#C3<Y_L K?"+I+#N^?\A97W7_PZT4O?;/F6V;_ &HC\0SBY"UP0"
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MNQ7"SDP>AS
M
M
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M4SO.T*FWE]2IX(JS%,Q,9?/TQ'!AF::*HO<G"*,S1=B**+=5GE14+];L@
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M5VK?B<9IHN1C5.5S/)B9JR]VJ9QBJ;-R];CLD^^5I-80
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M.KN4[OM*Y>5TJU/*C&S%7US.5T3AR;V<KB+DXTTU46:;%FO&JS-54DRRFHH
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MC/9W-Q$9N]=NQ3Q<NNJK#'CPQF<'Y%,1Q1$/O.J_0
M        $9O7IXI'3]T-8B[P>3O:7)/.-S91JX'AW6<G;2Y&TJ5K>6M99'?\
MM)+=TM'P5:6K)/)&M2K7]U3GA-;6M62$]2G>^R>PFK[4W(NVX[!I<3Y:]5$X
M3TXMQP<NKP)BF/IJHG")W!YLG,OWI<Y'/6]2R=NK2-W%%S"]JN8MU=CJB*IB
MNWDK4\F<Y>B8F)Y-5-FW,87KU%4TTU4D.K#K$YTZSN1JO(W-FTSY.I;>N;?5
M=1Q<M:PTK1<3<U9:DV)U3!35Z\EI)4\G3A<75:>O?WL:4DUQ7JQDEC+L[L_L
MYI6S62[3TRWR8G":ZYX:ZYCHUU='J1&%-.,\F(Q>BW<?N#W:\WS9*G9/=WDH
MLT5\FK,YJYA7F\Y=IC#LN9O81-4QC5R+=,46;7*JBU;HBJK'RXKK,X
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MHS,ON.)30
M
M
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M^5MY'(6K=C)6:*:+=NW3%%%%%,84T444Q%---,1$4TTQ$1$81&#\3Z=@
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MB>3.8O3]=S%<8\JN8HB>Q6K44^WUKM<@
M
M
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MW/Y^[<OYZ_<JN7+ERJJNY<N5U3577775,U5UUU3-5554S555,S,S,OVOEUP
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M9S-4<JJU3:G#8N1Q
M
M
M                             *^7C$^%%3ZAL7FNI_IXP="CSGKV)JWG
M(.CXNS[L_,F$Q-KWI<ABJ%K)VUN2\18V_DZ4G<FGS-O));PCZXI4):N7MW.W
M\Z/<IT+6*IG2JZL+=<S]AJF>*<?]G,\?G)QGBF<)3>8-SW:]U6=R^YK>KF:J
MMVV;OQ1D<Y<JX-*O7:O,7*JIX-/NUU<JJ<8C*7)JNX=BKNS13,JTJM"K5H5Z
M52C7HU)Z5:C5DFIU:56G-&2I2JTYX0GIU*<\(PFEC"$81AV1;)Q,3&,<,2]
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MS>-Q^ZJJB[L!LOH^G9VWAR<Q38INYJ,.+_F[_9<S/AW9Z?&\OJXS*
M   _[++---"66$9IIHPEEEEA&,TTT8]D(0A#U8QC$?DS%,8SP1"WGX-WA+U>
M+9,#U9=3^KPI\E5Z=EF.&.,\W;S0K\<V]22>M0WK;\;7EA"GO=W3J4Y\9959
M>]A*?\M6EAD)Y)+#7C>1O C/\O9_0[G_ "48Q>NT_P"T_J43ZW'TU4>;XH\I
MC-<$//\ N?)1MI5FMQ^YO.X[(4S7:U;4+-7!GZHF(JR>5N1QY*F8F,Q>IG#.
M3];MSVK355FK*#"J(D
M
M
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MBNBJ(JIKHJIF::J:J9B::HF8F)B8G!^1^N<
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ME!A5$2
M
M
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M:+E7#;S6J1'!CF,)QM92>&:,I$_7(F*\SC5R;5F<5BY'
M
M
M
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MFWYIHSN5G@BJJ;<3]>L<J8BC,VN5:JQBFJ;=WE6Z?$JYVQ0
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M*\WFZZ[N:NUU5UUUU357775,S5555,S-554S,U53,S,S,S.+]+Y<(
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MM?9G+W)JR>F6)FG*9:)QB*IC@G,9CDS,59F]C7.-5-N+5J8MT^Y5K-;@
M
M
M
M                '$-^X_TCE/4,[H'(^JX+=M*V>RFQ^>UG9,=;97$9.UC/
M)5DEN+2ZDGD\K;UZ<E6C5E[M6A6DDJ4YI:DDLT.QE,WFLAF*,WDKE=K,T3C3
M53,Q,3X,=:8XIC@G@5[9C:G:/8K7LMM1LEG<SIVT.3N<NSF,O<JMW;=6$Q/)
MJIF)PJIF::Z9QIKHFJBN*J:IB:LW7=X .;PU3,\E=$-Y4SV&[;G(WW VTY:'
MX?QE*'?K3T..MNRE6%//VU*6/=I8_+UJ=[+))][>7=6:6DSQLIO;M78IR6U$
M<B[P1%^F/*S]LHCS,].JB.3_ %:8X4TO-H[Z'IVH49?9#G&6XRNH>5MT:UEK
M7UBY/!$3G\K;C&S5/'5?RM%5F9GAR]BB)K5H=HU79M(V#+:EN>NYS4]IP-Y4
MQ^<UO9,5?8/.X>_I0A&I9Y/$Y*A;7]C<R0FA&,E6G+-V1A'L[(LV6+]C-6:<
MQEJZ;EBN,::J9BJF8Z<3&,3'@)?]&UK1]H]+L:YL_F\MGM%S5N*[.8R]RB]9
MNT3Q5V[MN:J*Z9Z=-4P^"Y53                      2*=%7AA]3W6UD+
M+)Z9K4^D<2>NX4<MS+N]M<V&ITZ5.K-)=T=6M(PI9+>LK1\E/)Y''RS6U*M"
M$EU<VL)Y9HV=M-MSH>S%$T9FOLNH8<%FB8FOJ<J>*B.K5PS'#334U0YP_/(W
M-\W7*W,GM!G(U+;GD8VM*R=5->9F9C&F<S5PV\G;G&)Y5^8N543-5FS>Y,PN
M5=$7AK=.'0UA:=?0L'';^4[RS];;%S'M]K:7.WWT*M+N7=AK].26>TTS7JTT
MTT/6=CV5*TG=A=5[J:26>&MVU&VNL[4W<,W5V/(1.--FB9BB.E-71KJZM7%]
M+%..#S_\XSG>;VN<CJ$VMILSVAL5;N<JQI65JJIRM&$XTUWYG"K-WXX/KM[R
MM,XS9MV8JFF9!EH-60               %+7TC3X[G%OR5](^%OG!LON:_5B
M_P"[Z_8K#T*]Z:_ATUK]M<Y^C-'0"LM)0     %B/T;_ .--SG^P"M\(NDL.
M[Y_R%E?=?_#K12]]L^9;9O\ :B/Q#.+D+7! (                  ZGYZY
M'FX=X,YGY<DM9;Z?BSB?D7D>2RFEC-+=S:1I^8V:6UFEA/3C-+<1QG<C"$TO
M;V_=@KNR^D1M!M-IV@S5R8SV>R^7QZ79KM%O'PN5B^+E7(MU5]*)GK0Q4=JV
MC8=XVC9-TVW+WNP;7M^>S&T;/GLC5\MD,WL.P9"XRV:R]_6[(>5O<EDKNK6J
MS=D.]//&+T89')933<E9T[(6Z;61R]JBW;HIC"FBW13%-%-,="*:8B(CI0L>
M9FJ9JGCE\!VGX LU>BB<S[%Q_P")Y-Q=97=W'6.>^$.1]:S^+D[LUC/E-%M+
M?DK7<W<235*<9;O%T=:O[2C4EA/-+)DJLO=[)XS2Z:<^79W*:KN7[MW*:>W=
M+U++W**OIN3>F<O<HCJ53<HJF.#AMTSCP835-(KFG-<CH54S]#A:7:'-=
M  #JKG;^Q#F3]E7(?YHY=W]*_*F6]T6_JX7KNU^<;0/AO(_C5IF(-XGL@
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MU3/!$1Q0Y X5+
M
M
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MKJKKKKJFJNNNJ9JJKKJJF:JJJJIF:JIF9F9F9G%^M\N
M!2U](T^.YQ;\E?2/A;YP;+[FOU8O^[Z_8K#T*]Z:_ATUK]M<Y^C-'0"LM)0
M    %B/T;_XTW.?[ *WPBZ2P[OG_ "%E?=?_  ZT4O?;/F6V;_:B/Q#.+D+7
M! (                  XIOFG8?D31]SX_V&2I5P&]:IL6G9RG2C++5J8?9
M\1>83)R4YII9I85)[*^GA",81AV_Z'>TO4,QI.I9?5<I,1FLM?MW:,>+EVZX
MKI^C$/RJF*J9IGBF,&+WU.]/7('2?U!\O=.'*-C/8;SP[O.;TO,QC;U;:WRE
M/'7'?P^R8R2M&-2?!;9@JUMD\?5[8PK6-W2J0C&$T(O1%L9M9I6W6RF0VOT2
MJ*M,U#+47J.&)FGE1Y>W5A]/:KBJW<CH5TU1T%D7;=5FY5:K\U3.#HE<[C 6
MZ_1&ND?:MZZM>5.L7*8:O1XUX)X[S/'&N9ZXM)86V3Y<Y+EQE.MC<3=UH=E:
MOKG'5*_GR,*';4MY<O90J1EDN)85-"N?EMYD=,V$R.[^S<B=8U/-T9BY1$\-
M.5R_*PJJB.*+F8Y$6\>"KL5S#&:)PK.CV9JO3>GS-,8>'/\ 1XK0Z1.KC >6
MNL/K,Z>NA#A/-\^]2N\T-)T/%7=##XVE1MJN4V7<=JOK:\N\3IFE:_;?^+S^
MSY:CCZ]2G1D[E*C;T*MS<5:%K0KUZ=[;O]WFUF\[:.WLML=EIS.IUTS75,S%
M-NU:IF(JO7JYX*+=,U4Q,SC,U3311%5=5-,\5Z_;R]OLEV<*?%ZD*Q=OZ8UT
MQ3[W#'7/1YSM;\:1OH4OZ84]VT&XW>7'1GEAZ\GX\[M+!PNX21C&-O+LTTOJ
M=D*L>UN=7WOO;.-,[-1M!IDZSR<>Q=AOQ9Y72[/PUX?UNU\?ZJE=VK7*PY%7
M(Z>,8];^E:%Z2^KK@'K?X3USJ Z;=\L]]XZV&K<XZI<24+C&YS6=DQU.WGS.
MG[A@+Z2EDM<VG"^NZ4:UK7DA"I0K4;FA/6M;BWKU=+-N]@MJ=VVT=[97;#*U
M975[415AC%5%RW5CR+MJNG&FY;KPG"J)X)BJBJ*:Z:Z::K9O6[]N+EJ<:9_\
M82]*+.<KJKG;^Q#F3]E7(?YHY=W]*_*F6]T6_JX7KNU^<;0/AO(_C5IF(-XG
ML@        <]XWXMY)YAVFRTCBG0]MY%V[(??6NNZ;@<EL.5FHRSR25;NK:X
MRWN)[7'VWE(1K7-7N4*$GWU2>66$8NKG<_DM.L3FL_=MV<O''575%,>!C/',
M]"(X9Z"V=KMM-D=@=%N;1[;:GD=)T*UYJ_F[UNQ;QPF8IBJY53%5=6$Q1;IQ
MKKG@IIF>!85Z1/1Y^2=LJ8[;.L'<J?&.OQC1N)N+N/[[%[!OU]3^]GFM<YML
MD,EJ&KPC]R,+.&9J3RQC#O4)^R9A_:+?!DLO%67V<M]GO>NW(FFW'5IHX*ZO
M#Y$>"BNW[=]3V1T.B[H>X73YUG5.&GNCG:+EC)43Q<JSEI['FLQ_]V<I3$X3
MA=IX%G+IZZ6N NE;4OZ%\#<::]H.*KPH1RU[8T:MYL>QW%M)&6E>;/M&2JWF
MP;!<T^_-W(W5Q4EHPFC+2EDD^]8/UC7M6U[,=LZM?KO7(XHG@IIQZ%-,84TQ
MX$1CT<4.6]3?3O/WUZ[_ )AWF:QFM4SM/*[%17,46+%-4\-.7R]N*+%BF<(Q
M[';IFO")KFJKA>@%(8N
M
M
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M&I7KN8S]ZN:[EV[75<N7*ZIQJKKKJF:JJJIX9JJF9F>&9?0?#J@
M         *6OI&GQW.+?DKZ1\+?.#9?<U^K%_P!WU^Q6'H5[TU_#IK7[:YS]
M&:.@%9:2@     +$?HW_ ,:;G/\ 8!6^$726'=\_Y"RONO\ X=:*7OMGS+;-
M_M1'XAG%R%K@@$                   06^,%X&?!WBEXS'\@XW8)>%.J;4
ML)2P6M\N6F)FS.#VS7;*M<W=CIG)^MT;NQJY;&6UQ>5O663M:M/)8V-:/J7=
MO+"SFV9W \Y?:7<G>KTJ]:[I;$W[DUW,K-7(KM7)B(F]EKDQ5%-4Q$<NW5$V
M[F'^SKGLCH9W(6\W'*B>3=CH^-*DORYZ-+XO7%VPW6)PW3S@>8\)2N9K>SW3
MBCECC:]P>2[/*32U:.(W39-)WFRI34Z?;WKO$6\D(QA+V]Z/8D=T'GB[@]:R
ME-_,:M=T_,S&,V<UE<Q%=/4FJS;O69GJ4W:IZ/$H5>EYRB<(IY4=.)CQ\)^@
M]C=&?HG?7!RQM.)R76#G-1Z6>,K:[H5L_B,7LNL<J<P9FRDK23UK#7;'2LGG
M>/<+4O[:6>G"_OLQ6GL9YY9XX^Z[LU)C[>'SZ-VVA9&Y9V M9C6]9FF8HJJM
MW,ME:)PX*KE5ZFB_7R9PGD46HBN(F.RT8Q4Y[&D7ZYQO844=>?H<'T?"7\.E
MGI;X4Z,^#='Z=^G[4*&F\:Z'8SV^/L_*S7N6S&3O*LUUFMHV?+U99;G.;/L.
M0J3W%Y=5.SO3S0DIRTZ,E*E)%KMMMMM'O#VES.UFU68G,:QFJL:IPPIHIB,*
M+=NB."BW;IPIHICH<,S-4U53<-JU;L6XMVXPIAZ$6HY % /TQG>]\N.HKI X
MRN;S(2<8XCA7;=[PV/A2N*.*NM\V+>;O7]EO*E:$86F1R%AK^K8F226/>J65
M.YFC#NPNIN]*=WOO3-,HV2U_6:*:)UFYJ-JS75C$U19MV8KMQAQTTU7+EV9G
MBKFF./D1A;VM55=EHH^DY./AX_\ ^*:R0E1%U#T-[>]YI\K]:W&5*XO:_&MY
MQ[QAO=]:SSS5,?B]YQNR9W7\5<6LD\)I;.]SN RUY+7C3[L;F3'4?*=[R%/N
M1T]\&TS3)T+9S6:HIC6*<WF;-,_356:K=%=43TXHKIHY../)FY5AARIQKFBU
M5<NNGZ7")\-?51?+@=5<[?V(<R?LJY#_ #1R[OZ5^5,M[HM_5PO7=K\XV@?#
M>1_&K3,0;Q/9      _39V5YD;NVL,?:7-_?7E>G;6=E9T*MU=W5S6GA3HV]
MM;4))ZU>O5GFA++)++&::,>R$'Y55313-=<Q%$1C,SP1$=67#F,QE\I8KS6:
MKHM9:W3-55==44TTTQ&,U553,1$1'#,S,1$<:2;@'PB>O3J$C9WF'X5R?&^L
MW?=C#;N:*M3C?%TZ<\T):=Q)A,G:U]ZR5I5E[9Y*UEB+JE-)#MA-]])WK*U?
M>'LGH^--S-4WK\?26?KD^FB>1$]2JN):C;T.?;S9=UD7,OG]HK.KZQ1_^+I,
M1G[DS''3-ZW5&3MU1Q33>S5NJ)X,."K"=OIO]'7X3U":QSG4WR=L/,&5DA1K
M5](T>G<\?Z+3JPC'UQ8W^<IW5SN^P6T80AW*]K6P-2';'MDCZD6*M:WQZGF,
M;6AV*,M;\_7A<K\&*<(HIGJ3%SP4:6]OOKV\77HN:;N=T;*Z#DIQBG.9R:<]
MG)CZ6NBS--.3L5=.BY1G:>E4GFXBX.X>X#UB33>&.-=-XSUN7R,U?':A@K'$
M?A&O;TXTJ=[FKRWI0O\ .Y+R<T8375Y5KW,_;'O3Q[8L4:CJFHZM?[9U._<O
MWNG75,X=2F.*F.I$1'41E[=[R-OMYVL3K^\'6-0UC5^'"YFKU=WL=-4XS1:I
MJGD6;>/%;M4T6XZ%,.U'064
M
M
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MC3X[G%OR5](^%OG!LON:_5B_[OK]BL/0KWIK^'36OVUSGZ,T= *RTE
M6(_1O_C3<Y_L K?"+I+#N^?\A97W7_PZT4O?;/F6V;_:B/Q#.+D+7! (
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MFI3&P
M
M
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MU3/17RN5VQF[][E<KS6/9+E6/*^FQX^B[!=-:P
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M35551PX\G&(F/9"VV
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
9                             '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_0.jpg
MB5!.1PT*&@H    -24A$4@  #+(   "R" 8   #LD >O    "7!(67,  $SE
M  !,Y0%USO"5   */DE$051XVNS!,0$   #"H/5/[6$-H
M
M
M                                  !N    ___LP3$!    PJ#U3^UA
M#:
M
M                                                    ;@   /__
M[,$Q 0   ,*@]4_M80V@
M
M
M         &X   #__^S!,0$   #"H/5/[6$-H
M
M
M                          !N    ___LP3$!    PJ#U3^UA#:
M
M
M                                            ;@   /__[,$Q 0
M ,*@]4_M80V@
M
M
M &X   #__^S!,0$   #"H/5/[6$-H
M
M
M                  !N    ___LP3$!    PJ#U3^UA#:
M
M
M                                    ;@   /__[,$Q 0   ,*@]4_M
M80V@
M
M                                                     &X   #_
M_^S!,0$   #"H/5/[6$-H
M
M
M          !N    ___LP3$!    PJ#U3^UA#:
M
M
M                            ;@   /__[,$Q 0   ,*@]4_M80V@
M
M
M                                             &X   #__^S!,0$
M  #"H/5/[6$-H
M
M
M  !N    ___LP3$!    PJ#U3^UA#:
M
M
M                    ;@   /__[,$Q 0   ,*@]4_M80V@
M
M
M                                     &X   #__^S!,0$   #"H/5/
M[6$-H
M
M                                                      !N
M___LP3$!    PJ#U3^UA#:
M
M
M            ;@   /__[<&!     ,.@^5-?X0!5 0
M
M                              #P&5'/  &"D(UX     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Aug. 13, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GRI BIO, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-4369909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2223 Avenida de la Playa<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">#208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">La Jolla<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">400-1170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GRI<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,515,305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001824293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 5,122<span></span>
</td>
<td class="nump">$ 5,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">454<span></span>
</td>
<td class="nump">587<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">5,576<span></span>
</td>
<td class="nump">5,615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">5,675<span></span>
</td>
<td class="nump">5,739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,297<span></span>
</td>
<td class="nump">897<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">960<span></span>
</td>
<td class="nump">691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,309<span></span>
</td>
<td class="nump">1,636<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,353<span></span>
</td>
<td class="nump">1,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, 0.0001 par value; 250,000,000 shares authorized as of June&#160;30, 2025 and December&#160;31, 2024; 2,496,800 and 525,485 shares issued and outstanding as of June&#160;30, 2025 and December&#160;31, 2024, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">49,000<span></span>
</td>
<td class="nump">43,772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(45,678)<span></span>
</td>
<td class="num">(39,740)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">3,322<span></span>
</td>
<td class="nump">4,032<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 5,675<span></span>
</td>
<td class="nump">$ 5,739<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of common shares held by shareholders. Excludes common shares repurchased and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">2,496,800<span></span>
</td>
<td class="nump">525,485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">2,496,800<span></span>
</td>
<td class="nump">525,485<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 1,879<span></span>
</td>
<td class="nump">$ 877<span></span>
</td>
<td class="nump">$ 3,520<span></span>
</td>
<td class="nump">$ 1,811<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,018<span></span>
</td>
<td class="nump">1,380<span></span>
</td>
<td class="nump">2,429<span></span>
</td>
<td class="nump">2,342<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">2,897<span></span>
</td>
<td class="nump">2,257<span></span>
</td>
<td class="nump">5,949<span></span>
</td>
<td class="nump">4,153<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(2,897)<span></span>
</td>
<td class="num">(2,257)<span></span>
</td>
<td class="num">(5,949)<span></span>
</td>
<td class="num">(4,153)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_ChangeInFairValueOfWarrantLiability', window );">Change in fair value of warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,892)<span></span>
</td>
<td class="num">$ (2,250)<span></span>
</td>
<td class="num">$ (5,938)<span></span>
</td>
<td class="num">$ (4,137)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of common stock, basic (in usd per share)</a></td>
<td class="num">$ (1.31)<span></span>
</td>
<td class="num">$ (61.85)<span></span>
</td>
<td class="num">$ (4.33)<span></span>
</td>
<td class="num">$ (150.32)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of common stock, diluted (in usd per share)</a></td>
<td class="num">$ (1.31)<span></span>
</td>
<td class="num">$ (61.85)<span></span>
</td>
<td class="num">$ (4.33)<span></span>
</td>
<td class="num">$ (150.32)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic (in shares)</a></td>
<td class="nump">2,205,139<span></span>
</td>
<td class="nump">36,379<span></span>
</td>
<td class="nump">1,369,933<span></span>
</td>
<td class="nump">27,522<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">2,205,139<span></span>
</td>
<td class="nump">36,379<span></span>
</td>
<td class="nump">1,369,933<span></span>
</td>
<td class="nump">27,522<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ChangeInFairValueOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value Of Warrant Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ChangeInFairValueOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Issuance of common stock and prefunded warrants in financing</div></th>
<th class="th"><div>Issuance of common stock</div></th>
<th class="th"><div>Common&#160;Stock</div></th>
<th class="th">
<div>Common&#160;Stock </div>
<div>Issuance of common stock and prefunded warrants in financing</div>
</th>
<th class="th">
<div>Common&#160;Stock </div>
<div>Issuance of common stock</div>
</th>
<th class="th"><div>Additional&#160; Paid-in Capital</div></th>
<th class="th">
<div>Additional&#160; Paid-in Capital </div>
<div>Issuance of common stock and prefunded warrants in financing</div>
</th>
<th class="th">
<div>Additional&#160; Paid-in Capital </div>
<div>Issuance of common stock</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">$ 259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (31,533)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment', window );">Fractional share adjustment (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock and prefunded warrants in financing (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock and prefunded warrants in financing</a></td>
<td class="nump">4,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise', window );">Prefunded warrant exercise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(1,887)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,887)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2024</a></td>
<td class="nump">2,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,420)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31,533)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(4,137)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2024</a></td>
<td class="nump">4,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,670)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2024</a></td>
<td class="nump">2,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,420)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment', window );">Fractional share adjustment (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock and prefunded warrants in financing (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock and prefunded warrants in financing</a></td>
<td class="nump">4,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise', window );">Prefunded warrant exercise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(2,250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,250)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2024</a></td>
<td class="nump">$ 4,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,670)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">525,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">525,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="nump">$ 4,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,740)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment', window );">Fractional share adjustment (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(127)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodValueFractionalShareAdjustment', window );">Fractional share adjustment</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(3,046)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,046)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">525,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2025</a></td>
<td class="nump">$ 1,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42,786)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">525,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">525,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="nump">$ 4,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,740)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (5,938)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2025</a></td>
<td class="nump">2,496,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,496,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2025</a></td>
<td class="nump">$ 3,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45,678)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">525,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2025</a></td>
<td class="nump">1,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42,786)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock and prefunded warrants in financing (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,388,888<span></span>
</td>
<td class="nump">582,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock and prefunded warrants in financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,143<span></span>
</td>
<td class="nump">$ 825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,143<span></span>
</td>
<td class="nump">$ 825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,892)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,892)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2025</a></td>
<td class="nump">2,496,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,496,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2025</a></td>
<td class="nump">$ 3,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (45,678)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Fractional Share Adjustment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Warrant Exercise</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodValueFractionalShareAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Fractional Share Adjustment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodValueFractionalShareAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">13 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,892)<span></span>
</td>
<td class="num">$ (3,046)<span></span>
</td>
<td class="num">$ (2,250)<span></span>
</td>
<td class="num">$ (1,887)<span></span>
</td>
<td class="num">$ (5,938)<span></span>
</td>
<td class="num">$ (4,137)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">261<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Change in operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition', window );">Change in operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(127)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133<span></span>
</td>
<td class="nump">370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">371<span></span>
</td>
<td class="num">(400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="num">(250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,902)<span></span>
</td>
<td class="num">(4,344)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_PaymentForFractionalSharesReverseStockSplit', window );">Payment for fractional shares in connection with reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(944)<span></span>
</td>
<td class="num">(1,571)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Cash provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,996<span></span>
</td>
<td class="nump">8,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="nump">4,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,808<span></span>
</td>
<td class="nump">5,028<span></span>
</td>
<td class="nump">1,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">5,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,122<span></span>
</td>
<td class="nump">6,353<span></span>
</td>
<td class="nump">$ 5,122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid', window );">Deferred stock issuance costs in accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_WarrantsIssued', window );">Issuance of warrants for payment of stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_ThroughFinancingMember', window );">Through Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">9,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_AtTheMarketOfferingMember', window );">ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 941<span></span>
</td>
<td class="nump">$ 961<span></span>
</td>
<td class="nump">$ 4,546<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Issuance Costs And Financing Costs Incurred But Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Right-Of-Use Asset, Periodic Addition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_PaymentForFractionalSharesReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment For Fractional Shares, Reverse Stock Split</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_PaymentForFractionalSharesReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_WarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_WarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_ThroughFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_ThroughFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND DESCRIPTION OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">ORGANIZATION AND DESCRIPTION OF BUSINESS</a></td>
<td class="text">ORGANIZATION AND DESCRIPTION OF BUSINESS<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">GRI Bio, Inc. (GRI or the Company), based in La Jolla, CA, was incorporated in Delaware in May 2009, which is the date of inception.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">GRI is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic and autoimmune disorders. The Company&#8217;s goal is to be an industry leader in developing therapies to treat these diseases and to improve the lives of patients suffering from such diseases. The Company&#8217;s lead product candidate, GRI-0621, is an oral inhibitor of type 1 invariant Natural Killer T (iNKT) cells and is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF). The Company&#8217;s product candidate portfolio also includes GRI-0803 and a proprietary library of 500+ compounds. GRI-0803, the lead molecule selected from the library, is a novel oral agonist of type 2 diverse Natural Killer T (dNKT) cells and is being developed for the treatment of autoimmune disorders, with much of its preclinical work in Systemic Lupus Erythematosus Disease (SLE) or lupus and multiple sclerosis (MS).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recapitalization</span></div>On January 29, 2024, the Company effected a reverse stock split of its common stock, par value $0.0001 per share (the Common Stock),  at a ratio of one-for-seven (the January 2024 Reverse Stock Split). On June 17, 2024, the Company effected a reverse stock split of its Common Stock at a ratio of one-for-thirteen (the June 2024 Reverse Stock Split). On February 21, 2025, the Company effected a reverse stock split of its Common Stock at a ratio of one-for-seventeen (the February 2025 Reverse Stock Split and together with the January 2024 Reverse Stock Split and the June 2024 Reverse Stock Split, the Reverse Stock Splits). Unless otherwise noted, all references to share and per share amounts in these consolidated financial statements reflect the Reverse Stock Splits.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">LIQUIDITY</a></td>
<td class="text">LIQUIDITY<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited interim consolidated financial statements have been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has not generated any significant revenues from operations since inception and does not expect to do so in the foreseeable future. The Company has incurred operating losses since its inception in 2009 and as a result has incurred $45,678 in accumulated deficit through June&#160;30, 2025. The Company has financed its working capital requirements to date through the issuance of equity and debt securities. As of June&#160;30, 2025, the Company had cash of approximately $5,122. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2024, the Company entered into a securities purchase agreement (the February 2024 Purchase Agreement), pursuant to which the Company issued and sold Common Stock, pre-funded warrants and common warrants in a public offering (the February 2024 Offering) for net proceeds of $4,389, after deducting offering expenses of $1,110. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On May 20, 2024, the Company entered into an At The Market Offering Agreement (the Sales Agreement) with H.C. Wainwright &amp; Co., LLC (Wainwright), pursuant to which the Company may sell and issue, subject to the limitations in the Sales Agreement, up to $10.0&#160;million shares of Common Stock from time to time through Wainwright as its sales agent (the ATM Offering). Under the Sales Agreement, Wainwright is entitled to compensation of 3.0% of the gross offering proceeds of all shares of Common Stock sold through it pursuant to the Sales Agreement. As of June&#160;30, 2025, the Company has sold 908,172 shares of Common Stock in the ATM Offering at a weighted-average price of $5.01 per share, for net proceeds of $4,292, after deducting commissions to the sales agent and other ATM Offering related expenses of $254. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On June 26, 2024, the Company entered into a securities purchase agreement (the June 2024 Purchase Agreement), pursuant to which the Company issued and sold Common Stock, pre-funded warrants and common warrants, in a public offering (the June 2024 Offering), for net proceeds of $3,172, after deducting offering expenses of $1,057.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On October 21, 2024, the Company entered into letter agreements (the Repricing Letter Agreements) with certain holders (the Holders) of certain of its issued and outstanding common warrants to purchase shares of its Common Stock, pursuant to which these Holders exercised their common warrants for cash at a reduced exercise price. In addition, these Holders received new unregistered common warrants. The net proceeds to the Company from the exercise of the common warrants were $609, after deducting placement agent fees and offering expenses of $154.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2025, the Company entered into a securities purchase agreement (the April 2025 Purchase Agreement), pursuant to which the Company issued and sold Common Stock, pre-funded warrants and common warrants, in a public offering (the April 2025 Offering), for net proceeds of $4,020, after deducting offering expenses of $979.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Company&#8217;s current operating plan, the Company believes that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2025.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue as a going concern is dependent on its ability to raise additional capital to fund its business activities, including its research and development program. The Company intends to raise capital through additional issuances of equity securities and/or short-term or long-term debt arrangements, but there can be no assurances any such financing will be available when needed, even if the Company&#8217;s research and development efforts are successful. If the Company is not able to obtain additional financing on acceptable terms and in the amounts necessary to fully fund its future operating requirements, it may be forced to reduce or discontinue its operations entirely. Therefore, there is substantial doubt about the Company&#8217;s ability to continue as a going concern for a period of one year from the issuance of these unaudited interim consolidated financial statements. These unaudited interim consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial periods and pursuant to the rules of the U.S. Securities and Exchange Commission (the SEC). Any reference in the accompanying unaudited interim financial statements to &#8220;authoritative guidance&#8221; is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). The December&#160;31, 2024 balance sheet was derived from the Company&#8217;s audited consolidated financial statements.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the unaudited interim consolidated financial statements furnished herein include all normal and recurring adjustments considered necessary to present fairly the Company&#8217;s financial position as of June&#160;30, 2025, and the consolidated results of operations and consolidated stockholders&#8217; equity for the three and six months ended June&#160;30, 2025 and 2024 and consolidated cash flows for the six months ended June&#160;30, 2025 and 2024. Consolidated results of operations for the three and six months ended June&#160;30, 2025, are not necessarily indicative of the operating results that may be expected for the year ending December&#160;31, 2025. The unaudited interim consolidated financial statements, presented herein, do not contain the required disclosures under GAAP for annual consolidated financial statements. The accompanying unaudited interim consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and related notes as of and for the year ended December&#160;31, 2024, included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March&#160;14, 2025.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited interim consolidated financial statements include the accounts of GRI Bio, Inc. and its wholly owned subsidiary, GRI Bio Operations, Inc. All intercompany balances and transactions have been eliminated.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, warrant issuance and subsequent revaluations, valuation allowances relating to deferred tax assets, accrued expenses and estimation of the incremental borrowing rate for the operating lease. If actual results differ from the </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Company&#8217;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#8217;s consolidated results of operations could either benefit from, or be adversely affected by, any such change in estimate.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820), establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The three levels of fair value hierarchy defined by ASC 820 are described below:</span></div><div style="margin-bottom:8pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></div><div style="margin-bottom:8pt;padding-left:67.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">:  Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="margin-bottom:8pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">:  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, the Company&#8217;s financial instruments included cash, cash equivalents, prepaid expenses and other current assets, accounts payable, accrued expenses and certain liability classified warrants. The carrying amounts reported in the consolidated balance sheets for cash, cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair value based on the short-term maturity of these instruments. The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. At June&#160;30, 2025, there were no financial assets or liabilities measured at fair value on a recurring basis other than the liability classified warrants.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, Vallon Pharmaceuticals, Inc. (Vallon) issued warrants (the May 2022 Warrants) in connection with a securities purchase agreement. Vallon evaluated the May 2022 Warrants in accordance with ASC 815-40, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 815-40), and concluded that a provision in the May 2022 Warrants related to the reduction of the exercise price in certain circumstances precluded the May 2022 Warrants from being accounted for as components of equity. As a result, the May 2022 Warrants were recorded as a liability on the consolidated balance sheet. Vallon recorded the fair value of the May 2022 Warrants upon issuance using a Black-Scholes valuation model. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to revalue the May 2022 Warrants at each reporting date with any changes in fair value recorded in its consolidated statements of operations. The valuation of the May 2022 Warrants is considered under Level 3 of the fair value hierarchy due to the need to use assumptions in the valuation that are both significant to the fair value measurement and unobservable. The change in the fair value of the Level 3 warrant liability is reflected in the consolidated statements of operations for the three and six months ended June&#160;30, 2025. As of June&#160;30, 2025 and December&#160;31, 2024, the fair value of the warrant liability was immaterial.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Deferred Stock Issuance Costs</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Deferred stock issuance costs represent incremental costs incurred that are directly attributable to proposed offerings of securities. The costs are charged against the gross proceeds of the respective offering upon closing.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss Per Common Share</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. For the six-month period ended June&#160;30, 2024, basic net loss per common share includes the weighted average of the June 2024 Pre-Funded Warrants (as defined below). Diluted net loss per common share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during each period, plus the dilutive effect of common stock equivalents outstanding during each period, in accordance with ASC 260,&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. As the Company had a net loss in each of the three and six months ended June&#160;30, 2025 and 2024, diluted net loss per common share is the same as basic net loss per common share for the period because the effects of potentially dilutive securities are antidilutive.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Common stock equivalents excluded from the diluted net loss per common share calculations are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21,270&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,623,292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">311,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,644,562&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">312,098&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company considered the applicability and impact of all ASUs issued during the quarter ended June&#160;30, 2025. ASUs not discussed below were assessed and determined to be either not applicable or expected to have minimal impact on these unaudited interim consolidated financial statements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280):</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Improvements to Reportable Segment Disclosures </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(ASU 2023-07). This amended guidance applies to all public entities and aims to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. This guidance is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The Company has adopted the provisions of ASU 2023-07 and has included the required disclosures in this Quarterly Report on Form 10-Q. See Note 8 for additional disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text">PROPERTY AND EQUIPMENT<div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.512%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense related to property and equipment was $1 in each of the three-month periods ended June&#160;30, 2025 and 2024 and  $2 in each of the six-month periods ended June&#160;30, 2025 and 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES</a></td>
<td class="text">ACCRUED EXPENSES<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following:</span></div><div style="margin-bottom:8pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">342</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">73</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">337</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">337</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">960&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">691&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY <div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">February 2024 Securities Purchase Agreement</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2024, the Company entered into the February 2024 Purchase Agreement, pursuant to which the Company sold, in the February 2024 Offering, (i) 1,495 shares (the February 2024 Shares) of Common Stock, (ii) 21,131 pre-funded warrants (the February 2024 Pre-Funded Warrants) exercisable for an aggregate of 21,131 shares of Common Stock, (iii) 22,631 Series B-1 common warrants (the Series B-1 Common Warrants) exercisable for an aggregate of 22,631 shares of Common Stock and (iv) 22,631 Series B-2 common warrants (the Series B-2 Common Warrants and together with the Series B-1 Common Warrants, the Series B Common Warrants) exercisable for an aggregate of 22,631 shares of Common Stock for net proceeds of $4,389, after deducting offering expenses of $1,110. The Series B Common Warrants together with the February 2024 Pre-Funded Warrants are referred to in this Quarterly Report on Form 10-Q (the Quarterly Report) as the &#8220;February 2024 Warrants.&#8221; The securities were offered in combinations of (a) one February 2024 Share or one February 2024 Pre-Funded Warrant, together with (b) one Series B-1 Common Warrant and one Series B-2 Common Warrant, for a combined purchase price of $243.10 (less $0.0221 for each February 2024 Pre-Funded Warrant).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain ownership limitations, the February 2024 Warrants were exercisable upon issuance. Each February 2024 Pre-Funded Warrant was exercisable for one share of Common Stock at a price per share of $0.0221 and expired when exercised in full. Each Series B-1 Common Warrant is exercisable into one share of Common Stock at a price per share of $243.10 for a five-year period after February 6, 2024, the date of issuance. Each Series B-2 Common Warrant is exercisable into one share of Common Stock at a price per share of $243.10 for an 18-month period after February 6, 2024, the date of issuance. The February 2024 Warrants were classified as equity and the allocated fair value of $4,279 is included in additional paid-in capital. As of June&#160;30, 2025, all of the February 2024 Pre-Funded Warrants have been exercised.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of the securities pursuant to the February 2024 Purchase Agreement, the exercise price of the Company&#8217;s previously outstanding Series A-1 Warrants was reduced to par, or $0.0001, per share pursuant to the terms of the Series A-1 Warrants. As of June&#160;30, 2025, all of the Series A-1 Warrants have been exercised.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">May 2024 At The Market Offering</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On May 20, 2024, the Company entered into the Sales Agreement with Wainwright, pursuant to which the Company may sell and issue, subject to the limitations in the Sales Agreement, shares up to $10.0&#160;million of Common Stock from time to time in the ATM Offering. Under the Sales Agreement, Wainwright is entitled to compensation of 3.0% of the gross offering proceeds of all shares of Common Stock sold through it pursuant to the Sales Agreement.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, the Company has sold 908,172 shares of Common Stock in the ATM Offering at a weighted-average price of $5.01 per share, for net proceeds of $4,292, after deducting commissions to the sales agent and other ATM Offering related expenses of $254</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> of which 582,554 shares of Common Stock were sold during the quarter ended June 30, 2025, for gross proceeds of $941 and net proceeds of $825. On May 23, 2025, the Company filed a prospectus supplement to its registration statement on Form S-3 (File No. 333-279348) to increase the amount of shares of Common Stock that the Company may offer and sell under the Sales Agreement and applicable registration statement to an aggregate offering price of up to $1,759, which amount does not include the shares of Common Stock having an aggregate gross sales price of approximately $4,546 that were sold under the ATM Offering through May 22, 2025, in accordance with the limitations set forth in Instruction I.B.6 of Form S-3.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">June 2024 Securities Purchase Agreement</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On June 26, 2024, the Company entered into the June 2024 Purchase Agreement, pursuant to which the Company issued and sold, in the June 2024 Offering, (i) 3,529 shares (the June 2024 Shares) of Common Stock, (ii) 125,047 pre-funded warrants (the June 2024 Pre-Funded Warrants) exercisable for an aggregate of 125,047 shares of Common Stock, (iii) 128,577 Series C-1 common warrants (the Series C-1 Common Warrants) exercisable for an aggregate of 128,577 shares of Common Stock, and (iv) 128,577 Series C-2 common warrants (the Series C-2 Common Warrants, and together with the Series C-1 Common Warrants, the Series C Common Warrants), exercisable for an aggregate of 128,577 shares of Common Stock for net proceeds of $3,172, after deducting offering expenses of $1,057. The Series C Common Warrants together with the June 2024 Pre-Funded Warrants are referred to in this Quarterly Report as the &#8220;June 2024 Warrants.&#8221; The securities were offered in combinations of (a) one June 2024 Share or one June 2024 Pre-Funded Warrant, together with (b) one Series C-1 Common Warrant and one Series C-2 Common Warrant, for a combined purchase price of $31.11 (less $0.0017 for each June 2024 Pre-Funded Warrant).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The June 2024 Pre-Funded Warrants were exercisable for one share of Common Stock at a price per share of $0.0017, were exercisable immediately and have been exercised in full as of June&#160;30, 2025. Each Series C-1 Common Warrant is exercisable into one share of Common Stock at a price per share of $31.11 for a five-year period beginning after September 6, 2024. Each Series C-2 Common Warrant is exercisable into one share of Common Stock at a price per share of $31.11 for an 18-month period beginning after September 6, 2024. The June 2024 Warrants were classified as equity and the allocated fair value of $2,908 is included in additional paid-in capital.</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to an engagement agreement with Wainwright, the Company, in connection with the June 2024 Offering, issued to Wainwright, or its designees, warrants to purchase up to an aggregate of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9,002</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> shares of Common Stock (the June 2024 PA Warrants). The June 2024 PA Warrants have an exercise price of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$38.89</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> per share, will expire on June 26, 2029 and are exercisable beginning after September 6, 2024. The June 2024 PA Warrants were classified as equity and the fair value of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">$229 is included in additional paid-in capital.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">October 2024 Repricing Letter Agreement</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On October 21, 2024, the Company entered into the Repricing Letter Agreements with certain Holders of its issued and outstanding Series B Common Warrants to purchase an aggregate of 44,842 shares of its Common Stock, offering pursuant to which these Holders exercised Series B Common Warrants for cash at a reduced exercise price equal to $17.00 per share. In addition, these Holders received new unregistered Series D-1 common warrants (the Series D-1 Common Warrants) exercisable for up to an aggregate of 44,839 shares of Common Stock and new unregistered Series D-2 common warrants (the Series D-2 Common Warrants and, together with the Series D-1 Common Warrants, the Series D Common Warrants) exercisable for up to an aggregate of 44,839 shares of Common Stock. The Series D Common Warrants are immediately exercisable and have an exercise price of $17.00 per share. The Series D-1 Common Warrants expire on October 22, 2029, and the Series D-2 Common Warrants expire on April 22, 2026. This transaction is referred to as the &#8220;Warrant Repricing Transaction.&#8221;</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Wainwright acted as the exclusive placement agent for the Warrant Repricing Transaction pu</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">rsuant to an engagement agreement between the Company and Wainwright dated as of October 21, 2024. As compensation for such placement agent services, the Company agreed to pay Wainwright an aggregate cash fee equal to 7.0% of the gross proceeds received by the Company from the Warrant Repricing Transaction, plus a management fee equal to 1.0% of the gross proceeds received by the Company from the Warrant Repricing Transaction, and reimbursement for accountable expenses of $25,000 and non-accountable expenses of $10,000. The Company has also issued to Wainwright or its designees the October 2024 PA Warrants to purchase up to an aggregate of 3,140 shares of Common Stock (the October 2024 PA Warrant). The October 2024 PA Warrants are immediately exercisable, expire on October 22, 2029, and have an exercise price of $21.25 per share.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The net proceeds to the Company from the exercise of the Series B Common Warrants were $202 after deducting placement agent fees and offering expenses of $560. The issuance under the Repricing Letter Agreements represented $1,526 in additional value provided to the investors, which was recorded as a deemed dividend to common stockholders.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">April 2025 Securities Purchase Agreement</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2025, the Company entered into the April 2025 Purchase Agreement, pursuant to which the Company issued and sold, in the April 2025 Offering, (i) 202,000 shares (the April 2025 Shares) of Common Stock, (ii) 1,186,888 pre-funded warrants (the April 2025 Pre-Funded Warrants) exercisable for an aggregate of 1,186,888 shares of Common Stock, (iii) 1,388,888 Series E-1 common stock warrants (the Series E-1 Common Warrants) to purchase up to 1,388,888 shares of Common Stock, (iv) 1,388,888 Series E-2 common stock warrants (the Series E-2 Common Warrants) to purchase up to 1,388,888 shares of Common Stock, and (v) 1,388,888 Series E-3 common stock warrants (the Series E-3 Common Warrants, and collectively with the Series E-1 Warrants and the Series E-2 Warrants, the Series E Common Warrants) to purchase up to 1,388,888 shares of Common Stock, for net proceeds of $4,020, after deducting offering expenses of $979. The April 2025 Offering closed on April 2, 2025. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The securities were offered in combinations of (a) one April 2025 Share or one April 2025 Pre-Funded Warrant, together with (b) one Series E-1 Common Warrant, one Series E-2 Common Warrant and one Series E-3 Common Warrant, for a combined purchase price of $3.60 (less $0.0001 for each April 2025 Pre-Funded Warrant). The April 2025 Pre-Funded Warrants had an exercise price of $0.0001 per share, became exercisable immediately upon issuance and expired when exercised in full. Each Series E Common Warrant has an exercise price of $3.20 per share and became exercisable immediately upon issuance. The Series E-1 Common Warrants expire April 2, 2030. The Series E-2 Common Warrants expire on October 2, 2026. The Series E-3 Common Warrants expire on January 2, 2026. As of June 30, 2025, the April 2025 Pre-Funded Warrants have been exercised in full.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Wainwright acted as the exclusive placement agent for the April 2025 Offering pursuant to an engagement agreement between the Company and Wainwright dated as of March 7, 2025. As compensation for such placement agent services, the Company agreed to pay Wainwright an aggregate cash fee equal to 7.0% of the gross proceeds received by the Company from the offering, plus a management fee equal to 1.0% of the gross proceeds received by the Company from the offering,  reimbursement for accountable expenses of $25,000,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> reimbursement of up to $100,000 for legal fees and expenses and other out-of-pocket expenses and up to $15,950 for the clearing expenses.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> The Company also issued to Wainwright, or its designees, warrants to purchase up to an aggregate of 97,222 shares of Common Stock (the April 2025 PA Warrants). The April 2025 PA Warrants became exercisable immediately upon issuance, expire on April 1, 2030, and have an exercise price of $4.50 per share. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The April 2025 PA Warrants were classified as equity and the fair value of $123</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> is included in additional paid-in capital.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the amount paid for the April 2025 Pre-Funded Warrants approximates their fair value. The Black-Scholes option-pricing model was used to estimate the fair value of the Series E Common Warrants and the April 2025 PA Warrants with the following weighted-average assumptions:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.123%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">156.44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.48</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, the Company had the following warrants outstanding to purchase Common Stock: </span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Exercise Price per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">210</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$243.10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">August 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,388,888</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$3.20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">January 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$464,100.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">February 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">128,577</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$31.11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">March 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">44,839</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$17.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">April 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,388,888</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$3.20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">October 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">16</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$43,548.05</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">May 2027</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$0.01</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">July 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$94,970.33</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">April 2028</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">210</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$243.10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">9,002</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$38.8875</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">June 2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">128,577</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$31.11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">September 2029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">44,839</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$17.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">October 2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,140</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$21.25</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">October 2029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,388,888</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$3.20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">April 2030</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">97,222</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$4.50</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">April 2030</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amended and Restated 2018 Equity Incentive Plan</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2023, the stockholders of the Company approved the Amended and Restated GRI Bio, Inc. 2018 Equity Incentive Plan (the A&amp;R 2018 Plan). The A&amp;R 2018 Plan provides the Company with the ability to grant stock options, restricted stock and other equity-based awards to employees, directors and consultants. Stock options granted by the Company under the A&amp;R 2018 Plan generally have a contractual life of up to 10 years. As of June&#160;30, 2025, awards granted under the A&amp;R 2018 Plan representing the right to purchase or contingent right to receive up to an aggregate of 21,270 shares of the Company's Common Stock were outstanding and 21,275 shares of the Company&#8217;s Common Stock were reserved for issuance under the A&amp;R 2018 Plan. The number of shares reserved for issuance under the A&amp;R 2018 Plan may be increased pursuant to the A&amp;R 2018 Plan&#8217;s &#8220;evergreen&#8221; provision on the first day of each calendar year beginning January 1, 2024 and ending on and including January 1, 2033, by a number of shares not to exceed 4% of the aggregate number of shares of the Company&#8217;s Common Stock outstanding on the final day of the immediately preceding calendar year.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation related to equity-based awards issued under the A&amp;R 2018 Plan in the following expense categories of its accompanying consolidated statements of operations for the three and six months ended June&#160;30, 2025 and 2024:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 4pt 0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">41</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">37</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">236</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">74</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">41</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">37</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">261</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">74</span></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures equity-based awards granted to employees and non-employees based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period or performance-based period, which is generally the vesting period of the respective award. The measurement date for service-based equity awards is the date of grant, and </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">equity-based compensation costs are recognized as expense over the requisite service period. The Company records expense for performance-based awards if the Company concludes that it is probable that the performance condition will be achieved.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table below represents the activity of stock options granted to employees and non-employees for the six months ended June&#160;30, 2025:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average exercise price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-average remaining contractual term&#160;(years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">142</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,376.92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.63</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21,128</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11.66</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/cancelled</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21,270</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">40.80</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9.56</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2025</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21,208&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">30.83</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9.56</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at June 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21,270</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">40.80</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9.56</span></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, all of the outstanding and exercisable stock options were out of the money and therefore had no intrinsic value. As of June&#160;30, 2025, the unrecognized compensation cost related to unvested stock options expected to vest was $174. This unrecognized compensation is expected to be recognized over a weighted-average amortization period of 0.78 years. </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted 21,128 stock options to its employees and non-employee directors during the six months ended June&#160;30, 2025. The Black-Scholes option-pricing model was used to estimate the grant date fair value of each stock option grant at the time of grant using the following weighted-average assumptions:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.205%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.595%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2025</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">110.94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5.00</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of option on grant date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">No equity-based awards were granted during the six-month period ended June&#160;30, 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT REPORTING</a></td>
<td class="text">SEGMENT REPORTING<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (CODM), or decision-making group, in deciding how to allocate resources in assessing performance. The Company has one reportable segment: biotechnology research. The biotechnology research segment consists of the research and development of products for the treatment of inflammatory disease. The Company&#8217;s CODM is W. Marc Hertz, Ph.D., Chief Executive Officer and Director.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies of the biotechnology research segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance for the biotechnology research segment based on research and development expenses and general and administrative expenses as part of the overall review of the Company&#8217;s consolidated net loss and consolidated cash flows as compared to prior quarters and the Company&#8217;s operating budget.</span></div>The Company has incurred significant losses since its inception and anticipates incurring continued losses in the future. As such, the CODM uses cash forecast models in deciding how to allocate resources based on the Company&#8217;s available cash resources, as well as its forecasted expenditures.  This information, in conjunction with the assessment of the probability of the success of the Company&#8217;s research and development activities, is used to plan the timing and size of future capital raises.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Employment Agreements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into employment contracts with its officers that provide for severance and continuation of benefits in the event of termination of employment by the Company without cause or by the employee for good reason. In addition, in the event of termination of employment following a change in control, the vesting of certain equity awards may be accelerated.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Separation and Release Agreement</span></div>In connection with the resignation of David Baker, the Company&#8217;s Former Chief Executive Officer, the Company and Mr. Baker entered into a Separation and Release Agreement on April 21, 2023 (the Separation Agreement). Pursuant to the terms of the Separation Agreement and his employment agreement, Mr. Baker received continuation of his then current salary and certain COBRA benefits for 18 months payable in accordance with the Company&#8217;s payroll practices. Mr. Baker also received a lump sum payment equal to 150% of his target bonus and agreed to reduce amounts payable with respect to certain future milestone payments.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">SUBSEQUENT EVENTS<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The One Big Beautiful Bill Act (&#8220;OBBBA&#8221;) was enacted on July 4, 2025. The Company is in the process of assessing the impact of this legislation on its financial statements. The OBBBA is not currently expected to materially impact the Company&#8217;s effective tax rate or cash flows in the current fiscal year.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial periods and pursuant to the rules of the U.S. Securities and Exchange Commission (the SEC). Any reference in the accompanying unaudited interim financial statements to &#8220;authoritative guidance&#8221; is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). The December&#160;31, 2024 balance sheet was derived from the Company&#8217;s audited consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited interim consolidated financial statements include the accounts of GRI Bio, Inc. and its wholly owned subsidiary, GRI Bio Operations, Inc. All intercompany balances and transactions have been eliminated.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, warrant issuance and subsequent revaluations, valuation allowances relating to deferred tax assets, accrued expenses and estimation of the incremental borrowing rate for the operating lease. If actual results differ from the </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Company&#8217;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#8217;s consolidated results of operations could either benefit from, or be adversely affected by, any such change in estimate.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820), establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The three levels of fair value hierarchy defined by ASC 820 are described below:</span></div><div style="margin-bottom:8pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></div><div style="margin-bottom:8pt;padding-left:67.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">:  Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="margin-bottom:8pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">:  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, the Company&#8217;s financial instruments included cash, cash equivalents, prepaid expenses and other current assets, accounts payable, accrued expenses and certain liability classified warrants. The carrying amounts reported in the consolidated balance sheets for cash, cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair value based on the short-term maturity of these instruments. The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. At June&#160;30, 2025, there were no financial assets or liabilities measured at fair value on a recurring basis other than the liability classified warrants.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, Vallon Pharmaceuticals, Inc. (Vallon) issued warrants (the May 2022 Warrants) in connection with a securities purchase agreement. Vallon evaluated the May 2022 Warrants in accordance with ASC 815-40, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 815-40), and concluded that a provision in the May 2022 Warrants related to the reduction of the exercise price in certain circumstances precluded the May 2022 Warrants from being accounted for as components of equity. As a result, the May 2022 Warrants were recorded as a liability on the consolidated balance sheet. Vallon recorded the fair value of the May 2022 Warrants upon issuance using a Black-Scholes valuation model. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to revalue the May 2022 Warrants at each reporting date with any changes in fair value recorded in its consolidated statements of operations. The valuation of the May 2022 Warrants is considered under Level 3 of the fair value hierarchy due to the need to use assumptions in the valuation that are both significant to the fair value measurement and unobservable. The change in the fair value of the Level 3 warrant liability is reflected in the consolidated statements of operations for the three and six months ended June&#160;30, 2025. As of June&#160;30, 2025 and December&#160;31, 2024, the fair value of the warrant liability was immaterial.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Stock Issuance Costs</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Deferred Stock Issuance Costs</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Deferred stock issuance costs represent incremental costs incurred that are directly attributable to proposed offerings of securities. The costs are charged against the gross proceeds of the respective offering upon closing.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss Per Common Share</span></div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. For the six-month period ended June&#160;30, 2024, basic net loss per common share includes the weighted average of the June 2024 Pre-Funded Warrants (as defined below). Diluted net loss per common share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during each period, plus the dilutive effect of common stock equivalents outstanding during each period, in accordance with ASC 260,&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share</span>. As the Company had a net loss in each of the three and six months ended June&#160;30, 2025 and 2024, diluted net loss per common share is the same as basic net loss per common share for the period because the effects of potentially dilutive securities are antidilutive<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company considered the applicability and impact of all ASUs issued during the quarter ended June&#160;30, 2025. ASUs not discussed below were assessed and determined to be either not applicable or expected to have minimal impact on these unaudited interim consolidated financial statements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280):</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Improvements to Reportable Segment Disclosures </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(ASU 2023-07). This amended guidance applies to all public entities and aims to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. This guidance is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The Company has adopted the provisions of ASU 2023-07 and has included the required disclosures in this Quarterly Report on Form 10-Q. See Note 8 for additional disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Common Stock Equivalents Excluded From Diluted Net Loss Per Share Calculation</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Common stock equivalents excluded from the diluted net loss per common share calculations are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21,270&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,623,292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">311,956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,644,562&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">312,098&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.512%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following:</span></div><div style="margin-bottom:8pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">342</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">73</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">337</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">337</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">960&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">691&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of the Fair Value of the Warrants</a></td>
<td class="text">The Black-Scholes option-pricing model was used to estimate the fair value of the Series E Common Warrants and the April 2025 PA Warrants with the following weighted-average assumptions:<div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.123%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">156.44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.48</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrants Outstanding to Purchase Common Stock</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2025, the Company had the following warrants outstanding to purchase Common Stock: </span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Exercise Price per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">210</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$243.10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">August 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,388,888</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$3.20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">January 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$464,100.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">February 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">128,577</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$31.11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">March 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">44,839</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$17.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">April 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,388,888</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$3.20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">October 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">16</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$43,548.05</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">May 2027</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$0.01</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">July 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$94,970.33</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">April 2028</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">210</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$243.10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">9,002</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$38.8875</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">June 2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">128,577</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$31.11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">September 2029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">44,839</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$17.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">October 2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,140</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$21.25</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">October 2029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,388,888</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$3.20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">April 2030</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">97,222</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$4.50</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">April 2030</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation related to equity-based awards issued under the A&amp;R 2018 Plan in the following expense categories of its accompanying consolidated statements of operations for the three and six months ended June&#160;30, 2025 and 2024:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 4pt 0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">41</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">37</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">236</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">74</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">41</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">37</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">261</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">74</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of Activity of Stock Options Granted</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The table below represents the activity of stock options granted to employees and non-employees for the six months ended June&#160;30, 2025:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average exercise price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-average remaining contractual term&#160;(years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">142</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,376.92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8.63</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21,128</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">11.66</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/cancelled</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21,270</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">40.80</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9.56</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2025</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21,208&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">30.83</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9.56</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at June 30, 2025</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">21,270</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">40.80</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9.56</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Valuation Assumptions</a></td>
<td class="text">The Black-Scholes option-pricing model was used to estimate the grant date fair value of each stock option grant at the time of grant using the following weighted-average assumptions:<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.205%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.595%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30, 2025</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">110.94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5.00</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of option on grant date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)<br></strong></div></th>
<th class="th"><div>Feb. 21, 2025</div></th>
<th class="th"><div>Jun. 17, 2024</div></th>
<th class="th">
<div>Jan. 29, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split</a></td>
<td class="nump">0.0588<span></span>
</td>
<td class="nump">0.0769<span></span>
</td>
<td class="nump">0.1429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">13 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 23, 2025</div></th>
<th class="th"><div>Apr. 01, 2025</div></th>
<th class="th"><div>Oct. 21, 2024</div></th>
<th class="th"><div>Jun. 26, 2024</div></th>
<th class="th"><div>May 20, 2024</div></th>
<th class="th"><div>Feb. 01, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (45,678)<span></span>
</td>
<td class="num">$ (45,678)<span></span>
</td>
<td class="num">$ (39,740)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,122<span></span>
</td>
<td class="nump">5,122<span></span>
</td>
<td class="nump">$ 5,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuanceCostsOfferingExpenses', window );">Offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesBCommonWarrantsMember', window );">Series B Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_ClassOfWarrantsOrRightAgentFeesAndOfferingExpense', window );">Placement agent fees and offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuanceCostsOfferingExpenses', window );">Offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">202,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 243.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_AtTheMarketOfferingMember', window );">ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 825<span></span>
</td>
<td class="nump">4,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuanceCostsOfferingExpenses', window );">Offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockMaximumValueOfSharesOffered', window );">Sale of stock, maximum value of shares offered</a></td>
<td class="nump">$ 1,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockAgentCompensationPercentage', window );">Sale of stock, agent compensation, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">582,554<span></span>
</td>
<td class="nump">908,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_AtTheMarketOfferingMember', window );">ATM | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.01<span></span>
</td>
<td class="nump">$ 5.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingsMember', window );">Public offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuanceCostsOfferingExpenses', window );">Offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ClassOfWarrantsOrRightAgentFeesAndOfferingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrants Or Right, Agent Fees and Offering Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ClassOfWarrantsOrRightAgentFeesAndOfferingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_SaleOfStockAgentCompensationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Agent Compensation, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_SaleOfStockAgentCompensationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_SaleOfStockMaximumValueOfSharesOffered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Value Of Shares Offered</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_SaleOfStockMaximumValueOfSharesOffered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuanceCostsOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs, Offering Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuanceCostsOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesBCommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesBCommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Diluted Net Loss Per Common Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">4,644,562<span></span>
</td>
<td class="nump">312,098<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">21,270<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">4,623,292<span></span>
</td>
<td class="nump">311,956<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(32)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent', window );">Research and development</a></td>
<td class="nump">$ 550<span></span>
</td>
<td class="nump">$ 342<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent', window );">General and administrative</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and related</a></td>
<td class="nump">337<span></span>
</td>
<td class="nump">337<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 960<span></span>
</td>
<td class="nump">$ 691<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued General And Administrative Expenses, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Research And Development Costs, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_AccruedResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">13 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 23, 2025</div></th>
<th class="th"><div>Apr. 01, 2025</div></th>
<th class="th"><div>Oct. 21, 2024</div></th>
<th class="th"><div>Jun. 26, 2024</div></th>
<th class="th"><div>May 20, 2024</div></th>
<th class="th"><div>Feb. 01, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuanceCostsOfferingExpenses', window );">Offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrants not settleable in cash, fair value disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds', window );">Cash fee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds', window );">Management fee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses', window );">Reimbursement of accountable expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses', window );">Reimbursement of non-accountable expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrant issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockClearingExpenses', window );">Clearing expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses', window );">Legal fees and expenses and other out of pocket expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_PreFundedWarrantsMember', window );">Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares called by each warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesBCommonWarrantsMember', window );">Series B Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense', window );">Proceeds from warrant exercise, net of offering cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_ClassOfWarrantOrRightOfferingCost', window );">Class of warrant or right, offering cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesB1CommonWarrantsMember', window );">Series B-1 Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 243.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares called by each warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, outstanding term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesB2CommonWarrantsMember', window );">Series B-2 Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 243.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares called by each warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, outstanding term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesA1WarrantsMember', window );">Series A-1 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesC1CommonWarrantsMember', window );">Series C-1 Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares called by each warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, outstanding term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesC2CommonWarrantsMember', window );">Series C-2 Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares called by each warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, outstanding term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_PreFundedAndSeriesCWarrantsMember', window );">Pre-Funded And Series C Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrants not settleable in cash, fair value disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_June2024PAWarrantsMember', window );">June 2024 PA Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrants not settleable in cash, fair value disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesDWarrantsMember', window );">Series D Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesD1WarrantsMember', window );">Series D-1 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesD2WarrantsMember', window );">Series D-2 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_October2024PAWarrantsMember', window );">October 2024 PA Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesECommonWarrantMember', window );">Series E Common Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_April2025PAWarrantsMember', window );">April 2025 PA Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrants not settleable in cash, fair value disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">202,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuanceCostsOfferingExpenses', window );">Offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction', window );">Number of securities issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 243.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember', window );">Public Offering | Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,186,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,186,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction', window );">Number of securities issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember', window );">Public Offering | Series B-1 Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction', window );">Number of securities issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember', window );">Public Offering | Series B-2 Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction', window );">Number of securities issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember', window );">Public Offering | Series C-1 Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction', window );">Number of securities issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember', window );">Public Offering | Series C-2 Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction', window );">Number of securities issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember', window );">Public Offering | Series E-1 Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,388,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,388,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction', window );">Number of securities issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember', window );">Public Offering | Series E-2 Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,388,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,388,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction', window );">Number of securities issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember', window );">Public Offering | Series E-3 Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,388,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,388,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction', window );">Number of securities issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_AtTheMarketOfferingMember', window );">ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">582,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">908,172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,292<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuanceCostsOfferingExpenses', window );">Offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockMaximumValueOfSharesOffered', window );">Sale of stock, maximum value of shares offered</a></td>
<td class="nump">$ 1,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockAgentCompensationPercentage', window );">Sale of stock, agent compensation, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 941<span></span>
</td>
<td class="nump">$ 941<span></span>
</td>
<td class="nump">$ 961<span></span>
</td>
<td class="nump">$ 4,546<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_AtTheMarketOfferingMember', window );">ATM | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.01<span></span>
</td>
<td class="nump">$ 5.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.01<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ClassOfWarrantOrRightOfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Offering Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ClassOfWarrantOrRightOfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Warrant Exercises, Net Of Offering Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_SaleOfStockAgentCompensationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Agent Compensation, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_SaleOfStockAgentCompensationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Aggregate Cash Fee, Percentage Of Gross Proceeds</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_SaleOfStockClearingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Clearing Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_SaleOfStockClearingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Legal Fees And expenses And Other Out Of Pocket Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Management Fee, Percentage Of Gross Proceeds</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_SaleOfStockMaximumValueOfSharesOffered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Value Of Shares Offered</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_SaleOfStockMaximumValueOfSharesOffered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Number Of Securities Issued Per Transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Reimbursement Of Accountable Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_SaleOfStockReimbursementOfAccountableExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Reimbursement Of Non-Accountable Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuanceCostsOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs, Offering Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuanceCostsOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesBCommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesBCommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesB1CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesB1CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesB2CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesB2CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesA1WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesA1WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesC1CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesC1CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesC2CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesC2CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_PreFundedAndSeriesCWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_PreFundedAndSeriesCWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_June2024PAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_June2024PAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesDWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesDWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesD1WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesD1WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesD2WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesD2WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_October2024PAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_October2024PAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesECommonWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesECommonWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_April2025PAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_April2025PAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesE1CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesE1CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesE2CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesE2CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesE3CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesE3CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Schedule of Estimate of the Fair Value of the Warrants and Assumptions (Details) - Series E Common Warrants and April 2025 PA Warrants<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>year</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">1.5644<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term in years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">2.48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.0402<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesECommonWarrantsAndApril2025PAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesECommonWarrantsAndApril2025PAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Schedule of Warrants Outstanding to Purchase Common Stock (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInAugust2025Member', window );">Warrants Expiring In August 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 243.10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInJanuary2026Member', window );">Warrants Expiring In January 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">1,388,888<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 3.20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInFebruary2026Member', window );">Warrants Expiring In February 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 464,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInMarch2026Member', window );">Warrants Expiring In March 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">128,577<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 31.11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInApril2026Member', window );">Warrants Expiring In April 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">44,839<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 17.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInOctober2026Member', window );">Warrants Expiring In October 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">1,388,888<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 3.20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInMay2027Member', window );">Warrants Expiring In May 2027</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 43,548.05<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInJuly2027Member', window );">Warrants Expiring In July 2027</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInApril2028Member', window );">Warrants Expiring In April 2028</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 94,970.33<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInFebruary2029Member', window );">Warrants Expiring In February 2029</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 243.10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInJune2029Member', window );">Warrants Expiring In June 2029</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">9,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 38.8875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInSeptember2029Member', window );">Warrants Expiring In September 2029</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">128,577<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 31.11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInOctober2029OneMember', window );">Warrants Expiring In October 2029, One</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">44,839<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 17.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInOctober2029TwoMember', window );">Warrants Expiring In October 2029, Two</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">3,140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 21.25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInApril2030OneMember', window );">Warrants Expiring In April 2030, One</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">1,388,888<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 3.20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInApril2030TwoMember', window );">Warrants Expiring In April 2030, Two</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">97,222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 4.50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInAugust2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInAugust2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInJanuary2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInJanuary2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInFebruary2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInFebruary2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInMarch2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInMarch2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInApril2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInApril2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInOctober2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInOctober2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInMay2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInMay2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInJuly2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInJuly2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInApril2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInApril2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInFebruary2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInFebruary2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInJune2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInJune2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInSeptember2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInSeptember2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInOctober2029OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInOctober2029OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInOctober2029TwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInOctober2029TwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInApril2030OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInApril2030OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInApril2030TwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInApril2030TwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options exercisable, intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">21,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Equity based award granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation, weighted average amortization period</a></td>
<td class="text">9 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember', window );">A&amp;R 2918 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="nump">21,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common shares reserved for future awards (in shares)</a></td>
<td class="nump">21,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum', window );">Maximum increase in shares reserved for issuance as a percentage of aggregate common stock outstanding</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember', window );">A&amp;R 2918 Plan | Maximum | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock awards, contractual life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Increase In Shares Reserved For Issuance As Percentage Of Aggregate Common Stock Outstanding, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 261<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 236<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Schedule of Activity of Stock Options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Beginning balance (in shares)</a></td>
<td class="nump">142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">21,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited/cancelled (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Ending balance (in shares)</a></td>
<td class="nump">21,270<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, Ending balance (in shares)</a></td>
<td class="nump">21,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">21,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Beginning balance (in usd per share)</a></td>
<td class="nump">$ 4,376.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share)</a></td>
<td class="nump">11.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited/cancelled (in usd per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Ending balance (in usd per share)</a></td>
<td class="nump">40.80<span></span>
</td>
<td class="nump">$ 4,376.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, Ending balance (in usd per share)</a></td>
<td class="nump">30.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (in usd per share)</a></td>
<td class="nump">$ 40.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-average remaining contractual term&#160;(years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding (years)</a></td>
<td class="text">9 years 6 months 21 days<span></span>
</td>
<td class="text">8 years 7 months 17 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable (years)</a></td>
<td class="text">9 years 6 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest (years)</a></td>
<td class="text">9 years 6 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Schedule of Assumptions Used to Estimate Fair Value of Options (Details) - Employee Stock Option<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility (as a percent)</a></td>
<td class="nump">110.94%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.45%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value of option on grant date (in usd per share)</a></td>
<td class="nump">$ 9.43<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2025 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details) - Former Chief Executive Officer<br></strong></div></th>
<th class="th"><div>Apr. 21, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_COBRABenefitsPaymentPeriod', window );">COBRA benefits, payment period</a></td>
<td class="text">18 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_PercentageOfTargetBonus', window );">Percentage of target bonus</a></td>
<td class="nump">150.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_COBRABenefitsPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>COBRA Benefits, Payment Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_COBRABenefitsPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_PercentageOfTargetBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Target Bonus</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_PercentageOfTargetBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ck0001824293_FormerChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ck0001824293_FormerChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>142</ContextCount>
  <ElementCount>181</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>59</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="ck0001824293-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ck0001824293-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ck0001824293-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ck0001824293-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ck0001824293-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - Consolidated Statements of Changes in Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ck0001824293-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ck0001824293-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS</Role>
      <ShortName>ORGANIZATION AND DESCRIPTION OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ck0001824293-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - LIQUIDITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/LIQUIDITY</Role>
      <ShortName>LIQUIDITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ck0001824293-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ck0001824293-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENT</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ck0001824293-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - ACCRUED EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ACCRUEDEXPENSES</Role>
      <ShortName>ACCRUED EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ck0001824293-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITY</Role>
      <ShortName>STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ck0001824293-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ck0001824293-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - SEGMENT REPORTING</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/SEGMENTREPORTING</Role>
      <ShortName>SEGMENT REPORTING</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ck0001824293-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ck0001824293-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ck0001824293-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ck0001824293-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ck0001824293-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="ck0001824293-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENT</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="ck0001824293-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - ACCRUED EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables</Role>
      <ShortName>ACCRUED EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/ACCRUEDEXPENSES</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="ck0001824293-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - STOCKHOLDERS??? EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYTables</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITY</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="ck0001824293-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ck0001824293-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails</Role>
      <ShortName>ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ck0001824293-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - LIQUIDITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/LIQUIDITYDetails</Role>
      <ShortName>LIQUIDITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/LIQUIDITY</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ck0001824293-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Diluted Net Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Diluted Net Loss Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ck0001824293-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ck0001824293-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - PROPERTY AND EQUIPMENT - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTNarrativeDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="ck0001824293-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - ACCRUED EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails</Role>
      <ShortName>ACCRUED EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ck0001824293-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - STOCKHOLDERS??? EQUITY - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="ck0001824293-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - STOCKHOLDERS??? EQUITY - Schedule of Estimate of the Fair Value of the Warrants and Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Schedule of Estimate of the Fair Value of the Warrants and Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="ck0001824293-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - STOCKHOLDERS??? EQUITY - Schedule of Warrants Outstanding to Purchase Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Schedule of Warrants Outstanding to Purchase Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="ck0001824293-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="ck0001824293-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="ck0001824293-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Activity of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Schedule of Activity of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="ck0001824293-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Assumptions Used to Estimate Fair Value of Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Schedule of Assumptions Used to Estimate Fair Value of Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="ck0001824293-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - SEGMENT REPORTING (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/SEGMENTREPORTINGDetails</Role>
      <ShortName>SEGMENT REPORTING (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/SEGMENTREPORTING</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ck0001824293-20250630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>38</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="ck0001824293-20250630.htm">ck0001824293-20250630.htm</File>
    <File>ck0001824293-20250630.xsd</File>
    <File>ck0001824293-20250630_cal.xml</File>
    <File>ck0001824293-20250630_def.xml</File>
    <File>ck0001824293-20250630_lab.xml</File>
    <File>ck0001824293-20250630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ck0001824293-20250630_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="391">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>59
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ck0001824293-20250630.htm": {
   "nsprefix": "ck0001824293",
   "nsuri": "http://www.vallon-pharma.com/20250630",
   "dts": {
    "inline": {
     "local": [
      "ck0001824293-20250630.htm"
     ]
    },
    "schema": {
     "local": [
      "ck0001824293-20250630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "ck0001824293-20250630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ck0001824293-20250630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "ck0001824293-20250630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ck0001824293-20250630_pre.xml"
     ]
    }
   },
   "keyStandard": 155,
   "keyCustom": 26,
   "axisStandard": 12,
   "axisCustom": 0,
   "memberStandard": 15,
   "memberCustom": 43,
   "hidden": {
    "total": 8,
    "http://xbrl.sec.gov/dei/2025": 5,
    "http://fasb.org/us-gaap/2025": 3
   },
   "contextCount": 142,
   "entityCount": 1,
   "segmentCount": 59,
   "elementCount": 409,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 391,
    "http://xbrl.sec.gov/dei/2025": 31,
    "http://xbrl.sec.gov/ecd/2025": 4
   },
   "report": {
    "R1": {
     "role": "http://www.vallon-pharma.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets",
     "longName": "9952151 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "9952152 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations",
     "longName": "9952153 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
     "longName": "9952154 - Statement - Consolidated Statements of Changes in Stockholders\u2019 Equity",
     "shortName": "Consolidated Statements of Changes in Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-30",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-35",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
     "longName": "9952155 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS",
     "longName": "9952156 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS",
     "shortName": "ORGANIZATION AND DESCRIPTION OF BUSINESS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.vallon-pharma.com/role/LIQUIDITY",
     "longName": "9952157 - Disclosure - LIQUIDITY",
     "shortName": "LIQUIDITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "longName": "9952158 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENT",
     "longName": "9952159 - Disclosure - PROPERTY AND EQUIPMENT",
     "shortName": "PROPERTY AND EQUIPMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.vallon-pharma.com/role/ACCRUEDEXPENSES",
     "longName": "9952160 - Disclosure - ACCRUED EXPENSES",
     "shortName": "ACCRUED EXPENSES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITY",
     "longName": "9952161 - Disclosure - STOCKHOLDERS\u2019 EQUITY",
     "shortName": "STOCKHOLDERS\u2019 EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION",
     "longName": "9952162 - Disclosure - STOCK-BASED COMPENSATION",
     "shortName": "STOCK-BASED COMPENSATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.vallon-pharma.com/role/SEGMENTREPORTING",
     "longName": "9952163 - Disclosure - SEGMENT REPORTING",
     "shortName": "SEGMENT REPORTING",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES",
     "longName": "9952164 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTS",
     "longName": "9952165 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "longName": "9955511 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables",
     "longName": "9955512 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTTables",
     "longName": "9955513 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables",
     "longName": "9955514 - Disclosure - ACCRUED EXPENSES (Tables)",
     "shortName": "ACCRUED EXPENSES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYTables",
     "longName": "9955515 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Tables)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables",
     "longName": "9955516 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
     "longName": "9955517 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)",
     "shortName": "ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-53",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-53",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
     "longName": "9955518 - Disclosure - LIQUIDITY (Details)",
     "shortName": "LIQUIDITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-62",
      "name": "us-gaap:ProceedsFromWarrantExercises",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails",
     "longName": "9955519 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Diluted Net Loss Per Common Share (Details)",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Diluted Net Loss Per Common Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails",
     "longName": "9955520 - Disclosure - PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details)",
     "shortName": "PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTNarrativeDetails",
     "longName": "9955521 - Disclosure - PROPERTY AND EQUIPMENT - Narrative (Details)",
     "shortName": "PROPERTY AND EQUIPMENT - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R29": {
     "role": "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails",
     "longName": "9955522 - Disclosure - ACCRUED EXPENSES (Details)",
     "shortName": "ACCRUED EXPENSES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ck0001824293:AccruedResearchAndDevelopmentCostsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "ck0001824293:AccruedResearchAndDevelopmentCostsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
     "longName": "9955523 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Narrative (Details)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-103",
      "name": "ck0001824293:StockIssuanceCostsOfferingExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-79",
      "name": "us-gaap:WarrantsNotSettleableInCashFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails",
     "longName": "9955524 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Schedule of Estimate of the Fair Value of the Warrants and Assumptions (Details)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Schedule of Estimate of the Fair Value of the Warrants and Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-109",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-109",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails",
     "longName": "9955525 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Schedule of Warrants Outstanding to Purchase Common Stock (Details)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Schedule of Warrants Outstanding to Purchase Common Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-113",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-113",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
     "longName": "9955526 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails",
     "longName": "9955527 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails",
     "longName": "9955528 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Activity of Stock Options (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Schedule of Activity of Stock Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails",
     "longName": "9955529 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Assumptions Used to Estimate Fair Value of Options (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Schedule of Assumptions Used to Estimate Fair Value of Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-140",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-140",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.vallon-pharma.com/role/SEGMENTREPORTINGDetails",
     "longName": "9955530 - Disclosure - SEGMENT REPORTING (Details)",
     "shortName": "SEGMENT REPORTING (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails",
     "longName": "9955531 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-142",
      "name": "ck0001824293:COBRABenefitsPaymentPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-142",
      "name": "ck0001824293:COBRABenefitsPaymentPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20250630.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ACCRUED EXPENSES",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r26",
      "r29",
      "r640"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r474"
     ]
    },
    "ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "AccruedGeneralAndAdministrativeExpensesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "Accrued General And Administrative Expenses, Current",
        "documentation": "Accrued General And Administrative Expenses, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails",
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "ck0001824293_AccruedResearchAndDevelopmentCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "AccruedResearchAndDevelopmentCostsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Accrued Research And Development Costs, Current",
        "documentation": "Accrued Research And Development Costs, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r76",
      "r321"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r525"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional\u00a0 Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r589",
      "r590",
      "r591",
      "r592",
      "r643",
      "r664"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r538"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r538"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r538"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r538"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant issuance",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r13",
      "r51"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to cash used in operating activities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r571"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r497",
      "r507",
      "r517",
      "r549"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r500",
      "r510",
      "r520",
      "r552"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r538"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r545"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r501",
      "r511",
      "r521",
      "r545",
      "r553",
      "r557",
      "r565"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r245",
      "r246"
     ]
    },
    "ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "AmendedAndRestated2018EquityIncentivePlanMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "A&amp;R 2918 Plan",
        "label": "Amended and Restated 2018 Equity Incentive Plan [Member]",
        "documentation": "Amended and Restated 2018 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "ck0001824293_April2025PAWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "April2025PAWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "April 2025 PA Warrants",
        "label": "April 2025 PA Warrants [Member]",
        "documentation": "April 2025 PA Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r60",
      "r78",
      "r92",
      "r93",
      "r94",
      "r125",
      "r138",
      "r142",
      "r145",
      "r152",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r258",
      "r260",
      "r287",
      "r313",
      "r314",
      "r317",
      "r377",
      "r448",
      "r449",
      "r455",
      "r474",
      "r476",
      "r477",
      "r488",
      "r607",
      "r608",
      "r652"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r82",
      "r92",
      "r93",
      "r94",
      "r152",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r258",
      "r260",
      "r287",
      "r474",
      "r607",
      "r608",
      "r652"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_AtTheMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "AtTheMarketOfferingMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ATM",
        "label": "At The Market Offering [Member]",
        "documentation": "At The Market Offering"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r561"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r559"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r557"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r557"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Accounting",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "ck0001824293_COBRABenefitsPaymentPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "COBRABenefitsPaymentPeriod",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COBRA benefits, payment period",
        "label": "COBRA Benefits, Payment Period",
        "documentation": "COBRA Benefits, Payment Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r74",
      "r430"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r41",
      "r91"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase in cash and cash equivalents",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r41"
     ]
    },
    "ck0001824293_ChangeInFairValueOfWarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "ChangeInFairValueOfWarrantLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of warrant liability",
        "label": "Change In Fair Value Of Warrant Liability",
        "documentation": "Change In Fair Value Of Warrant Liability"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r531"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r79",
      "r80",
      "r81",
      "r92",
      "r94",
      "r116",
      "r117",
      "r119",
      "r121",
      "r127",
      "r128",
      "r152",
      "r167",
      "r169",
      "r170",
      "r171",
      "r174",
      "r175",
      "r178",
      "r179",
      "r181",
      "r182",
      "r184",
      "r185",
      "r188",
      "r189",
      "r192",
      "r195",
      "r202",
      "r287",
      "r337",
      "r338",
      "r339",
      "r340",
      "r342",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r365",
      "r385",
      "r405",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r576",
      "r586",
      "r587",
      "r593"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80",
      "r81",
      "r127",
      "r181",
      "r188",
      "r189",
      "r190",
      "r192",
      "r195",
      "r200",
      "r202",
      "r266",
      "r337",
      "r338",
      "r339",
      "r340",
      "r456",
      "r576",
      "r585",
      "r586"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Axis]",
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Domain]",
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant exercise price (in usd per share)",
        "verboseLabel": "Exercise Price per Share (in usd per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r95",
      "r203"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares called by each warrant",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants granted (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "ck0001824293_ClassOfWarrantOrRightOfferingCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "ClassOfWarrantOrRightOfferingCost",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of warrant or right, offering cost",
        "label": "Class of Warrant or Right, Offering Cost",
        "documentation": "Class of Warrant or Right, Offering Cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares (in shares)",
        "verboseLabel": "Number of Shares (in shares)",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_ClassOfWarrantsOrRightAgentFeesAndOfferingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "ClassOfWarrantsOrRightAgentFeesAndOfferingExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Placement agent fees and offering expenses",
        "label": "Class Of Warrants Or Right, Agent Fees and Offering Expense",
        "documentation": "Class Of Warrants Or Right, Agent Fees and Offering Expense"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 9)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r56",
      "r318",
      "r364"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r159",
      "r160",
      "r425",
      "r602",
      "r604"
     ]
    },
    "ck0001824293_CommonStockAndPrefundedWarrantsInFinancingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "CommonStockAndPrefundedWarrantsInFinancingMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock and prefunded warrants in financing",
        "label": "Common Stock And Prefunded Warrants In Financing [Member]",
        "documentation": "Common Stock And Prefunded Warrants In Financing"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares reserved for future awards (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common\u00a0Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r478",
      "r479",
      "r480",
      "r482",
      "r483",
      "r484",
      "r485",
      "r589",
      "r590",
      "r592",
      "r643",
      "r662",
      "r664"
     ]
    },
    "ck0001824293_CommonStockOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "CommonStockOtherMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock",
        "label": "Common Stock, Other [Member]",
        "documentation": "Common Stock, Other"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in usd per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r365"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r33",
      "r365",
      "r383",
      "r664",
      "r665"
     ]
    },
    "us-gaap_CommonStockValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValueOutstanding",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, 0.0001 par value; 250,000,000 shares authorized as of June\u00a030, 2025 and December\u00a031, 2024; 2,496,800 and 525,485 shares issued and outstanding as of June\u00a030, 2025 and December\u00a031, 2024, respectively",
        "label": "Common Stock, Value, Outstanding",
        "documentation": "Value of common shares held by shareholders. Excludes common shares repurchased and held as treasury shares."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r365"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r541"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r543"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer equipment",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r438"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred stock issuance costs in accounts payable and accrued expenses",
        "label": "Debt Issuance Costs And Financing Costs Incurred But Not Yet Paid",
        "documentation": "Debt Issuance Costs And Financing Costs Incurred But Not Yet Paid"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredChargesPolicyTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Stock Issuance Costs",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r11",
      "r89",
      "r431",
      "r432",
      "r434",
      "r436"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCK-BASED COMPENSATION",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r211",
      "r240",
      "r241",
      "r243",
      "r458"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Activity of Stock Options Granted",
        "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]",
        "documentation": "Tabular disclosure of share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r611"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r492"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share of common stock, basic (in usd per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r88",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r109",
      "r110",
      "r114",
      "r116",
      "r119",
      "r120",
      "r121",
      "r124",
      "r177",
      "r244",
      "r254",
      "r257",
      "r279",
      "r280",
      "r312",
      "r325",
      "r439"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share of common stock, diluted (in usd per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r88",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r109",
      "r110",
      "r116",
      "r119",
      "r120",
      "r121",
      "r124",
      "r177",
      "r244",
      "r254",
      "r257",
      "r279",
      "r280",
      "r312",
      "r325",
      "r439"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Common Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r10",
      "r123"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payroll and related",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r638"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation, weighted average amortization period",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r242"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r639"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock options",
        "terseLabel": "Employee Stock Option",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r575"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r529"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r570"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r570"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r570"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r68",
      "r69",
      "r70",
      "r85",
      "r86",
      "r87",
      "r98",
      "r99",
      "r100",
      "r102",
      "r109",
      "r111",
      "r113",
      "r126",
      "r153",
      "r154",
      "r155",
      "r176",
      "r204",
      "r244",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r256",
      "r257",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r278",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r302",
      "r324",
      "r330",
      "r331",
      "r332",
      "r342",
      "r405"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r539"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r497",
      "r507",
      "r517",
      "r549"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r494",
      "r504",
      "r514",
      "r546"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r545"
     ]
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Change in fair value of warrant liability",
        "label": "Fair Value Adjustment of Warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of the Fair Value of the Warrants",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r282",
      "r469"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r501",
      "r511",
      "r521",
      "r553"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r501",
      "r511",
      "r521",
      "r553"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r501",
      "r511",
      "r521",
      "r553"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r501",
      "r511",
      "r521",
      "r553"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r501",
      "r511",
      "r521",
      "r553"
     ]
    },
    "ck0001824293_FormerChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "FormerChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Former Chief Executive Officer",
        "label": "Former Chief Executive Officer [Member]",
        "documentation": "Former Chief Executive Officer"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r534"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r387"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r157",
      "r158",
      "r262",
      "r263",
      "r264",
      "r265",
      "r284",
      "r285",
      "r286",
      "r288",
      "r289",
      "r290",
      "r327",
      "r329",
      "r390",
      "r428",
      "r429",
      "r461",
      "r462",
      "r466",
      "r467",
      "r468",
      "r473",
      "r641",
      "r642",
      "r661"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r262",
      "r263",
      "r264",
      "r265",
      "r284",
      "r285",
      "r286",
      "r288",
      "r289",
      "r290",
      "r327",
      "r329",
      "r390",
      "r428",
      "r429",
      "r461",
      "r462",
      "r466",
      "r467",
      "r468",
      "r473",
      "r641",
      "r642",
      "r661"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in operating assets and liabilities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r577",
      "r581"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r501",
      "r511",
      "r521",
      "r545",
      "r553",
      "r557",
      "r565"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r493",
      "r569"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r493",
      "r569"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r493",
      "r569"
     ]
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Interest Income (Expense), Nonoperating",
        "documentation": "Amount of interest income (expense) classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r465",
      "r579",
      "r596"
     ]
    },
    "ck0001824293_June2024PAWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "June2024PAWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "June 2024 PA Warrants",
        "label": "June 2024 PA Warrants [Member]",
        "documentation": "June 2024 PA Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r25",
      "r26",
      "r27",
      "r28",
      "r29",
      "r30",
      "r31",
      "r92",
      "r93",
      "r94",
      "r152",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r259",
      "r260",
      "r261",
      "r287",
      "r363",
      "r443",
      "r455",
      "r488",
      "r607",
      "r652",
      "r653"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders' equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r57",
      "r320",
      "r474",
      "r476",
      "r477",
      "r585",
      "r588",
      "r601",
      "r650"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and stockholders' equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r73",
      "r92",
      "r93",
      "r94",
      "r152",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r259",
      "r260",
      "r261",
      "r287",
      "r474",
      "r607",
      "r652",
      "r653"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Line Items]",
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r161",
      "r162",
      "r163",
      "r166",
      "r247",
      "r454",
      "r605",
      "r606"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Table]",
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r161",
      "r162",
      "r163",
      "r166",
      "r247",
      "r454",
      "r605",
      "r606"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r133",
      "r162",
      "r163",
      "r164",
      "r165",
      "r206",
      "r235",
      "r236",
      "r237",
      "r247",
      "r283",
      "r310",
      "r326",
      "r328",
      "r335",
      "r355",
      "r356",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r421",
      "r422",
      "r423",
      "r424",
      "r426",
      "r427",
      "r453",
      "r456",
      "r457",
      "r461",
      "r463",
      "r464",
      "r469",
      "r470",
      "r471",
      "r472",
      "r475",
      "r609",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend rate",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r646",
      "r647",
      "r648"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term in years",
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r646",
      "r647",
      "r648"
     ]
    },
    "us-gaap_MeasurementInputOptionVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputOptionVolatilityMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volatility",
        "label": "Measurement Input, Option Volatility [Member]",
        "documentation": "Measurement input using rate at which price of option increases (decreases) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r646",
      "r647",
      "r648"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r646",
      "r647",
      "r648"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Axis]",
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r281",
      "r282",
      "r283",
      "r461",
      "r463",
      "r464",
      "r469"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Domain]",
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r461",
      "r463",
      "r464",
      "r469"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r564"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r538"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ORGANIZATION AND DESCRIPTION OF BUSINESS",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r130",
      "r440",
      "r441"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash provided by financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing activities:",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash used in operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r43"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating activities:",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      },
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "verboseLabel": "Net loss",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r43",
      "r58",
      "r70",
      "r71",
      "r83",
      "r84",
      "r87",
      "r92",
      "r93",
      "r94",
      "r97",
      "r101",
      "r105",
      "r106",
      "r107",
      "r108",
      "r109",
      "r112",
      "r113",
      "r118",
      "r152",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r177",
      "r180",
      "r183",
      "r186",
      "r244",
      "r254",
      "r257",
      "r280",
      "r287",
      "r323",
      "r384",
      "r403",
      "r404",
      "r433",
      "r435",
      "r437",
      "r486",
      "r607"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r501",
      "r511",
      "r521",
      "r545",
      "r553"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r545"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r564"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r564"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.vallon-pharma.com/role/SEGMENTREPORTINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r452",
      "r595"
     ]
    },
    "ck0001824293_October2024PAWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "October2024PAWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "October 2024 PA Warrants",
        "label": "October 2024 PA Warrants [Member]",
        "documentation": "October 2024 PA Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r433",
      "r437",
      "r444",
      "r594",
      "r596",
      "r597",
      "r598",
      "r599"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, current",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, non-current",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r582"
     ]
    },
    "ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "OperatingLeaseRightOfUseAssetPeriodicAddition",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Change in operating lease right-of-use assets",
        "label": "Operating Lease, Right-Of-Use Asset, Periodic Addition",
        "documentation": "Operating Lease, Right-Of-Use Asset, Periodic Addition"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r499",
      "r509",
      "r519",
      "r551"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r502",
      "r512",
      "r522",
      "r554"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r502",
      "r512",
      "r522",
      "r554"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_PaymentForFractionalSharesReverseStockSplit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "PaymentForFractionalSharesReverseStockSplit",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment for fractional shares in connection with reverse stock split",
        "label": "Payment For Fractional Shares, Reverse Stock Split",
        "documentation": "Payment For Fractional Shares, Reverse Stock Split"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment of stock issuance costs",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r545"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r538"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "ck0001824293_PercentageOfTargetBonus": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "PercentageOfTargetBonus",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of target bonus",
        "label": "Percentage Of Target Bonus",
        "documentation": "Percentage Of Target Bonus"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r529"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "ck0001824293_PreFundedAndSeriesCWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "PreFundedAndSeriesCWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-Funded And Series C Warrants",
        "label": "Pre-Funded And Series C Warrants [Member]",
        "documentation": "Pre-Funded And Series C Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-Funded Warrants",
        "label": "Pre-Funded Warrants [Member]",
        "documentation": "Pre-Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from warrant exercise",
        "label": "Proceeds from Warrant Exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r580"
     ]
    },
    "ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "ProceedsFromWarrantExercisesNetOfOfferingExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from warrant exercise, net of offering cost",
        "label": "Proceeds From Warrant Exercises, Net Of Offering Expense",
        "documentation": "Proceeds From Warrant Exercises, Net Of Offering Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r301"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PROPERTY AND EQUIPMENT",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r64",
      "r65",
      "r66"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r75",
      "r322"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets",
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r301",
      "r316",
      "r322",
      "r474"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r301"
     ]
    },
    "ck0001824293_PublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "PublicOfferingMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public Offering",
        "label": "Public Offering [Member]",
        "documentation": "Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_PublicOfferingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "PublicOfferingsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public offerings",
        "label": "Public offerings [Member]",
        "documentation": "Public offerings"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r133",
      "r162",
      "r163",
      "r164",
      "r165",
      "r205",
      "r206",
      "r235",
      "r236",
      "r237",
      "r243",
      "r247",
      "r283",
      "r308",
      "r309",
      "r310",
      "r326",
      "r328",
      "r335",
      "r355",
      "r356",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r421",
      "r422",
      "r423",
      "r424",
      "r426",
      "r427",
      "r453",
      "r456",
      "r457",
      "r461",
      "r463",
      "r464",
      "r469",
      "r470",
      "r471",
      "r472",
      "r475",
      "r480",
      "r603",
      "r609",
      "r647",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r133",
      "r162",
      "r163",
      "r164",
      "r165",
      "r205",
      "r206",
      "r235",
      "r236",
      "r237",
      "r243",
      "r247",
      "r283",
      "r308",
      "r309",
      "r310",
      "r326",
      "r328",
      "r335",
      "r355",
      "r356",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r421",
      "r422",
      "r423",
      "r424",
      "r426",
      "r427",
      "r453",
      "r456",
      "r457",
      "r461",
      "r463",
      "r464",
      "r469",
      "r470",
      "r471",
      "r472",
      "r475",
      "r480",
      "r603",
      "r609",
      "r647",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r494",
      "r504",
      "r514",
      "r546"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Line Items]",
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r96",
      "r97",
      "r151",
      "r303",
      "r304",
      "r305",
      "r388",
      "r389",
      "r390"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r428",
      "r433",
      "r434",
      "r448",
      "r660"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r495",
      "r505",
      "r515",
      "r547"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r496",
      "r506",
      "r516",
      "r548"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r503",
      "r513",
      "r523",
      "r555"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r51",
      "r319",
      "r333",
      "r334",
      "r341",
      "r366",
      "r474"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r69",
      "r70",
      "r98",
      "r99",
      "r100",
      "r102",
      "r109",
      "r111",
      "r113",
      "r153",
      "r154",
      "r155",
      "r176",
      "r244",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r256",
      "r257",
      "r267",
      "r269",
      "r270",
      "r272",
      "r278",
      "r297",
      "r298",
      "r330",
      "r332",
      "r342",
      "r664"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r564"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r564"
     ]
    },
    "ck0001824293_SaleOfStockAgentCompensationPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "SaleOfStockAgentCompensationPercentage",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, agent compensation, percentage",
        "label": "Sale Of Stock, Agent Compensation, Percentage",
        "documentation": "Sale Of Stock, Agent Compensation, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "SaleOfStockAggregateCashFeePercentageOfGrossProceeds",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash fee (as a percent)",
        "label": "Sale Of Stock, Aggregate Cash Fee, Percentage Of Gross Proceeds",
        "documentation": "Sale Of Stock, Aggregate Cash Fee, Percentage Of Gross Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SaleOfStockClearingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "SaleOfStockClearingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clearing expenses",
        "label": "Sale Of Stock, Clearing Expenses",
        "documentation": "Sale Of Stock, Clearing Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from sale of stock",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal fees and expenses and other out of pocket expenses",
        "label": "Sale Of Stock, Legal Fees And expenses And Other Out Of Pocket Expenses",
        "documentation": "Sale Of Stock, Legal Fees And expenses And Other Out Of Pocket Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "SaleOfStockManagementFeePercentageOfGrossProceeds",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Management fee (as a percent)",
        "label": "Sale Of Stock, Management Fee, Percentage Of Gross Proceeds",
        "documentation": "Sale Of Stock, Management Fee, Percentage Of Gross Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SaleOfStockMaximumValueOfSharesOffered": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "SaleOfStockMaximumValueOfSharesOffered",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, maximum value of shares offered",
        "label": "Sale Of Stock, Maximum Value Of Shares Offered",
        "documentation": "Sale Of Stock, Maximum Value Of Shares Offered"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "SaleOfStockNumberOfSecuritiesIssuedPerTransaction",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of securities issued (in shares)",
        "label": "Sale Of Stock, Number Of Securities Issued Per Transaction",
        "documentation": "Sale Of Stock, Number Of Securities Issued Per Transaction"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, price per share (in usd per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SaleOfStockReimbursementOfAccountableExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "SaleOfStockReimbursementOfAccountableExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reimbursement of accountable expenses",
        "label": "Sale Of Stock, Reimbursement Of Accountable Expenses",
        "documentation": "Sale Of Stock, Reimbursement Of Accountable Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "SaleOfStockReimbursementOfNonAccountableExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reimbursement of non-accountable expenses",
        "label": "Sale Of Stock, Reimbursement Of Non-Accountable Expenses",
        "documentation": "Sale Of Stock, Reimbursement Of Non-Accountable Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Common Stock Equivalents Excluded From Diluted Net Loss Per Share Calculation",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r301"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Table]",
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r96",
      "r97",
      "r303",
      "r304",
      "r305",
      "r388",
      "r389",
      "r390"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r210",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r243"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Valuation Assumptions",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock, Class of Stock [Table]",
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r17",
      "r18",
      "r19",
      "r49",
      "r50",
      "r51",
      "r79",
      "r80",
      "r81",
      "r127",
      "r188",
      "r189",
      "r190",
      "r192",
      "r195",
      "r200",
      "r202",
      "r266",
      "r337",
      "r338",
      "r339",
      "r340",
      "r456",
      "r576",
      "r585",
      "r586"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Warrants Outstanding to Purchase Common Stock",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/SEGMENTREPORTING"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEGMENT REPORTING",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r125",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r445",
      "r446",
      "r447",
      "r448",
      "r450",
      "r451",
      "r452"
     ]
    },
    "ck0001824293_SeriesA1WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "SeriesA1WarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A-1 Warrants",
        "label": "Series A-1 Warrants [Member]",
        "documentation": "Series A-1 Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SeriesB1CommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "SeriesB1CommonWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B-1 Common Warrants",
        "label": "Series B-1 Common Warrants [Member]",
        "documentation": "Series B-1 Common Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SeriesB2CommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "SeriesB2CommonWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B-2 Common Warrants",
        "label": "Series B-2 Common Warrants [Member]",
        "documentation": "Series B-2 Common Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SeriesBCommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "SeriesBCommonWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Common Warrants",
        "label": "Series B Common Warrants [Member]",
        "documentation": "Series B Common Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SeriesC1CommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "SeriesC1CommonWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series C-1 Common Warrants",
        "label": "Series C-1 Common Warrants [Member]",
        "documentation": "Series C-1 Common Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SeriesC2CommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "SeriesC2CommonWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series C-2 Common Warrants",
        "label": "Series C-2 Common Warrants [Member]",
        "documentation": "Series C-2 Common Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SeriesD1WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "SeriesD1WarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series D-1 Warrants",
        "label": "Series D-1 Warrants [Member]",
        "documentation": "Series D-1 Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SeriesD2WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "SeriesD2WarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series D-2 Warrants",
        "label": "Series D-2 Warrants [Member]",
        "documentation": "Series D-2 Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SeriesDWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "SeriesDWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series D Warrants",
        "label": "Series D Warrants [Member]",
        "documentation": "Series D Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SeriesE1CommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "SeriesE1CommonWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series E-1 Common Warrants",
        "label": "Series E-1 Common Warrants [Member]",
        "documentation": "Series E-1 Common Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SeriesE2CommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "SeriesE2CommonWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series E-2 Common Warrants",
        "label": "Series E-2 Common Warrants [Member]",
        "documentation": "Series E-2 Common Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SeriesE3CommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "SeriesE3CommonWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series E-3 Common Warrants",
        "label": "Series E-3 Common Warrants [Member]",
        "documentation": "Series E-3 Common Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SeriesECommonWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "SeriesECommonWarrantMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series E Common Warrant",
        "label": "Series E Common Warrant [Member]",
        "documentation": "Series E Common Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SeriesECommonWarrantsAndApril2025PAWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "SeriesECommonWarrantsAndApril2025PAWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series E Common Warrants and April 2025 PA Warrants",
        "label": "Series E Common Warrants And April 2025 PA Warrants [Member]",
        "documentation": "Series E Common Warrants And April 2025 PA Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity based award granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volatility (as a percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r235"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r237"
     ]
    },
    "ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum increase in shares reserved for issuance as a percentage of aggregate common stock outstanding",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Increase In Shares Reserved For Issuance As Percentage Of Aggregate Common Stock Outstanding, Maximum",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Increase In Shares Reserved For Issuance As Percentage Of Aggregate Common Stock Outstanding, Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r210",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r243"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares authorized (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining contractual term\u00a0(years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable, Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Exercisable, Ending balance (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited/cancelled (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable, intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, Beginning balance (in shares)",
        "periodEndLabel": "Outstanding, Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r216"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, Beginning balance (in usd per share)",
        "periodEndLabel": "Outstanding, Ending balance (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r216"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average exercise price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r231"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r231"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Award Types",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited/cancelled (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharePrice",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of option on grant date (in usd per share)",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock awards, contractual life",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term in years",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r234"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r231"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r79",
      "r80",
      "r81",
      "r92",
      "r94",
      "r116",
      "r117",
      "r119",
      "r121",
      "r127",
      "r128",
      "r152",
      "r167",
      "r169",
      "r170",
      "r171",
      "r174",
      "r175",
      "r178",
      "r179",
      "r181",
      "r182",
      "r184",
      "r185",
      "r188",
      "r189",
      "r192",
      "r195",
      "r202",
      "r287",
      "r337",
      "r338",
      "r339",
      "r340",
      "r342",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r365",
      "r385",
      "r405",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r576",
      "r586",
      "r587",
      "r593"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r33",
      "r36",
      "r37",
      "r68",
      "r69",
      "r70",
      "r85",
      "r86",
      "r87",
      "r98",
      "r99",
      "r100",
      "r102",
      "r109",
      "r111",
      "r113",
      "r126",
      "r153",
      "r154",
      "r155",
      "r176",
      "r204",
      "r244",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r256",
      "r257",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r278",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r302",
      "r324",
      "r330",
      "r331",
      "r332",
      "r342",
      "r405"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r126",
      "r178",
      "r179",
      "r181",
      "r184",
      "r298",
      "r311",
      "r336",
      "r343",
      "r354",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r365",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r386",
      "r387",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r405",
      "r435",
      "r437",
      "r481",
      "r663"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r126",
      "r151",
      "r178",
      "r179",
      "r181",
      "r184",
      "r298",
      "r311",
      "r336",
      "r343",
      "r354",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r365",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r386",
      "r387",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r405",
      "r435",
      "r437",
      "r481",
      "r663"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r498",
      "r508",
      "r518",
      "r550"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637"
     ]
    },
    "ck0001824293_StockIssuanceCostsOfferingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "StockIssuanceCostsOfferingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering expenses",
        "label": "Stock Issuance Costs, Offering Expenses",
        "documentation": "Stock Issuance Costs, Offering Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "StockIssuedDuringPeriodSharesFractionalShareAdjustment",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Fractional share adjustment (in shares)",
        "label": "Stock Issued During Period, Shares, Fractional Share Adjustment",
        "documentation": "Stock Issued During Period, Shares, Fractional Share Adjustment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock and prefunded warrants in financing (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r32",
      "r33",
      "r51",
      "r337",
      "r405",
      "r416"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r32",
      "r33",
      "r51",
      "r220"
     ]
    },
    "ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "StockIssuedDuringPeriodSharesWarrantExercise",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prefunded warrant exercise (in shares)",
        "label": "Stock Issued During Period, Shares, Warrant Exercise",
        "documentation": "Stock Issued During Period, Shares, Warrant Exercise"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_StockIssuedDuringPeriodValueFractionalShareAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "StockIssuedDuringPeriodValueFractionalShareAdjustment",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Fractional share adjustment",
        "label": "Stock Issued During Period, Value, Fractional Share Adjustment",
        "documentation": "Stock Issued During Period, Value, Fractional Share Adjustment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock and prefunded warrants in financing",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r32",
      "r33",
      "r51",
      "r342",
      "r405",
      "r416",
      "r487"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets",
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r36",
      "r37",
      "r44",
      "r367",
      "r383",
      "r406",
      "r407",
      "r474",
      "r488",
      "r585",
      "r587",
      "r588",
      "r601",
      "r650",
      "r664"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r187",
      "r189",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r201",
      "r204",
      "r266",
      "r277",
      "r408",
      "r409",
      "r420"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse stock split",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUBSEQUENT EVENTS",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r307"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIQUIDITY",
        "label": "Substantial Doubt about Going Concern [Text Block]",
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of non-cash financing activities:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r544"
     ]
    },
    "ck0001824293_ThroughFinancingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "ThroughFinancingMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Through Financing",
        "label": "Through Financing [Member]",
        "documentation": "Through Financing"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title and Position [Axis]",
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r600",
      "r651"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title and Position [Domain]",
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r543"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r566"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r567"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r567"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r568"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r566"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r562"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r129",
      "r131",
      "r132",
      "r133",
      "r313",
      "r315",
      "r442"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r532"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r478",
      "r479",
      "r482",
      "r483",
      "r484",
      "r485"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants outstanding, measurement input",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r646",
      "r647",
      "r648"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, outstanding term",
        "label": "Warrants and Rights Outstanding, Term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r646",
      "r647",
      "r648"
     ]
    },
    "ck0001824293_WarrantsExpiringInApril2026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "WarrantsExpiringInApril2026Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In April 2026",
        "label": "Warrants Expiring In April 2026 [Member]",
        "documentation": "Warrants Expiring In April 2026"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInApril2028Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "WarrantsExpiringInApril2028Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In April 2028",
        "label": "Warrants Expiring In April 2028 [Member]",
        "documentation": "Warrants Expiring In April 2028"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInApril2030OneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "WarrantsExpiringInApril2030OneMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In April 2030, One",
        "label": "Warrants Expiring In April 2030, One [Member]",
        "documentation": "Warrants Expiring In April 2030, One"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInApril2030TwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "WarrantsExpiringInApril2030TwoMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In April 2030, Two",
        "label": "Warrants Expiring In April 2030, Two [Member]",
        "documentation": "Warrants Expiring In April 2030, Two"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInAugust2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "WarrantsExpiringInAugust2025Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In August 2025",
        "label": "Warrants Expiring In August 2025 [Member]",
        "documentation": "Warrants Expiring In August 2025"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInFebruary2026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "WarrantsExpiringInFebruary2026Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In February 2026",
        "label": "Warrants Expiring In February 2026 [Member]",
        "documentation": "Warrants Expiring In February 2026"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInFebruary2029Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "WarrantsExpiringInFebruary2029Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In February 2029",
        "label": "Warrants Expiring In February 2029 [Member]",
        "documentation": "Warrants Expiring In February 2029"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInJanuary2026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "WarrantsExpiringInJanuary2026Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In January 2026",
        "label": "Warrants Expiring In January 2026 [Member]",
        "documentation": "Warrants Expiring In January 2026"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInJuly2027Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "WarrantsExpiringInJuly2027Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In July 2027",
        "label": "Warrants Expiring In July 2027 [Member]",
        "documentation": "Warrants Expiring In July 2027"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInJune2029Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "WarrantsExpiringInJune2029Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In June 2029",
        "label": "Warrants Expiring In June 2029 [Member]",
        "documentation": "Warrants Expiring In June 2029"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInMarch2026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "WarrantsExpiringInMarch2026Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In March 2026",
        "label": "Warrants Expiring In March 2026 [Member]",
        "documentation": "Warrants Expiring In March 2026"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInMay2027Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "WarrantsExpiringInMay2027Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In May 2027",
        "label": "Warrants Expiring In May 2027 [Member]",
        "documentation": "Warrants Expiring In May 2027"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInOctober2026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "WarrantsExpiringInOctober2026Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In October 2026",
        "label": "Warrants Expiring In October 2026 [Member]",
        "documentation": "Warrants Expiring In October 2026"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInOctober2029OneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "WarrantsExpiringInOctober2029OneMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In October 2029, One",
        "label": "Warrants Expiring In October 2029, One [Member]",
        "documentation": "Warrants Expiring In October 2029, One"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInOctober2029TwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "WarrantsExpiringInOctober2029TwoMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In October 2029, Two",
        "label": "Warrants Expiring In October 2029, Two [Member]",
        "documentation": "Warrants Expiring In October 2029, Two"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInSeptember2029Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "WarrantsExpiringInSeptember2029Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In September 2029",
        "label": "Warrants Expiring In September 2029 [Member]",
        "documentation": "Warrants Expiring In September 2029"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20250630",
     "localname": "WarrantsIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of warrants for payment of stock issuance costs",
        "label": "Warrants Issued",
        "documentation": "Warrants Issued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsNotSettleableInCashFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsNotSettleableInCashFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants not settleable in cash, fair value disclosure",
        "label": "Warrants Not Settleable in Cash, Fair Value Disclosure",
        "documentation": "Fair value portion of warrants not settleable in cash classified as equity."
       }
      }
     },
     "auth_ref": [
      "r644",
      "r645",
      "r649"
     ]
    },
    "srt_WeightedAverageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "WeightedAverageMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average",
        "label": "Weighted Average [Member]"
       }
      }
     },
     "auth_ref": [
      "r235",
      "r236",
      "r283",
      "r309",
      "r426",
      "r427",
      "r469",
      "r654",
      "r656",
      "r659"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average common shares outstanding, diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r121"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average common shares outstanding, basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r121"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r530"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205-40/tableOfContent"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-2"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-4"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r577": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r578": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r581": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r582": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r583": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r585": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r590": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r591": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r592": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r593": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r594": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r596": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r597": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r598": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r599": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r600": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r601": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r602": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r603": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r604": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r605": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r606": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r607": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r608": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r609": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r610": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r611": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r639": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r640": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r643": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r647": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r650": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r651": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r653": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r654": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r655": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r656": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r657": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r658": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r659": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r660": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>60
<FILENAME>0001824293-25-000106-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001824293-25-000106-xbrl.zip
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M=PP/..?J33-]G>C7CCW#JPS?HT-,[B;AO478/_[;>_H+EF\]KF9STWXG; 3
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M;'3C\8'@_Z2^W027S2S'9]F(&33.!W*KH_2&0W&X%K3ENE\,=%R%$SY1ZA3
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M;./S=*8TRNC=CQU-Z^;]'&SC8S;OQ]1RX8;6$,M?,QHBQT]5@+![C5Q B(T
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M\>=X@]84+.+55LZ65@Z#Z+VI6AXHR*L0J+<D335B[X[:N.%#G!1$W9#.ESJ
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MO'/U@/%HO.4 13G3ZZL_"3SG./O=Z\U. 5*=7;GIQ.!14\YVE,-]B@^O3]6
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MYUQD!E6"3JH@<S)"CWN4.9U:YIRBS,F(*Y8@<[JT$<_Q94Y=,EB1DD':N.3
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M<0 SS5XY]4REC+AF_X!5TYT^\E%GV&L.Q+*:MY:!U"/YZ4>C5XXX/G_Q39E
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MO[<>M:F-][<+<V5FZ\3DNRY]*0?=7:1'T"0P!HQT2. P=A5,[<4=$=493)S
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MQAH]8R4+S>3Q;-H;CI7DT2J^8'^LNBIJ&@?/T=Y,\"ODT6C3X3CY+?I.\8S
M&TNXM5]H]BR"5V%)L]CO,L0-@!L>:=-O6V*_*3R29YI3_!#E8']ZLN? P?)
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M<%2"91RGP5%)#!/%&M>PP9IU_G]W4\6 4,UL$O:"2]>Z(OH!3!XEC+5:6:M
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M49-P)VLT:-0=SR,_?@H%<$HI1<R$X4ISR)W4JUO]RT3IC*%YR8*1/FRW"6%
MO,5CJ=$ZU*=ZZ[K@T_@0DC$ZZ3$8X.FW"(^QP;I[[SD@"?EV\(-W#)>--9*0
M'*R7\*O$-AQYAH+>V*!TYC2\V94K'V@!J$1HCB+FP:XAN7Z CATB/DE1$Z.
MM4_\F90X,UB<0Y0:G9'L/JMN@4E4P[)!L//30N#8]V;*@$$O9GS-<-X@)3HV
M_(O-9=RK?L69%MBHMA1@!L\7H[62LA?SN]M[+(,@'LIACBOF/O\0%$=@:"8\
MHXC+ %5Y]/'/IP;<>5-$%(G)GG%$5\^,I!\5*0?ZXNDB2Q<D_<UFV=D,BZ8
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MR/B#8)$12 UF>Z##B_8 \RA5FER2C>ODV8.,V'2$O*!D3F=;^A=/"XRQ !(
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M(KJF202^QX;TF&^1MFC,$K$?E8M0RG]+.44QT:.8>PR9DP%W:!^(Z"> +3-
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M7X\45BN)(K_-YT;('?7%7U,UER^S-9=/06/\=8N2T5)'6=904D8Y50D:L:_
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M.'$$*W,0'1-" 'B$S-D18:8454T18!#N47C"_&*R8MWC\7K29K<TR@RU Q"
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M:4L+I>(,@_IO;R]?'T-\Q;) ]VVKA[) NY(%7N)KIR\+="J+PHN7!7JM06L
M^@C\U>SUWLK-=/3ZX.</9O]45,4;:\3J7R<(OOJB_HJWCUW10>23-< JF>^0
M,M_K$WM>L<37>=NJC#\O]K67(/!5QI]7*O"U\@*?K GZV@2?%"2N7_'>*W&O
M$O<J<:\2]ZK77K"XUZ[$O=<I[K61T>M9>>^K8YA<]^YR@O];"0"5 % ) )4
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MV';MBO!5A*]Z[340OM\O/U2$CZB=,1).1?,JFE>]]M)IWM=OUQ7-H[I0O@B
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M^["X>"$[>1N\U7X7ANL*[7-#^TV #K./9G\85X_D#\0^0,T",=NV--S^NU,
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MR>5U0N4'OJ>2E+'"&N)1:AOCI35$U%1"%"NM$R+#9"YW2J4RI8KHA,V/?[]
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M]43S[!1WF3B3$I&,>>(C>**TLQF_REG&ST>OF-BAC8.CL^_"X.W%!0_*<![
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MN8J(G]3T+2):X-))3HE*8)$OI<_/)D<<R]IY&IQ1]ML(JQ7H=FDV;X<Y?C=
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MS??;SWSTW\M[S0QNI]%/,\;J,G-JR4EO8S[/X^IO0)/9<..NZ+B%B$$K<[.
M#W0(EB2E)#[=I3PMA$S )\JU4"G2ZDUS7@QOGXA>[#AM5U%M"W2]V8/*2>YU
MU?[IS93 T:D'0;34#/>1'-#!%XK$J*TW2GLE65OG9+-@MA_M>'Y=#]I05 M6
M72.%\(BD)H(*LX)J$HF:#U];,QTET5I1(93BK"6O+&IBBXP@!)6DYH+JI9RQ
M55>Y&N"WS]"=.C]\%@ZT1>;''OM%3_W)5='6:6[^.CJX&E\,AD74'1FCC-XJ
MG%!)=TI)$<OP864&!$2;+%>UE]'JD_A)[N?C1!NUR6Z+B$YZ*U\C/(,1BAO2
MN\'PW=7X:@BEU[+O1^@$JJD!75+ #?J4V@4$;(%DL-9YD*47<^U$N%5!_M@D
M;5>G;=6R6?O1.N['(>";Q_T'TYQ.\&"$0B['2/XSG.:#SY^'\-F/[U;0O5M3
M^3I.UHG"LZ1L)B+0$B)%,RV46(I0+JLHI'%FS8KH.S;3'_-IV6F5K$2^YXB\
M+9+'M3=RMV#U<7\\[*)['IL>RQU@5 I>#FQ3:3[HC26^I.HR[7"G"^B[^-IY
M5*U-YL=\<':+(Q4+)ZTDY)-!_RN,QG#MXX_.![C-WOU[$?3)8/Q/&-^JX(Z_
M/NI8%W,4(N)S+:!,LN0PZ(0NC@&>T1I,:JGT@=JYQYM.[,=^*':/.Q5+2+4^
MR6MUX-XY>:M\CG4"4&D-*UUJ2Z7%X$NQ"X7JH3)P !ZIKQT+VNX,?SXR.\JF
MBC6W:NV:OS:WGHXG,;)?AX/1J".20-E;3W*PFD@5T9$S% ANE0D$50;\SL25
M%D_CQWX*GIL7%0N*;3RE:>+G:#R\:LY73L<7,#R_\/VYD^TX"CZ%G G54I3*
MJ_APQ])=*2FCO"PY36Y7^+_BW'X^%#O'H(65UK9U=_2V/U1C%#XX:RF];?NC
M]FZ6KCA^N_=.-Q'&CMY*33RD[*@@2AB#9"SE&8QE)$<;>8@NB%#[9LD/<2LU
M"X/K4#:$ L?E"*0G-H=$@DZ")NI#<K5O^_Z\E;HFK[=S*W451NS*K=3C/JZ(
M\*G<DBE?]WXRSR:C24<:I,@E9B8G\PD.-[3LJ?-9@]&R=A[M(W#V*ZMV):X,
MVM%9"P? "Z!-;W8M :ZE9-E'@3U/UFLU-2Y'CPUTL'6B.%S:&<6G T1 I"X'
MM/*C("Q&%H#C$L_TRR?($^FES\./543? B_*B2=^X<5!/[V%K] ;?"D8)V;W
M)"T1G/'H0T625'$$*8HA<,6(X<:&P*)6>:D+.BNP8PE8V_>M*RIRT*X66LBG
M^Q7Z,/2]TOH\7:*HT3=O"@;=!QD89*K02*2Z%,$/-A#/728^<>-5"@R?H<I4
M60K8/I&EOB9:6%<F9AFD^5;;!&LGI2",8(EHSRR1.OARCXT7+5/K+82D:I<:
M6@[9RX_<;>*OM:"];;>K?R34=# :75U>!Q)_PYF-!T>C<?<2I_O.=X=-#L,@
M3P*-6XC"K8%F6S&Y3055*4*W=ASY]F$PRFI0C!(.Y<@]BT2\RAQ7PX &7%2I
MOH&[.>IZ<;CU[\!<>\^2QI",ID3HDLO/DR AH2DBO* RXDHC>7L5X38$OZUX
MVY99NCC$MDUE[TI8[?[5P.BTYSYYDAQC1 IP!#<J3I0WTD8!P;/:ERQW[$+Z
M5CGPZ"7T573Q4B[Q+C.GGY?05[J$OA)-MG&;=QT=OQ3^9N:C5*6=C/;H&KA8
M#O5YB2<8F2/-7 #\L+Q=Z1+ZSM%V%=5N]1*Z9IDJ 89 *A7%3;0(+%CB732:
MH;BX\)4YM^^7T%?2]=*7T%=1U"[=V[WQ2>]XK250$<>0_C[HX=?TNN/O9^B]
M=A@3*+H2$,E)HO2H)YX:13R(K#UCX%GM@/86IK6#K&[9Y=DQJNQ228;'IG@.
MPTO6X89'S14O(6A3,JD#L4%1PB(HH:GC/.Q,C88G9_-C<O_YB?$<%N\Z3_7;
M[M=N@GYJGNDL)==@-?$\"YR@4B24,S4;(K4L!NK-SEQB7'92/^8#L#,TJ7BM
MOI4)GG5'O[\; ASWQS"$T7BRMZ'K$K@E@LE(9-*,."4E,3DI52YK/NCPNUO/
MP;Q)_7P.GI4F;5UF;]I&=7AB3"8 DI5%))'%TLDRE2*9W"H(6>16%NYF]!^3
M6:L+?N&5[OH'O8>G'SX<GW\X.CG_='#R]O#TY/SXY->CD\/CHT\5#FZ7^/9:
M![&K3J32P>K[P6AT..B/N\BG?NS"W7L_WBB5\*&GR!\B03 2O DD,"^4 %TZ
M"U=^U!:CV70)>?#-UX<<R3''1,D$IJ(TQHVXMZ=2KR/1)+//3J?:'M!\)-LZ
MHJRD[]F%HH)XG_L<L538/N^.R]'9<3\5*_#*]YH(;Y/V"<&1)*@J)V&X] DO
M2<I<6QJ=-KQ&GXBY@S_7.6(-A0YJ"K9R_?D'@/[1'5^<0:_97T<7W2_G@R.<
M_?C[)-"Z#-2*32)6A+?]1A(5%/H8/5K0QC,32(.(,3B+9AB@*RD\+JPN W$:
MK8V$CY.!I3RMET"<1QI8/"]O5E%"6TVJW@V&ES \O.A"/OH&\:KD[9[FC#;V
M<-I613J')C4C.D6-&[&GN!$[0X#2J#0$KQE;UH)=;>CM]L1H57OSBL35%7W%
M6/\]E(>G;\X.WD ?I3\>37RZR2UW+S5X93C1*I1^;19].6X4"5 :>"6:G4QK
M,6/QF-OW>2N;J&W(MBW5WZTS>.Z'GV'\9M"_PGF[G*E"OD>IFEXOJ9A=:(5!
M,B$)):U=KU'=@@'W2^DUI+IJO_')V^5'.7_YVY_^/U!+ P04    "  I-PY;
M6#\$3Q-* @#Q8 , '    &-K,# P,3@R-#(Y,RTR,#(U,#8S,%]G,2YJ<&?L
M? >\V]3]K^_-#C.$/2]A!&)N)-F6+(<,9,M#GK*L81M*D&79EB7+LBQ;DAFA
M+:6%4FC9.V6775;8>[5 V7N4U1#VWB'DR==)22#PA[[V];WWR2^?^!X=G?,]
MY_S6^?V.+:U\>N5+KDWC$2+B&AH>&MIK:"^7:^4[KKW(6M-HMFM-;<0[&W2A
M02(U[AU7GS;MMW -N896_UWY<N;IFF%H<P! ;<_FR\V2.%MH-@"+UP!H-@BX
MYBZP-%Z016.D)%8E==Z,]VZ\=<:(5)XW@X-38$H+B34IUM/%7"]-"SU9")1G
M+)@_=:XUQVIH#='@1ZR&HK;G6/-FC('/<<K]:F#&R%@30YXW ^O?&,FGR)%0
M4Q=' K.A40$$H1%_8#:/EGU^V+O7B ?T> '0"WB\HR Z!T;F>/TCJVC&_*G.
MYUR]7)E#X9%5XSE7\V:L6IAIFK--[^RF7@6@0"  @![ XQEU6HRV;=7@K5&U
MO<L 9#4.+K8%7=(,J:F.]*_Y4K-CS)LQ8^K(&C08J"S\<QRMHRMCHY0%0%3$
MAJ@:;8>)$+"N?L[:_]EQG9S_GDY1HE']X8Y50&I4OZ][*O7#G1N-=?9L&Y18
M^>&>;=K61( 2V\V.+HA.\UW6#13N&C\%*-QUV+A.*$E1.FU#YXVFOF[ -1I\
M+T>U\O<LR[GA=/("_U2,OFZ4A3F5IM[@C?E2@Z^*0%T3JW.!;VK7;FI(AB+.
M7VO0,>W"%&/MVM4W%*D_JSD*KSHBMD;+8H7O*,:,^5&*6#B2S$0S([EP,ARB
MYP*#UM_"!KX+/C:Y;\]CKJ,'<U*.$99Y@\=Y0YS?MZY1$!F%/#3DG0-[YX#0
M*.B; X)S@>^T_39.LRQ5[.^@^,=0X.(J@&\:?:M[2!>=VA\SB35:K@NCJ=/-
MIC)_X$N(;R0_XO'/AD?V2/&"I/9]XIYKH*WJ\RTXNM9IE%1>4MH_47;]/QJO
MM\6^ L^;L5J#9WRGPZJ1^J8\QY3*1FV^!_*,S6N-JA_J5!.E:LV8[X&1;WJM
MJONA;JNT-$Z&H]_T^X[J?K??F++/!P)UP(=AV9Q<C%-5+(A5P\$D%FYC& [X
MLUB;B=:ZY6B@QT<#)H&G.BD,\V5E)8VY06R,@IC3OD]A;/==+&QO+-OO[% 6
M"P)N(L6%%3P+!;*,'(CF&"OB- PZ=U.YL*65&F@H[%R4.!@4E'@L*P4+'-NL
M!E%G2E4L/@#$"E@JZWQRZ9X0AFA*R8[AYQ@6)V+I' 42V'>(+'']&?4)M"&"
M"3EP#JT"_)>)*GB#=KE?8L>N>V. Q2C;*YC.9:$_LV"[[*7,L4:5L49,H6$,
MKJMC,V<$I5;D^O.IC4V**4*KKB7SGS-D"JL;R0.08A3J%/NEL>4'3>=:'KMN
M]Z]#1%EEE;%KL#^34+3<4)2RN7K)@;&1Y5*,-?A^$1B,7.+8FF#VA6B.W2]'
MV3K?A\?'!DT)"I7+]N_C_?O55!&B<F. :U86OM7( ?&-+=>I*7F#L.#X9#Z6
MK2:B*8W PW"&KE9S4=9;BK)@.01EQP =Z>J%?%PFPNEN*1^LE51GW5%*$3RI
M?W(_K(Y)N]J7?+H>AM/U@I&2?-:WA#28H0"-Z5.<8E*>%"U[TA)H)^OA?TGL
MWU6;B",<:?4%WF,<91\K4J44%U'X=6ADGQUCRKT68 EQFN)UJ(\BKP4:E!J.
MH P?XQ3K_%J@H5P?A*PY'T8[(!?SZ?K:,PP6^\NN\C$*%/!F-^DM>\LVK!6Y
M5*?@J7YK4NMN.U#L=77XB;3:.-:<86?,=O&"E:$+GB1-=%*Y8+C(%6MES@*)
MR)C@ZB6/U2WGB:K@#=8*'J::S 5[C%P.K0;^CP*N3=_2PV0DKA0;K%WDX'HQ
M%^1XCO7R'*R.Z6Z#TLI1I5N2@@,>EOXG'0Q9.6>FBM!@._U9L7V[]2B=HNU8
MCP>6^3REE3R^*L_YJF. _X/VKX."GOX,5UW0&NG#(A&TXU@G.0;HN&3<[WB!
M8##E>/*TH(X)//)/974 4B&V@#%CU4(%]D!*(?\-.[#L-\5U\#!!COU1TUK1
M7M4>BC-$- T):F%UHU4\8;!0%2.Q8!:+9C$1"Z4&@ E'T3&<P-(FYN\WI;+!
M!!9&'2<<+&(1'U8P@TTL"F)"->C%8J;C9T-1C&@[KC/$8O$FIIHA&4O(F%X-
MV8,9)@6LB^%!+%7 ;!//8FD&\YAX%<LP&&(Z?HPL8&[3V:BR0A#/AFF,DH,Q
M,ZQ@N78P50W[,-H7I+*1%,82P3% +ANI8IP0+%4C$)8W@U4SFL2*1+!1C=8P
M7@ZVLU$8$\)!.QNCL+(<]&5C&E8A@NXJ@6-5,Q3!B#(F%4))D_ -9BB'0SDS
MSF *&"J:<0M3FZ$:ELA@6C74K";:F%X(F=ED$C.8D ]+ZEB7<7RV(T"K@!/9
ME('UJGC63),8U,0'MEQ-VYC7ATO5#(<A!*Y7,PB&"CAHDE5GK;@[FXTZ&A F
ML*P1Q-OA'$:QP6@J+&0I=Y PPXUJKAE,%L(61M-C@,%,V!$![0YFP4@,8_0@
MW8SDLFPAR F1LLE%@\5"1*MR4%!@(E VKP0KA6BP6N""DA!-FPYO%#G*5XO^
M8-.,C@&J6;X;;#MRS);JP2X3"YI",6BW8V2V3 8]X5@9$Z-!6([IF @$ T0,
MSE9\(:Q-Q,RJ'0H7"*Y:ZX0(@E"J4FL,,)3T$6"UKH;(=CR,R4J(;L9I4Y%#
M>3E>-QMRJ-2,]TQ5"57:B7"VJ8;J8(+%M%:H&4XTL%8GU&827DSOA<QV<@R0
MJ+;A$!1.\MD.%H*KR3;6)4+N<-*=-7-XJ)G*FI: QYA4O6JK> I+>;*]'IX%
MT_$JA.%L,UW&/!F<E].FZ17' /%*-1,V?1U<EC-%# 9PK9TQJOX<WO&1H2RJ
MX&"8S%<#" X7R+8)D+C;S(8HK!$.I[(%*N@.Q]O9#H7GPR1#C0&&+><?@U(E
MRA$=WZ1L*M8,5X5<O!:/A!O97"V8J(?;J9S/2N%A.T5G+<>5^%*T%B0C83?#
M!&M9-1*6&;Z6&RPYD@"97HTV(Q3!IH,L%\D['LKB A$1XQQ=:T1DF2L%>3*B
M$QQ4*R$1"\QGJ;(2\<EYO5;)10"A$+5J6#3*%,8 I9K4C::9@KLF5Z,,4^2M
M!A4M"44OU0Q'I2;/4)HWJOEXB]+;42M;REA&/>IKEMJU+A_#""%1LW*Q6%MH
M6KW4&&",9,JQ&A2+Y;%R@_+B,=$4(S48BS6:HA)$W+&.7 E;J#OFD2M*T W$
MW,UJ)!<,$E&SV@CA88+$:K%0A"#R3&T,L)F+98A*6XK;<99H$I)N)\N$V:QG
M0ND& 6?KID2:\2 JTSD*C2?:LD=BXG&ZJO A+A\7!"5@%]2XX\]K-N\= XQW
MJFHT5(['O4VU95>$! 8V2;MF)1)$$PK)T01=U7B[44Z4L18F-:%$H]IJV#J9
M, D]+1E: @9U,&=&DKC<7K6GV%(R+1AX" HF\P6C97MKR5JA0X>04%(7.GX)
ME9-0LROG@%@2\)EI.MA.);*FIQ?.I9BF5:U'D52%L!/U^"!R2&EM&\)3Z118
MZ%5Z&5\*"(.)'J6DXS[0@S-TF@&A6B\?2E= 3[I7M-,MGP>A!3GMP;PJ7LEG
M@ED?@TNI3*H*#YP#K80R>13NXBJ<J1>0,MZR,QW4GZ0-/8,T_0ANJF24036\
M5R=S1*! >VJDB+D)'*Z2+<SMP]$:Z0D#S3H@#0+.4!HKAD.-;*8<3#"15I:W
M@GZ9,+-J/&0P26^VI^$5AL0H+!VFP%R"2L&.'K,L5=0B7KD@48URM 663*K'
MQL8 1;""Y1S_G0,E*I<NQV.,4L_Q2AP--[TY%4I8?3.!TLF&W)7HD)829!NA
ML_%T3O;0=-G*Q!FX0^ME$@L'!GD*#:=)+XNI3"R2[4#A*,,&J084:S#U2*X2
M2<88*TWGH4R+ 8I,5LF1;-I@$Q$68H4XAT-%@6TI7  JAUDXGA\#]$6J72X&
M%6Q(YCE.*78BS9CSA]<4'>) MJ2P726/LT)-Z7'Y7+DL1KSQ?$T32Q$DD#<#
ME0+K[A4PMLIZ0@-_6""M&NV)2H4**^6XA%#H!NM93R9?<!MRUDG.BAE%(3DN
M5Q3+#9+C<\5.324YD2ZZE2;ID3@^8VE93X/G*Y$!8"[:JO#=LDY[.BH/!-JL
MQ^Z6LC6C$/7 I5J\PWO\X9(%=\4H0 DAPZRI>%6@-4O)QTQ!-FQ-304%".IU
M8EEF#+ <"X*]&-,L%UC(Y\RKK!D>=ZS,E?UI7SA?ZX@I"TZHC;@HEA%*;2FB
M2?D+WFZH$HJ@U7RO5F$B@6;>%ZPTXNXQ0%-%ZQ4?!<"%8*R:D(*A9D2O"IY0
MBDCDJMT<SOHR2,W97*H$7:\Q8J3E*V1J:B(*^01_#7830:*F22DDGO(UB@/W
M54$214)/2+U04FEVT7HTD[*;H%4O2FG !S?J;81,-]VBC/'9DH9S,NVF6G&"
MDM56S@>GT[*?9XAX+J&0.78,, _GXX[F<2HL)!0OE_?%:ZE&4BK&XXULHV+S
M?%QG&V"BI,.FH!(-(0!#LEI.B-DXTE$M3T6" :09;50]B<A L9LE7HJW$ES3
MY.OE%MG0(KQL(8Q/XQN-:(M/:EV/6FI5JJU(HFDE9&^+;[1BB1;9,A-ZF>]J
M>L1N@PDHK)>DSAA@DD=JNL5W);^3;,8X$]$CU7:9MW/^9*C=DWJZGE6,N V%
M_5S"J$8]8JED&A[)ZTO6BIUT%,[I:JA3[R!&J3T [" B2I3L4I?B G6_+]%M
MYMR /X!T@3PFI/"VR56"/C1>,8TNSJ5(QHK$PKTVF[2$>I1JEW +C,6Z:#5@
M)WL#T\NT&[!=KR<,M.VQ_:546K"A'IU/&X+/T]-+9!IU^T!<S7:,, J6_#DR
MD R"($U;!A6'4EV6-O(4I.0Y3[HLC %";KQ03->;'JY71,N:Q]/MEJII,^(E
M]'(X[>&\M9[8-%#-BP#5="<4\#%TK9>)TSZC6R^X21V.D3*0X<)PU=L8 U0Z
M3MR,J,U41T(1IJ2!&:V$=/*ZD.GZ_43)"(L>P2_5.T8F@/G1GLF1N(+FDQ8
M)%*HI?8T( L&4DF((?.#R"'0\'K<@)AP!U5?BY1];J&"L("NNKT5- C8!2"G
M!CI=. D8/:!4 0# [>MGF'+)$U>P*#T(MRM "2.R@Q@[6,TZ\2X3#E:92+ J
M1X/90CQD5IV0K9K$L68B9#83_8 9Q\S^_RR.^<@PAF;P8(J.!+-TV#)+4:LM
MQ"RT,MB7G<+8?S/<#^72. 86G!$*T1I#1:AFY9_W?\3_M0'7^ ^@3NZ0K3K)
M-\Y@9IC",(+"LBG*65H8&V3,,:R_L.R:65<V,HBQ32+J)"^Q$"8[RW,:](/Q
M;S?.8B%GM0Y+!"*4;2:=.R%G +R?8SAU#D<<#,>-#0"K*<J92H2@""O+AJ-A
M3U@2"F$FI45K08NSLA(99(Q8+645)31$V=5N6,GV*%IN)>R"EPREF:PJ(YE>
MNE8>^,-BC,;!#D'$FZEXJ%8MUN(.ZUHYD#72;"*HVSZ #$,9&BSF^P<$'&25
M\TJ *WIJCK$;[1('=PM>"BJK99\XV%,T?R4&N2O>3+A6X&,2T4A(/MM1='=(
MAG.LHHF%1K%54N,>4843=2W!-31$TEJM3EOGD6ZSSU]G^00>S#+A@=ID"^&0
MHQ6E/L]J83P8ZH<8X0A#I6M$M6A5BV&[68J9D52,\N72H0@;EX1NN!?'*;Q:
MXW.,S4D%QY$$O>3@W"8MQL-5J\S(9G5LR?%Z,1*5RG(YPGC15J9GVE4-=).]
M6CPG&RF:@4E**3NYJE;*1R Q#U%.:EYN\IRFEP9I!=0I>5;SX'N7CRMQ9XN%
MI6)#ZPAJ$:G(K8RL\;S:2C1:+<0V]):["_"KTEL3[ZM%N*]G.(H%&%\+E=!
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M"FAHKI</0"V<1 I!*E:HQAT=9@(L1C.RRC<2;#Z0K#B\8T@ BQ0KR3P0],:
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M\@B>TSR/>S?R1KR+O-=Y/_"Y?:+O3-_3\'0X!?\:O@->@?@1';D,><._J_\
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MY^[,W_GX7=F['KP[<?=?[HG<<^>]V+VW_F7>7V[ZZYR_7G\?>M^U]R/W+WD
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MF#LIF2@--U"K[E+;K:OD"YY63B4A8?(,?>[S&C_^![?\B;O3O]@CR4FO#83
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M>!E--K1FM".4H,L3NL%8^W[UP]E'?[0K_YW\ X/EJ61'G@%>0>[$N)M7R(]
MK:7&4&JX T[<QD"9OA(;_*-$ \'6/C+##\4S33)5&_VR=G-+=KX'"[!+$D9D
M>Q@HA0YUZ=KNM?MH2-79Q^$4]V]CO3<7/*M3J*JZ<D_%9BRJL)P2$1+/B]R<
M94;CI6@2K&;[PQ@?*"6,\@$WM1XFQX6;$5"(^U!RC?#LB]02^H]EE<."G;SR
M"54%X<AV9VAP.<E_4#-HN7Q+9D7:=VFQU2+1)L#HEGY  ]CEF@[7#]LN<I$2
MF20)]$L\+!O$>!@(XC8R9QAV@(Q,-.5!"MS<W(W<U_27XN*0+G&;.7+=GUO^
MYQV.M >K&1.Q:6!M Q*DDM]Y[A_+GG"HY-)9I-LN:U9A6I*]A&.@5&I]5;'^
M0(M(<FD^ ,+ &<FHFT\C^W2^CW*>:7<MX^MHKL&8QK-GB$PC'A-#(Y"EO1E/
MGY$B34$)I,#%):B@$*4MYBS*-QGSHS! 2T'MA..REBN^*0R0V>9<=6=B-+X\
M4/-)+ZB%P3KJ$M'?X WI0"@A5U-F#-33?-@R6]4"R2SIDB"W2KQQXNAR\SD%
M77ID=J=EH " ?[O;]F7M).2J2QECID#*K3B^0,*'*.T?#^FP!'X=<N-V$83B
M$X\CDR\LS>"G3;;/N3_# [2O.PPP)7[]PYWU[Z3[H'M]-WE+;1U/6GU(>Y^]
M\E/8]%S]%RU3UM&M!>%/ZW6G[HTL7[#X71G3[#Z98SK\N^V-_K.3ER0>=2&8
MZ[1^1+;H%BR=TW9#^9!O+4U!;WW\CVOG<7:.$/IJ@*4%J%^=F<E-\LS=>;Z:
M82MN1 TC,R,672<])6J*&FE^E=4D?B;,6('@P&M5=3=D)JG>IE#B%O;^E4N;
MEAMC([GJ8@3C'>7@3GZ'B&G;?HDB59D9[!(,>>-.? "78':J:GC$C=-)\0G'
MU\VO9O8"M\D!K(*.72&Y\TVKO#=T&\H_5^G/.^.*Y^%F7ICS;-?TQA@_0&DY
M/%-:9B0-7CGZ5L4O>Y46W#89S<CX<@IZ=2-2W(4TVHV:\EPWTX$PNPL3,!"_
MBE9;9FJ2Z^'X:8\;V-UN:#EDM/GW+C&%G>/BXCH9AD=*[S'&ML*2:I:3XAEN
M51[\Q!"^95NS=YM]4S" #SHE3N3Q3W^\/?^C_&-']C-5ZD&SG8_F?7-VRU[[
MW&@__FK:Y\9(B4 1":8IV>7NL,CG6+'"F4$IL!E#'$4ZT?H)R:TV.RP4NV&&
MS%<PBI$*\0QVU!WV1G=Y86I]2^?Y#FN#?72_D;^B^W6@8=.ZCRW^W#(C-IV(
MAB1=@]I20?@7T&0EP\D/>05UKW<W"+)9H;[%;#EJ"A';CO:.:;P02;Q95340
MS&\&HOGP.Y@2U)ZD>'6F5UB-3;*GI*_?9"R+H8T'1:5[-G9J+L8S*$$5\)CF
M1?,.]U*^>,+ZVP99VQQ),CQS(X, >M@&UT2_%(^]YA#LTQ?!4/&8S#SA.$K^
M;MXUA_6Y!_ZLM?9GG,*15Z2 %QW2I ;7V#9=N]A9G'6XQK.2'E3ZJ+=.9_0Y
M18KPC^\'^Y-3MC#)[I'Z&'7]M\4R \'L7NO7 Q6%L.EME^QOIF5]8WV<9P@^
MI'6=#$7[3E C5[";F[<K.'."MMFG '7YKHBN<@>'7J DWW],WR;D26W;5(H6
M]^6=;W;U3VM[L@'33/)4>E'7/G-WAPDSK+"5"/'_I95U%W8^/B-D3S#Q:%2?
M8DEA4D#N>!NR]4RQZ:L>M =-'FD6Y$;/(:/O[L$E*!D40S,CQ:;3J^_:Z0>-
MBZ?IP;^)TWEC-S=_C,I':/T?[JA_+__8 XOC/&[_QF@(G;025CVQ4C.#/;Q2
MWUTW>^G;@O 0?1YOBA!"R-N]K2I&-A=<1,4[.O>_(2@$>L\'F^2+G1>UN;NS
MV*7HDI=7M.2B4CBM0BBR3>I*1T-A@T7B?&1H<0YYZ.W'YY1@2)D2\ )]T7PJ
M6O[<3')F ZZ4X0^\$ JXMNBW:UKW] [O[VS_DZ+Z%\P:<AM:Y*Q_TE&'7?[;
MP86<$)H-*B1XI$)@[Z!BMS;2OH79^L3G^DWM-"H5'?UMZ[UH52.;R9I>4ZPT
M0QQEQ2B7X30?LO>4*MN7P9$6!H<WK<D^&'4\U=S,,$B4CP;!G'/A+W*^X;IA
M'SC\TI/H5R3*]T1DTH09>3TT,2B@U=[ 5\'1I40MN](SQ[+0WAX^$RNXIOS-
M)-M>!5@1E2YI:Q!BG,BP7<K5!PQ96F<O5L>YHJY4O\T3ZO)IT1L5?O=D6\-P
MFADQ"DA5@(M^U^&&?[Y$<2^(D>>QC9LH8ER=R\(82ZDH9>(5X#Z,YNZDM$#1
M$PXAWF=\/S#_>"?Z>_D'?:'L_Y65.E35LY&JQPL*T?!?IO93[WM.).D,J'2$
M8XF20]UT6R>H(F0F*"<:HMW6R$6>$*/2QMKE\(#"4;W(7G+%L*OB$7502/>)
MDM4)QXM^:(8T2/4!G=M>@<>N2/Q9!J3.J$T=9'9YF@S%JX"K@4(*"6YU$M/T
M^^C0QJ2]9\GK=UF;#J8]6S[W^M93:$B7\#=L50.99]\%:-ZVJ"RX95.Y%*W:
M)4T6CTK=;A\6;L%X!^AT+;')V=U*-AK"V!<=HR7!&!$I*"/ IW+B>8Z:>2=W
ME(N@U%!\,?$Y,4]!'AGJ$U&H]9F3_JQS>;],$D:YQRFN&Q2'0OPM0DIM>G]4
ML\6=KPEJ$AU+N7*SS1_(/48WKG&YU)96O*QF $_+%S'[#J">=\+!973+KCE$
MFWMPIYEH,Q%'DL$^-#E.<E<2%+)NM\6)KV9F;ES^=6&/*$T0ONB@&'KDRF]J
M\^O_0+?X>_G'IG*.;[+J$CA!X]CZBU6""MFM^QM!\W*_*(1Y6B0V,XE0)=4I
M'[Q_W1K->)(K.2(Q\;MUJI=0SHNM6_D_1[W=^DO,& )Q\=AR['#YDDV2<2Z1
M=;OC09,3T,OF>4EFD7H04(RQ,-OEV!P(5JD6LWVA!8EK;,!<6YMJL';"ZO_Z
MF1)_TE*JL,_""4<Q_7R!<18UK[C3@"!=E<<YSV?TDJC%R[/L$ZPYOAYZ!#2F
M,?'2_=/M; 1H"R79JW"?>CZ[553ER5ND4ZC7-S1(=N.PC(:+8N@)!Z9?07$X
M_BU-IF>&.(H3G9<>*JHF!\(4C05EI9C@$@B>[&\FLIM\,4E$(T#GH-]= 1JI
M"4VR\&+^97ULI<2WVNW^GIZ'$>K#.FC]"D%^4](<+R"M<U>_=]C:UD!$W!.L
MDRNA<3/%ZGZW1<<2.Z-4 Y RF'AYW*6WE,\S6,:L9WJX2"(.%RI/?*,&8K2
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MX,+4/LYIN8NG881;=&U$M.<B5\D;7\Z;C?D:;RNUKQ_5=26JS]:Q][&S8%>
M3U+)IO:NS=[/@<4K*E@$?UB];]F4,76ENN[ULC26T#.@%7O"<=[QCFPZ8&9S
MQ068L;P=!F8"=D(80H5I6U7J+:=#<,)SYNM>;,U8[A+X;T\O*"_%4'2M]D4.
M9<)^JS+?R>ZK3=1RI RN8>UV1L?-@U%F W.+(O=/.*))F;SZF UX2 FV??M
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MO<]YJ.QO.'3ISZI3C@[[Z#(A&N[I[^Z8;WPU)9$N,=>/Z1QW:[$WN/5(Q[K
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M;;@39OF0]W9VR U)BKFAH:$+-_<[>7E-;FY!OR/OY'>"">)W_"(O0D<EP.W
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M55'7N*;/58D8:MK^,N3AC!LVJ%R_Z@;;.I:96N!]C(8K[0#&%J(-@Z+I\+M
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M:R]4+V >W?E^A#AC RO;W]B6GR4TABB<!>YV.U 9?V;W!!!8>4.K^XA-9E[
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M->:?'*GV]JNS-/\XT\ISMB:3"/;6X'RO7O*-U\.*,]>6S>OOE7C *>=IP=K
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MY=X[.;85Q!A2+BD7WXL;PLJ&$_6P:44N&-YW!2E#,Y@4@LIK" 6A!!' +X%
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MGD*YH2O>X#@IQA2^]0)&80L!JG'PH>DX-[SJNG<E%5&)_/%6N^<]B;Z*;=A
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ML&!D?*=6T-/AI[7!MN$10IYEK*%-^S14J@?,75Y?&IT2D@#@ IP;>1E%X+B
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M7N_*PV1F65>OH1/OFO^PZCG15"M^T4M=MB$BOJ;!5[O*\NKUI$2)(:;.S<L
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M197*L&+_-@^$ GA35N%G@KBP5@H[A/9Z7 K"(4.$'$X#R ";M1GJ.:J:24L
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M,/ET.F$Z%>JBZQCHPH^EN)\'O;AEG&).KL1G273C046E69"NBOH*:WK@8/5
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M4**$?J<5'IE=5F=F6LAP;$$EJ"WO6DT1L-#XD'GO+^MNG]2+;&*1J,S:<MQ
M]);ARJ6\6&CHP*Y/YIY<GX3S9J:6=^T2AW]-&M-LA]0%#B@$*Q"Z)8UXDE&C
MJL:7A0J5B#K5=%Y#2-T0+G9>S1K9O9R=VTO.+Q&<FR-!?627H)&[$V25/ER-
M>A,W[FO]D?0<:IOE8[Z]\!<=2Q_S>W' Z^49Y"?R#QQ!>X >T<Z,PJGZ^E_\
M8D7L9QBZ))N.NK#+*^.VFDK(SK&A%$!FUP3[$W(8^VU^=:XVG Q#:IYQZM"(
MFBJL6G[)&.YBA;)C#VLL&6@"GMC'$_%6 JX:]2%,$;1JZ4RCHY49^'GG5BKR
MW=E%-K^8;C=2]^6 TI4%?[643I7L<IMVM] .)1&JBZFRFXQCP"WCD%2Q,*!=
MQ"$4+MF4YH%Q,;+S/UU3;8.'?O!M0RR4#N^GFE,0%6^[F*:FN3IK=(L<G=*V
MY]T,L!Y(64=QKRG)8CJ;8A;7]NE3JF, 9*3VQ.K*S:+RCV0OR8ISKC:7O1X#
M/>YXRG&GS#G7[62Z_<2$Q9EI6O7IVJOC<9?KU(OW>WVU<X>5>F%Z:,X)PR%H
MBD!8R?^&4.R!7A]^!!9\Y'*]857OS[\ZT(4=HE$ZVNK>2(DI67AXL<@ZW582
M;T223:$;I:V <3PIZ(!.P=;[&(F+K<#7D4-6EDQ^L#+_HUE>43^)UI/1F9B9
MV6'#"F+ !0-';4ZH0Z9O!2I>U+T<<4SK\(4=3;+?P'Z:>O-EQ44Y/ZPY%4?)
M9]?D++'IG?[P?K4$ZRK7)+F +*I_3]2^#P,5-1RTVC5?'MH@D[VI@=YJC6G^
MF7;CG.N:DW'&V3E7-*K7;YFH:@<O3.J8J>MR*/EYK-73[( BJ/CD32I;J2C%
MLYNU-G&OH_%B*P +V'CH6@?)]SA0@1>/#-H,!6&:0@E$LB9R+X1_?B%'Y7@B
M7-IH(3F#&#O%--F;7=H\Y;L4!%A*#=IK3W&K9NGX*UT/,GQ6N_VZJFVPA=AZ
MDO,ZX_MA3.I#>[:2[^?]R18CV\A][? A_;=AE=']<6CM[ZJ:C@_L28R;:C4R
MI9[9A"9F@(G']NXYUX%\N_IBW#G7H>O]F169@\#P=E&U!>PL2<_P^1*1,2QM
MF&<9F)]]\O5PLEDNI?4@2-&CMJIQNC9\G?</.<2[TAL@DK<J1Z*,<Y-5NQ"7
MT>'(,L<,@BZ")N7[8\>\BC?5)'S\3VNJCLH?FE-X$LU=]_A''T4U47C'%?H$
MONZ"XP0_SL2HS>?4P2[7,G2O $5^LU&+&/A?5W7D4O^!7:9?X4=K PUK7K9A
M+&OO$TD;PC[=4(A U8I]['6AZE6A$_?(-22T)D2425J7DX/:/6BC&=!DTQ;6
MXKS$&'H_]"UK3J(S,B/W[<UK+*U\.(05BG]\83Q!KL"5@$B*'@(H=>&+2^>8
M/"I](-M>RBE_4BPZ+E^!LMN-'=/2F4/V.3@^Y"79FS5MXDSWWTH3Q1W]V$A)
M6-:(#AGN5B+]4:<]0W?P2]35K]0$NUS]P*( .?-KN?8?O-,;[;]["X[V+S=S
MZ06+.@@L%7M2HZ'*XR2(/[5-I'83'[R;2^M30 K+KG;8?\CG-E^OHMUJX4U*
M+NY>**^WJ-#SJU-#[+G/1>;).?D#:^7A!@A<0_=2;9F\IM[7"K0*=V,LL[*J
M\LVMW=M!%K90[?#@B-[& .VHF]O#"/,B)/^,6$7^B^X^630?&TOHAF VP3QA
MF3JW+*2>FF_ QXDZ.C@KH%9(9)QXO[[C?-Z"UO:J^"LRM:JEBEH!BX"&ZI-(
M\WGS)-M2APF6/23#:.1 ;>\M]LD<S@9TM_]+B!I<3:;XLU8#661+*T3IRW\!
MY@OE>>8*C972D!*[I<@="9O\#RQ5^_UUVM_B4B3ZS_FB.)7#!\LME\)[QQ2&
M(\O9!]Z1[>X:K+5SKJQ$^WV*ZI&>\7?/I=_^^4O[/RT>Z46)XHP/'ZP[7PJ_
M3Q<9/76L69\ QF]K'R^( X3-.#Z0W<C2>A'G'_Q_VY-.#7/40$PG:(#^^=;M
ME0!CZIRBZB\;GQ6?9(*+JKW0Y&(P=!20O>8DY5#WT+)SIB9]*Q#NI;J(8Z<S
MA9!F\J_P0OA6N!2M[G)(CFTCT&F]I2H[JPLIX$^>/Y:?I/C#*?X$66(J: )9
M()M-X>$'*4=#8WFC._A7;^[PM0M A5W]4!>X=Y=_B5!##,(=]3;[A)[2B?*U
M;R"7Z0W6+243SI9%W(V44)L9>?E5CP>\#)TA2VH#EMQNNX"%+V+AA8*#=<G(
MNA(OY9I2CG5AWG# E 8DB^8XCD'S;:]D%>#25=Z#>;[@VZ,"5J-Y)\4$+/;]
MNZGNT/V_TH'&V1 >T3CRE21A?:*WI7[E$,M#[EX-,Q41J_SXH&X (R$2GB&N
MX!V<U/Q&L)4'DPYG*'GISE)>]RW6]C"%.&I[4\VHJ=G'W59,GP98"2BPQ\ID
MS]7E$,!OP/_(Y(ZXW$>%F7?(X8KK>R[OIYX$#XW*;2Y*K^0686IGPFM5R]7'
MJ['%3ATRR!=]?HFGQ5"S]RY$8[BJ1G>%_8\K^\,;#)VMZ-NB!]"\;PZ(8YR'
M+N2I4ZVZF%*W\GE"+@N8"O#)J;4R&37PR"[@!-$U3B.) ^^B'VD%E,PW*JB7
M)GT9C=D%@0O@!-(S#^'M]9^X_BVX?CT(-%/1GV^'.HAZ7V+B8/^!VMWU+24G
M[(1;S#ZUU"+U;"6]Y!Z<O'=ZQHZ1.9:*$?+7U0?$33]1T7813:_2GF'[K!-+
M3O)),/]L!.Q66_<:%8[#]-JM.50I W4[DHU<W@7+9;;LV]V!E0RL=ERBL$R/
MQ!WUO,%N-1&208 /#H]?X160.8[B6?=MV);#TE1,5 I]=C]<#"3M/>KGWSU^
M0F(IQ"[P1(>%]6.T&\.J<L^Y4$0)/O>Z#8,N&,> 1[V:S,QHC#,@D$;'20Y$
MO,E8R2]+0XI+(XNQC #>09RX1 =DL;3%(*P][*<%&NV7IV>D8=,JF&IH8>73
M6UN8,<59_>_W^S$J$<VXU ^9P>I\9QQM>=#<72Q/AG)'W?<,LK9$G[A?#IAO
MDH$0V,WEV$3X CV(?LF&JR.-JB]>+(^B,-"X:SHRHX%-K&99U](5LT0-(WY-
ML^=4XG/E@%6'T?<Z>>]%^%(9IEX"TDOVIG&9&YWL#7U!3@E_0F-.3:.X]0T#
MGFAM>Z$";\5>CIH]12U +Z5O7DJ';7?:N(M&!EF)/QXH9Z$6+RUC841!+;)]
M^-^WZK\-OU>Q_0V^-M8)U=B)FD339G.3B(4^(FJZR:")F'3D:90MP\.KE#TT
MM_YCA<4@:42K:R%&FQ"H".]3U6!PST@^@0JB0->F]AJFV&"EFH/2%A2+O]>?
MVDHHD+[6@8SCQMT=/JBO*_2H=?R H#K"S#_,*UMY.WG4%^P=6Q.PL-O%CZSX
M1AV557J&+!^]=\&80#%&O%'ZN=U'17/3'X#$L6*C]8R\SX_SS<Q2IL^Y=L[>
MG84- @\SCV>.^!:<F4I29]]QG-K%!H=:+M8L+V^;_==J\,FKZ9O/.U'##;0Y
MKR1FH8]PKRX%-!F1+G+ZW);A4D9T&IY;%Z\P'4P?,>B:B#$FI"D0S!0T0$*S
MDIJ%%U'&MWJ0-'DV&%"S[UF%8@71_5^V8@M@USJ"XR[BI'X*[D 5>I!)'^"V
MCB+F'Q9V+#E.=M0"QC$$$0^]C7_/5!EP!/.]9YJ8]+A@WD,QK1->EV)^_(^)
MG_"K.5;, P=5-I6*#+E*<6K)N.'\8YV7KC8PEI9AL]^MP%:2\PV"!LA+'-S6
M2=6VU=D/-NT!YPQM.%;E%/:,^C24ENM<PF=E;1;]RP)B<!_C!-\$;KY9)(R.
MAG4\"M=^T>G, "(.365K&)LQ:[ZRZ!HWZ>1K'H%()+&3&"5C@=A=Z79Z"Q7N
MQ[-S:-G[P;FXDWTGK/=RXY-2AQK#/X&SL<JOX_+.N7(*=M^[O!/-3C()S;V/
MT2+//<C483;XK3P-R;I3DQ'!XWO]:BNRD:TX'UFL@3ZKG?[L%=YHFMFRHN:_
MS[C5Z9<CE?H06?%EPK]H$+X6\7W$APZFQ^GE_.)]E<_%;,KK ?)E\PX(E.;Z
MA:X4^>Q.)%_JQCM]295Z0)9[Q3IF8B*YZ4M>_C$8)'-FG1JH4&#;"*NKG"L7
M&@O4Z.?@6E#L9F<(6U-8P,DTM_88:>QNV*(R%"4I+QD7I;1TNIEX<YV/\PW#
MHRQPI7N!,]V1$"M#A2G%&3[/U'@:"N]X3K1.<!YT>+D)O7[+B6?ZE+>"CZ.O
MNC#BJP6;M_,WMD#?6':@8-]/03)L/7!Y]X;F2)>_>V.P4.$FB9&P5IG'Z1V\
MSMP8US9:'*#*G_'DEMA^Z-G:]R+Q/PJ*FM^8SDZ^+*HEN*FU!Q=J"*$J?S1+
M_7:+O;BT'=+NN>/ >+W4XM$S^0.V%LY:SDUMS:FEI,E,'4T8)R 5[%/\J9[&
M?H*MH3)6E"*_2WX;(%,;?9^>OY0$5"Z<XEUNHN(9#8O7+H^'S^=*7WF:3<TL
MQEV3R2+ .YY)A8BJPL<G0I;R+[F&!V/WS;BO\RE8A"[/Z^@U-#1@\Z;VP8;V
M'WT>3;U-1#S%P4M2RM_\I1>,APL^N<4)A0KS&E9_BP-@M'U%<6?J"CB,%\?Z
MN0E(XS1 VW7TPE]0#1I1Q(6&))G.A<(D5@0\TQ"&EEC5@Y3XV7LL\^)/48E%
M/5[KA,60R^E5?)R*VQ8(\]KZ_-OXR6Z#!7XW3+.I9ZO/KL2UWC%%A[IM]>"\
MK!+IBB4*@0!X40C,( K.TC7588)MA>\_YPC,)L7/MF8Z+(3PYJE.6"*]1!6Z
M-6355:6*?"'*'=JQBNGH:N-I;)YP9CWZAA5>'E?F(@\5?,BTVCXVK]%L*,XM
M+GS=:&F@S.>A8 40<Y#+%>?UF?,; LQHG',MM:6T0'+ZYC*BQ@Z0C79Z,Z&^
M#0,K^;G8!HM(C*;<7FC3V1/8:;(VN?!,(..8=.M+9CB8NNO2Z4QD+&X;ZZV%
MLDCBFTT4EN>>H51Y6G[A-:-3)U^]%-MS+F@OQ_-+OC#?O&I(T%0-?'LJZ ]9
MV0D]2>D[OA6,-#Q14CBP YIW$HND_VH,._]S"$D@1QD] ]'THR9VU-V:LXZ\
MB8%SKLO=$2/)EOZ(Y2=']^<JF L[AY+Y^SKK(\F?G>S7:]&%J1 CLX$XR<@*
M]?Q.^7.NJD54;53K]G10(5/T=X%^%^AW@7X7Z'>!?A?H'Q7(3V3U\IH[*^Q*
M>AY;]VSD+=S1UME^I+:QCGA1'U#B-/')**AT.%KB0"J#)YCC2$%/.=98J4X0
M "^+75VA>, [I5Y%]3E_O=\PWG_7]MU?EN.1]K<ZZ*<7GU3\J!RZS%&/#,>N
MF*C)'LNHUI*?ZD N@1V,H?I-GMW6*@O153DU-%8R;.K[N+ #S;0NQ+&99F,=
MY[&M5Y)H [Y$5*YG-E99\&,!TEP9U*05,'NOZ*^L Y3Z*\O]_'^OZ?Y_YXO_
M'H' P4NS2SET$3JL$),!!4ULV:SZ?A(8%3A4"%."NOO.-U@OBJ!U[596>M,O
M.5G3;-TR:2K:0XR+#YD885;O*G@H0)2-BNUU!K@V#DT(@D%=LMEM%IT],SS*
MRM&/^G[:6$YC"DU(N:+UP HF/V0U_/*?O?GP7P;_I$L+_T_XW0"_XG<#_"<#
MNC7[AZP3S4^IHYR-F>NMD0\)O>YM1XO=H5'2I[>FJFVNOSL]&SN(^M/9E;V*
M@'.NK<-;BWB66>_'ZE,2%9A!^3 '?3,OUW9%MQ.!/71>]J?:[/IU%-0$I";Y
M+!;F\XO*-ZW\]-?=#<#Z#]M #]MV2B-BU6\PI,!EWOE7%<IDZ+SF.5^UYDI$
M -\C#F:YYZFQ'?*5F8W7-E(P85#VWAWC_'57679Y:EI;;&(^Q0FHZQ2@*>@R
MO!9E6$H-_#)E9Q*B*F;UQQ/YK7[Y.P+_<RI/__"]+Y\B!=W\Z:SI*+[_\RI>
M$3I82PMV&^%4VC53:# _&Y/'M-[G^.DI\\J."=80I:[$;G^=9/M&_O;%/@O/
MT[&Z*!>4,RQ@4CJ5L?C %DG%+A$0!((,MN1R>L>5GJ>;CQX.Y"OK^H3%3>IZ
M-4K73MI6:WU36*O95.Q*',?031F3HX@2[>R"[/(&/):058"%8V#/9%XLZ;AC
MMDRW+KTW&%2C0;;SG&WUGWB>\3:W+\SHW,ULO.[8IIS0$JL/B&,E1LD(%:YT
MU,EET)Z/'6=MUQZ+ N]AT6,F+C,_CHDN/NA%C*]WCN]+/"ZIAB9#"^9S 3NT
M^'G1I!*)U+CO)M&+B9DO#6AS;_'#5YO;X 9/YC/ZH)_8=VD;!F$O'$ 6Y?JC
MAE4,Z_Q3Q-,-%DB^=G$MX]OU3B'X 05:!:F'2JM8 85]6,EO5!EZ#SML)BAA
M%*P4OHN0F$&4B\0G*T#-AY<^E:1&FUO[-P)$P1KV+[&%0MGTL@B9HJ-'CL@?
M847&7H,: F$UT>[;>XID4(U3CV4&+T.EOS#L&:O4M=0@5&I]GY&,'V=EW(\[
M8JU(P0(:E5& ;A9C@HAWY#>T(P#.N>P$XSS#AIO8JEJ(BH?#J'R3EMTJ4YA"
MY/#30$]:&F%M!I#\]5'((CZN)F1GT.(7ZVVUDZI!NK,8*P6CJ"P:VGG3-E])
M)\+X9>EJF%3-7_;*4O:#WV9XD3P9DRR,RS@[D9P[15J:&=K990Y3?>!?^L,2
M.@8?.M=5T*[C)^<=QR+(5<%".%#9OGZCC>'@;%;W@I)_R1ME(<3]-L&7'1=?
M-2ML]6[NS&63.-M-+RE^BOHK#SH-VM)J==K3*O$J;G&H6=5B4./JS1\R:;?&
M5Z>'2JZM11ZOHR:$3D>\8XV%*!YLUQ=+$U3>,U)X?$EKL3MA$LZ>7 17 ZRF
M,E)?C?K7/NH9+8%Y0]X)'N;8-@_U0(;CY9F0*T_]WG9@#BOB0O-%U* OJ.!D
M36T1TSRM]/5=A6[GB>4)_1*\?&9_JYL2K++B"S\+4]7J+[%X,B/DD<&K?S_F
M-6Y(54RMN:-TC.;:G-XE6RC^53I/<O00JY+%GO8YUA2ZVCB@ZBBBJ0P :4Z1
M3FJ9<09)C,<\#BYM_.9=Q5#NEUE9F3 M.8W_+:RMQ>GY[[7+=%,:BOI#9DO8
MSF<_P;/+_\"D>.%$CO[0/@DI1X5GWO$OOG0@_=D0-8@R(8DKQ(^LX4.%@^8H
MF1\.BDJX%_$JXQVH,/&:G.]^9O>N'$8RLDO4K7B *1Q!\$V.%4\,_Y!HD)7&
M3/+U6SS<KS9"=RRGI$XH2GB.SV[MK17O;YP1RIK&P6'!YMW^_OO;6MXK"ML/
MLIMHU-8%5XY#0REV,3.:J3)D OXV'Q3WLB6WXXP1>'J,=S-+58@[N7#.90\X
M&/D<I;@.<^8]YUIIF#[]<.2E SI9T-M'EFRPGFR[5YYS_73.M>JA>_1_0ZM.
M92?NL_\&=-CSZ\LE%05=[G9^*P:S^W0IQY17Z/2K607PB.UX,-">]_*&$US8
M@_R*NM8QAP1O6R&&"P].UQ?1-^B"HZ&-$C63P+?S.UJZSI73%8!.0ICDQ%;)
M:\N9F" F3]N77[SN\2>=T6#^>M*89\[C!MIE*IH>X(0AK^8UEGJ$HL+ RL&O
M/_1Z[/"!YSD#$%DLO.+Y-6M>@)JMRZ/O?OK?G$B'U.WH%_C\7:KCY':^>9,Q
MT6U-FFBZXY@TG<CPKMOICX9:&V$C&\%*M<%S&&WMVS#!@^:#]:/X_?SJX\>$
M]U:O.CT4[7&R5%[0+5R9S)'\:.74E/I64Q8EV+7.V*%W;OT]2/W8>CZ7;*X#
M%B)N(16BMTXS$^(28D1%7R__*?!VB64]9<@S0$!A)"7T;5WC\*Z1\)EPDSL6
MF(YTV)9"FO9,3O;):[L(0E<L.9C;0K=7Z +%QH'VD.P7N3WSU5L#\>O^)20?
M[.RIYZ8]LAJXZN-_=*K"&EWI5Y$+$&2:PC35USLL9#Z,,^P(I4NSD=B034+(
MG?#O&M%&S%D@0M1O,$A(IHVV&E[.Z>8=QD59>SZ9)Y_<3#:R<TQIY4D.EM;S
M@@JB\_*J&AXTIF'N!#1$SPX6C)YS65F=<^W6:</"^NL*L#X<GRDKU5/5IN(<
M'IZAUM.UN=F9^=F$6TD\\[3,0?G5A]+6\""V^O(DI";&%@'F,"EK;#,J-Z);
MF']#*?1.8HP1F![J@7&K*=%#?X\"732XGXBB+^PC7ASMK<UWT?@;H*2;6T</
M>HX,T5$Y;-,7>?:0B:;Y,],O;J><4N-[Z[H"W\ K["<H=Y((V8"W/8E73#IE
M:WI+H!F7MM_T\LU,4<E==UR&>GSM1+4U!CIY*1V:5=EM&;W=-ASG#Y=<.Z[$
M1%B9)@ZO>?/$6/LP/[(JZ%EN#OEA#[&1=MG%^ZGX!2G8,Q^$;7W6BJ%K^;#+
MQ_=]5JURGR="L-85=B3=MS)V0T3KHB<*I4^G_\C09S]9Q SV%ZKV"4PY,(PP
M5>O=PNFR9H(/-XJQP*IDA#JTBH>'-X6.CL"><UVW6]/_1&:O+H3ZL%2LJE4A
M5BKO05:(AA%5$T,LSK00I-$GN@TO!GQZD71AMV:+LO7@U\,,*.:H\4N6LX)]
ML-"V7'Y)<HB!;5$TV:-RUECD@[Y-!^W:O*W$Y$44_3XG.DJ6%?O>RI0G%0LK
M$:B8W?4QB;C .#LP4YX<05!\W5;)#EL04V(9P_SC8W1,X)X&'-=R.6_F)#3\
M454J/8RUF+0O [5._-ZBQ\^C0O_[)T8 S.YML<BD:Q4I]=%ATA@/S&:T[C8<
MNM) 43>O8M+Y)FB&?T%5G)5#;DP,:X_G#@>D;?L?^9#2<"9T-;+H^U[E=LCH
MPB[4[.'SZT!^[1;(+@9-I_<9X(;:\W0X-U/,+C)QH\YS5X/E[&Q&,] IZ.WD
MVW-5M<<*Q\-S&/DP]V2WH>!C"6Y\\(%Z33I=36E1@<DDL,Q'UOST5@&]->S<
MJ9O^6,) $(G8Z9SU,;YBKF+RY=P,;V=N8F/J?&7VT<$5*$\G70IH5GAD5!>
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MT=XL\J- 35LO1H1622+042TD91?.=!NQ8<LO>%V]VK5_HUM)=$/L5#Q\KV<
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M_GWGI:=O?,&->I%/WJ9$_BARV8$U<O :6WC9#Z05Z81/TLPN.$- BZ(-[.Y
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M0F:=6#[JRH4HI2@Y=%FS1SQINN#IKZ>YEF8MF9A=,>)5)0G8C#,@@#?>WT
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M@YPB4V? S?Z:D-PH;Z13J4JM@8"Y2G6B-]*QK5[ _+.C>H"06C7ZY?L$@,J
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MU&GQ#0CU7O@/R[.Y%$APU_-GE3]#L4$F^@FC*]-+C4 V]=I99[8<"-/55*U
MK"4;%Q6_Q 2ELI[L#ZU&31X-%FZX.?W\QO1^=48.$I!86546E"4;[3G2FE>H
M&LVNA)6WE4'S+"(%7+C7?1MYCR5HJSF3#/7)4M>A754/ 10CR@E!5.X"]55,
M4"%T_K/5C1!*088L/P*_W==T@2ZNPP&%$@/F+:EIX::W5<UN.NM)-Q>WF$T[
M'GC%/.WMN=R0]E1\AI-[2TUU0V%>1>J^#"?1XRH5O3H!J<[C$!Z>4O>C0_LU
MPN32M:!8.T/N]5?4TZ6-@^C&NP&\&R3$LZK7UM^,YE$%F8%5FM%3L^$=?1HQ
MXJL_5%U*7IA]L'KOQ[B_F7C]TJ\1*7;'S?74P9(_'=]*>-(%-DW]F';.HQPF
M-#RQ':ZVQ24+^=]BSDOLTU+KRH4\ F'6?.]O#AGT KA,[4C7M<7=^NL/20YU
MC;J2.TPK=0Y#PA.:S@$L06*G3 I*%!8A40\\9JXONEKUN]%W_\RR!U[[%PX<
M[M0#QCQ5"&ELJB_W3$DXB<FQ"&<U>JW=DH;S<Y$;^U=4'J1(_/%?ST7^"1DC
M^-2X7DQUH="(]U1UU9V*D\<='K/2^E]53=B3L[2I'')=H)P'23PDK6_'/#B[
M^VBBPG21^YA45PY>Q'C+J4I='AE8UN24#R\S'O)S>QM@N."%0</@47OQBUUM
M!2E>SSSR(B0I 34SBUL[,=0QO.,27&@T_M3&;KR'_0;IN0$[80CTD(-R+ %B
M$8JC@72AT9#\HH,CXFIY3G3;HFM& <5+7A2!MG\=H'H:/M3<%\:2="#C[6/M
M,95@%Q!VS<)-#UQKJ3-S0'90E9NR1S!Q RKA!W_\$"*JB1Y$K^S-&NFH@C1"
M\/AR5^!@P9JA!_^[[[F:%/'>=:M9]81LUEG;^,+C=1.YTZ,RU$!1'XC_EK)F
M"O8%VZ7JXHL,Y4"6"IA\8[(L/T,-;]'P5[S^Q3S:>2MW#8C# L8)$6FX8++$
MPFTKDJ()>VQZ)?\*7JX&2+#:_38%ZQ%!]M\?M9/AE 9[I!.\;",C( U93,1]
M0D2DMO)O.P2WUO'=5V?]_8),@2%<<(IL_G('R,C5%/;=D>8./&JJPJ&.X^"0
MY@X+\!)X.70H3-T;%0"H3%,$&3DTID577AGW2 DH!H 1+Q9>V-M<WMUKZ]IQ
M9%/.><*FHM;TK6[ IC[ZRXW.N^GFOGZ<R U U[Q[K$BV0/Q@GQ$.GGD6<)=P
MM[EVDC:->-DNTOE)M6^*WGR'V52!2@)R:2A>54,;B0MWGNQVUTR3XZQC"VU
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M2-@Y3TX3]IWSF:?O^FJX^>2:[I67-6$0@I_.8.[W%;XHK*TI&N6+Z0'F7F=
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M58QJSKUR (U(K7/6[ZD=UX;>EES?Z.OG/S4[8>K^-(O660LC\PTP$D0S"K5
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M,]$21]'-&K$RH[%L78IS#<W8/C+&9PI9C(*E 24"LSI.>U/080,\Y&0!U/W
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M:,\<V2I[95-[):;1AR?1+GZ_?N;]%>S7PK]$9.T[$]^'ND(&0(F]D6/<(,8
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M$O?P#8<A=(/-WP:Z(?0,8[W0P*8^;"I260)MU;32*"=>'$,:4++DLS3J, K
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M[AI81.9<E]9S."PS&3+8;PMQ8I_6[]MV^G;-!7ZM/,,KA J,SZR<+\Z^9_[
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M:T@6B9X1/+SYV+&Z7"</Z#[H$$_]7/\Q0R]W/YE955DL=FCZ\4+DJ&-EQ3&
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M$4HV[:U<^6%P72,HFK"463F"I>*=GC+)0B(FCP8W+9FP(8-VWF=--IRI#=5
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M?FS"YQ?8Q\R%U/$9GUVCZUK=*Q,>E>+;::GJZQ_9M$SH=B&--R?AD+L^+<<
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MZF*,NQ*P#@CZ)?A]546GX:XA3C<<S^BT.'=O2Z,B/7UG7:'-C4TP_Q=M&NO
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M%35CPMY$HR<439*\\=WES_XE3UZ"+B[3$_4T%I)8S)E'2_MD_H-]SPDMR#C
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MMV[E',E=8QI)8]%GMU2]EM9/=D^W#2\;)"N[0U".6K80E$NNN(#B\.I96K:
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M,M]Y!].Q(Y1HWT-.%?5/<SMR]]<2W1]]RC6? *)&,-<&M-'.C-HQ!@NK2IP
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MBU:8^+S%.-Y<UW"=\.KO_7)J0(@+]YRU[!8@!RSA/-%"P=1*=*P$O,:R]X+
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M4^^S6E7YILJENPZ?&_LR'YYPB.B2+Z>F'B]=RRUZ)=(8 ,)W0X?/AZ1'8H=
M[+ .!^IR/BE_J;OU"1Y-C=9KXWM:39I^PU$P=YSQ<NZ/F5P><B*7SM;*LK5H
M/S5$=8.LYP/KQBIFM"8N9QM!^R=BZAJZ#TL?J(8_?=/K'%C(NO^P,EZY,'"V
MCIW>%!:W$N:)L.Q>&PW?FP?X >U'>N87N%J@@@^5.KD%+=@(5RZ!67QC$E%
M&AA;R?:4'+\+HN.G/_O<SI_.J'2(\U^N_'-Z3OA4KYC7+_O,MLA2S#+)W+F!
M]::O1_AZ. RT+.]G\>64#O=3=J4=3OY!&-?-P^6E]6<X*@BK65F!<$X+"H$-
M0?L'7P+]H>0LYOW&XZ P>%#.J-F5?#:DC#J^#+07."!T<)<ZD90T9&'PB9!N
MB9;R+V:1RLC9IC*%'!D" -U\+@8L0,8+I7XZG6)@-SK^N22Z/T\-]^2<U) $
M<,UJL08T?,!V'J[:)M/.R;AIU::9VP4(%\?NV^INRG1C[\RYL17'TE2R4"03
M'U;/&A@3UH7;W>G.)13,MHWQEJ0PLVNCM!(' QI)V&VZ0\A3([[X2YO[7MBG
M<2K+-)EJ',;5W3:-I'TR,I,ELF)J9C%!&@-/KZV-*X<M>F?5-4Q$F#NT@\HV
M!^,E+5 :GLL>T5RC(_^57<)WMH7]_7G*A-<U[:Z=SC'OTD5HA:H*1!"NZ/.J
MOO@/',1#0 $F-B"@V(??R/#,T[ "OY'2F;M%[-!?G")V(!O6AG0ECK%XMI;I
M, :@&U-&J-)S7YCIF++)/KYXVW F4Z]':6;U>LK^\C=^-'^Y($K B'Y.Q<R4
M\U57>3BDW=W[MB'!7T@L12VZ(C0IX 2A"O'5\<3V5TTOW9I124,;[](*!G=B
M&0^$N+PU+TXHW7AMG!I I[3^<HU:4'BBZ5.4ONT%Z?79.]E[VUM_/Y>"6_C+
MPU#8+W<3YW5"=_:,-U6MY:Q>AWK!E>$ 0E?+D]:D-X%N!$)7Y!XK_<6]-WY5
M^._X.9U>X,V\2(-]-GX(YPCF@>X^ITQTC]PUQ.SX7_O6!/!J]>KCP71L4G%*
M"-,S8B%IMOWJ^I 5;%5@'PP&2:FE!&?86XL]A3;F.C<<*;M8#GTYE?'TBFU(
M5"/RLDQ&RU3(H&&:^0VN0"JY;7I5:V._VPMP/<BAOU4^XW4MV7:PB]LU^/QY
M65_IS=I%0>X5WAF+[W^Y_* Y%A#3V(-LH".U(4 (!'QR01R^?DCCGR33KV;(
M8XB)2=N([QG^=Y3^4]_QO7"9-C.MD Q<[@$YL$88;@HTHKS+BNI\ *P2S95
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M6+O8Y<:EYO_X?Z5\,<(0.<7&<?RBC_;':),1C^P> WTGVD]3XWZJ&&WK_M*
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MIOH8SN&].6,=T6/ST2Q,X<JN8(P=&1;#/XP-G;P(SFK6E0"7N1;K%J)(:B5
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M/._(^FFN&V@V&//E5*@X**0>[N$=?74ZBG?IK04)B5*\#F./2N^^;R"M[-J
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M+6Y VA.P8HC>GE1>^!P%%QT.+44+>J&OMFS @(-/$^1"UHM>F $@$HVG4F,
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M] M)*R;V?D2/_4Q*\SM4T-+HZ'O8K!8 F#2K8%[3S#[!KM;WKI/8AM+$:T.
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MX]%A5TUV6##F$O^J;43O]0W'ZU[REC<(B@I6D6,4[5)OJA;!V^>AND::=RQ
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MDN;QT;^OD7\X;#.MT/7*[>W?_OS/+_G#4;)AFTPL*\W_U#3PHM^AVE^7ZU,
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MHC<;>R;X2IS ;7RIML;\='.Y@G^>;=0-)F9\G']=$-N19'K5GUX\T?:(:F4
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MK9%2I:]VC"MS5Z)#HZIK./5[W7J'R2J3(YBR\*+- DX(#2J=$%I]Z1[,BFV
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M:]1NL7^_S]_G3\^7WU>E<LW6_J*YKT'8OV_*JJ[NJW(9WI+^5!T>^S.@6.N
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MP@.@GU89OZ[XDTJS X5=YOL$6^!6US6M U][GQ('X=;(\LK?)2Y6C8RA@!.
M;*W0D\K^BP6A ,3NAZ,@RS0]RG7]ECCKSV5H,TD>HB2R,0Y=Q!)9Y,B%AQ@[
MX@2.;=M/DX0Q%L-FXBF!?:-4(J"'I\9!16?-.%\,7P@93RV"46S*F5(#NJQ?
M!&+$B8L#6ZVG+,['MG;#:'SFT,#QA%@%'&'*,4HB88O2U,.<>FX<AJ#"F'&0
M<RN)-K(G4X@[9 Y#LS!UH<!#-55AEC/F0]7SI!>K4VU(52@ 7%1-J#/@6$4
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MIB<MJ4$!9::A6E%8P+0 I628 +AH'.!K2B::39<5A@-"3J3@\+?P&/%]0>3
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M,2=VXJ#(9;XP#-($$2?T4$)]V98UL@.F9!CH@9]9@W0(U*E.;(>"1G!?G:.
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M8)_:T3H/4V#"O(>#52.Q5RBQY95$9(:D/3C]AHYA .!%CV,X0XZ/98T==),
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ML0L.U_>"FOGD;F!:'Z;TL^EG$2":/IEPH"]R3/.4F'@_\1J![\E,T(MNJW\
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M\^QNL^:.G?B.4"N7+'^NA)98DT?53+[S.\PL> (PDI M"1HY!^9'BX5Z:M\
M'X;ESAP+@+(W3KWUNT3!4+G#.(U:B8 #VRZ6$SA.VGYZH,+3FH?C1J;BWJ1W
M_#DO*ED_]84_UCUW'SSF8(Y]&[&0VK*_H2\'RB0HH,RAQ$]\CX(:E9T'-;?,
MUH#EB5%L05ME"QMX0IYGE^)):80)0*G=TK^#:GT9HQ]^6HZ29NK4/ ]HV=-S
ME."34W1\Q91 KC2?I:'-V8>-3+IO+I$:6[Q-R.\2-Q[BU$X<GM1M"'V$A4&,
M2"3L8!KZ29*&@1_8'CS("L!@]GN@H];4%N]RN7[:QD(5,P+UN0P)+L[$.V#@
MKXYL-&A8#1[M9>]%&S2YZ)I.;)/CYF:B3H!L)F9J!J],,E4SD*3!$%B0!P+@
M#0(P&O3W!T=T-M*SS;H:JLN,W<GLNW(O-")G'3U@QR9NY$6(^2E&V*.NT.:>
MC1(/$Y_RE'NV#;'0Q@#.K+([\!?[5TQ6-30;38]O:J::26[ E/"VM%'>SS>P
M#X/-9N?%J1)JR'P;!;>H$:=*_+$II[Q.,REV\_R\KAUKLI:-TSZN\V_76=W4
ML@[&=J-Z@I2Z/&#"27-D>FSJ.-))<Q&C2>2'ML/2$(/28]7@SJP)]K&PV*Z!
MIW!ALCQ#5#8.W$X9V6NJ^&=@)JTBD]7TQ0RL ]IN^URKFRM*%*P]'&:9@02D
MVU3RK2+49=-P8:PX2<@%+H='7F^JK[R0W7%_Y:0>GZ1>/-VS=.Y+#@GQH)=O
M"WJTC;@2W>,AUHDDPZ17GUI02'6 )JU8:M]^BP51!XC9CYX./?8V-:**E35W
M^7HM/@>Y\,&F/D^('Z/$\;"<.!:AA'*"O#0EF#E^&*1LR;I0. ESNP\M%HBT
MQ7O;@,_S8/'>C_*"%:V,'_JU 0T6@T6>D#K.><R@-WLQ/T@9IP8!_U2EF_HO
MR'2YY@1,=*NY+AD3@ES6)6,W1=W&6S#] =M.Z.&8(^;Z+L*.T+Z1G7#DI!$A
M+ HX"Y5ZBXP!FOGH:&N<6MBRD:E,]LL+JX,/K>TZPZYA%6^2"3!%K$^_1J77
M,'$3JKW.;+QPQ=<P>:=57R//3VTT?2F L-5Z(\>D?>%T4]2!DJOO<I8"9Q\%
M 5(';9H;C9OTBA294"LR2Z]60<UHEX21)**IC<+ (0AC&R/B"8$/?)<0S_5#
M/X)%F8RB-[-RV$?1:G%\O; Z'*VKVR_6>[*FFW4;8QF9,K/$"U.T)=_L-<#4
MD^DW,*&OM$E&&>\K;02Y-^HK;9*QY_M*&X6BIYH_DE4A>\_R-A@AC;O;?+VB
MK\V?N\[(=LH\']L>\E@2(\Q]!R6Q\/V#,(GM@*5IR$*(UE6&/+-"E7C4792W
M(2Z-3"QU-JKIPEF8 U-S_7RYL!H$K-_;_\^2Z@PFWY#R4H>[J%X"L^-8Y< W
MF)#X=4.K/.&%8"Z^O3P::D-]0ET:!(B3$"/L<A?%J4>0G09>$/G8=5D,SO,:
M #CWG4 #63;XQ=;MY90)2$-<&]89<_ ">%EPA@U3FD4/\4,C!<L07_0RKL"?
MB5Y6E0*-H"2JH?V6SYE2H*XW14IEG9[M]&E%DM6ZMMG>;XI"?!8/:53GHWLH
M)=1'.'8B821ABN(HQ4Z4$H^Q"#)!\A0$2*/!)T4V#91I \M:[\##[*$>UJ@9
M/M,(AJFM/5@75@O-G USGA)#QDH/@$6MDO,$'IL? T].'JOXKBG6/+8SJ!,3
MQR6(IG: , M"86<(.?2H%_NN8_LT=C2'*_8"G#L#J9FP]ZZK^)X\:;&?:P [
MPQ O@#=T9]@P??AB/S^T1S!.YLND08SJG\F4>8R#-&I,9>S?[ZUF,PY2-S"A
M<7C=%&U'ZDED,M^[+42O';IV.%EY4\\*8@]AB#E/9!=#SW80QO(*S \(<IEO
MIZD3.YX+=[#48,^M TDS\:]N^W-A/;4MA5[J"(7\>=-$(V^0T=$$:AR&*$GC
M? /J2\FRF[1I$+)M"M(&=6[2KN_(S=PLT]&CQEFGJ5+-L%!3T8*8 -.Y:EN_
M@?H%T=ROB6%;P/-6KS.V>EFQ#5G738X54U8/5\VL+7? %+/0>^@:UG332((I
MLAT<8RV:SZ.OE7AZM-5B.:?]).RGFYYY0B_D(7OHB$5?+S/V@;_P=5XW@+QJ
M9N&T5K.00D(PCE&0^+)AHNVA)+ 9XB&-TB@.><I /=(58,XL3!T&=044V^$
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M'C_)G@2?5B19K87G]%D0U#3T>* ^2UPW3%# '(9DE30BMB.\&AH[28I#.PU
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MR\+V);6U?4E_SNU+.G7[<KH _/"SU1WW@=/-#UZ\WZP99%YV_PJ632-L-O:
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M5513O3!'Z<W;$%-5_+.NF,HW&@T]7+X6RY7O!N[=FM>;OR!FPC0$.2*,">O
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M:*9/GQA:<WW.%IMMMD^?&.WY/KW73&BT6_;K:-KXEK&XNSSG1?L\FX>^3^2
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MX8@&//%]%P=*/3%@9"V[3((^JAAP! =.7:IR-:6@:1Q)@.$VB@_,6(]!,Z7
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MW\+</H#$ALR0"L59[0P @E-# KEULJ6H*KUOMMLWSA813]R(!3EB4<P03K(
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MT__\;\UOQ/]D8O'_^=_^?U!+ P04    "  I-PY;/(4[+*->   M>00 '0
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M8#Q:?>I16"SG/BY'&8+2X +1VD0BDQ8D4)Z(RS0EGVB6--[=?Z%[@82OQ+*
M^-?/LV^_X@?_6GA1_K)BRHHA#Y:[9,Y^=*_/X2?\W1&W'HD3E.28'9+-,G&:
M2J*<M3Y;KXRBG<B^O=I=JF\+]6@>?YG-$\Q1D:R7\_/X0,!W(7SU&[]^]7/\
M(!*_C"=I_:_S?'9>0U;+607.78H%R?W++[CK#/,YI'>74GET<ZN=+5&]PNHW
M:TC\?U[X.7[BY,<9?)W-ER/C4Y(!* 'J Y&".^1##(0[&A,S28H8J@C_WL);
MX8"WCX,N_&P$$A]@/IZEXVEZ@U?R2"I'O5224,D4WI0J$A==)%E8"\X(4,Q4
M <2=9;>"@V@?#OOSLA$P?)K[Z6)<&'\%:&V1%8Q1HC1'CA@O21 JHY5@J>*2
M:D5EG=OAWLI;04*V#XE.'!T8%<?3Y7CYX^UX N\OS@/,1RFP'#0#0D-BJ-[P
MQ@L6)+$:I-=X&SJ5.J'A_HI;H4"UBX).'&Q"^F?P>5R8,%V^]^<PTDHJ .Y)
M,(417 KB.1,$K$-[QRC&@JB @+NK;H4"W3H*.G"R"22<H&L_1Q6V8OQ'Y#^\
MGEU,E_,?KV<)C6&GG=?*D. $)])#)MY;15+.CH-F2HENAL,61&R%$],Z3NKQ
MN0G8?/+?3Q*R;YS'ES&+*TUH)?K^F47"K$7O"7(Y"3(1FUF";$ PL!4 \\CR
M6T'%M@Z5&KQM B1'*:$(%E?_>3>> AL9G@.SV1 I72(R1$4\=8*@LRV%23ZC
ML50!(!N6W@H<KG5P=.5IH\#@(^:- P>>.!"([BC1?#)*$^9E,B& ,=KW @R^
M7?B*OCQD[,;4EI#Q&O]Z.O\T^W,Z4C112P,G6@2/%A6SQ)MDB+ \444%F%3#
M-GVP\':H:#BJ68.A+6%B932=SC_,9]_&TPBC9"E%MG"24[:H^C0ESF=)?(HZ
M '[)G*H'C'NK;X>.AF.=U5C;$D0^S!9+/_E?XZ\KHUI:J05G91>B>.4AX ;P
M2T;! \)><U-1<]Q9>SMX-!S[K,36@<%1M-[1'/R*[@C",T\-2>A2$<DT)X%[
MO!659])G[ZAWG>!P>[7M -!PI'-OU@TL\O*&/OGP939=Q^:"9T%ZFH@ 1=$X
M1J1:8Q0:0\%&Q= (<MVTP/T5MQ-]P^'-3BP<6/P?(5[,$;J,AT_CY02O,H:V
M#3-H 0>%VLK10()+$O_ "TT9*FSNYE;<7W$[\3<<U^S$PH'%_VGN2Y[2QQ_G
M839!W$:FI>(D\H3*RFI)7,+K2CI(1CJ67$?9WUEN.\$W'*C<GWF-'/KC[_&+
MGWZ&521>ZJ2L\X%$U%U(?W%]H\ _0%NF*>>:=TN"V+3J=AAH. +9F95-N .O
M+^:%79=OLP72*(.+Q2@;%R&COZM9Y$1F=&L\:B^2J;2 M&:HXC%N7GT[:#0?
M?ZS VB8@<C+%3T-VC+_!&[_T5]L:J00VL."(4!H-'$4MP4N.$B7QID,=*$V5
M]XO-JV^7/]5\(+(":YN 2'G@G[_V2_@\F_\8"<424RD2QYP@DB-CO(1(5#96
M9L^,R+P",NXLNAT@FH]![L_()G#P\=Q/)J\N%N,I+!:CY'1VW*%)I(LU;%0F
M(7!)-$C-#,):T1K9,G<6W0X'S4<;]V=D$S@X/H?Y9[SR?IO/_EQ^>3T[_^JG
M/T:X:0Y<.0+<TI(<FA'.7I.LC0[1".I]#;VP<?'M<-%\F+$[8]O Q_>;M,#+
MG-&1S"FK  Y!#7CG)2&(3]R1Q+,!HSR751*K'JZ\'3(:CC]686D3L/CX!2:3
M-:AY]LEHKP@%*HEDSA";F"0L>-1X $[F&@E5M]?<#@H-QR,[LK$)$"#AYR7O
M:Q;__O$+\FUQ>K$L!6 EX#+BV@JGHD27*9>D06 D:#24C:,&O'7*4%T!%$_1
ML!U(&HY:5F9S&Z!!SLW]Y&2:X/N_PH^15%YXS1@15)0D<P#<0*3$> N6!I<\
MA1HXN;OL=M!H.*[9G9E#/V->>M!OQXOH)W\#/U_7HEB=4JE7(X:7"EB6$_$,
M#*%.>)9I0!.IXY/F(RMOAXF&XYQ56-I(><_-)M[B=Q8CZQRZT2P31G,F4DE-
M+)= .$"@VH.6LD[YW[V%MP-%PQ'.&@QM"A.7)O/E)KSUU##.2.82?6X>D!\0
M(P&71>2&*6ZZ138?77J[.L"&PYIUF#HP,HYP!VFUBXE'6TA)""PP8K*C)0CG
MB(L9K6CTKC+7.5CH%L6ZL]QV"&@XCKD_\ZI)_1]_?<"\=_B-CAT=IHO99)Q*
MVXY7?E+Z4:";!<O%7>IW[?+PV(?6[/RP%>$=NT%<+,AG[[^.5NF11?JG^>UX
MBHN-40O,+J,2U]!R!HP/RI%43$E)$5\V9T=0/U!KG98N/77K9K\(*P1<+7IY
MK&"R7*R_<W.^=J%K7Y6Q7N-HL4"V7N^2X4D1BE(2*==H'EE)7 G?6NE"2((G
M-*8K[_(N!</TFN@-"6LE4X'= ]XO=ZF_LJVO-V&T93YS(-Y8-)\R7I*VM-7@
M*N?,C ;AGDK#V1\S]P@9%CI=)+L1)%W8W !67OO%EZ-I*O\Y_L^+,2IZW,SB
M:/G:S^<_QM//_^8G%S *5J040)'$#;IC0B826/(D".#*<J_RD]4?^V!G*\):
MP%(G ,SZED8#$/LPAZ]^G(Z_?X7I G![I\LO: S>9AYN*83,K2$ZX1&4Z/H3
MYX(@,3AM9&3>A-K7]A9D#=-)IS]XU99$ ^"Z2SQ7 L J02!Q7RIF2HA &&)X
M-M*XQ)2O#:/= 5/](;@_P.S/W?VA,5OZ226],_L*\^6/#^B8+!'L1:-^+5;C
M>UB.1(@"_^>)!:H0YA2M0VD5T5[:D*U-/.;J"N=Q>EK0-%6,HFI,;T"WG.).
M?,FN? =^ 6>E5>9I_@,59V'72(ID%5 \5RPZ(H/@Q KJ24I,.ZNRX.:IV,T^
M"'J2H!9T3Q4(U6-[ QBZY,LHNN3 IT!2(1U=3T9"C)$PR4KNA# ^/?6VO/_%
M-$RKK]Z\K9T8V< =]&[LPW@R7HYA@<IP]2+^939!IB^*8ES^N&8-=]J+;"CR
MHK0(*,'1('DNO:MHS-HZ+I_*2-D'(-O2-NS=U'NLIQ<1-:!Y;NWKODF8,C4>
M3"(LN%Q:-@?B2R?-)+-QFCJ=GRS)[@BVIN)!_4C_<8AU$44#H#J*L?3+6GSP
M/WR8P-HS2! \EQJ(I:O*9-R B\H3+[0.)H"6M'IL<2,ES8"IDYSO7WW=F=X&
M=.87N.H#'HUR1,_4,D."P3^D\K@ED1-J;^29"%1K>"IW>T_T;"9FV,NN/P!5
M8'T#&+KK&JSWLZZ&&WF&YA\MLP=",0YUR"10FXA@CCNOC3*^MAIZFJ)A?;*>
MT%11" U :L.AD"8IS9,BC $RAPM;K,FB9Z/7,M!R-'HWCX9UW'J"3D=F-^#0
M/0+^][-I7*M4Y@W$X$A4I:!*2?1O=2Q-1&E$SP2B>;++>T4E=$-4,[=:?S9V
M7<&TI9A&B0DE903B=0F<BH@\40;/G#!4*BKQE#R58=Q1(S5SBQW$0]N)V0UH
MI%)L,5Z>KQZ*I^GU;%H. 4QCV0KHS+*114.[DD8M%6XJ)N*!*@@ >%77SA-Z
M@IQFKK3^<%1+& WHGR<X)!FWB:= F/#^LM-M23L@,@'N2'B(LK:!U#$\6;VN
M[J"HJB2*!D!UJS)LE<MRNS",6LZM#+94&J,E2*TFP>%-[;*@+)0,UR>+,O=5
M5H^0,W2&8QV);U!/-=C? )*.4EJ] ?C)!S].)]/7_NL8K]1;.QR%K ,SH<3&
M'!2#3Y"0DR :%7#D!MU47OW1[5FJAGY-Z057E871 +S.8.G'4TC'?C[%T[$X
MBO'B_&)2,MW?0!['\7*$[BEG*4GB9"QI>)X2KZ0EGFOOC)/(O-K&U?-4#6NK
M]P2ORL)H %X/&37BDK%0\K2X2*:\8>(!T<R2(/#_ M?:VZ<JP^H85<.:Z#W!
MIR.S&_#QGK,R1T&)I+S+A,GBLVK."GLX^JPI U.4,UU;%SU'TS"#I8:*&G07
M2S68';1$[<-*&E]@.8Y^<G<KE>K5[JYP@.*U)[9TR$HVEB$PGX $2DN[SP),
MK1&8T2J(&H2%IT;TM%K)=LLF1$:?SE=KII4W\@'FJW8A(^J4"@(L,=Y#R?&S
MQ%F:"6CG7#9>,-VC)_@864-[A)4Q\X1O6$4P#5A9#_K0'%TLO\SFX_^"-%+2
M:^&R)$R7:!QUACAO [$^.JUIE#'W$1I]A)RAO<+#8:N3(%K$U,EB<8';B,HZ
MDY@F*I9&-@[*Z-G("6<BJ&R42]43.!\A96@7\-!8VD, +>+H=BPNYQ23+>VQ
ME$4]R\LH.308\70(JVA,WH7:M06=VY+UZ!4>&E'[BN+%=)FX9NEBEJ\>SO&G
MM<SW1SZ]']-]FZU4,MO+\-ASN%[P)OM<@F4\ DE<:")S="08SM&9-%9:B__1
MM9_#'B&E6G;+58GH3>D&31QTZ:[B'20BRZ2I0!,E41IIL@)CJG</>)2880WQ
M&BAX-'FE$]\;N-7.4!9(0"EB?P/?8#);U?Y=[6K$-2M3V#7AHF0LRZ31RDMH
MZF4NG"[5@;%^Q/P)@H8%4B6A/XB5UY)  W#Z#:;(HPGNY2B=CZ>K$>]EH,%Z
M.SXJH;V2!+P5:/-%C?ZH\43+(%-PE&M:&U#/D#2L(]</I&I*H0%0/6#2*!CA
MF?.44*G0> 21B W>$NUH>54RVE+6]^4VK-?6#W"Z<;J!=Y?K#5Q>^N]F96!"
MT9JEW8KF7*$*C8;8TII4&F%]X)YR\=3XHDY@N2%C6#W3JPVT)Z\'A,MMMVCT
M>C6QZV3ZUH_GETDV^=_]?.ZGR^NDY)&D05NA&.%XAE!C:DJ"]ZN2"<:H!CQ6
M]_S[QSVO71<?5M'41$ZO;&_@HEI-<(+%\I)G5SKT_6PZ6Y^4TE/#9B],Q'LW
M@A:7B0^NE#X[2G50SECN:Z<-;$/7L"&C/O13=6DT@# D^9:VE9HG+:4@VB1Q
M.0^H5$P0Q2FCQD@'YJG&]OM Z0X!PV;R]H&9_?G;@/&SSK9:O_Z]\HMQ'$FO
MG,#;EQC* S*A-)9"!I%L0#CEN3:F]K/T1D*&32_I RS=^=V 1KF_B3?CR<6R
MO/+92(T,D3!*<^E9B#YB2(E$1C-X804ZBCW#YHJ4K8!3?8[&(8&S#\\;@,Z_
M0VGU!.GH&UZHGZ^FGI_F!T\RE^?"6"V"=YI0E4O+%[QSK8QHRS')$XV1>E:[
M@=M.!&X%L^JC.?J$67_R:1=\5T?IX;.@MRJ =X8H8"43!D^9DTR@6J:,NRQL
MH/(P\'N,Q*T 6'T,R   K"*C%_ET>^GS+L;3#=FW/;SE/K5<_X^[6V^V?I+F
M$^G#R@& M(Z "IY(SQ7:]$D33Y66(L>01>VTGZT(ZUZ@<+7(I])R:$2]S.B]
M4 *YQ&VIAC*L(Q.CO!$Y,;1%:R>DW*6@F>3+2EAX6*.P-[\;N#VOJ;_D2)D/
M.9NNBJ"_CQ<C='2I2<H4 \"B'LZ4^.A+6Y@0O8K1TNK=XY\DJ!$L[2'IQT#3
MF>T-8.C>'M[,SOUX.I)*6RET)):;\K8H%'&.<@(\J(P.L#*^=DQJ(R&-8*:[
MH._[CIVYW@!T;B7P_0[%*!R9$*WU@9&(?BZJ8IF(=5&29!0MT7Y4R+73E1X0
M,2QD*@CV\33)/;C< $P>J5*^V@Q$*RG5E*C2K4RRG(EC7!.MI3)XH\ML:[_K
M/DG0L"^\]>%3C_L-0.E^1?+5+@1+.EF\S)V+% ^$8<1+<,27HE*5 I?5+9W-
ME S[R%L?/!7XW0!JKJ_QUQ._6%SY$JLK'/(J4BL)FH.!R)0#6H%)$)6C<SS;
MI%)M,^=18AJI1:IH'G=B=P.XN4W_U6%BC$<:44LJ56:Q%%5IB\,)P$W@@1O'
M:J>L/:2B$:.XFWCO6SG=>#T@6NZFP]P8:T?3] %)N2@QL:N4F,7)]*J49OIY
MK4JC%D$H3I+CDLB(.[62!\(2U\PIX-+=2Z7=-B5I1TJ&!557\6],3>I3%@T"
M;C55;+T5'8,5$(CQTN -[1+QR>-Y-$Y(%QP7(G2%U:WUAKV[>@;/OGQMX :[
MUM7OT(H[P;^BDHZQ@!IWD!(C,N,VO/**I&A\9@&HJMZL^R$5C=3*5K1U]F-P
M Q YF<9Y:=W[!B[_>[+AH>=L-IF\G<W_]/,T2BG@92Z  )Z3,OX@$E>&B">7
M\5A9W+NO_22Q(XF-F$=[(N)!^F-_XFD ?4_6 +N,MZXUI0]P!%*>J8FUX$ET
M(F;.M9"ZNK'=M1R[S_K'_H"P2V7V+E+9&V%?83Z>E7?H^;*OQF\)5##@.(F"
M12*EB'B54T.X35XD&X+5M3.9]NS6U6<]R<$PU5$"S2#I*/WOB\5EJ^E/LT>"
MJZM#$Y"AJ03C8+I82?0,<-N+\1(^POS;.);V/DC9&<39Y^GJ4R['3#O.E<3_
M)TY;9+)QBGB.QRU#<$P*8W*NG>+4]YX&KWTY&,J;0D<K/NJ*W9?M8MY<S/$.
MN=S;Y=7RMN1PK)BT^OJ&@2-O(QKFZ,,%W!9NU2J\:*0C*:@4J,TABWL*>DL?
M=C]Z!B^MZ1W$AQ;:[OATE_B<PN>2IM8[0E='[O&]&@-&@6$D)"V)5$Z3$+PC
MUN%]9C5CE.\79-F+G,'+>)K 9T61=87GI[IMBQ\[B^_AS]6/T,^4BCNJT)2R
M4I5GN4R<!4V<HN  LM0N]&'1/DO9X$5#A[5RZTJJ 2_]J;-VLRFJM"ZV"=%*
MEUP"Y& (G!&O.$,W,1O-:]<:;478X)5'0Z.O@YQ>A EY]:)S_!WF<;R 44B"
M)>$E@91M26J!4F]."7#J4@;JO73U#<=[5 Q>B-3$==Q=0 VHO[OEQ-G89!B7
M)$6*K%*:(JLB$H];0@-"1:"U$]9V+]?NL\#H8.IL?[XW )HG8ZC1)<>,9D1$
M0=%+2D L4YD(#XD*(X.[_SS;0&2;_@R8JB:6C@')XVDW]_6)L&J06CLC$S$0
MRJ1873+4I2?*&1VUHZ!:F6C"?HK7DHXBJ JD@Y9!^L67MY/9G[TTL+WY\ .4
M.&[>2/V"QNN%;N;KZ,03-:7W>GD:UC$3CU9XR4+P@@H;M:C]Q/D4/97+%UFV
MWGKP).E0.CGK0!RLRH$S> 6\).?TM;NVRA>[2?Z9JL5=V-R 9?3Q(BS&:>SG
M/S[Z"=Q.(&6!:AET),*4N3W((A),SH3'$IDS*:(-6!LOCQ'3"'3VD/!]L%1A
M=PNXN2'_O3_'OWY"IW)Q&>E=I_T!U<QYO&.$D*6Y 26>:DV4"F7,)C?!52\+
M?Y:J@9%41_SW0557%JV$F3Y]F<\N/G^YGQB<A 6FO2/"9N14-E"&:":"V\#S
MZ+*+]^? ;QE0VKS>P("I+-I-T:(*?&X%,D?+3U_@=S__.^ UCV3<V@V L[8,
MPXPER@5XN:,63X1%%S/W(0G/]T+-HTL.7$)T .#4X78+E]G#-%%IK$DF(S=,
MT$1&- LM;H8 RY2!=5*'WOHUO-LI,_M056B=S)YN#&X (N]A6=R&#_/9MS&Z
MH:]^_+& =#*];MA\A"?KV^44S+53D436*AE&0.$?LM1DAM*_$*RQD06+QZ"V
M ;T[E8U8UGOBXF&,ND\AM0'#6U%X:RA27%K'"XMJ-CI4LR(#X<#QM!KI3:S]
MR+O[ZT=OX.E;VD\^@.S"^KUQ\PWF85:M\<.M9,B2R8BVW@3N;.K3;%=^\A1H
MY&@],,5<:?6L2-">D^Q]\%H!8[:VB]?'/H:]9P^,X\&!T( :?0.X<ARO1#P*
M+*@8R\A-;M#1,<H3RY5 8YAF&XU%S[PVB&^O/ZP2'1X-LTJB:0!6ZY;5=Y/)
M1V7:5-!.DV23)R4OG'A7?&JEF7?4,I>KORMLI&18/=<<U"J(JP'070_[N.'O
M]=B/Q<@E\((Q3;1/!NT4#R3P$M2A3"L6G)>L]JO/DP0-6WW2' 3K":\)(_.:
M3>_*._]9:55\FI&#1XL%+(_.9_/E^+]6PEZ/35-,E3R.1*)GH1@RBGB6)1$Z
M,V#1&\UY97CN2N.PI2;-(;97$;<21WYRDY?)E..XKB@; 4TA&8D7AB[C*91$
M=F:!QU1D#MJ%'-2]^WW+V/).9 Q;<M(,3@\DQW;J41YF5UWO^JK&\69 N-5X
M:Q0_T;DRQU &8LNE LS21!EHJ-Y(=GOJAJU+:0:_/8NU 8/UX<X^S.&K'Z<W
M5_1<W1Q'T[3J]K,ZK(N1HC&&P"E)V9<RG4")YY83S30WGM%@5.TYM_M1VEIK
MBCJX>1:>U878LHH]BG%V@;KB@_^Q>AR3G%&O9"(AY5+*R T)GN'!1R,'KW;'
M0M:]@_,>4:VULS@0#KN(IDGMB!N:7R =5R,\\8(9N6@%#9H3Q= ^D=1)XJ/Q
MA(8,RC,5V7V+LQ^XW:.KM=82AT-<%P$U";J[EO/-^%CFA?8"-;;/H"^31EP$
M6^9A6YF]\:EZ+'-KXEIK"G$@^-4050,8W/X9;!154H%F2PRS9<@,2!*, ,*H
MI2IHDSBKW?9N>^J&58*'?Q3O0V@-3'Y]9&?769(;&&FU5=GE2%1IQRY+S,O'
M:%;SM9ETH!*O[:'L3F4C.66])OS4$E(#6A&W%@'2XBVRLE1TX[[@--\JG!Q9
M!]D)&8FV.2/_9(FO0D0/2^;(4=%S53NH\RQ1328&54/%K$\1M1("1_>IG-.W
ML_F]!CZ+,_A6EKHLV_V*IL:(1XC&E5Q01PV107D2N'6$>RJ9SX;%>,_[W3(
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M@04O)<%KNG2]0L/ 6NH)2RY+FK5RN;81>9"--57%N0L6'WWI:@8&#02?;^Z
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M;\:+.)DM+M#X8#$:<#*0J#VR;M4L,%-/% V@:';.B-IM8G>CL(UTWQX UX.
M&G1HKQZ&5[M:O\"LG'9((P/:>1L]T5S@R1)*$6\8)R9GX3* RFZ_RI7MUF\C
M$[A'W[46[QN$U='GU1BF\Q+UN1Q_BA9M$=]G&$$VV5% XU65@4S)E($6&0^0
M%5X;]-,?# ?='59/K-]&EG"/L*K%^P8NRP_S601(B[?(QG5<\31?)D&O]CI2
M#IAT5!,3/<-S F5R*IJ4,B2A04F63>U7^V>):B.AN.*56%<,3:JKS_/5@.35
M+0]P<V).\VKZ^)H#HV!ER$*D\F",&[4.<*,V$<C62P-H"]S/0-Y'>6U)S79
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M(^TM(+0'ZQL$T>G*#OBWV00%-$&UO>Z_RFQ66C"BF:=$"I&)#;1,_V(L)2I
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MGS>%8A*]9F$&4]M4*12M&+3GV;L2'F3V'O(?B]2?I\LLW7W;IT@MP57)2PV
M5BG:E=4VL"$S?/0M,$!76BT5K72T*Y>- *FS =XE^3>VWZD95!FWS !HE:0
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M4;ED>;Q@["-RR?-L#$P?" ',C]2$(A>DF##"*1"^V7]U9  5^_OLS,H-U!^
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MF,K8 YI*]6/JAXU%NEE.(;ANE2SF.B;PW@9UD&/7_:G6]YI^O3:W4Z(+0O4
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MW;TMW_S^N?N?Z0YKU6IMH]4)5T.$K9%9^R2;(A'/@SI_WI17!.]5B7T&GJ;
M_EUA_X(XGI28#\J(<,),Q,V[_>;)Z>Y:SR(^ J9@)&",1&8BH=FO.5>(F'C"
M>I!)99A,V2>I$N95R[^R4"H4 _;'3"K#M67 ( U0PS_S%-[M>\?5TWJUY)A/
MANSGWA7[*&2)7:5^!5W2VM8EIQD/ B37<@RA:=>/\1N"ML#%4M,N>W^)V[S*
MU/Q777C9&2V[\X]<H],Q0,F$W:=R'$,PA)*+HW+1"R0NG4K,5JB>BY3Q=,+R
MU*@<T'+,7Y3*,$B<)?BD!(]9R'W\2C&9("\;Z>16!%+P06NN)E8DX?= P)CI
MU/A=@,;@DC'E05S#"OA"8=Y#L12GHR4!*#:.A!\QG=N/^?PQ*"B4V TD0L>8
M(&VN'0L3X09U!CX9:/46./3E"*<%;#!9= .!;C-?O@74U78?=<!"D6)<+43F
M<2PAY% <A]7"N$B12A!0 O6(U(]S2Q^(E86@E1!G@B@&0VU1:M$;QW,8%@C0
MCY9&I ?"*BY9B3Q& <2>1(#0<IKL\;F.6!C+L9X"4\%0:*,X+L3ME\YNM+*T
M@"\]-6;%VK?/:_6=05A_*1SO]D]JWOM376"HR*^6!V08"GRD0%TQKH @@2$6
M@Q@H5P'B<! +'5EQ*Y8@!UH>M,^!T'XL=8[S+#LJ&3ML9$KZ$.#7FAT@% )
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M@!WP.I)R8O;=UBOY<E)R;Y:0  F:Z\TE6_?<VL_B#PK[]@\9?P-02P,$%
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MDJS3 Y+0_P^9_&=%)IX@0Y;$5BM $P274;P+]S(M)-Q<I9(I4^JJ421Q#&@
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M,#8S,"YH=&U02P$"% ,4    "  I-PY;,AIZ<#<-  ">C0  &0
M    @ &<P   8VLP,# Q.#(T,CDS+3(P,C4P-C,P+GAS9%!+ 0(4 Q0    (
M "DW#ELN&@3UK0T  #IQ   =              "  0K.  !C:S P,#$X,C0R
M.3,M,C R-3 V,S!?8V%L+GAM;%!+ 0(4 Q0    ( "DW#EL'6.P=>3(  '\B
M @ =              "  ?+;  !C:S P,#$X,C0R.3,M,C R-3 V,S!?9&5F
M+GAM;%!+ 0(4 Q0    ( "DW#EM8/P1/$TH" /%@ P <              "
M :8. 0!C:S P,#$X,C0R.3,M,C R-3 V,S!?9S$N:G!G4$L! A0#%     @
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M8V5R=#8S,#(U+FAT;5!+ 0(4 Q0    ( "DW#EO"#U1W50@  !<J   9
M          "  8=X! !E>#,Q,E]C9F\S,#)C97)T-C,P,C4N:'1M4$L! A0#
M%     @ *3<.6R$JRZG$!0  SQ@  !X              ( !$X$$ &5X,S(Q
M7V-E;W-E8W1I;VXY,#9C97)T-C,P+FAT;5!+ 0(4 Q0    ( "DW#ELF_,WE
MLP4  *48   >              "  1.'! !E>#,R,E]C9F]S96-T:6]N.3 V
A8V5R=#8S,"YH=&U02P4&      P # !T P   HT$

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>ck0001824293-20250630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:ck0001824293="http://www.vallon-pharma.com/20250630"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ck0001824293-20250630.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2025-08-13</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ck0001824293:CommonStockAndPrefundedWarrantsInFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ck0001824293:CommonStockAndPrefundedWarrantsInFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ck0001824293:CommonStockAndPrefundedWarrantsInFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ck0001824293:CommonStockOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ck0001824293:CommonStockOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ck0001824293:CommonStockOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:ThroughFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:ThroughFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2024-01-29</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2024-01-29</startDate>
            <endDate>2024-01-29</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2024-06-17</startDate>
            <endDate>2024-06-17</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2025-02-21</startDate>
            <endDate>2025-02-21</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-01</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-20</startDate>
            <endDate>2024-05-20</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-21</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-26</startDate>
            <endDate>2024-06-26</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesBCommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-21</startDate>
            <endDate>2024-10-21</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-01</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesB1CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesB2CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesB1CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesB2CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesA1WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-23</startDate>
            <endDate>2025-05-23</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-26</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesC1CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-26</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesC2CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-26</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-26</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-26</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesC1CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-26</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesC2CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-26</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedAndSeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-26</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:June2024PAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-26</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesBCommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-21</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesD1WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-21</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesD2WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-21</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesDWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-21</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2024-10-21</startDate>
            <endDate>2024-10-21</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:October2024PAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-21</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-01</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-01</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesE1CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-01</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesE2CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-01</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesE3CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-01</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-01</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-01</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-01</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesECommonWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-01</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-04-01</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:April2025PAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-01</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesECommonWarrantsAndApril2025PAWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesECommonWarrantsAndApril2025PAWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesECommonWarrantsAndApril2025PAWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesECommonWarrantsAndApril2025PAWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInAugust2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInJanuary2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInFebruary2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInMarch2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInApril2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInOctober2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInMay2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInJuly2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInApril2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInFebruary2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInJune2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInSeptember2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInOctober2029OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInOctober2029TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInApril2030OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInApril2030TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:AmendedAndRestated2018EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:AmendedAndRestated2018EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ck0001824293:FormerChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-21</startDate>
            <endDate>2023-04-21</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="year">
        <measure>ck0001824293:year</measure>
    </unit>
    <unit id="segment">
        <measure>ck0001824293:segment</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-27">0001824293</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-28">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-29">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-30">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-31">false</dei:AmendmentFlag>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="c-54" decimals="4" id="f-227" unitRef="number">0.1429</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="c-55" decimals="4" id="f-228" unitRef="number">0.0769</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="c-56" decimals="4" id="f-229" unitRef="number">0.0588</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2025-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-40034</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">GRI BIO, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">82-4369909</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">2223 Avenida de la Playa</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-10">#208</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">La Jolla</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">92037</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">619</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">400-1170</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common Stock, par value $0.0001per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">GRI</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-19">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-20">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-21">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-22">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-23">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c-1" id="f-24">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany contextRef="c-1" id="f-25">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-26" unitRef="shares">2515305</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-32" unitRef="usd">5122000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-33" unitRef="usd">5028000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-34" unitRef="usd">454000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-35" unitRef="usd">587000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="-3" id="f-36" unitRef="usd">5576000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-37" unitRef="usd">5615000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-38" unitRef="usd">2000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-39" unitRef="usd">4000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-40" unitRef="usd">97000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-41" unitRef="usd">120000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets contextRef="c-3" decimals="-3" id="f-42" unitRef="usd">5675000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-43" unitRef="usd">5739000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-3" decimals="-3" id="f-44" unitRef="usd">1297000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-45" unitRef="usd">897000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-46" unitRef="usd">960000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-47" unitRef="usd">691000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-48" unitRef="usd">52000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-49" unitRef="usd">48000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-50" unitRef="usd">2309000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-51" unitRef="usd">1636000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-52" unitRef="usd">44000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-53" unitRef="usd">71000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="-3" id="f-54" unitRef="usd">2353000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-55" unitRef="usd">1707000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-3" id="f-56" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-57" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-58"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-59"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="0" id="f-60" unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="0" id="f-61" unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="0" id="f-62" unitRef="shares">2496800</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="0" id="f-63" unitRef="shares">2496800</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="0" id="f-64" unitRef="shares">525485</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="0" id="f-65" unitRef="shares">525485</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValueOutstanding contextRef="c-3" decimals="-3" id="f-66" unitRef="usd">0</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding contextRef="c-4" decimals="-3" id="f-67" unitRef="usd">0</us-gaap:CommonStockValueOutstanding>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-3" decimals="-3" id="f-68" unitRef="usd">49000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-4" decimals="-3" id="f-69" unitRef="usd">43772000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-70" unitRef="usd">-45678000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-71" unitRef="usd">-39740000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-72" unitRef="usd">3322000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-73" unitRef="usd">4032000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="-3" id="f-74" unitRef="usd">5675000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-75" unitRef="usd">5739000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-5" decimals="-3" id="f-76" unitRef="usd">1879000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-6" decimals="-3" id="f-77" unitRef="usd">877000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-78" unitRef="usd">3520000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-7" decimals="-3" id="f-79" unitRef="usd">1811000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-5" decimals="-3" id="f-80" unitRef="usd">1018000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-6" decimals="-3" id="f-81" unitRef="usd">1380000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-82" unitRef="usd">2429000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-7" decimals="-3" id="f-83" unitRef="usd">2342000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-5" decimals="-3" id="f-84" unitRef="usd">2897000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-6" decimals="-3" id="f-85" unitRef="usd">2257000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-86" unitRef="usd">5949000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-7" decimals="-3" id="f-87" unitRef="usd">4153000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-5" decimals="-3" id="f-88" unitRef="usd">-2897000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-6" decimals="-3" id="f-89" unitRef="usd">-2257000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-90" unitRef="usd">-5949000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-7" decimals="-3" id="f-91" unitRef="usd">-4153000</us-gaap:OperatingIncomeLoss>
    <ck0001824293:ChangeInFairValueOfWarrantLiability contextRef="c-5" decimals="-3" id="f-92" unitRef="usd">0</ck0001824293:ChangeInFairValueOfWarrantLiability>
    <ck0001824293:ChangeInFairValueOfWarrantLiability contextRef="c-6" decimals="-3" id="f-93" unitRef="usd">1000</ck0001824293:ChangeInFairValueOfWarrantLiability>
    <ck0001824293:ChangeInFairValueOfWarrantLiability contextRef="c-1" decimals="-3" id="f-94" unitRef="usd">0</ck0001824293:ChangeInFairValueOfWarrantLiability>
    <ck0001824293:ChangeInFairValueOfWarrantLiability contextRef="c-7" decimals="-3" id="f-95" unitRef="usd">3000</ck0001824293:ChangeInFairValueOfWarrantLiability>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-5" decimals="-3" id="f-96" unitRef="usd">5000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-6" decimals="-3" id="f-97" unitRef="usd">6000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-1" decimals="-3" id="f-98" unitRef="usd">11000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-7" decimals="-3" id="f-99" unitRef="usd">13000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-100" unitRef="usd">-2892000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-101" unitRef="usd">-2250000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-102" unitRef="usd">-5938000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-103" unitRef="usd">-4137000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-104"
      unitRef="usdPerShare">-1.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-105"
      unitRef="usdPerShare">-1.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-6"
      decimals="2"
      id="f-106"
      unitRef="usdPerShare">-61.85</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-6"
      decimals="2"
      id="f-107"
      unitRef="usdPerShare">-61.85</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-108"
      unitRef="usdPerShare">-4.33</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-109"
      unitRef="usdPerShare">-4.33</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-7"
      decimals="2"
      id="f-110"
      unitRef="usdPerShare">-150.32</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-7"
      decimals="2"
      id="f-111"
      unitRef="usdPerShare">-150.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="0" id="f-112" unitRef="shares">2205139</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="0" id="f-113" unitRef="shares">2205139</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-6" decimals="0" id="f-114" unitRef="shares">36379</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-6" decimals="0" id="f-115" unitRef="shares">36379</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-116" unitRef="shares">1369933</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-117" unitRef="shares">1369933</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-7" decimals="0" id="f-118" unitRef="shares">27522</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-7" decimals="0" id="f-119" unitRef="shares">27522</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-8" decimals="INF" id="f-120" unitRef="shares">525485</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="-3" id="f-121" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-9" decimals="-3" id="f-122" unitRef="usd">43772000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-10" decimals="-3" id="f-123" unitRef="usd">-39740000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-124" unitRef="usd">4032000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-11" decimals="-3" id="f-125" unitRef="usd">220000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-12" decimals="-3" id="f-126" unitRef="usd">220000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <ck0001824293:StockIssuedDuringPeriodSharesFractionalShareAdjustment
      contextRef="c-13"
      decimals="INF"
      id="f-127"
      unitRef="shares">127</ck0001824293:StockIssuedDuringPeriodSharesFractionalShareAdjustment>
    <ck0001824293:StockIssuedDuringPeriodValueFractionalShareAdjustment contextRef="c-11" decimals="-3" id="f-128" unitRef="usd">1000</ck0001824293:StockIssuedDuringPeriodValueFractionalShareAdjustment>
    <ck0001824293:StockIssuedDuringPeriodValueFractionalShareAdjustment contextRef="c-12" decimals="-3" id="f-129" unitRef="usd">1000</ck0001824293:StockIssuedDuringPeriodValueFractionalShareAdjustment>
    <us-gaap:NetIncomeLoss contextRef="c-14" decimals="-3" id="f-130" unitRef="usd">-3046000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="-3" id="f-131" unitRef="usd">-3046000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-15"
      decimals="INF"
      id="f-132"
      unitRef="shares">525358</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-15" decimals="-3" id="f-133" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-16" decimals="-3" id="f-134" unitRef="usd">43991000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-3" id="f-135" unitRef="usd">-42786000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-136" unitRef="usd">1205000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-19" decimals="-3" id="f-137" unitRef="usd">41000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-5" decimals="-3" id="f-138" unitRef="usd">41000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-20"
      decimals="INF"
      id="f-139"
      unitRef="shares">1388888</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-21" decimals="-3" id="f-140" unitRef="usd">4143000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-22" decimals="-3" id="f-141" unitRef="usd">4143000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-23"
      decimals="INF"
      id="f-142"
      unitRef="shares">582554</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-24" decimals="-3" id="f-143" unitRef="usd">825000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-25" decimals="-3" id="f-144" unitRef="usd">825000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss contextRef="c-26" decimals="-3" id="f-145" unitRef="usd">-2892000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-146" unitRef="usd">-2892000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-27"
      decimals="INF"
      id="f-147"
      unitRef="shares">2496800</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-3" id="f-148" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="-3" id="f-149" unitRef="usd">49000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-29" decimals="-3" id="f-150" unitRef="usd">-45678000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-151" unitRef="usd">3322000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-30"
      decimals="INF"
      id="f-152"
      unitRef="shares">2909</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-30" decimals="-3" id="f-153" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-3" id="f-154" unitRef="usd">31792000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="-3" id="f-155" unitRef="usd">-31533000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="-3" id="f-156" unitRef="usd">259000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-34" decimals="-3" id="f-157" unitRef="usd">37000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-35" decimals="-3" id="f-158" unitRef="usd">37000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <ck0001824293:StockIssuedDuringPeriodSharesFractionalShareAdjustment
      contextRef="c-36"
      decimals="INF"
      id="f-159"
      unitRef="shares">1</ck0001824293:StockIssuedDuringPeriodSharesFractionalShareAdjustment>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-36"
      decimals="INF"
      id="f-160"
      unitRef="shares">1495</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-34" decimals="-3" id="f-161" unitRef="usd">4389000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-35" decimals="-3" id="f-162" unitRef="usd">4389000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <ck0001824293:StockIssuedDuringPeriodSharesWarrantExercise
      contextRef="c-36"
      decimals="INF"
      id="f-163"
      unitRef="shares">10047</ck0001824293:StockIssuedDuringPeriodSharesWarrantExercise>
    <us-gaap:NetIncomeLoss contextRef="c-37" decimals="-3" id="f-164" unitRef="usd">-1887000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-35" decimals="-3" id="f-165" unitRef="usd">-1887000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-38"
      decimals="INF"
      id="f-166"
      unitRef="shares">14450</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-38" decimals="-3" id="f-167" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-39" decimals="-3" id="f-168" unitRef="usd">36218000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-40" decimals="-3" id="f-169" unitRef="usd">-33420000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-41" decimals="-3" id="f-170" unitRef="usd">2798000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-42" decimals="-3" id="f-171" unitRef="usd">37000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-6" decimals="-3" id="f-172" unitRef="usd">37000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <ck0001824293:StockIssuedDuringPeriodSharesFractionalShareAdjustment
      contextRef="c-43"
      decimals="INF"
      id="f-173"
      unitRef="shares">11</ck0001824293:StockIssuedDuringPeriodSharesFractionalShareAdjustment>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-43"
      decimals="INF"
      id="f-174"
      unitRef="shares">20816</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-42" decimals="-3" id="f-175" unitRef="usd">4134000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-6" decimals="-3" id="f-176" unitRef="usd">4134000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <ck0001824293:StockIssuedDuringPeriodSharesWarrantExercise
      contextRef="c-43"
      decimals="INF"
      id="f-177"
      unitRef="shares">11905</ck0001824293:StockIssuedDuringPeriodSharesWarrantExercise>
    <us-gaap:NetIncomeLoss contextRef="c-44" decimals="-3" id="f-178" unitRef="usd">-2250000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-179" unitRef="usd">-2250000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-45"
      decimals="INF"
      id="f-180"
      unitRef="shares">47160</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-45" decimals="-3" id="f-181" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-46" decimals="-3" id="f-182" unitRef="usd">40389000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-47" decimals="-3" id="f-183" unitRef="usd">-35670000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-48" decimals="-3" id="f-184" unitRef="usd">4719000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-185" unitRef="usd">-5938000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-186" unitRef="usd">-4137000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation contextRef="c-1" decimals="-3" id="f-187" unitRef="usd">2000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-7" decimals="-3" id="f-188" unitRef="usd">2000</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-189" unitRef="usd">261000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-7" decimals="-3" id="f-190" unitRef="usd">74000</us-gaap:ShareBasedCompensation>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-1" decimals="-3" id="f-191" unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-7" decimals="-3" id="f-192" unitRef="usd">-3000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-1" decimals="-3" id="f-193" unitRef="usd">23000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <ck0001824293:OperatingLeaseRightOfUseAssetPeriodicAddition contextRef="c-7" decimals="-3" id="f-194" unitRef="usd">127000</ck0001824293:OperatingLeaseRightOfUseAssetPeriodicAddition>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-195" unitRef="usd">-133000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-7" decimals="-3" id="f-196" unitRef="usd">-370000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-197" unitRef="usd">371000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-7" decimals="-3" id="f-198" unitRef="usd">-400000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-1" decimals="-3" id="f-199" unitRef="usd">269000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-7" decimals="-3" id="f-200" unitRef="usd">-250000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-201" unitRef="usd">-23000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-7" decimals="-3" id="f-202" unitRef="usd">127000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-203" unitRef="usd">-4902000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-7" decimals="-3" id="f-204" unitRef="usd">-4344000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-49" decimals="-3" id="f-205" unitRef="usd">5000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-50" decimals="-3" id="f-206" unitRef="usd">9499000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-51" decimals="-3" id="f-207" unitRef="usd">941000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-52" decimals="-3" id="f-208" unitRef="usd">961000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ck0001824293:PaymentForFractionalSharesReverseStockSplit contextRef="c-1" decimals="-3" id="f-209" unitRef="usd">1000</ck0001824293:PaymentForFractionalSharesReverseStockSplit>
    <ck0001824293:PaymentForFractionalSharesReverseStockSplit contextRef="c-7" decimals="-3" id="f-210" unitRef="usd">0</ck0001824293:PaymentForFractionalSharesReverseStockSplit>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-1" decimals="-3" id="f-211" unitRef="usd">944000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-7" decimals="-3" id="f-212" unitRef="usd">1571000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-213" unitRef="usd">4996000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-7" decimals="-3" id="f-214" unitRef="usd">8889000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-215" unitRef="usd">94000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-7" decimals="-3" id="f-216" unitRef="usd">4545000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-217" unitRef="usd">5028000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-33" decimals="-3" id="f-218" unitRef="usd">1808000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-219" unitRef="usd">5122000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-48" decimals="-3" id="f-220" unitRef="usd">6353000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <ck0001824293:DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-221" unitRef="usd">29000</ck0001824293:DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid>
    <ck0001824293:DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid contextRef="c-7" decimals="-3" id="f-222" unitRef="usd">367000</ck0001824293:DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid>
    <ck0001824293:WarrantsIssued contextRef="c-1" decimals="-3" id="f-223" unitRef="usd">123000</ck0001824293:WarrantsIssued>
    <ck0001824293:WarrantsIssued contextRef="c-7" decimals="-3" id="f-224" unitRef="usd">0</ck0001824293:WarrantsIssued>
    <us-gaap:NatureOfOperations contextRef="c-1" id="f-225">ORGANIZATION AND DESCRIPTION OF BUSINESS&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;GRI Bio, Inc. (GRI or the Company), based in La Jolla, CA, was incorporated in Delaware in May 2009, which is the date of inception.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;GRI is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic and autoimmune disorders. The Company&#x2019;s goal is to be an industry leader in developing therapies to treat these diseases and to improve the lives of patients suffering from such diseases. The Company&#x2019;s lead product candidate, GRI-0621, is an oral inhibitor of type 1 invariant Natural Killer T (iNKT) cells and is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF). The Company&#x2019;s product candidate portfolio also includes GRI-0803 and a proprietary library of 500+ compounds. GRI-0803, the lead molecule selected from the library, is a novel oral agonist of type 2 diverse Natural Killer T (dNKT) cells and is being developed for the treatment of autoimmune disorders, with much of its preclinical work in Systemic Lupus Erythematosus Disease (SLE) or lupus and multiple sclerosis (MS).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recapitalization&lt;/span&gt;&lt;/div&gt;On January 29, 2024, the Company effected a reverse stock split of its common stock, par value $0.0001 per share (the Common Stock),  at a ratio of one-for-seven (the January 2024 Reverse Stock Split). On June 17, 2024, the Company effected a reverse stock split of its Common Stock at a ratio of one-for-thirteen (the June 2024 Reverse Stock Split). On February 21, 2025, the Company effected a reverse stock split of its Common Stock at a ratio of one-for-seventeen (the February 2025 Reverse Stock Split and together with the January 2024 Reverse Stock Split and the June 2024 Reverse Stock Split, the Reverse Stock Splits). Unless otherwise noted, all references to share and per share amounts in these consolidated financial statements reflect the Reverse Stock Splits.</us-gaap:NatureOfOperations>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-53"
      decimals="INF"
      id="f-226"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="c-1" id="f-230">LIQUIDITY&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited interim consolidated financial statements have been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has not generated any significant revenues from operations since inception and does not expect to do so in the foreseeable future. The Company has incurred operating losses since its inception in 2009 and as a result has incurred $45,678 in accumulated deficit through June&#160;30, 2025. The Company has financed its working capital requirements to date through the issuance of equity and debt securities. As of June&#160;30, 2025, the Company had cash of approximately $5,122. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 1, 2024, the Company entered into a securities purchase agreement (the February 2024 Purchase Agreement), pursuant to which the Company issued and sold Common Stock, pre-funded warrants and common warrants in a public offering (the February 2024 Offering) for net proceeds of $4,389, after deducting offering expenses of $1,110. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 20, 2024, the Company entered into an At The Market Offering Agreement (the Sales Agreement) with H.C. Wainwright &amp;amp; Co., LLC (Wainwright), pursuant to which the Company may sell and issue, subject to the limitations in the Sales Agreement, up to $10.0&#160;million shares of Common Stock from time to time through Wainwright as its sales agent (the ATM Offering). Under the Sales Agreement, Wainwright is entitled to compensation of 3.0% of the gross offering proceeds of all shares of Common Stock sold through it pursuant to the Sales Agreement. As of June&#160;30, 2025, the Company has sold 908,172 shares of Common Stock in the ATM Offering at a weighted-average price of $5.01 per share, for net proceeds of $4,292, after deducting commissions to the sales agent and other ATM Offering related expenses of $254. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 26, 2024, the Company entered into a securities purchase agreement (the June 2024 Purchase Agreement), pursuant to which the Company issued and sold Common Stock, pre-funded warrants and common warrants, in a public offering (the June 2024 Offering), for net proceeds of $3,172, after deducting offering expenses of $1,057.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 21, 2024, the Company entered into letter agreements (the Repricing Letter Agreements) with certain holders (the Holders) of certain of its issued and outstanding common warrants to purchase shares of its Common Stock, pursuant to which these Holders exercised their common warrants for cash at a reduced exercise price. In addition, these Holders received new unregistered common warrants. The net proceeds to the Company from the exercise of the common warrants were $609, after deducting placement agent fees and offering expenses of $154.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 1, 2025, the Company entered into a securities purchase agreement (the April 2025 Purchase Agreement), pursuant to which the Company issued and sold Common Stock, pre-funded warrants and common warrants, in a public offering (the April 2025 Offering), for net proceeds of $4,020, after deducting offering expenses of $979.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the Company&#x2019;s current operating plan, the Company believes that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s ability to continue as a going concern is dependent on its ability to raise additional capital to fund its business activities, including its research and development program. The Company intends to raise capital through additional issuances of equity securities and/or short-term or long-term debt arrangements, but there can be no assurances any such financing will be available when needed, even if the Company&#x2019;s research and development efforts are successful. If the Company is not able to obtain additional financing on acceptable terms and in the amounts necessary to fully fund its future operating requirements, it may be forced to reduce or discontinue its operations entirely. Therefore, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern for a period of one year from the issuance of these unaudited interim consolidated financial statements. These unaudited interim consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-231" unitRef="usd">-45678000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-232" unitRef="usd">5122000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-57" decimals="-3" id="f-233" unitRef="usd">4389000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <ck0001824293:StockIssuanceCostsOfferingExpenses contextRef="c-57" decimals="-3" id="f-234" unitRef="usd">1110000</ck0001824293:StockIssuanceCostsOfferingExpenses>
    <ck0001824293:SaleOfStockMaximumValueOfSharesOffered contextRef="c-58" decimals="-5" id="f-235" unitRef="usd">10000000</ck0001824293:SaleOfStockMaximumValueOfSharesOffered>
    <ck0001824293:SaleOfStockAgentCompensationPercentage contextRef="c-58" decimals="3" id="f-236" unitRef="number">0.030</ck0001824293:SaleOfStockAgentCompensationPercentage>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-59"
      decimals="INF"
      id="f-237"
      unitRef="shares">908172</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-60"
      decimals="2"
      id="f-238"
      unitRef="usdPerShare">5.01</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-59" decimals="-3" id="f-239" unitRef="usd">4292000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <ck0001824293:StockIssuanceCostsOfferingExpenses contextRef="c-59" decimals="-3" id="f-240" unitRef="usd">254000</ck0001824293:StockIssuanceCostsOfferingExpenses>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-61" decimals="-3" id="f-241" unitRef="usd">3172000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <ck0001824293:StockIssuanceCostsOfferingExpenses contextRef="c-61" decimals="-3" id="f-242" unitRef="usd">1057000</ck0001824293:StockIssuanceCostsOfferingExpenses>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c-62" decimals="-3" id="f-243" unitRef="usd">609000</us-gaap:ProceedsFromWarrantExercises>
    <ck0001824293:ClassOfWarrantsOrRightAgentFeesAndOfferingExpense contextRef="c-62" decimals="-3" id="f-244" unitRef="usd">154000</ck0001824293:ClassOfWarrantsOrRightAgentFeesAndOfferingExpense>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-63" decimals="-3" id="f-245" unitRef="usd">4020000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <ck0001824293:StockIssuanceCostsOfferingExpenses contextRef="c-63" decimals="-3" id="f-246" unitRef="usd">979000</ck0001824293:StockIssuanceCostsOfferingExpenses>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-247">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial periods and pursuant to the rules of the U.S. Securities and Exchange Commission (the SEC). Any reference in the accompanying unaudited interim financial statements to &#x201c;authoritative guidance&#x201d; is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). The December&#160;31, 2024 balance sheet was derived from the Company&#x2019;s audited consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, the unaudited interim consolidated financial statements furnished herein include all normal and recurring adjustments considered necessary to present fairly the Company&#x2019;s financial position as of June&#160;30, 2025, and the consolidated results of operations and consolidated stockholders&#x2019; equity for the three and six months ended June&#160;30, 2025 and 2024 and consolidated cash flows for the six months ended June&#160;30, 2025 and 2024. Consolidated results of operations for the three and six months ended June&#160;30, 2025, are not necessarily indicative of the operating results that may be expected for the year ending December&#160;31, 2025. The unaudited interim consolidated financial statements, presented herein, do not contain the required disclosures under GAAP for annual consolidated financial statements. The accompanying unaudited interim consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and related notes as of and for the year ended December&#160;31, 2024, included in the Company&#x2019;s Annual Report on Form 10-K filed with the SEC on March&#160;14, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited interim consolidated financial statements include the accounts of GRI Bio, Inc. and its wholly owned subsidiary, GRI Bio Operations, Inc. All intercompany balances and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, warrant issuance and subsequent revaluations, valuation allowances relating to deferred tax assets, accrued expenses and estimation of the incremental borrowing rate for the operating lease. If actual results differ from the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company&#x2019;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#x2019;s consolidated results of operations could either benefit from, or be adversely affected by, any such change in estimate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 820), establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The three levels of fair value hierarchy defined by ASC 820 are described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:63pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:67.5pt;text-indent:-40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:63pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2025, the Company&#x2019;s financial instruments included cash, cash equivalents, prepaid expenses and other current assets, accounts payable, accrued expenses and certain liability classified warrants. The carrying amounts reported in the consolidated balance sheets for cash, cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair value based on the short-term maturity of these instruments. The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. At June&#160;30, 2025, there were no financial assets or liabilities measured at fair value on a recurring basis other than the liability classified warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022, Vallon Pharmaceuticals, Inc. (Vallon) issued warrants (the May 2022 Warrants) in connection with a securities purchase agreement. Vallon evaluated the May 2022 Warrants in accordance with ASC 815-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging &#x2014; Contracts in Entity&#x2019;s Own Equity &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 815-40), and concluded that a provision in the May 2022 Warrants related to the reduction of the exercise price in certain circumstances precluded the May 2022 Warrants from being accounted for as components of equity. As a result, the May 2022 Warrants were recorded as a liability on the consolidated balance sheet. Vallon recorded the fair value of the May 2022 Warrants upon issuance using a Black-Scholes valuation model. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is required to revalue the May 2022 Warrants at each reporting date with any changes in fair value recorded in its consolidated statements of operations. The valuation of the May 2022 Warrants is considered under Level 3 of the fair value hierarchy due to the need to use assumptions in the valuation that are both significant to the fair value measurement and unobservable. The change in the fair value of the Level 3 warrant liability is reflected in the consolidated statements of operations for the three and six months ended June&#160;30, 2025. As of June&#160;30, 2025 and December&#160;31, 2024, the fair value of the warrant liability was immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred Stock Issuance Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred stock issuance costs represent incremental costs incurred that are directly attributable to proposed offerings of securities. The costs are charged against the gross proceeds of the respective offering upon closing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Loss Per Common Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per common share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. For the six-month period ended June&#160;30, 2024, basic net loss per common share includes the weighted average of the June 2024 Pre-Funded Warrants (as defined below). Diluted net loss per common share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during each period, plus the dilutive effect of common stock equivalents outstanding during each period, in accordance with ASC 260,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Earnings Per Share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. As the Company had a net loss in each of the three and six months ended June&#160;30, 2025 and 2024, diluted net loss per common share is the same as basic net loss per common share for the period because the effects of potentially dilutive securities are antidilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock equivalents excluded from the diluted net loss per common share calculations are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.177%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,623,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,644,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;312,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considered the applicability and impact of all ASUs issued during the quarter ended June&#160;30, 2025. ASUs not discussed below were assessed and determined to be either not applicable or expected to have minimal impact on these unaudited interim consolidated financial statements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280):&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Improvements to Reportable Segment Disclosures &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASU 2023-07). This amended guidance applies to all public entities and aims to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. This guidance is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The Company has adopted the provisions of ASU 2023-07 and has included the required disclosures in this Quarterly Report on Form 10-Q. See Note 8 for additional disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-248">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial periods and pursuant to the rules of the U.S. Securities and Exchange Commission (the SEC). Any reference in the accompanying unaudited interim financial statements to &#x201c;authoritative guidance&#x201d; is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). The December&#160;31, 2024 balance sheet was derived from the Company&#x2019;s audited consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-249">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited interim consolidated financial statements include the accounts of GRI Bio, Inc. and its wholly owned subsidiary, GRI Bio Operations, Inc. All intercompany balances and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-250">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, warrant issuance and subsequent revaluations, valuation allowances relating to deferred tax assets, accrued expenses and estimation of the incremental borrowing rate for the operating lease. If actual results differ from the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company&#x2019;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#x2019;s consolidated results of operations could either benefit from, or be adversely affected by, any such change in estimate.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c-1" id="f-251">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 820), establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The three levels of fair value hierarchy defined by ASC 820 are described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:63pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:67.5pt;text-indent:-40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:63pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2025, the Company&#x2019;s financial instruments included cash, cash equivalents, prepaid expenses and other current assets, accounts payable, accrued expenses and certain liability classified warrants. The carrying amounts reported in the consolidated balance sheets for cash, cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair value based on the short-term maturity of these instruments. The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. At June&#160;30, 2025, there were no financial assets or liabilities measured at fair value on a recurring basis other than the liability classified warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022, Vallon Pharmaceuticals, Inc. (Vallon) issued warrants (the May 2022 Warrants) in connection with a securities purchase agreement. Vallon evaluated the May 2022 Warrants in accordance with ASC 815-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging &#x2014; Contracts in Entity&#x2019;s Own Equity &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 815-40), and concluded that a provision in the May 2022 Warrants related to the reduction of the exercise price in certain circumstances precluded the May 2022 Warrants from being accounted for as components of equity. As a result, the May 2022 Warrants were recorded as a liability on the consolidated balance sheet. Vallon recorded the fair value of the May 2022 Warrants upon issuance using a Black-Scholes valuation model. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is required to revalue the May 2022 Warrants at each reporting date with any changes in fair value recorded in its consolidated statements of operations. The valuation of the May 2022 Warrants is considered under Level 3 of the fair value hierarchy due to the need to use assumptions in the valuation that are both significant to the fair value measurement and unobservable. The change in the fair value of the Level 3 warrant liability is reflected in the consolidated statements of operations for the three and six months ended June&#160;30, 2025. As of June&#160;30, 2025 and December&#160;31, 2024, the fair value of the warrant liability was immaterial.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:DeferredChargesPolicyTextBlock contextRef="c-1" id="f-252">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred Stock Issuance Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred stock issuance costs represent incremental costs incurred that are directly attributable to proposed offerings of securities. The costs are charged against the gross proceeds of the respective offering upon closing.&lt;/span&gt;&lt;/div&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-253">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Loss Per Common Share&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per common share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. For the six-month period ended June&#160;30, 2024, basic net loss per common share includes the weighted average of the June 2024 Pre-Funded Warrants (as defined below). Diluted net loss per common share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during each period, plus the dilutive effect of common stock equivalents outstanding during each period, in accordance with ASC 260,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Earnings Per Share&lt;/span&gt;. As the Company had a net loss in each of the three and six months ended June&#160;30, 2025 and 2024, diluted net loss per common share is the same as basic net loss per common share for the period because the effects of potentially dilutive securities are antidilutive</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-254">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock equivalents excluded from the diluted net loss per common share calculations are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.177%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,623,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,644,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;312,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-64" decimals="0" id="f-255" unitRef="shares">21270</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-65" decimals="0" id="f-256" unitRef="shares">142</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-66" decimals="0" id="f-257" unitRef="shares">4623292</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-67" decimals="0" id="f-258" unitRef="shares">311956</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-259" unitRef="shares">4644562</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-7" decimals="0" id="f-260" unitRef="shares">312098</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-261">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considered the applicability and impact of all ASUs issued during the quarter ended June&#160;30, 2025. ASUs not discussed below were assessed and determined to be either not applicable or expected to have minimal impact on these unaudited interim consolidated financial statements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280):&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Improvements to Reportable Segment Disclosures &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASU 2023-07). This amended guidance applies to all public entities and aims to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. This guidance is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The Company has adopted the provisions of ASU 2023-07 and has included the required disclosures in this Quarterly Report on Form 10-Q. See Note 8 for additional disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-262">PROPERTY AND EQUIPMENT&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.122%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.512%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense related to property and equipment was $1 in each of the three-month periods ended June&#160;30, 2025 and 2024 and  $2 in each of the six-month periods ended June&#160;30, 2025 and 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-263">&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.122%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.512%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-68" decimals="-3" id="f-264" unitRef="usd">21000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-69" decimals="-3" id="f-265" unitRef="usd">21000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-70" decimals="-3" id="f-266" unitRef="usd">13000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-71" decimals="-3" id="f-267" unitRef="usd">13000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-3" decimals="-3" id="f-268" unitRef="usd">34000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-4" decimals="-3" id="f-269" unitRef="usd">34000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-3" decimals="-3" id="f-270" unitRef="usd">32000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-271" unitRef="usd">30000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-272" unitRef="usd">2000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-273" unitRef="usd">4000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c-5" decimals="-3" id="f-274" unitRef="usd">1000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-6" decimals="-3" id="f-275" unitRef="usd">1000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-1" decimals="-3" id="f-276" unitRef="usd">2000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-7" decimals="-3" id="f-277" unitRef="usd">2000</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c-1" id="f-278">ACCRUED EXPENSES&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.791%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-279">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.791%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <ck0001824293:AccruedResearchAndDevelopmentCostsCurrent contextRef="c-3" decimals="-3" id="f-280" unitRef="usd">550000</ck0001824293:AccruedResearchAndDevelopmentCostsCurrent>
    <ck0001824293:AccruedResearchAndDevelopmentCostsCurrent contextRef="c-4" decimals="-3" id="f-281" unitRef="usd">342000</ck0001824293:AccruedResearchAndDevelopmentCostsCurrent>
    <ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent contextRef="c-3" decimals="-3" id="f-282" unitRef="usd">73000</ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent>
    <ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent contextRef="c-4" decimals="-3" id="f-283" unitRef="usd">12000</ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-284" unitRef="usd">337000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-285" unitRef="usd">337000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-286" unitRef="usd">960000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-287" unitRef="usd">691000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-288">STOCKHOLDERS&#x2019; EQUITY &lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;February 2024 Securities Purchase Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 1, 2024, the Company entered into the February 2024 Purchase Agreement, pursuant to which the Company sold, in the February 2024 Offering, (i) 1,495 shares (the February 2024 Shares) of Common Stock, (ii) 21,131 pre-funded warrants (the February 2024 Pre-Funded Warrants) exercisable for an aggregate of 21,131 shares of Common Stock, (iii) 22,631 Series B-1 common warrants (the Series B-1 Common Warrants) exercisable for an aggregate of 22,631 shares of Common Stock and (iv) 22,631 Series B-2 common warrants (the Series B-2 Common Warrants and together with the Series B-1 Common Warrants, the Series B Common Warrants) exercisable for an aggregate of 22,631 shares of Common Stock for net proceeds of $4,389, after deducting offering expenses of $1,110. The Series B Common Warrants together with the February 2024 Pre-Funded Warrants are referred to in this Quarterly Report on Form 10-Q (the Quarterly Report) as the &#x201c;February 2024 Warrants.&#x201d; The securities were offered in combinations of (a) one February 2024 Share or one February 2024 Pre-Funded Warrant, together with (b) one Series B-1 Common Warrant and one Series B-2 Common Warrant, for a combined purchase price of $243.10 (less $0.0221 for each February 2024 Pre-Funded Warrant).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to certain ownership limitations, the February 2024 Warrants were exercisable upon issuance. Each February 2024 Pre-Funded Warrant was exercisable for one share of Common Stock at a price per share of $0.0221 and expired when exercised in full. Each Series B-1 Common Warrant is exercisable into one share of Common Stock at a price per share of $243.10 for a five-year period after February 6, 2024, the date of issuance. Each Series B-2 Common Warrant is exercisable into one share of Common Stock at a price per share of $243.10 for an 18-month period after February 6, 2024, the date of issuance. The February 2024 Warrants were classified as equity and the allocated fair value of $4,279 is included in additional paid-in capital. As of June&#160;30, 2025, all of the February 2024 Pre-Funded Warrants have been exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the issuance of the securities pursuant to the February 2024 Purchase Agreement, the exercise price of the Company&#x2019;s previously outstanding Series A-1 Warrants was reduced to par, or $0.0001, per share pursuant to the terms of the Series A-1 Warrants. As of June&#160;30, 2025, all of the Series A-1 Warrants have been exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;May 2024 At The Market Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 20, 2024, the Company entered into the Sales Agreement with Wainwright, pursuant to which the Company may sell and issue, subject to the limitations in the Sales Agreement, shares up to $10.0&#160;million of Common Stock from time to time in the ATM Offering. Under the Sales Agreement, Wainwright is entitled to compensation of 3.0% of the gross offering proceeds of all shares of Common Stock sold through it pursuant to the Sales Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2025, the Company has sold 908,172 shares of Common Stock in the ATM Offering at a weighted-average price of $5.01 per share, for net proceeds of $4,292, after deducting commissions to the sales agent and other ATM Offering related expenses of $254&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of which 582,554 shares of Common Stock were sold during the quarter ended June 30, 2025, for gross proceeds of $941 and net proceeds of $825. On May 23, 2025, the Company filed a prospectus supplement to its registration statement on Form S-3 (File No. 333-279348) to increase the amount of shares of Common Stock that the Company may offer and sell under the Sales Agreement and applicable registration statement to an aggregate offering price of up to $1,759, which amount does not include the shares of Common Stock having an aggregate gross sales price of approximately $4,546 that were sold under the ATM Offering through May 22, 2025, in accordance with the limitations set forth in Instruction I.B.6 of Form S-3.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;June 2024 Securities Purchase Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 26, 2024, the Company entered into the June 2024 Purchase Agreement, pursuant to which the Company issued and sold, in the June 2024 Offering, (i) 3,529 shares (the June 2024 Shares) of Common Stock, (ii) 125,047 pre-funded warrants (the June 2024 Pre-Funded Warrants) exercisable for an aggregate of 125,047 shares of Common Stock, (iii) 128,577 Series C-1 common warrants (the Series C-1 Common Warrants) exercisable for an aggregate of 128,577 shares of Common Stock, and (iv) 128,577 Series C-2 common warrants (the Series C-2 Common Warrants, and together with the Series C-1 Common Warrants, the Series C Common Warrants), exercisable for an aggregate of 128,577 shares of Common Stock for net proceeds of $3,172, after deducting offering expenses of $1,057. The Series C Common Warrants together with the June 2024 Pre-Funded Warrants are referred to in this Quarterly Report as the &#x201c;June 2024 Warrants.&#x201d; The securities were offered in combinations of (a) one June 2024 Share or one June 2024 Pre-Funded Warrant, together with (b) one Series C-1 Common Warrant and one Series C-2 Common Warrant, for a combined purchase price of $31.11 (less $0.0017 for each June 2024 Pre-Funded Warrant).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The June 2024 Pre-Funded Warrants were exercisable for one share of Common Stock at a price per share of $0.0017, were exercisable immediately and have been exercised in full as of June&#160;30, 2025. Each Series C-1 Common Warrant is exercisable into one share of Common Stock at a price per share of $31.11 for a five-year period beginning after September 6, 2024. Each Series C-2 Common Warrant is exercisable into one share of Common Stock at a price per share of $31.11 for an 18-month period beginning after September 6, 2024. The June 2024 Warrants were classified as equity and the allocated fair value of $2,908 is included in additional paid-in capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to an engagement agreement with Wainwright, the Company, in connection with the June 2024 Offering, issued to Wainwright, or its designees, warrants to purchase up to an aggregate of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,002&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; shares of Common Stock (the June 2024 PA Warrants). The June 2024 PA Warrants have an exercise price of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$38.89&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; per share, will expire on June 26, 2029 and are exercisable beginning after September 6, 2024. The June 2024 PA Warrants were classified as equity and the fair value of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$229 is included in additional paid-in capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;October 2024 Repricing Letter Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 21, 2024, the Company entered into the Repricing Letter Agreements with certain Holders of its issued and outstanding Series B Common Warrants to purchase an aggregate of 44,842 shares of its Common Stock, offering pursuant to which these Holders exercised Series B Common Warrants for cash at a reduced exercise price equal to $17.00 per share. In addition, these Holders received new unregistered Series D-1 common warrants (the Series D-1 Common Warrants) exercisable for up to an aggregate of 44,839 shares of Common Stock and new unregistered Series D-2 common warrants (the Series D-2 Common Warrants and, together with the Series D-1 Common Warrants, the Series D Common Warrants) exercisable for up to an aggregate of 44,839 shares of Common Stock. The Series D Common Warrants are immediately exercisable and have an exercise price of $17.00 per share. The Series D-1 Common Warrants expire on October 22, 2029, and the Series D-2 Common Warrants expire on April 22, 2026. This transaction is referred to as the &#x201c;Warrant Repricing Transaction.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Wainwright acted as the exclusive placement agent for the Warrant Repricing Transaction pu&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;rsuant to an engagement agreement between the Company and Wainwright dated as of October 21, 2024. As compensation for such placement agent services, the Company agreed to pay Wainwright an aggregate cash fee equal to 7.0% of the gross proceeds received by the Company from the Warrant Repricing Transaction, plus a management fee equal to 1.0% of the gross proceeds received by the Company from the Warrant Repricing Transaction, and reimbursement for accountable expenses of $25,000 and non-accountable expenses of $10,000. The Company has also issued to Wainwright or its designees the October 2024 PA Warrants to purchase up to an aggregate of 3,140 shares of Common Stock (the October 2024 PA Warrant). The October 2024 PA Warrants are immediately exercisable, expire on October 22, 2029, and have an exercise price of $21.25 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net proceeds to the Company from the exercise of the Series B Common Warrants were $202 after deducting placement agent fees and offering expenses of $560. The issuance under the Repricing Letter Agreements represented $1,526 in additional value provided to the investors, which was recorded as a deemed dividend to common stockholders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;April 2025 Securities Purchase Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 1, 2025, the Company entered into the April 2025 Purchase Agreement, pursuant to which the Company issued and sold, in the April 2025 Offering, (i) 202,000 shares (the April 2025 Shares) of Common Stock, (ii) 1,186,888 pre-funded warrants (the April 2025 Pre-Funded Warrants) exercisable for an aggregate of 1,186,888 shares of Common Stock, (iii) 1,388,888 Series E-1 common stock warrants (the Series E-1 Common Warrants) to purchase up to 1,388,888 shares of Common Stock, (iv) 1,388,888 Series E-2 common stock warrants (the Series E-2 Common Warrants) to purchase up to 1,388,888 shares of Common Stock, and (v) 1,388,888 Series E-3 common stock warrants (the Series E-3 Common Warrants, and collectively with the Series E-1 Warrants and the Series E-2 Warrants, the Series E Common Warrants) to purchase up to 1,388,888 shares of Common Stock, for net proceeds of $4,020, after deducting offering expenses of $979. The April 2025 Offering closed on April 2, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The securities were offered in combinations of (a) one April 2025 Share or one April 2025 Pre-Funded Warrant, together with (b) one Series E-1 Common Warrant, one Series E-2 Common Warrant and one Series E-3 Common Warrant, for a combined purchase price of $3.60 (less $0.0001 for each April 2025 Pre-Funded Warrant). The April 2025 Pre-Funded Warrants had an exercise price of $0.0001 per share, became exercisable immediately upon issuance and expired when exercised in full. Each Series E Common Warrant has an exercise price of $3.20 per share and became exercisable immediately upon issuance. The Series E-1 Common Warrants expire April 2, 2030. The Series E-2 Common Warrants expire on October 2, 2026. The Series E-3 Common Warrants expire on January 2, 2026. As of June 30, 2025, the April 2025 Pre-Funded Warrants have been exercised in full.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Wainwright acted as the exclusive placement agent for the April 2025 Offering pursuant to an engagement agreement between the Company and Wainwright dated as of March 7, 2025. As compensation for such placement agent services, the Company agreed to pay Wainwright an aggregate cash fee equal to 7.0% of the gross proceeds received by the Company from the offering, plus a management fee equal to 1.0% of the gross proceeds received by the Company from the offering,  reimbursement for accountable expenses of $25,000,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; reimbursement of up to $100,000 for legal fees and expenses and other out-of-pocket expenses and up to $15,950 for the clearing expenses.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company also issued to Wainwright, or its designees, warrants to purchase up to an aggregate of 97,222 shares of Common Stock (the April 2025 PA Warrants). The April 2025 PA Warrants became exercisable immediately upon issuance, expire on April 1, 2030, and have an exercise price of $4.50 per share. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The April 2025 PA Warrants were classified as equity and the fair value of $123&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is included in additional paid-in capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the amount paid for the April 2025 Pre-Funded Warrants approximates their fair value. The Black-Scholes option-pricing model was used to estimate the fair value of the Series E Common Warrants and the April 2025 PA Warrants with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.123%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.48&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2025, the Company had the following warrants outstanding to purchase Common Stock: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Exercise Price per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expiration Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;210&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$243.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;August 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,388,888&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$3.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$464,100.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;128,577&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$31.11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;March 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,839&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$17.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,388,888&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$3.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$43,548.05&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;May 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$0.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$94,970.33&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;210&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$243.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,002&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$38.8875&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;128,577&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$31.11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;September 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,839&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$17.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,140&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$21.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,388,888&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$3.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2030&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97,222&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$4.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2030&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-57"
      decimals="INF"
      id="f-289"
      unitRef="shares">1495</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-72"
      decimals="INF"
      id="f-290"
      unitRef="shares">21131</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-72"
      decimals="INF"
      id="f-291"
      unitRef="shares">21131</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-73"
      decimals="INF"
      id="f-292"
      unitRef="shares">22631</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-73"
      decimals="INF"
      id="f-293"
      unitRef="shares">22631</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-74"
      decimals="INF"
      id="f-294"
      unitRef="shares">22631</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-74"
      decimals="INF"
      id="f-295"
      unitRef="shares">22631</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-57" decimals="-3" id="f-296" unitRef="usd">4389000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <ck0001824293:StockIssuanceCostsOfferingExpenses contextRef="c-57" decimals="-3" id="f-297" unitRef="usd">1110000</ck0001824293:StockIssuanceCostsOfferingExpenses>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-75"
      decimals="INF"
      id="f-298"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-72"
      decimals="INF"
      id="f-299"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-73"
      decimals="INF"
      id="f-300"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-74"
      decimals="INF"
      id="f-301"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-75"
      decimals="INF"
      id="f-302"
      unitRef="usdPerShare">243.10</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-76"
      decimals="INF"
      id="f-303"
      unitRef="usdPerShare">0.0221</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c-76"
      decimals="INF"
      id="f-304"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-76"
      decimals="INF"
      id="f-305"
      unitRef="usdPerShare">0.0221</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c-77"
      decimals="INF"
      id="f-306"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-77"
      decimals="INF"
      id="f-307"
      unitRef="usdPerShare">243.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-77" id="f-308">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c-78"
      decimals="INF"
      id="f-309"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-78"
      decimals="INF"
      id="f-310"
      unitRef="usdPerShare">243.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-78" id="f-311">P18M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="c-79" decimals="-3" id="f-312" unitRef="usd">4279000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-80"
      decimals="INF"
      id="f-313"
      unitRef="usdPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ck0001824293:SaleOfStockMaximumValueOfSharesOffered contextRef="c-58" decimals="-5" id="f-314" unitRef="usd">10000000</ck0001824293:SaleOfStockMaximumValueOfSharesOffered>
    <ck0001824293:SaleOfStockAgentCompensationPercentage contextRef="c-58" decimals="3" id="f-315" unitRef="number">0.030</ck0001824293:SaleOfStockAgentCompensationPercentage>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-59"
      decimals="INF"
      id="f-316"
      unitRef="shares">908172</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-60"
      decimals="2"
      id="f-317"
      unitRef="usdPerShare">5.01</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-59" decimals="-3" id="f-318" unitRef="usd">4292000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <ck0001824293:StockIssuanceCostsOfferingExpenses contextRef="c-59" decimals="-3" id="f-319" unitRef="usd">254000</ck0001824293:StockIssuanceCostsOfferingExpenses>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-81"
      decimals="INF"
      id="f-320"
      unitRef="shares">582554</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-81" decimals="-3" id="f-321" unitRef="usd">941000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-81" decimals="-3" id="f-322" unitRef="usd">825000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <ck0001824293:SaleOfStockMaximumValueOfSharesOffered contextRef="c-82" decimals="-3" id="f-323" unitRef="usd">1759000</ck0001824293:SaleOfStockMaximumValueOfSharesOffered>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-59" decimals="-3" id="f-324" unitRef="usd">4546000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-61"
      decimals="INF"
      id="f-325"
      unitRef="shares">3529</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-83"
      decimals="INF"
      id="f-326"
      unitRef="shares">125047</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-83"
      decimals="INF"
      id="f-327"
      unitRef="shares">125047</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-84"
      decimals="INF"
      id="f-328"
      unitRef="shares">128577</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-84"
      decimals="INF"
      id="f-329"
      unitRef="shares">128577</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-85"
      decimals="INF"
      id="f-330"
      unitRef="shares">128577</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-85"
      decimals="INF"
      id="f-331"
      unitRef="shares">128577</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-61" decimals="-3" id="f-332" unitRef="usd">3172000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <ck0001824293:StockIssuanceCostsOfferingExpenses contextRef="c-61" decimals="-3" id="f-333" unitRef="usd">1057000</ck0001824293:StockIssuanceCostsOfferingExpenses>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-86"
      decimals="INF"
      id="f-334"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-83"
      decimals="INF"
      id="f-335"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-84"
      decimals="INF"
      id="f-336"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-85"
      decimals="INF"
      id="f-337"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-86"
      decimals="INF"
      id="f-338"
      unitRef="usdPerShare">31.11</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-87"
      decimals="INF"
      id="f-339"
      unitRef="usdPerShare">0.0017</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c-87"
      decimals="INF"
      id="f-340"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-87"
      decimals="INF"
      id="f-341"
      unitRef="usdPerShare">0.0017</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c-88"
      decimals="INF"
      id="f-342"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-88"
      decimals="INF"
      id="f-343"
      unitRef="usdPerShare">31.11</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-88" id="f-344">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c-89"
      decimals="INF"
      id="f-345"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-89"
      decimals="INF"
      id="f-346"
      unitRef="usdPerShare">31.11</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-89" id="f-347">P18M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="c-90" decimals="-3" id="f-348" unitRef="usd">2908000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-91"
      decimals="INF"
      id="f-349"
      unitRef="shares">9002</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-91"
      decimals="INF"
      id="f-350"
      unitRef="usdPerShare">38.89</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="c-91" decimals="-3" id="f-351" unitRef="usd">229000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-92"
      decimals="INF"
      id="f-352"
      unitRef="shares">44842</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-92"
      decimals="INF"
      id="f-353"
      unitRef="usdPerShare">17.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-93"
      decimals="INF"
      id="f-354"
      unitRef="shares">44839</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-94"
      decimals="INF"
      id="f-355"
      unitRef="shares">44839</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-95"
      decimals="INF"
      id="f-356"
      unitRef="usdPerShare">17.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ck0001824293:SaleOfStockAggregateCashFeePercentageOfGrossProceeds
      contextRef="c-96"
      decimals="INF"
      id="f-357"
      unitRef="number">0.070</ck0001824293:SaleOfStockAggregateCashFeePercentageOfGrossProceeds>
    <ck0001824293:SaleOfStockManagementFeePercentageOfGrossProceeds
      contextRef="c-96"
      decimals="INF"
      id="f-358"
      unitRef="number">0.010</ck0001824293:SaleOfStockManagementFeePercentageOfGrossProceeds>
    <ck0001824293:SaleOfStockReimbursementOfAccountableExpenses contextRef="c-96" decimals="-3" id="f-359" unitRef="usd">25000</ck0001824293:SaleOfStockReimbursementOfAccountableExpenses>
    <ck0001824293:SaleOfStockReimbursementOfNonAccountableExpenses contextRef="c-96" decimals="-3" id="f-360" unitRef="usd">10000</ck0001824293:SaleOfStockReimbursementOfNonAccountableExpenses>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-97"
      decimals="INF"
      id="f-361"
      unitRef="shares">3140</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-97"
      decimals="INF"
      id="f-362"
      unitRef="usdPerShare">21.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ck0001824293:ProceedsFromWarrantExercisesNetOfOfferingExpense contextRef="c-62" decimals="-3" id="f-363" unitRef="usd">202000</ck0001824293:ProceedsFromWarrantExercisesNetOfOfferingExpense>
    <ck0001824293:ClassOfWarrantOrRightOfferingCost contextRef="c-62" decimals="-3" id="f-364" unitRef="usd">560000</ck0001824293:ClassOfWarrantOrRightOfferingCost>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c-96" decimals="-3" id="f-365" unitRef="usd">1526000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-98"
      decimals="INF"
      id="f-366"
      unitRef="shares">202000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-99"
      decimals="INF"
      id="f-367"
      unitRef="shares">1186888</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-99"
      decimals="INF"
      id="f-368"
      unitRef="shares">1186888</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-100"
      decimals="INF"
      id="f-369"
      unitRef="shares">1388888</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-100"
      decimals="INF"
      id="f-370"
      unitRef="shares">1388888</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-101"
      decimals="INF"
      id="f-371"
      unitRef="shares">1388888</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-101"
      decimals="INF"
      id="f-372"
      unitRef="shares">1388888</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-102"
      decimals="INF"
      id="f-373"
      unitRef="shares">1388888</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-102"
      decimals="INF"
      id="f-374"
      unitRef="shares">1388888</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-98" decimals="-3" id="f-375" unitRef="usd">4020000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <ck0001824293:StockIssuanceCostsOfferingExpenses contextRef="c-103" decimals="-3" id="f-376" unitRef="usd">979000</ck0001824293:StockIssuanceCostsOfferingExpenses>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-104"
      decimals="INF"
      id="f-377"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-99"
      decimals="INF"
      id="f-378"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-100"
      decimals="INF"
      id="f-379"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-101"
      decimals="INF"
      id="f-380"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-102"
      decimals="INF"
      id="f-381"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-104"
      decimals="INF"
      id="f-382"
      unitRef="usdPerShare">3.60</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-105"
      decimals="INF"
      id="f-383"
      unitRef="usdPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-105"
      decimals="INF"
      id="f-384"
      unitRef="usdPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-106"
      decimals="INF"
      id="f-385"
      unitRef="usdPerShare">3.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ck0001824293:SaleOfStockAggregateCashFeePercentageOfGrossProceeds
      contextRef="c-103"
      decimals="INF"
      id="f-386"
      unitRef="number">0.070</ck0001824293:SaleOfStockAggregateCashFeePercentageOfGrossProceeds>
    <ck0001824293:SaleOfStockManagementFeePercentageOfGrossProceeds
      contextRef="c-103"
      decimals="INF"
      id="f-387"
      unitRef="number">0.010</ck0001824293:SaleOfStockManagementFeePercentageOfGrossProceeds>
    <ck0001824293:SaleOfStockReimbursementOfAccountableExpenses contextRef="c-103" decimals="-3" id="f-388" unitRef="usd">25000000</ck0001824293:SaleOfStockReimbursementOfAccountableExpenses>
    <ck0001824293:SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses contextRef="c-107" decimals="-3" id="f-389" unitRef="usd">100000000</ck0001824293:SaleOfStockLegalFeesAndExpensesAndOtherOutOfPocketExpenses>
    <ck0001824293:SaleOfStockClearingExpenses contextRef="c-103" decimals="-3" id="f-390" unitRef="usd">15950000</ck0001824293:SaleOfStockClearingExpenses>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-108"
      decimals="INF"
      id="f-391"
      unitRef="shares">97222</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-108"
      decimals="2"
      id="f-392"
      unitRef="usdPerShare">4.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="c-108" decimals="-3" id="f-393" unitRef="usd">123000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="c-1" id="f-394">The Black-Scholes option-pricing model was used to estimate the fair value of the Series E Common Warrants and the April 2025 PA Warrants with the following weighted-average assumptions:&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.123%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.48&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-109" decimals="4" id="f-395" unitRef="number">1.5644</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-110" decimals="2" id="f-396" unitRef="year">2.48</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-111" decimals="2" id="f-397" unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-112" decimals="4" id="f-398" unitRef="number">0.0402</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c-1" id="f-399">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2025, the Company had the following warrants outstanding to purchase Common Stock: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Exercise Price per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expiration Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;210&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$243.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;August 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,388,888&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$3.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$464,100.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;128,577&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$31.11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;March 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,839&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$17.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,388,888&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$3.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$43,548.05&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;May 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$0.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$94,970.33&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;210&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$243.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,002&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$38.8875&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;128,577&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$31.11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;September 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,839&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$17.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,140&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$21.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,388,888&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$3.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2030&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97,222&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$4.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2030&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-113"
      decimals="INF"
      id="f-400"
      unitRef="shares">210</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-113"
      decimals="INF"
      id="f-401"
      unitRef="usdPerShare">243.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-114"
      decimals="INF"
      id="f-402"
      unitRef="shares">1388888</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-114"
      decimals="INF"
      id="f-403"
      unitRef="usdPerShare">3.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-115"
      decimals="INF"
      id="f-404"
      unitRef="shares">9</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-115"
      decimals="INF"
      id="f-405"
      unitRef="usdPerShare">464100</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-116"
      decimals="INF"
      id="f-406"
      unitRef="shares">128577</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-116"
      decimals="INF"
      id="f-407"
      unitRef="usdPerShare">31.11</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-117"
      decimals="INF"
      id="f-408"
      unitRef="shares">44839</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-117"
      decimals="INF"
      id="f-409"
      unitRef="usdPerShare">17.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-118"
      decimals="INF"
      id="f-410"
      unitRef="shares">1388888</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-118"
      decimals="INF"
      id="f-411"
      unitRef="usdPerShare">3.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-119"
      decimals="INF"
      id="f-412"
      unitRef="shares">16</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-119"
      decimals="INF"
      id="f-413"
      unitRef="usdPerShare">43548.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-120"
      decimals="INF"
      id="f-414"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-120"
      decimals="INF"
      id="f-415"
      unitRef="usdPerShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-121"
      decimals="INF"
      id="f-416"
      unitRef="shares">3</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-121"
      decimals="INF"
      id="f-417"
      unitRef="usdPerShare">94970.33</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-122"
      decimals="INF"
      id="f-418"
      unitRef="shares">210</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-122"
      decimals="INF"
      id="f-419"
      unitRef="usdPerShare">243.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-123"
      decimals="INF"
      id="f-420"
      unitRef="shares">9002</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-123"
      decimals="INF"
      id="f-421"
      unitRef="usdPerShare">38.8875</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-124"
      decimals="INF"
      id="f-422"
      unitRef="shares">128577</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-124"
      decimals="INF"
      id="f-423"
      unitRef="usdPerShare">31.11</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-125"
      decimals="INF"
      id="f-424"
      unitRef="shares">44839</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-125"
      decimals="INF"
      id="f-425"
      unitRef="usdPerShare">17.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-126"
      decimals="INF"
      id="f-426"
      unitRef="shares">3140</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-126"
      decimals="INF"
      id="f-427"
      unitRef="usdPerShare">21.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-127"
      decimals="INF"
      id="f-428"
      unitRef="shares">1388888</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-127"
      decimals="INF"
      id="f-429"
      unitRef="usdPerShare">3.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-128"
      decimals="INF"
      id="f-430"
      unitRef="shares">97222</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-128"
      decimals="INF"
      id="f-431"
      unitRef="usdPerShare">4.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-432">STOCK-BASED COMPENSATION&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Amended and Restated 2018 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 21, 2023, the stockholders of the Company approved the Amended and Restated GRI Bio, Inc. 2018 Equity Incentive Plan (the A&amp;amp;R 2018 Plan). The A&amp;amp;R 2018 Plan provides the Company with the ability to grant stock options, restricted stock and other equity-based awards to employees, directors and consultants. Stock options granted by the Company under the A&amp;amp;R 2018 Plan generally have a contractual life of up to 10 years. As of June&#160;30, 2025, awards granted under the A&amp;amp;R 2018 Plan representing the right to purchase or contingent right to receive up to an aggregate of 21,270 shares of the Company's Common Stock were outstanding and 21,275 shares of the Company&#x2019;s Common Stock were reserved for issuance under the A&amp;amp;R 2018 Plan. The number of shares reserved for issuance under the A&amp;amp;R 2018 Plan may be increased pursuant to the A&amp;amp;R 2018 Plan&#x2019;s &#x201c;evergreen&#x201d; provision on the first day of each calendar year beginning January 1, 2024 and ending on and including January 1, 2033, by a number of shares not to exceed 4% of the aggregate number of shares of the Company&#x2019;s Common Stock outstanding on the final day of the immediately preceding calendar year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation related to equity-based awards issued under the A&amp;amp;R 2018 Plan in the following expense categories of its accompanying consolidated statements of operations for the three and six months ended June&#160;30, 2025 and 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.261%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.261%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.261%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.264%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 4pt 0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures equity-based awards granted to employees and non-employees based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period or performance-based period, which is generally the vesting period of the respective award. The measurement date for service-based equity awards is the date of grant, and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;equity-based compensation costs are recognized as expense over the requisite service period. The Company records expense for performance-based awards if the Company concludes that it is probable that the performance condition will be achieved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below represents the activity of stock options granted to employees and non-employees for the six months ended June&#160;30, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.625%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-average remaining contractual term&#160;(years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,376.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.63&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,128&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.66&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited/cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,270&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.80&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.56&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.56&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,270&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.80&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.56&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2025, all of the outstanding and exercisable stock options were out of the money and therefore had no intrinsic value. As of June&#160;30, 2025, the unrecognized compensation cost related to unvested stock options expected to vest was $174. This unrecognized compensation is expected to be recognized over a weighted-average amortization period of 0.78 years. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company granted 21,128 stock options to its employees and non-employee directors during the six months ended June&#160;30, 2025. The Black-Scholes option-pricing model was used to estimate the grant date fair value of each stock option grant at the time of grant using the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of option on grant date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No equity-based awards were granted during the six-month period ended June&#160;30, 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-129" id="f-433">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-130"
      decimals="INF"
      id="f-434"
      unitRef="shares">21270</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-130"
      decimals="INF"
      id="f-435"
      unitRef="shares">21275</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <ck0001824293:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum contextRef="c-130" decimals="2" id="f-436" unitRef="number">0.04</ck0001824293:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-437">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation related to equity-based awards issued under the A&amp;amp;R 2018 Plan in the following expense categories of its accompanying consolidated statements of operations for the three and six months ended June&#160;30, 2025 and 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.261%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.261%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.261%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.264%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 4pt 0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-131" decimals="-3" id="f-438" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-132" decimals="-3" id="f-439" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-133" decimals="-3" id="f-440" unitRef="usd">25000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-134" decimals="-3" id="f-441" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-135" decimals="-3" id="f-442" unitRef="usd">41000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-136" decimals="-3" id="f-443" unitRef="usd">37000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-137" decimals="-3" id="f-444" unitRef="usd">236000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-138" decimals="-3" id="f-445" unitRef="usd">74000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-5" decimals="-3" id="f-446" unitRef="usd">41000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-6" decimals="-3" id="f-447" unitRef="usd">37000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-448" unitRef="usd">261000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-7" decimals="-3" id="f-449" unitRef="usd">74000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="c-1" id="f-450">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below represents the activity of stock options granted to employees and non-employees for the six months ended June&#160;30, 2025:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.625%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-average remaining contractual term&#160;(years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,376.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.63&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,128&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.66&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited/cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,270&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.80&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.56&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.56&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,270&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.80&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.56&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-4" decimals="INF" id="f-451" unitRef="shares">142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-452"
      unitRef="usdPerShare">4376.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-139" id="f-453">P8Y7M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-454" unitRef="shares">21128</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-455"
      unitRef="usdPerShare">11.66</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-456" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-457"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-1" decimals="INF" id="f-458" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-459"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-3" decimals="INF" id="f-460" unitRef="shares">21270</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-461"
      unitRef="usdPerShare">40.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-462">P9Y6M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c-3" decimals="INF" id="f-463" unitRef="shares">21208</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-464"
      unitRef="usdPerShare">30.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-465">P9Y6M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="c-3" decimals="INF" id="f-466" unitRef="shares">21270</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-467"
      unitRef="usdPerShare">40.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-468">P9Y6M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-3" decimals="-3" id="f-469" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-3" decimals="-3" id="f-470" unitRef="usd">174000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-140" id="f-471">P0Y9M10D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-472" unitRef="shares">21128</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-473">The Black-Scholes option-pricing model was used to estimate the grant date fair value of each stock option grant at the time of grant using the following weighted-average assumptions:&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of option on grant date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-140" decimals="4" id="f-474" unitRef="number">1.1094</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-140" id="f-475">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-140" decimals="4" id="f-476" unitRef="number">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-140" decimals="4" id="f-477" unitRef="number">0.0445</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharePrice
      contextRef="c-141"
      decimals="2"
      id="f-478"
      unitRef="usdPerShare">9.43</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="c-7" decimals="INF" id="f-479" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-480">SEGMENT REPORTING&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (CODM), or decision-making group, in deciding how to allocate resources in assessing performance. The Company has one reportable segment: biotechnology research. The biotechnology research segment consists of the research and development of products for the treatment of inflammatory disease. The Company&#x2019;s CODM is W. Marc Hertz, Ph.D., Chief Executive Officer and Director.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accounting policies of the biotechnology research segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance for the biotechnology research segment based on research and development expenses and general and administrative expenses as part of the overall review of the Company&#x2019;s consolidated net loss and consolidated cash flows as compared to prior quarters and the Company&#x2019;s operating budget.&lt;/span&gt;&lt;/div&gt;The Company has incurred significant losses since its inception and anticipates incurring continued losses in the future. As such, the CODM uses cash forecast models in deciding how to allocate resources based on the Company&#x2019;s available cash resources, as well as its forecasted expenditures.  This information, in conjunction with the assessment of the probability of the success of the Company&#x2019;s research and development activities, is used to plan the timing and size of future capital raises.</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-481"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-482">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Employment Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into employment contracts with its officers that provide for severance and continuation of benefits in the event of termination of employment by the Company without cause or by the employee for good reason. In addition, in the event of termination of employment following a change in control, the vesting of certain equity awards may be accelerated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Separation and Release Agreement&lt;/span&gt;&lt;/div&gt;In connection with the resignation of David Baker, the Company&#x2019;s Former Chief Executive Officer, the Company and Mr. Baker entered into a Separation and Release Agreement on April 21, 2023 (the Separation Agreement). Pursuant to the terms of the Separation Agreement and his employment agreement, Mr. Baker received continuation of his then current salary and certain COBRA benefits for 18 months payable in accordance with the Company&#x2019;s payroll practices. Mr. Baker also received a lump sum payment equal to 150% of his target bonus and agreed to reduce amounts payable with respect to certain future milestone payments.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <ck0001824293:COBRABenefitsPaymentPeriod contextRef="c-142" id="f-483">P18M</ck0001824293:COBRABenefitsPaymentPeriod>
    <ck0001824293:PercentageOfTargetBonus
      contextRef="c-142"
      decimals="INF"
      id="f-484"
      unitRef="number">1.50</ck0001824293:PercentageOfTargetBonus>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-485">SUBSEQUENT EVENTS&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The One Big Beautiful Bill Act (&#x201c;OBBBA&#x201d;) was enacted on July 4, 2025. The Company is in the process of assessing the impact of this legislation on its financial statements. The OBBBA is not currently expected to materially impact the Company&#x2019;s effective tax rate or cash flows in the current fiscal year.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-5" id="f-486">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-5" id="f-487">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-5" id="f-488">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-5" id="f-489">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
